1	The	DT	O	the	det	4	SENT_1	[p1l714t81r752b103],
2	NEW	NNP	O	NEW	nn	4	SENT_1	[p1l764t83r844b103],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_1	[p1l858t83r1033b103],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_1	[p1l1047t83r1213b110],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_1	[p1l1227t81r1443b109],

1	SOUNDING	VBG	O	sound	_	0	SENT_2	[p1l802t265r1133b297],
2	BOARD	NNP	O	BOARD	dobj	1	SENT_2	[p1l1157t265r1356b297],

1	Beyond	IN	O	beyond	dep	9	SENT_3	[p1l586t463r777b527],
2	Fast	JJ	O	fast	amod	3	SENT_3	[p1l801t467r904b512],
3	Track	NNP	O	Track	pobj	1	SENT_3	[p1l919t463r1058b512],
4	for	IN	O	for	_	0	SENT_3	[p1l1073t462r1147b512],
5	Drug	NNP	O	Drug	nn	6	SENT_3	[p1l1167t467r1297b527],
6	Approvals	NNP	O	Approvals	prep_for	3	SENT_3	[p1l1313t463r1578b526],
7	Thomas	NNP	PERSON	Thomas	nn	9	SENT_3	[p1l584t543r722b574],
8	G.	NNP	PERSON	G.	nn	9	SENT_3	[p1l736t546r771b574],
9	Roberts	NNP	PERSON	Roberts	_	0	SENT_3	[p1l788t543r978b583],
10	,	,	O	,	_	0	SENT_3	[p1l788t543r978b583],
11	Jr.	NNP	PERSON	Jr.	conj_and	9	SENT_3	[p1l788t543r978b583],
12	,	,	O	,	_	0	SENT_3	[p1l788t543r978b583],
13	M.D.	NNP	O	M.D.	conj_and	9	SENT_3	[p1l996t546r1086b580],
14	,	,	O	,	_	0	SENT_3	[p1l996t546r1086b580],
15	and	CC	O	and	_	0	SENT_3	[p1l1101t543r1160b574],
16	Bruce	NNP	PERSON	Bruce	nn	20	SENT_3	[p1l1178t546r1271b574],
17	A.	NNP	PERSON	A.	nn	20	SENT_3	[p1l1283t545r1315b574],
18	Chabner	NNP	PERSON	Chabner	nn	20	SENT_3	[p1l1329t543r1477b580],
19	,	,	O	,	_	0	SENT_3	[p1l1329t543r1477b580],
20	M.D.	NNP	O	M.D.	conj_and	9	SENT_3	[p1l1494t546r1574b574],

1	In	IN	O	in	_	0	SENT_4	[p1l10t749r99b819],
2	the	DT	DATE	the	det	4	SENT_4	[p1l139t741r272b820],
3	past	JJ	DATE	past	amod	4	SENT_4	[p1l310t758r494b842],
4	decade	NN	DATE	decade	prep_in	19	SENT_4	[p1l529t741r850b838],
5	,	,	O	,	_	0	SENT_4	[p1l529t741r850b838],
6	the	DT	O	the	det	8	SENT_4	[p1l896t741r1029b820],
7	primary	JJ	O	primary	amod	8	SENT_4	[p1l1067t742r1412b842],
8	strategy	NN	O	strategy	nsubj	19	SENT_4	[p1l1449t758r1790b843],
9	for	IN	O	for	_	0	SENT_4	[p1l1825t740r1951b820],
10	discovering	VBG	O	discover	prepc_for	8	SENT_4	[p1l1989t741r2147b820, p1l12t871r376b972],
11	new	JJ	O	new	amod	12	SENT_4	[p1l399t896r574b950],
12	drugs	NNS	O	drug	dobj	10	SENT_4	[p1l597t870r834b972],
13	for	IN	O	for	_	0	SENT_4	[p1l862t869r985b949],
14	the	DT	O	the	det	15	SENT_4	[p1l1009t870r1138b949],
15	treatment	NN	O	treatment	prep_for	10	SENT_4	[p1l1165t887r1578b949],
16	of	IN	O	of	_	0	SENT_4	[p1l1600t869r1700b950],
17	cancer	NN	O	cancer	prep_of	15	SENT_4	[p1l1709t896r1983b949],
18	has	VBZ	O	have	aux	19	SENT_4	[p1l2007t870r2148b949],
19	shifted	VBN	O	shift	_	0	SENT_4	[p1l13t998r306b1078],
20	from	IN	O	from	_	0	SENT_4	[p1l343t998r555b1078],
21	screening	VBG	O	screen	prepc_from	19	SENT_4	[p1l594t1000r1017b1101],
22	for	IN	O	for	_	0	SENT_4	[p1l1051t998r1177b1079],
23	cytotoxic	JJ	O	cytotoxic	amod	24	SENT_4	[p1l1212t1000r1596b1100],
24	compounds	NNS	O	compound	prep_for	21	SENT_4	[p1l1634t999r2146b1100],
25	to	TO	O	to	_	0	SENT_4	[p1l12t1145r93b1207],
26	seeking	VBG	O	seek	prepc_to	21	SENT_4	[p1l143t1128r477b1229],
27	agents	NNS	O	agent	dobj	26	SENT_4	[p1l520t1145r800b1229],
28	that	WDT	O	that	nsubj	29	SENT_4	[p1l849t1128r1021b1206],
29	block	VBP	O	block	rcmod	27	SENT_4	[p1l1064t1128r1304b1207],
30	the	DT	O	the	det	33	SENT_4	[p1l1348t1128r1479b1206],
31	key	JJ	O	key	amod	33	SENT_4	[p1l1527t1128r1672b1228],
32	molecular	JJ	O	molecular	amod	33	SENT_4	[p1l1714t1128r2152b1207],
33	pathways	NNS	O	pathway	dobj	29	SENT_4	[p1l10t1256r412b1356],
34	that	WDT	O	that	nsubj	35	SENT_4	[p1l440t1256r611b1334],
35	lead	VBP	O	lead	rcmod	33	SENT_4	[p1l630t1256r807b1334],
36	to	TO	O	to	_	0	SENT_4	[p1l832t1273r912b1335],
37	cancer	NN	O	cancer	prep_to	35	SENT_4	[p1l939t1282r1239b1334],
38	.	.	O	.	_	0	SENT_4	[p1l939t1282r1239b1334],

1	A	DT	O	a	det	2	SENT_5	[p1l1266t1264r1332b1333],
2	ﬂurry	NN	O	ﬂurry	nsubj	11	SENT_5	[p1l1354t1255r1594b1356],
3	of	IN	O	of	_	0	SENT_5	[p1l1614t1255r1717b1335],
4	recent	JJ	O	recent	amod	5	SENT_5	[p1l1723t1273r1993b1334],
5	approvals	NNS	O	approval	prep_of	2	SENT_5	[p1l2013t1282r2147b1356, p1l10t1384r322b1485],
6	of	IN	O	of	_	0	SENT_5	[p1l366t1383r468b1463],
7	so-called	JJ	O	so-called	amod	10	SENT_5	[p1l493t1384r880b1463],
8	molecularly	RB	O	molecularly	advmod	9	SENT_5	[p1l921t1384r1433b1485],
9	targeted	VBN	O	target	amod	10	SENT_5	[p1l1470t1384r1825b1486],
10	agents	NNS	O	agent	prep_of	5	SENT_5	[p1l1866t1401r2146b1486],
11	suggests	VBZ	O	suggest	_	0	SENT_5	[p1l13t1530r385b1615],
12	that	IN	O	that	complm	17	SENT_5	[p1l422t1513r594b1592],
13	this	DT	O	this	det	15	SENT_5	[p1l624t1513r781b1592],
14	new	JJ	O	new	amod	15	SENT_5	[p1l817t1539r996b1593],
15	approach	NN	O	approach	nsubj	17	SENT_5	[p1l1026t1513r1433b1614],
16	is	VBZ	O	be	aux	17	SENT_5	[p1l1466t1514r1533b1592],
17	bearing	VBG	O	bear	ccomp	11	SENT_5	[p1l1570t1513r1902b1615],
18	fruit	NN	O	fruit	dobj	17	SENT_5	[p1l1933t1512r2143b1593],
19	.	.	O	.	_	0	SENT_5	[p1l1933t1512r2143b1593],

1	However	RB	O	however	advmod	46	SENT_6	[p1l11t1649r413b1738],
2	,	,	O	,	_	0	SENT_6	[p1l11t1649r413b1738],
3	when	WRB	O	when	advmod	12	SENT_6	[p1l455t1642r694b1721],
4	the	DT	O	the	det	8	SENT_6	[p1l735t1642r868b1720],
5	Food	NNP	ORGANIZATION	Food	nn	8	SENT_6	[p1l908t1642r1126b1721],
6	and	CC	ORGANIZATION	and	_	0	SENT_6	[p1l1166t1642r1325b1721],
7	Drug	NNP	ORGANIZATION	Drug	nn	8	SENT_6	[p1l1365t1648r1588b1743],
8	Administration	NNP	ORGANIZATION	Administration	nsubj	12	SENT_6	[p1l1622t1642r2147b1721, p1l12t1771r180b1850],
9	(	CD	NUMBER	(	num	10	SENT_6	[p1l214t1777r454b1862],
10	FDA	NNP	ORGANIZATION	FDA	dep	8	SENT_6	[p1l214t1777r454b1862],
11	)	CD	NUMBER	)	num	10	SENT_6	[p1l214t1777r454b1862],
12	approved	VBD	O	approve	advcl	46	SENT_6	[p1l488t1770r876b1871],
13	geﬁtinib	JJ	O	geﬁtinib	amod	16	SENT_6	[p1l904t1769r1254b1872],
14	(	NN	O	(	nn	16	SENT_6	[p1l1290t1777r1590b1862],
15	Iressa	NN	O	iressa	nn	16	SENT_6	[p1l1290t1777r1590b1862],
16	)	NN	O	)	dobj	12	SENT_6	[p1l1290t1777r1590b1862],
17	for	IN	O	for	_	0	SENT_6	[p1l1624t1769r1747b1850],
18	the	DT	O	the	det	19	SENT_6	[p1l1774t1770r1902b1849],
19	treatment	NN	O	treatment	prep_for	16	SENT_6	[p1l1932t1787r2149b1849, p1l12t1916r233b1977],
20	of	IN	O	of	_	0	SENT_6	[p1l278t1898r381b1978],
21	patients	NNS	O	patient	prep_of	19	SENT_6	[p1l411t1900r755b1999],
22	with	IN	O	with	_	0	SENT_6	[p1l804t1899r998b1978],
23	advanced	JJ	O	advanced	amod	25	SENT_6	[p1l1047t1899r1448b1978],
24	non	JJ	O	non	amod	25	SENT_6	[p1l1499t1899r2149b1978],
25	—	NN	O	—	prep_with	12	SENT_6	[p1l1499t1899r2149b1978],
26	small	JJ	O	small	amod	30	SENT_6	[p1l1499t1899r2149b1978],
27	—	NN	O	—	nn	30	SENT_6	[p1l1499t1899r2149b1978],
28	cell	NN	O	cell	nn	30	SENT_6	[p1l1499t1899r2149b1978],
29	lung	NN	O	lung	nn	30	SENT_6	[p1l11t2027r209b2128],
30	cancer	NN	O	cancer	tmod	12	SENT_6	[p1l251t2053r533b2105],
31	in	IN	O	in	_	0	SENT_6	[p1l574t2028r657b2104],
32	whom	WP	O	whom	rel	43	SENT_6	[p1l697t2027r974b2106],
33	both	DT	O	both	det	34	SENT_6	[p1l1019t2027r1217b2106],
34	platinum-based	JJ	O	platinum-based	nsubj	43	SENT_6	[p1l1260t2027r1946b2127],
35	and	CC	O	and	_	0	SENT_6	[p1l1989t2027r2148b2106],
36	docetaxel	NN	O	docetaxel	conj_and	34	SENT_6	[p1l12t2155r408b2234],
37	(	CD	NUMBER	(	num	41	SENT_6	[p1l447t2161r860b2246],
38	Taxotere	NNP	O	Taxotere	nn	41	SENT_6	[p1l447t2161r860b2246],
39	)	CD	NUMBER	)	num	41	SENT_6	[p1l447t2161r860b2246],
40	chemotherapy	NN	O	chemotherapy	nn	41	SENT_6	[p1l900t2155r1505b2255],
41	regimens	NNS	O	regimen	dep	36	SENT_6	[p1l1535t2156r1926b2256],
42	have	VBP	O	have	aux	43	SENT_6	[p1l1962t2155r2149b2234],
43	failed	VBN	O	fail	rcmod	30	SENT_6	[p1l12t2282r272b2379],
44	,	,	O	,	_	0	SENT_6	[p1l12t2282r272b2379],
45	it	PRP	O	it	nsubj	46	SENT_6	[p1l301t2284r362b2361],
46	was	VBD	O	be	_	0	SENT_6	[p1l377t2309r541b2362],
47	not	RB	O	not	neg	46	SENT_6	[p1l566t2300r713b2362],
48	without	IN	O	without	_	0	SENT_6	[p1l727t2283r1071b2363],
49	controversy	NN	O	controversy	prep_without	46	SENT_6	[p1l1091t2300r1608b2383],
50	.	.	O	.	_	0	SENT_6	[p1l1091t2300r1608b2383],

1	The	DT	O	the	dep	105	SENT_7	[p1l1634t2283r1799b2361],
2	statistical	JJ	O	statistical	dep	105	SENT_7	[p1l1824t2284r2147b2361, p1l12t2411r130b2489],
3	reviewer	NN	O	reviewer	dep	105	SENT_7	[p1l159t2412r524b2490],
4	for	IN	O	for	dep	105	SENT_7	[p1l550t2410r676b2490],
5	the	DT	O	the	dep	105	SENT_7	[p1l703t2411r835b2489],
6	FDA	NNP	ORGANIZATION	FDA	dep	105	SENT_7	[p1l864t2418r1055b2489],
7	concluded	VBD	O	conclude	dep	105	SENT_7	[p1l1082t2411r1529b2490],
8	that	IN	O	that	dep	105	SENT_7	[p1l1559t2411r1730b2489],
9	the	DT	O	the	dep	105	SENT_7	[p1l1755t2411r1887b2489],
10	“	CD	NUMBER	“	dep	105	SENT_7	[p1l1921t2411r2150b2490],
11	data	NNS	O	datum	dep	105	SENT_7	[p1l1921t2411r2150b2490],
12	and	CC	O	and	dep	105	SENT_7	[p1l11t2539r170b2618],
13	results	NNS	O	result	dep	105	SENT_7	[p1l196t2539r481b2619],
14	of	IN	O	of	dep	105	SENT_7	[p1l510t2538r612b2618],
15	the	DT	O	the	dep	105	SENT_7	[p1l620t2539r752b2618],
16	one	CD	NUMBER	one	dep	105	SENT_7	[p1l779t2565r960b2636],
17	,	,	O	,	_	0	SENT_7	[p1l779t2565r960b2636],
18	small	JJ	O	small	dep	105	SENT_7	[p1l993t2539r1251b2636],
19	,	,	O	,	_	0	SENT_7	[p1l993t2539r1251b2636],
20	single-arm	JJ	O	single-arm	dep	105	SENT_7	[p1l1283t2539r1777b2641],
21	,	,	O	,	_	0	SENT_7	[p1l1283t2539r1777b2641],
22	phase	NN	O	phase	dep	105	SENT_7	[p1l1807t2539r2060b2640],
23	II	CD	NUMBER	ii	dep	105	SENT_7	[p1l2084t2547r2149b2617],
24	study	NN	O	study	dep	105	SENT_7	[p1l13t2668r245b2768],
25	do	VBP	O	do	dep	105	SENT_7	[p1l274t2668r379b2747],
26	not	RB	O	not	dep	105	SENT_7	[p1l414t2685r561b2747],
27	support	VB	O	support	dep	105	SENT_7	[p1l591t2685r932b2768],
28	the	DT	O	the	dep	105	SENT_7	[p1l961t2668r1093b2746],
29	sponsor	NN	O	sponsor	dep	105	SENT_7	[p1l1129t2674r1549b2768],
30	’s	POS	O	’s	dep	105	SENT_7	[p1l1129t2674r1549b2768],
31	claim	NN	O	claim	dep	105	SENT_7	[p1l1587t2668r1821b2746],
32	of	IN	O	of	dep	105	SENT_7	[p1l1856t2667r1958b2747],
33	efficacy	NN	O	efficacy	dep	105	SENT_7	[p1l1974t2667r2147b2746, p1l12t2802r258b2896],
34	,	,	O	,	_	0	SENT_7	[p1l1974t2667r2147b2746, p1l12t2802r258b2896],
35	”	NN	O	”	dep	105	SENT_7	[p1l1974t2667r2147b2746, p1l12t2802r258b2896],
36	and	CC	O	and	dep	105	SENT_7	[p1l295t2796r454b2874],
37	Public	NN	ORGANIZATION	public	dep	105	SENT_7	[p1l485t2796r754b2875],
38	Citizen	NNP	ORGANIZATION	Citizen	dep	105	SENT_7	[p1l787t2797r1118b2892],
39	,	,	O	,	_	0	SENT_7	[p1l787t2797r1118b2892],
40	a	DT	O	a	dep	105	SENT_7	[p1l1156t2822r1200b2874],
41	nonprofit	JJ	O	nonprofit	dep	105	SENT_7	[p1l1232t2795r1653b2896],
42	consumeradvocacy	NN	O	consumeradvocacy	dep	105	SENT_7	[p1l1682t2822r2147b2875, p1l11t2924r400b3024],
43	organization	NN	O	organization	dep	105	SENT_7	[p1l436t2925r1015b3025],
44	,	,	O	,	_	0	SENT_7	[p1l436t2925r1015b3025],
45	admonished	VBD	O	admonish	dep	105	SENT_7	[p1l1059t2924r1599b3003],
46	the	DT	O	the	dep	105	SENT_7	[p1l1639t2924r1771b3002],
47	FDA	NNP	ORGANIZATION	FDA	dep	105	SENT_7	[p1l1809t2930r2022b3020],
48	,	,	O	,	_	0	SENT_7	[p1l1809t2930r2022b3020],
49	in	IN	O	in	dep	105	SENT_7	[p1l2066t2925r2148b3001],
50	part	NN	O	part	dep	105	SENT_7	[p1l10t3069r207b3153],
51	,	,	O	,	_	0	SENT_7	[p1l10t3069r207b3153],
52	for	IN	O	for	dep	105	SENT_7	[p1l238t3051r364b3132],
53	approving	VBG	O	approve	dep	105	SENT_7	[p1l385t3053r829b3154],
54	a	DT	O	a	dep	105	SENT_7	[p1l850t3078r895b3131],
55	drug	NN	O	drug	dep	105	SENT_7	[p1l918t3052r1122b3154],
56	that	WDT	O	that	dep	105	SENT_7	[p1l1145t3052r1316b3131],
57	produced	VBD	O	produce	dep	105	SENT_7	[p1l1334t3052r1745b3153],
58	objective	JJ	O	objective	dep	105	SENT_7	[p1l1771t3052r2148b3153],
59	responses	NNS	O	response	dep	105	SENT_7	[p1l12t3207r443b3281],
60	in	IN	O	in	dep	105	SENT_7	[p1l474t3182r558b3258],
61	only	RB	O	only	dep	105	SENT_7	[p1l588t3181r773b3281],
62	10	CD	NUMBER	10	dep	105	SENT_7	[p1l802t3187r900b3260],
63	to	TO	O	to	dep	105	SENT_7	[p1l931t3198r1012b3260],
64	15	CD	PERCENT	15	dep	105	SENT_7	[p1l1046t3187r1142b3260],
65	percent	NN	PERCENT	percent	dep	105	SENT_7	[p1l1174t3198r1503b3281],
66	of	IN	O	of	dep	105	SENT_7	[p1l1528t3180r1630b3260],
67	the	DT	O	the	dep	105	SENT_7	[p1l1641t3181r1774b3259],
68	patients	NNS	O	patient	dep	105	SENT_7	[p1l1802t3182r2147b3281],
69	who	WP	O	who	dep	105	SENT_7	[p1l7t3309r194b3388],
70	took	VBD	O	take	dep	105	SENT_7	[p1l226t3309r423b3388],
71	it	PRP	O	it	dep	105	SENT_7	[p1l448t3304r643b3387],
72	.1	NN	NUMBER	.1	dep	105	SENT_7	[p1l448t3304r643b3387],
73	‘	CD	NUMBER	‘	dep	105	SENT_7	[p1l448t3304r643b3387],
74	3	CD	NUMBER	3	dep	105	SENT_7	[p1l448t3304r643b3387],
75	Observers	NNS	O	observer	dep	105	SENT_7	[p1l675t3309r1105b3388],
76	in	IN	O	in	dep	105	SENT_7	[p1l1136t3310r1220b3386],
77	the	DT	O	the	dep	105	SENT_7	[p1l1250t3309r1382b3387],
78	medical	JJ	O	medical	dep	105	SENT_7	[p1l1413t3309r1753b3388],
79	community	NN	O	community	dep	105	SENT_7	[p1l1783t3335r2147b3388, p1l12t3439r175b3538],
80	also	RB	O	also	dep	105	SENT_7	[p1l203t3438r374b3517],
81	criticized	VBD	O	criticize	dep	105	SENT_7	[p1l409t3438r807b3517],
82	the	DT	O	the	dep	105	SENT_7	[p1l840t3438r973b3516],
83	study	NN	O	study	dep	105	SENT_7	[p1l1008t3438r1239b3538],
84	sponsor	NN	O	sponsor	dep	105	SENT_7	[p1l1269t3464r1638b3538],
85	,	,	O	,	_	0	SENT_7	[p1l1269t3464r1638b3538],
86	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	dep	105	SENT_7	[p1l1673t3445r2147b3516, p1l12t3592r125b3663],
87	,	,	O	,	_	0	SENT_7	[p1l1673t3445r2147b3516, p1l12t3592r125b3663],
88	for	IN	O	for	dep	105	SENT_7	[p1l167t3565r293b3645],
89	failing	VBG	O	fail	dep	105	SENT_7	[p1l325t3565r608b3668],
90	to	TO	O	to	dep	105	SENT_7	[p1l641t3583r721b3646],
91	deﬁne	VB	O	deﬁne	dep	105	SENT_7	[p1l760t3565r1026b3646],
92	the	DT	O	the	dep	105	SENT_7	[p1l1063t3566r1195b3645],
93	subgroup	NN	O	subgroup	dep	105	SENT_7	[p1l1233t3566r1646b3668],
94	of	IN	O	of	dep	105	SENT_7	[p1l1684t3565r1786b3645],
95	patients	NNS	O	patient	dep	105	SENT_7	[p1l1802t3567r2146b3667],
96	with	IN	O	with	dep	105	SENT_7	[p1l7t3695r201b3774],
97	lung	NN	O	lung	dep	105	SENT_7	[p1l230t3695r428b3796],
98	cancer	NN	O	cancer	dep	105	SENT_7	[p1l456t3721r738b3773],
99	in	IN	O	in	dep	105	SENT_7	[p1l764t3696r847b3772],
100	whom	WP	O	whom	dep	105	SENT_7	[p1l873t3695r1149b3774],
101	the	DT	O	the	dep	105	SENT_7	[p1l1180t3695r1312b3773],
102	drug	NN	O	drug	dep	105	SENT_7	[p1l1343t3695r1547b3796],
103	worked	VBD	O	work	dep	105	SENT_7	[p1l1569t3690r1968b3774],
104	.4	CD	NUMBER	.4	dep	105	SENT_7	[p1l1569t3690r1968b3774],
105	Despite	IN	O	despite	_	0	SENT_7	[p1l1996t3701r2147b3773, p2l13t22r216b121],

1	these	DT	O	these	det	2	SENT_8	[p2l244t21r468b99],
2	concerns	NNS	O	concern	nsubj	56	SENT_8	[p2l495t47r910b117],
3	,	,	O	,	_	0	SENT_8	[p2l495t47r910b117],
4	the	DT	O	the	det	5	SENT_8	[p2l943t21r1074b99],
5	FDA	NNP	ORGANIZATION	FDA	nsubj	6	SENT_8	[p2l1100t27r1291b99],
6	used	VBD	O	use	parataxis	56	SENT_8	[p2l1314t21r1513b100],
7	its	PRP$	O	its	poss	10	SENT_8	[p2l1539t22r1638b99],
8	accelerated	VBN	O	accelerate	amod	10	SENT_8	[p2l1665t21r2148b100],
9	approval	NN	O	approval	nn	10	SENT_8	[p2l11t149r386b250],
10	mechanism	NN	O	mechanism	dobj	6	SENT_8	[p2l426t149r932b228],
11	to	TO	O	to	aux	12	SENT_8	[p2l973t166r1054b228],
12	approve	VB	O	approve	xcomp	6	SENT_8	[p2l1095t175r1439b250],
13	geﬁtinib	NN	O	geﬁtinib	dobj	12	SENT_8	[p2l1479t148r1845b251],
14	as	IN	O	as	_	0	SENT_8	[p2l1887t175r1973b228],
15	the	DT	O	the	det	16	SENT_8	[p2l2016t149r2148b228],
16	ﬁrst	NN	O	ﬁrst	prep_as	12	SENT_8	[p2l12t277r190b357],
17	molecularly	RB	O	molecularly	advmod	18	SENT_8	[p2l215t278r726b379],
18	targeted	VBN	O	target	partmod	16	SENT_8	[p2l752t278r1108b380],
19	treatment	NN	O	treatment	dobj	18	SENT_8	[p2l1138t295r1564b357],
20	for	IN	O	for	_	0	SENT_8	[p2l1588t277r1714b358],
21	lung	NN	O	lung	nn	22	SENT_8	[p2l1740t278r1939b380],
22	cancer	NN	O	cancer	prep_for	19	SENT_8	[p2l1966t304r2147b357, p2l12t433r158b503],
23	,	,	O	,	_	0	SENT_8	[p2l1966t304r2147b357, p2l12t433r158b503],
24	an	DT	O	a	det	25	SENT_8	[p2l205t433r307b485],
25	approval	NN	O	approval	conj_and	19	SENT_8	[p2l348t407r723b507],
26	that	WDT	O	that	nsubjpass	29	SENT_8	[p2l765t407r935b485],
27	was	VBD	O	be	auxpass	29	SENT_8	[p2l968t433r1132b486],
28	strongly	RB	O	strongly	advmod	29	SENT_8	[p2l1177t407r1534b508],
29	supported	VBN	O	support	rcmod	25	SENT_8	[p2l1572t407r2012b507],
30	by	IN	O	by	_	0	SENT_8	[p2l2054t407r2153b507],
31	patient	NN	O	patient	nn	32	SENT_8	[p2l10t536r309b635],
32	advocates	NNS	O	advocate	agent	29	SENT_8	[p2l329t530r800b631],
33	,5	CD	NUMBER	,5	dep	32	SENT_8	[p2l329t530r800b631],
34	most	RBS	O	most	advmod	35	SENT_8	[p2l829t552r1045b614],
35	oncologists	NNS	O	oncologist	xcomp	29	SENT_8	[p2l1065t535r1574b636],
36	,	,	O	,	_	0	SENT_8	[p2l1065t535r1574b636],
37	and	CC	O	and	_	0	SENT_8	[p2l1605t535r1760b614],
38	the	DT	O	the	det	40	SENT_8	[p2l1786t535r1914b613],
39	business	NN	O	business	nn	40	SENT_8	[p2l1940t535r2148b614, p2l12t689r194b742],
40	community	NN	O	community	conj_and	19	SENT_8	[p2l220t657r778b764],
41	.6	CD	NUMBER	.6	nsubj	49	SENT_8	[p2l220t657r778b764],
42	In	IN	O	in	_	0	SENT_8	[p2l801t671r890b741],
43	some	DT	O	some	det	44	SENT_8	[p2l915t689r1144b743],
44	patients	NNS	O	patient	prep_in	41	SENT_8	[p2l1166t665r1538b764],
45	,	,	O	,	_	0	SENT_8	[p2l1166t665r1538b764],
46	the	DT	O	the	det	47	SENT_8	[p2l1568t663r1700b742],
47	drug	NN	O	drug	appos	44	SENT_8	[p2l1725t663r1929b765],
48	does	VBZ	O	do	aux	49	SENT_8	[p2l1950t663r2146b743],
49	have	VB	O	have	rcmod	40	SENT_8	[p2l12t792r201b872],
50	a	DT	O	a	det	52	SENT_8	[p2l230t818r275b871],
51	dramatic	JJ	O	dramatic	amod	52	SENT_8	[p2l304t792r676b871],
52	beneﬁt	NN	O	beneﬁt	dobj	49	SENT_8	[p2l705t791r1018b889],
53	,	,	O	,	_	0	SENT_8	[p2l705t791r1018b889],
54	the	DT	O	the	det	55	SENT_8	[p2l1054t792r1183b871],
55	advocates	NNS	O	advocate	nsubj	56	SENT_8	[p2l1212t792r1616b872],
56	argued	VBD	O	argue	_	0	SENT_8	[p2l1647t792r1960b894],
57	,	,	O	,	_	0	SENT_8	[p2l1647t792r1960b894],
58	and	CC	O	and	_	0	SENT_8	[p2l1994t792r2150b871],
59	these	DT	O	these	det	60	SENT_8	[p2l12t922r232b1000],
60	patients	NNS	O	patient	nsubj	61	SENT_8	[p2l257t923r602b1022],
61	have	VBP	O	have	conj_and	56	SENT_8	[p2l631t922r824b1001],
62	no	DT	O	no	det	64	SENT_8	[p2l852t948r959b1001],
63	other	JJ	O	other	amod	64	SENT_8	[p2l988t922r1218b1001],
64	options	NNS	O	option	dobj	61	SENT_8	[p2l1243t923r1596b1022],
65	.	.	O	.	_	0	SENT_8	[p2l1243t923r1596b1022],

1	The	DT	O	the	det	2	SENT_9	[p2l138t1050r302b1129],
2	approval	NN	O	approval	nsubj	7	SENT_9	[p2l347t1050r721b1151],
3	of	IN	O	of	_	0	SENT_9	[p2l767t1049r869b1129],
4	geﬁtinib	NN	O	geﬁtinib	prep_of	2	SENT_9	[p2l895t1049r1261b1152],
5	not	RB	O	not	dep	6	SENT_9	[p2l1308t1067r1455b1129],
6	only	RB	O	only	advmod	7	SENT_9	[p2l1495t1050r1681b1151],
7	illustrates	VBZ	O	illustrate	_	0	SENT_9	[p2l1721t1050r2147b1130],
8	the	DT	O	the	det	9	SENT_9	[p2l12t1179r144b1257],
9	scrutiny	NN	O	scrutiny	dobj	7	SENT_9	[p2l173t1180r521b1279],
10	that	IN	O	that	complm	15	SENT_9	[p2l544t1179r713b1257],
11	a	DT	O	a	det	12	SENT_9	[p2l733t1205r777b1257],
12	myriad	JJ	O	myriad	nsubj	15	SENT_9	[p2l800t1179r1095b1279],
13	of	IN	O	of	_	0	SENT_9	[p2l1121t1178r1222b1258],
14	stakeholders	NNS	O	stakeholder	prep_of	12	SENT_9	[p2l1230t1179r1770b1258],
15	place	VBP	O	place	ccomp	7	SENT_9	[p2l1796t1179r2017b1279],
16	on	IN	O	on	_	0	SENT_9	[p2l2043t1205r2149b1258],
17	contemporary	JJ	O	contemporary	amod	19	SENT_9	[p2l12t1324r611b1407],
18	FDA	NNP	ORGANIZATION	FDA	nn	19	SENT_9	[p2l634t1313r823b1385],
19	reviews	NNS	O	review	prep_on	15	SENT_9	[p2l848t1308r1187b1402],
20	;	:	O	;	_	0	SENT_9	[p2l848t1308r1187b1402],
21	it	PRP	O	it	nsubj	23	SENT_9	[p2l1218t1308r1279b1385],
22	also	RB	O	also	advmod	23	SENT_9	[p2l1301t1307r1470b1386],
23	highlights	VBZ	O	highlight	parataxis	7	SENT_9	[p2l1500t1307r1935b1408],
24	substantive	JJ	O	substantive	amod	25	SENT_9	[p2l1967t1307r2148b1386, p2l13t1436r338b1514],
25	changes	NNS	O	change	dobj	23	SENT_9	[p2l364t1435r708b1536],
26	in	IN	O	in	_	0	SENT_9	[p2l734t1436r816b1512],
27	FDA	NNP	ORGANIZATION	FDA	nn	28	SENT_9	[p2l839t1441r1028b1513],
28	policy	NN	O	policy	prep_in	25	SENT_9	[p2l1047t1435r1304b1535],
29	that	WDT	O	that	nsubj	30	SENT_9	[p2l1324t1435r1492b1513],
30	warrant	VBP	O	warrant	rcmod	25	SENT_9	[p2l1506t1452r1844b1514],
31	examination	NN	O	examination	dobj	30	SENT_9	[p2l1863t1436r2148b1513, p2l12t1565r308b1643],
32	.	.	O	.	_	0	SENT_9	[p2l1863t1436r2148b1513, p2l12t1565r308b1643],

1	Had	VBD	O	have	aux	3	SENT_10	[p2l342t1564r520b1643],
2	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	nsubj	3	SENT_10	[p2l546t1571r1071b1642],
3	submitted	VBD	O	submit	dep	23	SENT_10	[p2l1100t1564r1530b1643],
4	the	DT	O	the	det	6	SENT_10	[p2l1560t1564r1690b1642],
5	same	JJ	O	same	amod	6	SENT_10	[p2l1722t1590r1939b1642],
6	data	NNS	O	datum	dobj	3	SENT_10	[p2l1971t1564r2151b1643],
7	to	TO	O	to	_	0	SENT_10	[p2l12t1709r92b1772],
8	the	DT	O	the	det	9	SENT_10	[p2l124t1692r256b1771],
9	FDA	NNP	ORGANIZATION	FDA	prep_to	3	SENT_10	[p2l286t1699r477b1771],
10	for	IN	O	for	_	0	SENT_10	[p2l504t1691r630b1772],
11	consideration	NN	O	consideration	prep_for	3	SENT_10	[p2l659t1692r1255b1771],
12	15	CD	DATE	15	num	13	SENT_10	[p2l1289t1698r1385b1772],
13	years	NNS	DATE	year	npadvmod	14	SENT_10	[p2l1414t1718r1634b1793],
14	ago	RB	DATE	ago	advmod	3	SENT_10	[p2l1666t1718r1845b1794],
15	,	,	O	,	_	0	SENT_10	[p2l1666t1718r1845b1794],
16	its	PRP$	O	its	poss	17	SENT_10	[p2l1881t1693r1980b1771],
17	application	NN	O	application	nsubjpass	23	SENT_10	[p2l2013t1718r2147b1793, p2l10t1822r392b1922],
18	almost	RB	O	almost	advmod	19	SENT_10	[p2l423t1822r717b1901],
19	certainly	RB	O	certainly	advmod	23	SENT_10	[p2l745t1822r1111b1922],
20	would	MD	O	would	aux	23	SENT_10	[p2l1134t1822r1402b1901],
21	have	VB	O	have	aux	23	SENT_10	[p2l1434t1822r1623b1901],
22	been	VBN	O	be	auxpass	23	SENT_10	[p2l1656t1822r1856b1901],
23	rejected	VBN	O	reject	_	0	SENT_10	[p2l1889t1823r2148b1922, p2l12t1950r132b2029],
24	.	.	O	.	_	0	SENT_10	[p2l1889t1823r2148b1922, p2l12t1950r132b2029],

1	Even	RB	O	even	advmod	6	SENT_11	[p2l164t1958r366b2030],
2	if	IN	O	if	dep	6	SENT_11	[p2l392t1949r468b2028],
3	the	DT	O	the	det	4	SENT_11	[p2l477t1950r607b2029],
4	FDA	NNP	ORGANIZATION	FDA	nsubj	6	SENT_11	[p2l633t1957r822b2029],
5	had	VBD	O	have	aux	6	SENT_11	[p2l846t1950r1003b2029],
6	granted	VBN	O	grant	advcl	13	SENT_11	[p2l1029t1950r1356b2052],
7	approval	NN	O	approval	dobj	6	SENT_11	[p2l1382t1950r1772b2051],
8	,	,	O	,	_	0	SENT_11	[p2l1382t1950r1772b2051],
9	it	PRP	O	it	nsubjpass	13	SENT_11	[p2l1805t1951r1865b2029],
10	would	MD	O	would	aux	13	SENT_11	[p2l1883t1950r2149b2030],
11	have	VB	O	have	aux	13	SENT_11	[p2l12t2079r203b2158],
12	been	VBN	O	be	auxpass	13	SENT_11	[p2l250t2079r454b2158],
13	delayed	VBN	O	delay	_	0	SENT_11	[p2l500t2079r824b2179],
14	by	IN	O	by	_	0	SENT_11	[p2l869t2079r968b2179],
15	several	JJ	DURATION	several	amod	16	SENT_11	[p2l1010t2079r1303b2158],
16	years	NNS	DURATION	year	agent	13	SENT_11	[p2l1344t2105r1564b2179],
17	pending	VBG	O	pend	_	0	SENT_11	[p2l1610t2079r1973b2180],
18	the	DT	O	the	det	19	SENT_11	[p2l2016t2079r2148b2157],
19	completion	NN	O	completion	prep_pending	16	SENT_11	[p2l12t2207r507b2307],
20	of	IN	O	of	_	0	SENT_11	[p2l539t2206r641b2286],
21	additional	JJ	O	additional	amod	23	SENT_11	[p2l652t2207r1092b2286],
22	clinical	JJ	O	clinical	amod	23	SENT_11	[p2l1123t2207r1434b2285],
23	trials	NNS	O	trial	prep_of	19	SENT_11	[p2l1465t2207r1705b2285],
24	.	.	O	.	_	0	SENT_11	[p2l1465t2207r1705b2285],

1	What	WDT	O	what	nsubj	3	SENT_12	[p2l1738t2207r1977b2285],
2	has	VBZ	O	have	aux	3	SENT_12	[p2l2002t2207r2147b2285],
3	changed	VBN	O	change	_	0	SENT_12	[p2l11t2333r415b2437],
4	?	.	O	?	_	0	SENT_12	[p2l11t2333r415b2437],

1	The	DT	O	the	det	2	SENT_13	[p2l442t2335r604b2414],
2	FDA	NNP	ORGANIZATION	FDA	nsubj	4	SENT_13	[p2l633t2342r821b2414],
3	has	VBZ	O	have	aux	4	SENT_13	[p2l848t2335r990b2414],
4	introduced	VBN	O	introduce	_	0	SENT_13	[p2l1021t2335r1485b2415],
5	a	DT	O	a	det	6	SENT_13	[p2l1513t2362r1558b2414],
6	series	NN	O	series	dobj	4	SENT_13	[p2l1588t2337r1825b2414],
7	of	IN	O	of	_	0	SENT_13	[p2l1857t2334r1958b2415],
8	programs	NNS	O	program	prep_of	6	SENT_13	[p2l1968t2361r2147b2436, p2l10t2490r297b2566],
9	,	,	O	,	_	0	SENT_13	[p2l1968t2361r2147b2436, p2l10t2490r297b2566],
10	grouped	VBN	O	group	dep	4	SENT_13	[p2l326t2464r677b2566],
11	under	IN	O	under	_	0	SENT_13	[p2l700t2464r947b2544],
12	the	DT	O	the	det	15	SENT_13	[p2l969t2464r1098b2543],
13	fast	JJ	O	fast	amod	15	SENT_13	[p2l1121t2463r1518b2544],
14	—	NN	O	—	nn	15	SENT_13	[p2l1121t2463r1518b2544],
15	tracl	NN	O	tracl	prep_under	10	SENT_13	[p2l1121t2463r1518b2544],
16	<	JJR	O	<	amod	17	SENT_13	[p2l1121t2463r1518b2544],
17	rubric	NN	O	rubric	tmod	15	SENT_13	[p2l1538t2464r1811b2561],
18	,	,	O	,	_	0	SENT_13	[p2l1538t2464r1811b2561],
19	that	WDT	O	that	nsubjpass	21	SENT_13	[p2l1840t2464r2005b2543],
20	are	VBP	O	be	auxpass	21	SENT_13	[p2l2024t2490r2149b2543],
21	designed	VBN	O	design	rcmod	17	SENT_13	[p2l11t2593r391b2695],
22	to	TO	O	to	aux	23	SENT_13	[p2l425t2610r504b2673],
23	shorten	VB	O	shorten	ccomp	21	SENT_13	[p2l540t2593r863b2672],
24	review	NN	O	review	nn	25	SENT_13	[p2l896t2594r1169b2673],
25	times	NNS	O	time	dobj	23	SENT_13	[p2l1199t2594r1429b2672],
26	and	CC	O	and	_	0	SENT_13	[p2l1464t2593r1620b2672],
27	to	TO	O	to	aux	28	SENT_13	[p2l1654t2610r1733b2672],
28	allow	VB	O	allow	ccomp	21	SENT_13	[p2l1767t2593r1999b2673],
29	for	IN	O	for	_	0	SENT_13	[p2l2027t2592r2151b2672],
30	approvals	NNS	O	approval	prep_for	28	SENT_13	[p2l10t2722r425b2823],
31	at	IN	O	at	_	0	SENT_13	[p2l456t2739r537b2801],
32	much	RB	O	much	advmod	34	SENT_13	[p2l561t2722r806b2802],
33	earlier	JJR	O	earlier	amod	34	SENT_13	[p2l837t2722r1112b2801],
34	stages	NNS	O	stage	prep_at	30	SENT_13	[p2l1140t2739r1407b2824],
35	of	IN	O	of	_	0	SENT_13	[p2l1439t2721r1542b2802],
36	clinical	JJ	O	clinical	amod	37	SENT_13	[p2l1553t2722r1864b2801],
37	development	NN	O	development	prep_of	34	SENT_13	[p2l1893t2722r2145b2802, p2l11t2868r371b2951],
38	,	,	O	,	_	0	SENT_13	[p2l1893t2722r2145b2802, p2l11t2868r371b2951],
39	thereby	RB	O	thereby	advmod	40	SENT_13	[p2l407t2851r731b2951],
40	addressing	VBG	O	address	xcomp	4	SENT_13	[p2l757t2851r1237b2952],
41	two	CD	NUMBER	two	num	43	SENT_13	[p2l1265t2868r1420b2930],
42	major	JJ	O	major	amod	43	SENT_13	[p2l1452t2852r1706b2951],
43	problems	NNS	O	problem	dobj	40	SENT_13	[p2l1733t2851r2145b2951],
44	in	IN	O	in	_	0	SENT_13	[p2l10t2980r93b3057],
45	the	DT	O	the	det	46	SENT_13	[p2l130t2979r262b3058],
46	development	NN	O	development	prep_in	40	SENT_13	[p2l300t2979r864b3080],
47	of	IN	O	of	_	0	SENT_13	[p2l896t2978r998b3059],
48	drugs	NNS	O	drug	prep_of	46	SENT_13	[p2l1017t2979r1287b3081],
49	.	.	O	.	_	0	SENT_13	[p2l1017t2979r1287b3081],

1	The	DT	O	the	det	2	SENT_14	[p2l1326t2979r1491b3058],
2	effect	NN	O	effect	nsubj	19	SENT_14	[p2l1529t2978r1769b3058],
3	of	IN	O	of	_	0	SENT_14	[p2l1802t2978r1904b3058],
4	these	DT	O	these	det	5	SENT_14	[p2l1923t2979r2147b3058],
5	programs	NNS	O	program	prep_of	2	SENT_14	[p2l9t3134r458b3209],
6	,	,	O	,	_	0	SENT_14	[p2l9t3134r458b3209],
7	which	WDT	O	which	nsubj	9	SENT_14	[p2l496t3108r762b3187],
8	have	VBP	O	have	aux	9	SENT_14	[p2l799t3108r992b3187],
9	provided	VBN	O	provide	rcmod	2	SENT_14	[p2l1027t3108r1409b3208],
10	earlier	RBR	O	earlier	advmod	9	SENT_14	[p2l1447t3108r1722b3186],
11	access	NN	O	access	pobj	10	SENT_14	[p2l1755t3134r2026b3186],
12	to	TO	O	to	_	0	SENT_14	[p2l2065t3125r2145b3187],
13	new	JJ	O	new	amod	14	SENT_14	[p2l11t3262r188b3315],
14	drugs	NNS	O	drug	prep_to	9	SENT_14	[p2l207t3236r468b3337],
15	,	,	O	,	_	0	SENT_14	[p2l207t3236r468b3337],
16	has	VBZ	O	have	aux	19	SENT_14	[p2l496t3236r637b3314],
17	been	VBN	O	be	cop	19	SENT_14	[p2l663t3236r862b3315],
18	mostly	RB	O	mostly	advmod	19	SENT_14	[p2l883t3236r1169b3336],
19	salutary	JJ	O	salutary	_	0	SENT_14	[p2l1188t3236r1530b3336],
20	.	.	O	.	_	0	SENT_14	[p2l1188t3236r1530b3336],

1	The	DT	O	the	det	2	SENT_15	[p2l1554t3236r1716b3314],
2	programs	NNS	O	program	nsubj	5	SENT_15	[p2l1736t3262r2147b3337],
3	have	VBP	O	have	aux	5	SENT_15	[p2l11t3364r204b3443],
4	also	RB	O	also	advmod	5	SENT_15	[p2l236t3364r407b3443],
5	demonstrated	VBN	O	demonstrate	_	0	SENT_15	[p2l442t3364r1044b3443],
6	the	DT	O	the	det	7	SENT_15	[p2l1077t3364r1209b3442],
7	ﬂexibility	NN	O	ﬂexibility	dobj	5	SENT_15	[p2l1243t3363r1650b3464],
8	of	IN	O	of	_	0	SENT_15	[p2l1679t3363r1781b3443],
9	the	DT	O	the	det	10	SENT_15	[p2l1796t3364r1928b3442],
10	FDA	NNP	ORGANIZATION	FDA	prep_of	7	SENT_15	[p2l1959t3371r2150b3442],
11	in	IN	O	in	_	0	SENT_15	[p2l10t3493r93b3569],
12	adapting	VBG	O	adapt	prepc_in	5	SENT_15	[p2l136t3492r520b3593],
13	and	CC	O	and	_	0	SENT_15	[p2l560t3492r719b3571],
14	reacting	VBG	O	react	prepc_in	5	SENT_15	[p2l763t3493r1117b3593],
15	to	TO	O	to	_	0	SENT_15	[p2l1158t3508r1238b3571],
16	public	JJ	O	public	amod	18	SENT_15	[p2l1282t3492r1553b3592],
17	health	NN	O	health	nn	18	SENT_15	[p2l1596t3492r1865b3570],
18	problems	NNS	O	problem	prep_to	12	SENT_15	[p2l1907t3492r2145b3592, p2l10t3620r213b3698],
19	such	JJ	O	such	_	0	SENT_15	[p2l258t3620r457b3699],
20	as	IN	O	as	_	0	SENT_15	[p2l498t3646r584b3698],
21	the	DT	O	the	det	22	SENT_15	[p2l628t3620r760b3698],
22	AIDS	NNP	MISC	AIDS	prep_such_as	18	SENT_15	[p2l798t3626r1021b3699],
23	epidemic	JJ	O	epidemic	amod	22	SENT_15	[p2l1066t3620r1486b3720],
24	.	.	O	.	_	0	SENT_15	[p2l1066t3620r1486b3720],

1	The	DT	O	the	det	4	SENT_16	[p2l1530t3620r1695b3698],
2	fast	JJ	O	fast	amod	4	SENT_16	[p2l1737t3619r2152b3699],
3	—	NN	O	—	nn	4	SENT_16	[p2l1737t3619r2152b3699],
4	tracl	NN	O	tracl	_	0	SENT_16	[p2l1737t3619r2152b3699],
5	<	JJR	O	<	dep	4	SENT_16	[p2l1737t3619r2152b3699],

1	programs	NNS	O	program	nsubj	7	SENT_17	[p3l9t47r444b122],
2	,	,	O	,	_	0	SENT_17	[p3l9t47r444b122],
3	however	RB	O	however	advmod	7	SENT_17	[p3l475t21r842b117],
4	,	,	O	,	_	0	SENT_17	[p3l475t21r842b117],
5	have	VBP	O	have	aux	7	SENT_17	[p3l874t21r1060b100],
6	not	RB	O	not	neg	7	SENT_17	[p3l1086t38r1229b100],
7	addressed	VBN	O	address	_	0	SENT_17	[p3l1248t21r1669b100],
8	an	DT	O	a	det	11	SENT_17	[p3l1694t47r1794b99],
9	increasingly	RB	O	increasingly	advmod	10	SENT_17	[p3l1819t22r2148b99, p3l10t149r223b251],
10	important	JJ	O	important	amod	11	SENT_17	[p3l252t150r689b250],
11	aspect	NN	O	aspect	dobj	7	SENT_17	[p3l716t166r987b250],
12	of	IN	O	of	_	0	SENT_17	[p3l1015t148r1116b228],
13	drug	NN	O	drug	nn	14	SENT_17	[p3l1130t149r1331b251],
14	development	NN	O	development	prep_of	11	SENT_17	[p3l1361t149r1934b250],
15	:	:	O	:	_	0	SENT_17	[p3l1361t149r1934b250],
16	promoting	VBG	O	promote	parataxis	7	SENT_17	[p3l1968t175r2147b250, p3l11t279r324b380],
17	the	DT	O	the	det	18	SENT_17	[p3l354t278r484b357],
18	use	NN	O	use	dobj	16	SENT_17	[p3l517t304r658b358],
19	of	IN	O	of	_	0	SENT_17	[p3l692t277r793b357],
20	targeted	VBN	O	target	amod	21	SENT_17	[p3l808t278r1156b380],
21	drugs	NNS	O	drug	prep_of	18	SENT_17	[p3l1190t278r1429b380],
22	in	IN	O	in	_	0	SENT_17	[p3l1464t279r1546b356],
23	a	DT	O	a	det	26	SENT_17	[p3l1578t304r1622b357],
24	more	RBR	O	more	advmod	25	SENT_17	[p3l1654t304r1875b357],
25	selective	JJ	O	selective	amod	26	SENT_17	[p3l1910t278r2147b357, p3l11t408r153b486],
26	fashion	NN	O	fashion	prep_in	21	SENT_17	[p3l177t406r513b486],
27	.	.	O	.	_	0	SENT_17	[p3l177t406r513b486],

1	In	IN	O	in	_	0	SENT_18	[p3l542t415r628b484],
2	this	DT	O	this	det	3	SENT_18	[p3l653t407r803b485],
3	article	NN	O	article	prep_in	6	SENT_18	[p3l829t407r1106b503],
4	,	,	O	,	_	0	SENT_18	[p3l829t407r1106b503],
5	we	PRP	O	we	nsubj	6	SENT_18	[p3l1131t433r1250b486],
6	discuss	VBP	O	discuss	_	0	SENT_18	[p3l1275t407r1577b486],
7	the	DT	O	the	det	9	SENT_18	[p3l1604t407r1732b485],
8	fast-track	JJ	O	fast-track	amod	9	SENT_18	[p3l1756t406r2153b486],
9	programs	NNS	O	program	dobj	6	SENT_18	[p3l9t561r422b636],
10	and	CC	O	and	_	0	SENT_18	[p3l456t535r612b614],
11	propose	VBP	O	propose	conj_and	6	SENT_18	[p3l643t561r990b635],
12	a	DT	O	a	det	15	SENT_18	[p3l1022t561r1067b613],
13	new	JJ	O	new	amod	15	SENT_18	[p3l1098t561r1274b614],
14	approval	NN	O	approval	nn	15	SENT_18	[p3l1303t535r1670b635],
15	policy	NN	O	policy	dobj	11	SENT_18	[p3l1701t535r1957b635],
16	that	WDT	O	that	nsubj	18	SENT_18	[p3l1986t535r2153b613],
17	would	MD	O	would	aux	18	SENT_18	[p3l6t663r273b742],
18	broaden	VB	O	broaden	rcmod	15	SENT_18	[p3l299t663r649b742],
19	their	PRP$	O	they	poss	20	SENT_18	[p3l674t663r873b741],
20	effect	NN	O	effect	dobj	18	SENT_18	[p3l895t662r1150b741],
21	.	.	O	.	_	0	SENT_18	[p3l895t662r1150b741],

1	THE	DT	O	the	det	3	SENT_19	[p3l655t981r848b1038],
2	FAST	NN	O	fast	nn	3	SENT_19	[p3l908t979r1134b1039],
3	TRACK	NN	O	track	_	0	SENT_19	[p3l1178t979r1494b1039],

1	The	DT	O	the	det	3	SENT_20	[p3l7t1171r172b1250],
2	fast-track	JJ	O	fast-track	amod	3	SENT_20	[p3l204t1170r619b1251],
3	programs	NNS	O	program	nsubj	4	SENT_20	[p3l645t1197r1067b1273],
4	include	VBP	O	include	_	0	SENT_20	[p3l1100t1171r1418b1251],
5	a	DT	O	a	det	6	SENT_20	[p3l1450t1197r1495b1250],
6	series	NN	O	series	dobj	4	SENT_20	[p3l1527t1172r1769b1250],
7	of	IN	O	of	_	0	SENT_20	[p3l1804t1170r1906b1251],
8	regulations	NNS	O	regulation	prep_of	6	SENT_20	[p3l1919t1197r2145b1273, p3l10t1300r293b1379],
9	designed	VBN	O	design	partmod	8	SENT_20	[p3l323t1300r702b1401],
10	to	TO	O	to	aux	11	SENT_20	[p3l729t1316r808b1379],
11	expedite	VB	O	expedite	ccomp	9	SENT_20	[p3l837t1300r1185b1400],
12	the	DT	O	the	det	14	SENT_20	[p3l1213t1300r1342b1378],
13	drug-development	NN	O	drug-development	nn	14	SENT_20	[p3l1370t1300r2152b1401],
14	process	NN	O	process	dobj	11	SENT_20	[p3l9t1455r337b1529],
15	and	CC	O	and	_	0	SENT_20	[p3l372t1429r531b1508],
16	to	TO	O	to	aux	17	SENT_20	[p3l563t1446r644b1508],
17	enhance	VB	O	enhance	conj_and	11	SENT_20	[p3l678t1429r1038b1507],
18	cooperation	NN	O	cooperation	dobj	17	SENT_20	[p3l1071t1430r1591b1529],
19	between	IN	O	between	_	0	SENT_20	[p3l1624t1429r1982b1508],
20	the	DT	O	the	det	21	SENT_20	[p3l2015t1429r2147b1507],
21	FDA	NNP	ORGANIZATION	FDA	prep_between	18	SENT_20	[p3l10t1564r200b1635],
22	and	CC	O	and	_	0	SENT_20	[p3l219t1557r378b1635],
23	the	DT	O	the	det	25	SENT_20	[p3l402t1557r533b1635],
24	pharmaceutical	JJ	O	pharmaceutical	amod	25	SENT_20	[p3l555t1557r1227b1657],
25	industry	NN	O	industry	prep_between	18	SENT_20	[p3l1249t1557r1621b1657],
26	.	.	O	.	_	0	SENT_20	[p3l1249t1557r1621b1657],

1	Many	JJ	O	many	dep	129	SENT_21	[p3l1647t1565r1889b1657],
2	of	IN	O	of	dep	129	SENT_21	[p3l1908t1556r2010b1636],
3	the	DT	O	the	dep	129	SENT_21	[p3l2015t1557r2147b1635],
4	programs	NNS	O	program	dep	129	SENT_21	[p3l9t1711r431b1786],
5	came	VBD	O	come	dep	129	SENT_21	[p3l469t1711r693b1763],
6	into	IN	O	into	dep	129	SENT_21	[p3l729t1686r898b1764],
7	existence	NN	O	existence	dep	129	SENT_21	[p3l936t1686r1331b1763],
8	in	IN	O	in	dep	129	SENT_21	[p3l1366t1686r1450b1762],
9	the	DT	DATE	the	dep	129	SENT_21	[p3l1486t1685r1617b1763],
10	early	JJ	DATE	early	dep	129	SENT_21	[p3l1654t1685r1860b1785],
11	1990s	CD	DATE	1990s	dep	129	SENT_21	[p3l1894t1690r2145b1764],
12	but	CC	O	but	dep	129	SENT_21	[p3l11t1813r155b1892],
13	were	VBD	O	be	dep	129	SENT_21	[p3l181t1839r387b1892],
14	codiﬁed	VBN	O	codiﬁed	dep	129	SENT_21	[p3l423t1812r772b1892],
15	and	CC	O	and	dep	129	SENT_21	[p3l806t1813r964b1892],
16	formalized	VBN	O	formalize	dep	129	SENT_21	[p3l999t1812r1472b1892],
17	under	IN	O	under	dep	129	SENT_21	[p3l1506t1813r1761b1892],
18	the	DT	O	the	dep	129	SENT_21	[p3l1793t1813r1926b1891],
19	FDA	NNP	ORGANIZATION	FDA	dep	129	SENT_21	[p3l1959t1820r2150b1891],
20	Modernization	NNP	O	Modernization	dep	129	SENT_21	[p3l7t1942r654b2021],
21	Act	NNP	O	Act	dep	129	SENT_21	[p3l675t1949r822b2020],
22	in	IN	O	in	dep	129	SENT_21	[p3l841t1943r924b2019],
23	1997.7	CD	NUMBER	1997.7	dep	129	SENT_21	[p3l952t1938r1232b2021],
24	In	IN	O	in	dep	129	SENT_21	[p3l1256t1949r1344b2019],
25	a	DT	O	a	dep	129	SENT_21	[p3l1368t1968r1413b2020],
26	dramatic	JJ	O	dramatic	dep	129	SENT_21	[p3l1436t1942r1819b2021],
27	display	NN	O	display	dep	129	SENT_21	[p3l1844t1942r2152b2042],
28	of	IN	O	of	dep	129	SENT_21	[p3l11t2069r114b2149],
29	political	JJ	O	political	dep	129	SENT_21	[p3l120t2070r458b2170],
30	mobilization	NN	O	mobilization	dep	129	SENT_21	[p3l484t2070r1042b2166],
31	,	,	O	,	_	0	SENT_21	[p3l484t2070r1042b2166],
32	AIDS	NN	O	aid	dep	129	SENT_21	[p3l1071t2076r1287b2149],
33	advocates	NNS	O	advocate	dep	129	SENT_21	[p3l1317t2070r1717b2149],
34	who	WP	O	who	dep	129	SENT_21	[p3l1742t2070r1925b2149],
35	were	VBD	O	be	dep	129	SENT_21	[p3l1949t2096r2149b2149],
36	lobbying	VBG	O	lobby	dep	129	SENT_21	[p3l10t2198r394b2300],
37	for	IN	O	for	dep	129	SENT_21	[p3l429t2197r555b2278],
38	early	JJ	O	early	dep	129	SENT_21	[p3l591t2198r797b2299],
39	access	NN	O	access	dep	129	SENT_21	[p3l830t2224r1100b2277],
40	to	TO	O	to	dep	129	SENT_21	[p3l1142t2215r1222b2278],
41	antiretroviral	JJ	O	antiretroviral	dep	129	SENT_21	[p3l1261t2198r1827b2278],
42	agents	NNS	O	agent	dep	129	SENT_21	[p3l1865t2215r2145b2300],
43	in	IN	O	in	dep	129	SENT_21	[p3l10t2328r93b2404],
44	the	DT	DATE	the	dep	129	SENT_21	[p3l119t2327r251b2405],
45	1980s	CD	DATE	1980s	dep	129	SENT_21	[p3l280t2333r531b2406],
46	provided	VBD	O	provide	dep	129	SENT_21	[p3l557t2327r938b2427],
47	the	DT	O	the	dep	129	SENT_21	[p3l964t2327r1097b2405],
48	initial	JJ	O	initial	dep	129	SENT_21	[p3l1122t2327r1373b2405],
49	impetus	NN	O	impetus	dep	129	SENT_21	[p3l1397t2328r1746b2427],
50	for	IN	O	for	dep	129	SENT_21	[p3l1774t2326r1900b2406],
51	these	DT	O	these	dep	129	SENT_21	[p3l1923t2327r2147b2405],
52	programs	NNS	O	program	dep	129	SENT_21	[p3l9t2481r459b2557],
53	;	:	O	;	_	0	SENT_21	[p3l9t2481r459b2557],
54	they	PRP	O	they	dep	129	SENT_21	[p3l502t2455r682b2556],
55	were	VBD	O	be	dep	129	SENT_21	[p3l711t2481r917b2535],
56	joined	VBN	O	join	dep	129	SENT_21	[p3l941t2455r1222b2556],
57	shortly	RB	O	shortly	dep	129	SENT_21	[p3l1261t2455r1561b2556],
58	thereafter	RB	O	thereafter	dep	129	SENT_21	[p3l1595t2454r2018b2534],
59	by	IN	O	by	dep	129	SENT_21	[p3l2053t2455r2152b2556],
60	advocates	NNS	O	advocate	dep	129	SENT_21	[p3l10t2584r427b2663],
61	from	IN	O	from	dep	129	SENT_21	[p3l461t2583r672b2663],
62	the	DT	O	the	dep	129	SENT_21	[p3l705t2584r837b2662],
63	cancer	NN	O	cancer	dep	129	SENT_21	[p3l869t2610r1152b2662],
64	community	NN	O	community	dep	129	SENT_21	[p3l1182t2585r1692b2684],
65	,	,	O	,	_	0	SENT_21	[p3l1182t2585r1692b2684],
66	especially	RB	O	especially	dep	129	SENT_21	[p3l1731t2584r2152b2684],
67	those	DT	O	those	dep	129	SENT_21	[p3l11t2712r241b2791],
68	concerned	VBN	O	concern	dep	129	SENT_21	[p3l263t2712r699b2791],
69	with	IN	O	with	dep	129	SENT_21	[p3l716t2712r905b2791],
70	breast	NN	O	breast	dep	129	SENT_21	[p3l926t2712r1185b2791],
71	cancer	NN	O	cancer	dep	129	SENT_21	[p3l1202t2707r1536b2791],
72	.8	CD	NUMBER	.8	dep	129	SENT_21	[p3l1202t2707r1536b2791],
73	The	DT	O	the	dep	129	SENT_21	[p3l1554t2712r1716b2790],
74	programs	NNS	O	program	dep	129	SENT_21	[p3l1736t2738r2146b2813],
75	were	VBD	O	be	dep	129	SENT_21	[p3l6t2866r213b2920],
76	not	RB	O	not	dep	129	SENT_21	[p3l249t2857r395b2919],
77	designed	VBN	O	design	dep	129	SENT_21	[p3l426t2840r816b2942],
78	exclusively	RB	O	exclusively	dep	129	SENT_21	[p3l853t2840r1316b2941],
79	to	TO	O	to	dep	129	SENT_21	[p3l1348t2857r1429b2919],
80	beneﬁt	NN	O	beneﬁt	dep	129	SENT_21	[p3l1466t2839r1772b2920],
81	patients	NNS	O	patient	dep	129	SENT_21	[p3l1801t2841r2145b2941],
82	with	IN	O	with	dep	129	SENT_21	[p3l6t2970r200b3049],
83	AIDS	NN	MISC	aid	dep	129	SENT_21	[p3l230t2975r453b3049],
84	or	CC	O	or	dep	129	SENT_21	[p3l490t2996r581b3049],
85	cancer	NN	O	cancer	dep	129	SENT_21	[p3l613t2996r912b3066],
86	,	,	O	,	_	0	SENT_21	[p3l613t2996r912b3066],
87	however	RB	O	however	dep	129	SENT_21	[p3l952t2970r1333b3066],
88	,	,	O	,	_	0	SENT_21	[p3l952t2970r1333b3066],
89	and	CC	O	and	dep	129	SENT_21	[p3l1372t2970r1531b3049],
90	pharmaceutical	JJ	O	pharmaceutical	dep	129	SENT_21	[p3l1563t2970r2145b3070, p3l11t3098r129b3177],
91	sponsors	NNS	O	sponsor	dep	129	SENT_21	[p3l159t3124r550b3199],
92	may	MD	O	may	dep	129	SENT_21	[p3l581t3124r761b3199],
93	apply	VB	O	apply	dep	129	SENT_21	[p3l785t3098r1020b3199],
94	for	IN	O	for	dep	129	SENT_21	[p3l1045t3097r1171b3177],
95	fast-track	JJ	O	fast-track	dep	129	SENT_21	[p3l1196t3097r1612b3178],
96	designation	NN	O	designation	dep	129	SENT_21	[p3l1636t3098r2147b3200],
97	for	IN	O	for	dep	129	SENT_21	[p3l11t3226r136b3307],
98	their	PRP$	O	they	dep	129	SENT_21	[p3l165t3227r367b3306],
99	drugs	NNS	O	drug	dep	129	SENT_21	[p3l396t3227r639b3329],
100	in	IN	O	in	dep	129	SENT_21	[p3l671t3228r754b3305],
101	any	DT	O	any	dep	129	SENT_21	[p3l784t3253r934b3328],
102	therapeutic	JJ	O	therapeutic	dep	129	SENT_21	[p3l961t3227r1450b3328],
103	class	NN	O	class	dep	129	SENT_21	[p3l1481t3227r1685b3306],
104	as	RB	O	as	dep	129	SENT_21	[p3l1717t3253r1803b3306],
105	long	RB	O	long	dep	129	SENT_21	[p3l1835t3227r2033b3329],
106	as	IN	O	as	dep	129	SENT_21	[p3l2059t3253r2145b3306],
107	each	DT	O	each	dep	129	SENT_21	[p3l11t3356r204b3435],
108	drug	NN	O	drug	dep	129	SENT_21	[p3l224t3356r423b3458],
109	is	VBZ	O	be	dep	129	SENT_21	[p3l438t3357r503b3435],
110	intended	VBN	O	intend	dep	129	SENT_21	[p3l524t3356r893b3435],
111	to	TO	O	to	dep	129	SENT_21	[p3l913t3373r992b3435],
112	treat	VB	O	treat	dep	129	SENT_21	[p3l1014t3373r1204b3435],
113	a	DT	O	a	dep	129	SENT_21	[p3l1218t3382r1263b3435],
114	serious	JJ	O	serious	dep	129	SENT_21	[p3l1283t3357r1578b3436],
115	or	CC	O	or	dep	129	SENT_21	[p3l1601t3382r1690b3435],
116	lifethreatening	JJ	O	lifethreatening	dep	129	SENT_21	[p3l1706t3355r2148b3435, p3l11t3486r256b3586],
117	illness	NN	O	illness	dep	129	SENT_21	[p3l278t3485r554b3563],
118	and	CC	O	and	dep	129	SENT_21	[p3l581t3485r740b3564],
119	as	RB	O	as	dep	129	SENT_21	[p3l765t3511r851b3563],
120	long	RB	O	long	dep	129	SENT_21	[p3l878t3485r1076b3586],
121	as	IN	O	as	dep	129	SENT_21	[p3l1098t3511r1183b3563],
122	it	PRP	O	it	dep	129	SENT_21	[p3l1210t3486r1272b3563],
123	addresses	VBZ	O	address	dep	129	SENT_21	[p3l1292t3485r1714b3564],
124	an	DT	O	a	dep	129	SENT_21	[p3l1741t3511r1844b3563],
125	unmet	JJ	O	unmet	dep	129	SENT_21	[p3l1869t3502r2152b3564],
126	need	NN	O	need	dep	129	SENT_21	[p3l11t3613r215b3692],
127	for	IN	O	for	dep	129	SENT_21	[p3l242t3612r368b3692],
128	new	JJ	O	new	dep	129	SENT_21	[p3l393t3639r572b3692],
129	therapy	NN	O	therapy	_	0	SENT_21	[p3l595t3613r933b3713],
130	.	.	O	.	_	0	SENT_21	[p3l595t3613r933b3713],

1	From	IN	O	from	_	0	SENT_22	[p4l139t29r372b100],
2	an	DT	O	a	det	4	SENT_22	[p4l420t47r522b99],
3	industry	NN	O	industry	nn	4	SENT_22	[p4l569t21r929b121],
4	perspective	NN	O	perspective	prep_from	8	SENT_22	[p4l970t22r1483b121],
5	,	,	O	,	_	0	SENT_22	[p4l970t22r1483b121],
6	fast	JJ	O	fast	amod	7	SENT_22	[p4l1536t20r1696b99],
7	track	NN	O	track	nsubj	8	SENT_22	[p4l1739t21r1957b100],
8	has	VBZ	O	have	_	0	SENT_22	[p4l2001t21r2145b99],
9	three	CD	NUMBER	three	num	11	SENT_22	[p4l11t149r224b227],
10	major	JJ	O	major	amod	11	SENT_22	[p4l252t150r500b249],
11	advantages	NNS	O	advantage	dobj	8	SENT_22	[p4l524t149r1015b250],
12	.	.	O	.	_	0	SENT_22	[p4l524t149r1015b250],

1	First	RB	ORDINAL	first	advmod	4	SENT_23	[p4l1047t150r1258b245],
2	,	,	O	,	_	0	SENT_23	[p4l1047t150r1258b245],
3	sponsors	NNS	O	sponsor	nsubj	4	SENT_23	[p4l1293t175r1673b249],
4	enjoy	VBP	O	enjoy	_	0	SENT_23	[p4l1704t150r1926b249],
5	closENGLJ	NN	O	closenglj	dobj	4	SENT_23	[p4l1950t149r2148b228, p4l554t326r638b348],

1	MED	NN	O	med	_	0	SENT_24	[p4l653t327r706b342],
2	351	CD	NUMBER	351	num	1	SENT_24	[p4l718t326r778b348],
3	;	:	O	;	_	0	SENT_24	[p4l718t326r778b348],
4	5	CD	NUMBER	5	num	6	SENT_24	[p4l718t326r778b348],
5	WWW.NEjM.ORG	NN	O	www.nejm.org	nn	6	SENT_24	[p4l813t326r1024b348],
6	ULY	NN	O	uly	dep	1	SENT_24	[p4l1073t327r1118b342],
7	29	CD	NUMBER	29	dep	6	SENT_24	[p4l1130t326r1168b348],
8	,	,	O	,	_	0	SENT_24	[p4l1130t326r1168b348],
9	2004	CD	DATE	2004	num	10	SENT_24	[p4l1181t326r1249b348],
10	501	CD	NUMBER	501	appos	7	SENT_24	[p4l1960t325r2016b347],

1	The	DT	O	the	det	6	SENT_25	[p4l702t359r753b382],
2	New	NNP	O	New	nn	6	SENT_25	[p4l762t360r824b382],
3	England	NNP	O	England	nn	6	SENT_25	[p4l833t359r944b389],
4	J	NNP	O	J	nn	6	SENT_25	[p4l952t360r965b382],
5	ouma	NN	O	ouma	nn	6	SENT_25	[p4l966t366r1041b382],
6	o	NN	O	o	_	0	SENT_25	[p4l1060t366r1075b382],
7	Medicine	NN	O	medicine	dep	6	SENT_25	[p4l1095t359r1220b382],

1	Downloaded	VBN	O	download	_	0	SENT_26	[p4l144t399r314b422],
2	from	IN	O	from	_	0	SENT_26	[p4l323t399r387b422],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_26	[p4l396t399r514b429],
4	at	IN	O	at	_	0	SENT_26	[p4l524t403r547b422],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_26	[p4l556t399r739b422],
6	on	IN	O	on	_	0	SENT_26	[p4l748t406r780b422],
7	Janu	NNP	DATE	Janu	prep_on	1	SENT_26	[p4l789t399r849b422],
8	5	CD	DATE	5	num	7	SENT_26	[p4l902t399r924b426],
9	,	,	DATE	,	_	0	SENT_26	[p4l902t399r924b426],
10	2014	CD	DATE	2014	num	7	SENT_26	[p4l935t399r1007b422],
11	.	.	O	.	_	0	SENT_26	[p4l935t399r1007b422],

1	For	IN	O	for	_	0	SENT_27	[p4l1018t399r1064b422],
2	personal	JJ	O	personal	amod	3	SENT_27	[p4l1072t399r1184b429],
3	use	NN	O	use	pobj	1	SENT_27	[p4l1194t406r1237b422],
4	only	RB	O	only	advmod	3	SENT_27	[p4l1247t399r1311b429],
5	.	.	O	.	_	0	SENT_27	[p4l1247t399r1311b429],

1	No	DT	O	no	det	3	SENT_28	[p4l1322t399r1362b422],
2	other	JJ	O	other	amod	3	SENT_28	[p4l1372t399r1440b422],
3	uses	NNS	O	use	_	0	SENT_28	[p4l1448t406r1504b422],
4	without	IN	O	without	_	0	SENT_28	[p4l1514t399r1615b422],
5	permission	NN	O	permission	prep_without	3	SENT_28	[p4l1624t399r1776b429],
6	.	.	O	.	_	0	SENT_28	[p4l1624t399r1776b429],

1	Copyright	NN	O	copyright	nn	5	SENT_29	[p4l494t440r629b470],
2	©	CD	NUMBER	©	num	5	SENT_29	[p4l638t440r661b463],
3	2004	CD	DATE	2004	num	5	SENT_29	[p4l672t440r737b463],
4	Massac	NNP	LOCATION	Massac	nn	5	SENT_29	[p4l746t441r844b463],
5	usetts	NNP	O	usetts	_	0	SENT_29	[p4l863t444r937b463],
6	Medical	NNP	ORGANIZATION	Medical	nn	7	SENT_29	[p4l947t440r1055b463],
7	Society	NNP	ORGANIZATION	Society	dep	5	SENT_29	[p4l1065t440r1170b470],
8	.	.	O	.	_	0	SENT_29	[p4l1065t440r1170b470],

1	All	DT	O	all	det	2	SENT_30	[p4l1181t440r1223b463],
2	rights	NNS	O	rights	nsubj	3	SENT_30	[p4l1232t440r1306b470],
3	reserved	VBN	O	reserve	_	0	SENT_30	[p4l1316t440r1435b463],
4	.	.	O	.	_	0	SENT_30	[p4l1316t440r1435b463],

1	The	DT	O	the	det	4	SENT_31	[p4l715t545r752b566],
2	NEW	NNP	O	NEW	nn	4	SENT_31	[p4l764t547r845b566],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_31	[p4l859t547r1034b566],
4	IOURNAL	NNP	O	IOURNAL	_	0	SENT_31	[p4l1048t547r1214b573],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_31	[p4l1228t545r1444b572],

1	er	NN	O	er	nn	2	SENT_32	[p4l11t795r92b847],
2	communication	NN	O	communication	_	0	SENT_32	[p4l128t769r816b848],
3	with	IN	O	with	_	0	SENT_32	[p4l851t768r1045b848],
4	the	DT	O	the	det	5	SENT_32	[p4l1083t769r1216b847],
5	FDA	NNP	ORGANIZATION	FDA	prep_with	2	SENT_32	[p4l1253t775r1444b847],
6	throughout	IN	O	throughout	_	0	SENT_32	[p4l1480t769r1980b869],
7	the	DT	O	the	det	8	SENT_32	[p4l2014t768r2146b847],
8	planning	NN	O	planning	prep_throughout	2	SENT_32	[p4l9t896r404b997],
9	of	IN	O	of	_	0	SENT_32	[p4l441t896r544b975],
10	clinical	JJ	O	clinical	amod	11	SENT_32	[p4l565t896r876b975],
11	trials	NNS	O	trial	prep_of	8	SENT_32	[p4l915t897r1129b975],
12	and	CC	O	and	_	0	SENT_32	[p4l1170t896r1329b975],
13	regulatory	JJ	O	regulatory	amod	14	SENT_32	[p4l1369t897r1813b997],
14	review	NN	O	review	prep_of	8	SENT_32	[p4l1849t897r2141b976],
15	.	.	O	.	_	0	SENT_32	[p4l1849t897r2141b976],

1	This	DT	O	this	det	2	SENT_33	[p4l7t1025r191b1103],
2	communication	NN	O	communication	nsubj	4	SENT_33	[p4l219t1025r888b1104],
3	has	VBZ	O	have	aux	4	SENT_33	[p4l912t1025r1052b1103],
4	enhanced	VBN	O	enhance	_	0	SENT_33	[p4l1079t1024r1485b1103],
5	the	DT	O	the	det	6	SENT_33	[p4l1509t1024r1638b1103],
6	predictability	NN	O	predictability	dobj	4	SENT_33	[p4l1661t1024r2147b1125, p4l10t1153r111b1253],
7	of	IN	O	of	_	0	SENT_33	[p4l128t1152r228b1231],
8	FDA	NNP	ORGANIZATION	FDA	nn	10	SENT_33	[p4l232t1159r423b1231],
9	decision	NN	O	decision	nn	10	SENT_33	[p4l444t1153r806b1231],
10	making	NN	O	making	prep_of	6	SENT_33	[p4l829t1153r1184b1253],
11	,	,	O	,	_	0	SENT_33	[p4l829t1153r1184b1253],
12	which	WDT	O	which	nsubj	16	SENT_33	[p4l1208t1153r1475b1232],
13	is	VBZ	O	be	cop	16	SENT_33	[p4l1497t1153r1564b1231],
14	a	DT	O	a	det	16	SENT_33	[p4l1589t1179r1634b1231],
15	major	JJ	O	major	amod	16	SENT_33	[p4l1656t1153r1909b1253],
16	issue	NN	O	issue	rcmod	10	SENT_33	[p4l1930t1153r2147b1232],
17	for	IN	O	for	_	0	SENT_33	[p4l10t1280r136b1359],
18	drug	NN	O	drug	nn	19	SENT_33	[p4l158t1280r360b1381],
19	sponsors	NNS	O	sponsor	prep_for	16	SENT_33	[p4l380t1306r764b1381],
20	in	IN	O	in	_	0	SENT_33	[p4l787t1281r868b1358],
21	their	PRP$	O	they	poss	22	SENT_33	[p4l890t1281r1089b1359],
22	attempts	NNS	O	attempt	prep_in	19	SENT_33	[p4l1107t1297r1476b1381],
23	to	TO	O	to	aux	24	SENT_33	[p4l1500t1297r1580b1359],
24	manage	VB	O	manage	infmod	22	SENT_33	[p4l1603t1306r1939b1381],
25	risk	NN	O	risk	dobj	24	SENT_33	[p4l1961t1281r2142b1360],
26	.	.	O	.	_	0	SENT_33	[p4l1961t1281r2142b1360],

1	Second	RB	ORDINAL	second	advmod	15	SENT_34	[p4l12t1408r338b1504],
2	,	,	O	,	_	0	SENT_34	[p4l12t1408r338b1504],
3	drugs	NNS	O	drug	nsubj	15	SENT_34	[p4l367t1409r604b1509],
4	that	WDT	O	that	nsubjpass	7	SENT_34	[p4l629t1409r795b1487],
5	have	VBP	O	have	aux	7	SENT_34	[p4l813t1408r1000b1488],
6	been	VBN	O	be	auxpass	7	SENT_34	[p4l1024t1408r1223b1487],
7	given	VBN	O	give	rcmod	3	SENT_34	[p4l1245t1409r1468b1509],
8	a	DT	O	a	det	10	SENT_34	[p4l1490t1435r1535b1487],
9	fast	JJ	O	fast	amod	10	SENT_34	[p4l1556t1408r1956b1488],
10	—	NN	O	—	iobj	7	SENT_34	[p4l1556t1408r1956b1488],
11	track	NN	O	track	nn	12	SENT_34	[p4l1556t1408r1956b1488],
12	designation	NN	O	designation	dobj	7	SENT_34	[p4l1975t1408r2147b1487, p4l10t1537r365b1637],
13	are	VBP	O	be	cop	15	SENT_34	[p4l402t1563r528b1615],
14	more	RBR	O	more	advmod	15	SENT_34	[p4l567t1562r788b1615],
15	likely	JJ	O	likely	_	0	SENT_34	[p4l825t1536r1052b1637],
16	to	TO	O	to	aux	17	SENT_34	[p4l1086t1553r1165b1615],
17	receive	VB	O	receive	xcomp	15	SENT_34	[p4l1204t1537r1491b1616],
18	priority	NN	O	priority	nn	19	SENT_34	[p4l1528t1537r1845b1637],
19	review	NN	O	review	dobj	17	SENT_34	[p4l1879t1537r2152b1616],
20	once	IN	DATE	once	mark	29	SENT_34	[p4l11t1690r209b1743],
21	the	DT	O	the	det	22	SENT_34	[p4l240t1665r370b1743],
22	application	NN	O	application	nsubjpass	29	SENT_34	[p4l399t1664r876b1765],
23	for	IN	O	for	_	0	SENT_34	[p4l905t1664r1029b1743],
24	a	DT	O	a	det	26	SENT_34	[p4l1056t1691r1100b1743],
25	new	JJ	O	new	amod	26	SENT_34	[p4l1128t1690r1305b1744],
26	drug	NN	O	drug	prep_for	22	SENT_34	[p4l1332t1664r1532b1765],
27	has	VBZ	O	have	aux	29	SENT_34	[p4l1558t1665r1700b1743],
28	been	VBN	O	be	auxpass	29	SENT_34	[p4l1734t1665r1934b1743],
29	submitted	VBN	O	submit	advcl	17	SENT_34	[p4l1965t1665r2146b1744, p4l10t1793r290b1871],
30	for	IN	O	for	_	0	SENT_34	[p4l325t1792r450b1871],
31	approval	NN	O	approval	prep_for	29	SENT_34	[p4l482t1793r881b1893],
32	.	.	O	.	_	0	SENT_34	[p4l482t1793r881b1893],

1	If	IN	O	if	mark	5	SENT_35	[p4l920t1792r1002b1870],
2	priority	NN	O	priority	nn	3	SENT_35	[p4l1017t1793r1342b1893],
3	review	NN	O	review	nsubjpass	5	SENT_35	[p4l1372t1793r1651b1872],
4	is	VBZ	O	be	auxpass	5	SENT_35	[p4l1681t1793r1747b1871],
5	granted	VBN	O	grant	advcl	17	SENT_35	[p4l1784t1792r2141b1893],
6	,	,	O	,	_	0	SENT_35	[p4l1784t1792r2141b1893],
7	the	DT	O	the	det	9	SENT_35	[p4l11t1920r143b1999],
8	target	NN	O	target	nn	9	SENT_35	[p4l182t1937r438b2021],
9	length	NN	O	length	nsubjpass	17	SENT_35	[p4l471t1920r744b2021],
10	of	IN	O	of	_	0	SENT_35	[p4l781t1920r881b1999],
11	time	NN	O	time	prep_of	9	SENT_35	[p4l899t1921r1087b1999],
12	for	IN	O	for	_	0	SENT_35	[p4l1123t1920r1247b1999],
13	an	DT	O	a	det	15	SENT_35	[p4l1279t1946r1380b1999],
14	FDA	NNP	ORGANIZATION	FDA	nn	15	SENT_35	[p4l1414t1927r1603b1999],
15	action	NN	O	action	prep_for	11	SENT_35	[p4l1635t1921r1896b1999],
16	is	VBZ	O	be	auxpass	17	SENT_35	[p4l1931t1921r1996b1999],
17	reduced	VBN	O	reduce	_	0	SENT_35	[p4l2035t1947r2147b1999, p4l11t2048r264b2128],
18	from	IN	O	from	_	0	SENT_35	[p4l295t2048r504b2127],
19	the	DT	O	the	det	21	SENT_35	[p4l537t2048r668b2127],
20	10-month	JJ	DURATION	10-month	amod	21	SENT_35	[p4l706t2049r1136b2127],
21	standard	NN	O	standard	prep_from	17	SENT_35	[p4l1171t2048r1552b2127],
22	to	TO	O	to	_	0	SENT_35	[p4l1586t2065r1666b2127],
23	6	CD	DURATION	6	num	24	SENT_35	[p4l1701t2054r1748b2127],
24	months	NNS	NUMBER	month	prep_to	17	SENT_35	[p4l1783t2049r2141b2127],
25	.	.	O	.	_	0	SENT_35	[p4l1783t2049r2141b2127],

1	Third	NNP	ORDINAL	Third	nsubj	14	SENT_36	[p4l7t2176r273b2272],
2	,	,	O	,	_	0	SENT_36	[p4l7t2176r273b2272],
3	and	CC	O	and	dep	5	SENT_36	[p4l305t2177r464b2255],
4	most	RBS	O	most	advmod	5	SENT_36	[p4l490t2193r712b2255],
5	important	JJ	O	important	dep	14	SENT_36	[p4l733t2177r1197b2277],
6	,	,	O	,	_	0	SENT_36	[p4l733t2177r1197b2277],
7	sponsors	NNS	O	sponsor	nsubj	14	SENT_36	[p4l1231t2202r1622b2277],
8	may	MD	O	may	aux	14	SENT_36	[p4l1652t2203r1844b2277],
9	,	,	O	,	_	0	SENT_36	[p4l1652t2203r1844b2277],
10	in	IN	O	in	_	0	SENT_36	[p4l1875t2177r1958b2254],
11	certain	JJ	O	certain	amod	12	SENT_36	[p4l1986t2203r2145b2255, p4l11t2305r176b2383],
12	instances	NNS	O	instance	prep_in	14	SENT_36	[p4l204t2305r637b2400],
13	,	,	O	,	_	0	SENT_36	[p4l204t2305r637b2400],
14	seek	VBP	O	seek	_	0	SENT_36	[p4l673t2304r864b2384],
15	approval	NN	O	approval	dobj	14	SENT_36	[p4l887t2305r1263b2405],
16	under	IN	O	under	_	0	SENT_36	[p4l1291t2304r1546b2384],
17	the	DT	O	the	det	21	SENT_36	[p4l1571t2305r1704b2383],
18	accelerated	VBN	O	accelerate	amod	21	SENT_36	[p4l1732t2305r2145b2383, p4l11t2432r524b2533],
19	—	NN	O	—	nn	21	SENT_36	[p4l1732t2305r2145b2383, p4l11t2432r524b2533],
20	approval	NN	O	approval	nn	21	SENT_36	[p4l1732t2305r2145b2383, p4l11t2432r524b2533],
21	mechanism	NN	O	mechanism	prep_under	14	SENT_36	[p4l562t2433r1082b2511],
22	.	.	O	.	_	0	SENT_36	[p4l562t2433r1082b2511],

1	Using	VBG	O	use	partmod	8	SENT_37	[p4l1130t2433r1385b2533],
2	this	DT	O	this	det	3	SENT_37	[p4l1424t2433r1577b2511],
3	mechanism	NN	O	mechanism	dobj	1	SENT_37	[p4l1622t2433r2142b2528],
4	,	,	O	,	_	0	SENT_37	[p4l1622t2433r2142b2528],
5	the	DT	O	the	det	6	SENT_37	[p4l11t2560r141b2639],
6	FDA	NNP	ORGANIZATION	FDA	nsubj	8	SENT_37	[p4l178t2567r369b2639],
7	can	MD	O	can	aux	8	SENT_37	[p4l404t2586r551b2639],
8	grant	VB	O	grant	_	0	SENT_37	[p4l588t2577r821b2661],
9	a	DT	O	a	det	11	SENT_37	[p4l853t2587r898b2639],
10	provisional	JJ	O	provisional	amod	11	SENT_37	[p4l933t2561r1420b2661],
11	approval	NN	O	approval	dobj	8	SENT_37	[p4l1456t2560r1831b2661],
12	on	IN	O	on	_	0	SENT_37	[p4l1869t2586r1977b2639],
13	the	DT	O	the	det	14	SENT_37	[p4l2014t2560r2147b2639],
14	basis	NN	O	basis	prep_on	8	SENT_37	[p4l11t2689r220b2767],
15	of	IN	O	of	_	0	SENT_37	[p4l245t2688r345b2767],
16	a	DT	O	a	det	18	SENT_37	[p4l346t2715r391b2767],
17	surrogate	JJ	O	surrogate	amod	18	SENT_37	[p4l412t2705r807b2789],
18	measure	NN	O	measure	prep_of	14	SENT_37	[p4l829t2715r1182b2768],
19	of	IN	O	of	_	0	SENT_37	[p4l1204t2688r1304b2767],
20	clinical	JJ	O	clinical	amod	21	SENT_37	[p4l1308t2689r1604b2767],
21	beneﬁt	NN	O	beneﬁt	prep_of	18	SENT_37	[p4l1626t2688r1918b2767],
22	(	CD	NUMBER	(	num	21	SENT_37	[p4l1940t2696r2143b2789],
23	e.g.	FW	O	e.g.	amod	21	SENT_37	[p4l1940t2696r2143b2789],
24	,	,	O	,	_	0	SENT_37	[p4l1940t2696r2143b2789],
25	tumor	NN	O	tumor	nn	27	SENT_37	[p4l11t2833r274b2896],
26	shrinkage	NN	O	shrinkage	nn	27	SENT_37	[p4l303t2817r753b2917],
27	)	NN	O	)	dep	23	SENT_37	[p4l303t2817r753b2917],
28	in	IN	O	in	_	0	SENT_37	[p4l788t2817r869b2894],
29	a	DT	O	a	det	33	SENT_37	[p4l899t2843r944b2895],
30	single	JJ	O	single	amod	33	SENT_37	[p4l974t2816r1250b2917],
31	,	,	O	,	_	0	SENT_37	[p4l974t2816r1250b2917],
32	uncontrolled	JJ	O	uncontrolled	amod	33	SENT_37	[p4l1286t2817r1834b2896],
33	trial	NN	O	trial	prep_in	27	SENT_37	[p4l1865t2816r2032b2895],
34	as	RB	O	as	advmod	35	SENT_37	[p4l2061t2843r2145b2895],
35	long	RB	O	long	advmod	8	SENT_37	[p4l10t2945r204b3045],
36	as	IN	O	as	_	0	SENT_37	[p4l228t2971r313b3023],
37	the	DT	O	the	det	39	SENT_37	[p4l343t2944r473b3023],
38	treatment	NN	O	treatment	nn	39	SENT_37	[p4l502t2961r919b3023],
39	addresses	NNS	O	address	prep_as	35	SENT_37	[p4l941t2944r1355b3023],
40	an	DT	O	a	det	43	SENT_37	[p4l1384t2970r1485b3023],
41	unmet	JJ	O	unmet	amod	43	SENT_37	[p4l1513t2961r1791b3024],
42	medical	JJ	O	medical	amod	43	SENT_37	[p4l1814t2944r2148b3023],
43	need	NN	O	need	dobj	8	SENT_37	[p4l10t3072r211b3151],
44	for	IN	O	for	_	0	SENT_37	[p4l237t3072r361b3151],
45	a	DT	O	a	det	51	SENT_37	[p4l383t3099r428b3151],
46	serious	JJ	O	serious	amod	51	SENT_37	[p4l454t3073r754b3152],
47	or	CC	O	or	_	0	SENT_37	[p4l783t3098r873b3151],
48	life	NN	O	life	npadvmod	50	SENT_37	[p4l895t3072r1561b3173],
49	—	CD	NUMBER	—	num	48	SENT_37	[p4l895t3072r1561b3173],
50	threatening	JJ	O	threatening	conj_or	46	SENT_37	[p4l895t3072r1561b3173],
51	illness	NN	O	illness	prep_for	43	SENT_37	[p4l1583t3072r1852b3151],
52	and	CC	O	and	cc	43	SENT_37	[p4l1879t3073r2036b3151],
53	as	RB	O	as	advmod	54	SENT_37	[p4l2061t3099r2145b3151],
54	long	RB	O	long	advmod	43	SENT_37	[p4l10t3201r204b3301],
55	as	IN	O	as	mark	60	SENT_37	[p4l225t3227r310b3279],
56	the	DT	O	the	det	57	SENT_37	[p4l338t3201r468b3279],
57	surrogate	NN	O	surrogate	nsubj	60	SENT_37	[p4l495t3217r897b3301],
58	is	VBZ	O	be	cop	60	SENT_37	[p4l922t3201r988b3279],
59	reasonably	RB	O	reasonably	advmod	60	SENT_37	[p4l1016t3200r1477b3301],
60	likely	JJ	O	likely	advcl	8	SENT_37	[p4l1496t3200r1725b3301],
61	to	TO	O	to	aux	62	SENT_37	[p4l1746t3217r1825b3279],
62	predict	VB	O	predict	xcomp	60	SENT_37	[p4l1851t3200r2153b3301],
63	a	DT	O	a	det	65	SENT_37	[p4l10t3355r54b3407],
64	clinical	JJ	O	clinical	amod	65	SENT_37	[p4l75t3329r378b3407],
65	beneﬁt	NN	O	beneﬁt	dobj	62	SENT_37	[p4l399t3328r716b3407],
66	.	.	O	.	_	0	SENT_37	[p4l399t3328r716b3407],

1	The	DT	O	the	det	3	SENT_38	[p4l741t3329r903b3407],
2	FDA	NNP	ORGANIZATION	FDA	nn	3	SENT_38	[p4l924t3335r1112b3407],
3	grants	NNS	O	grant	nsubj	8	SENT_38	[p4l1130t3345r1396b3429],
4	the	DT	O	the	det	5	SENT_38	[p4l1421t3329r1551b3407],
5	approval	NN	O	approval	dep	3	SENT_38	[p4l1572t3328r1939b3429],
6	conditionally	RB	O	conditionally	advmod	5	SENT_38	[p4l1961t3354r2147b3407, p4l11t3456r433b3557],
7	,	,	O	,	_	0	SENT_38	[p4l1961t3354r2147b3407, p4l11t3456r433b3557],
8	extracting	VBG	O	extract	_	0	SENT_38	[p4l475t3457r910b3557],
9	the	DT	O	the	det	10	SENT_38	[p4l942t3457r1074b3535],
10	sponsor	NN	O	sponsor	poss	12	SENT_38	[p4l1112t3462r1532b3557],
11	’s	POS	O	’s	_	0	SENT_38	[p4l1112t3462r1532b3557],
12	agreement	NN	O	agreement	dobj	8	SENT_38	[p4l1569t3473r2034b3557],
13	to	TO	O	to	aux	14	SENT_38	[p4l2065t3473r2145b3535],
14	complete	VB	O	complete	infmod	12	SENT_38	[p4l11t3585r407b3685],
15	conﬁrmatory	JJ	O	conﬁrmatory	amod	18	SENT_38	[p4l445t3584r1002b3685],
16	phase	NN	O	phase	nn	18	SENT_38	[p4l1033t3585r1280b3685],
17	4	CD	NUMBER	4	num	18	SENT_38	[p4l1315t3590r1365b3663],
18	trials	NNS	O	trial	dobj	14	SENT_38	[p4l1401t3584r1610b3663],
19	in	IN	O	in	_	0	SENT_38	[p4l1648t3585r1729b3662],
20	the	DT	O	the	det	22	SENT_38	[p4l1766t3585r1896b3663],
21	postapproval	JJ	O	postapproval	amod	22	SENT_38	[p4l1931t3601r2147b3685, p4l10t3713r379b3813],
22	period	NN	O	period	prep_in	14	SENT_38	[p4l416t3712r721b3813],
23	.	.	O	.	_	0	SENT_38	[p4l416t3712r721b3813],

1	If	IN	O	if	mark	6	SENT_39	[p4l765t3712r849b3790],
2	these	DT	O	these	det	3	SENT_39	[p4l870t3713r1094b3791],
3	trials	NNS	O	trial	nsubj	6	SENT_39	[p4l1135t3713r1348b3791],
4	do	VBP	O	do	aux	6	SENT_39	[p4l1391t3713r1496b3791],
5	not	RB	O	not	neg	6	SENT_39	[p4l1537t3729r1683b3791],
6	conﬁrm	VB	O	conﬁrm	advcl	15	SENT_39	[p4l1719t3712r2065b3791],
7	a	DT	O	a	det	9	SENT_39	[p4l2104t3739r2148b3791],
8	clinical	JJ	O	clinical	amod	9	SENT_39	[p5l11t23r321b102],
9	beneﬁt	NN	O	beneﬁt	dobj	6	SENT_39	[p5l355t23r680b119],
10	,	,	O	,	_	0	SENT_39	[p5l355t23r680b119],
11	the	DT	O	the	det	12	SENT_39	[p5l720t23r851b102],
12	drug	NN	O	drug	nsubjpass	15	SENT_39	[p5l886t24r1090b124],
13	can	MD	O	can	aux	15	SENT_39	[p5l1122t49r1269b102],
14	be	VB	O	be	auxpass	15	SENT_39	[p5l1303t23r1400b102],
15	withdrawn	VBN	O	withdraw	_	0	SENT_39	[p5l1430t23r1901b103],
16	from	IN	O	from	_	0	SENT_39	[p5l1935t23r2147b102],
17	the	DT	O	the	det	18	SENT_39	[p5l11t151r141b230],
18	market	NN	O	market	prep_from	15	SENT_39	[p5l167t152r486b231],
19	.	.	O	.	_	0	SENT_39	[p5l167t152r486b231],

1	To	TO	O	to	_	0	SENT_40	[p5l514t157r619b230],
2	date	NN	O	date	prep_to	10	SENT_40	[p5l647t151r843b247],
3	,	,	O	,	_	0	SENT_40	[p5l647t151r843b247],
4	however	RB	O	however	advmod	10	SENT_40	[p5l874t152r1245b247],
5	,	,	O	,	_	0	SENT_40	[p5l874t152r1245b247],
6	the	DT	O	the	det	7	SENT_40	[p5l1276t152r1404b230],
7	FDA	NNP	ORGANIZATION	FDA	nsubj	10	SENT_40	[p5l1430t158r1617b230],
8	has	VBZ	O	have	aux	10	SENT_40	[p5l1639t152r1780b230],
9	not	RB	O	not	neg	10	SENT_40	[p5l1808t168r1951b230],
10	pursued	VBN	O	pursue	_	0	SENT_40	[p5l1970t178r2148b252, p5l12t280r205b359],
11	a	DT	O	a	det	13	SENT_40	[p5l236t306r280b358],
12	single	JJ	O	single	amod	13	SENT_40	[p5l316t280r572b380],
13	withdrawal	NN	O	withdrawal	dobj	10	SENT_40	[p5l604t279r1118b375],
14	,	,	O	,	_	0	SENT_40	[p5l604t279r1118b375],
15	despite	IN	O	despite	_	0	SENT_40	[p5l1160t280r1468b380],
16	the	DT	O	the	det	17	SENT_40	[p5l1504t280r1636b358],
17	fact	NN	O	fact	prep_despite	10	SENT_40	[p5l1672t279r1833b358],
18	that	IN	O	that	complm	32	SENT_40	[p5l1863t280r2035b358],
19	in	IN	O	in	_	0	SENT_40	[p5l2064t280r2147b357],
20	the	DT	O	the	det	21	SENT_40	[p5l11t407r143b486],
21	cases	NNS	O	case	prep_in	32	SENT_40	[p5l175t434r397b486],
22	of	IN	O	of	_	0	SENT_40	[p5l431t407r533b486],
23	only	RB	O	only	quantmod	24	SENT_40	[p5l546t408r732b508],
24	6	CD	NUMBER	6	prep_of	21	SENT_40	[p5l759t413r806b486],
25	of	IN	O	of	_	0	SENT_40	[p5l838t407r940b486],
26	the	DT	O	the	det	28	SENT_40	[p5l952t408r1085b486],
27	23	CD	NUMBER	23	num	28	SENT_40	[p5l1116t413r1215b486],
28	oncology	NN	O	oncology	prep_of	24	SENT_40	[p5l1250t407r1981b508],
29	—	RB	O	—	advmod	30	SENT_40	[p5l1250t407r1981b508],
30	related	JJ	O	related	amod	31	SENT_40	[p5l1250t407r1981b508],
31	approvals	NNS	O	approval	nsubj	32	SENT_40	[p5l2010t434r2145b508, p5l9t536r326b636],
32	have	VBP	O	have	dep	17	SENT_40	[p5l354t536r550b615],
33	the	DT	O	the	det	34	SENT_40	[p5l576t535r710b614],
34	sponsors	NNS	O	sponsor	dobj	32	SENT_40	[p5l738t561r1137b636],
35	completed	VBD	O	complete	rcmod	34	SENT_40	[p5l1166t535r1630b636],
36	the	DT	O	the	det	37	SENT_40	[p5l1656t535r1790b614],
37	phase	NN	O	phase	dobj	35	SENT_40	[p5l1814t536r2071b636],
38	4	CD	NUMBER	4	num	39	SENT_40	[p5l2096t541r2146b614],
39	trials	NNS	O	trial	tmod	35	SENT_40	[p5l11t664r230b742],
40	required	VBN	O	require	partmod	39	SENT_40	[p5l269t664r634b764],
41	for	IN	O	for	_	0	SENT_40	[p5l668t663r792b742],
42	an	DT	O	a	det	43	SENT_40	[p5l820t689r921b742],
43	upgrade	NN	O	upgrade	prep_for	40	SENT_40	[p5l953t663r1302b764],
44	to	TO	O	to	_	0	SENT_40	[p5l1335t680r1414b742],
45	regular	JJ	O	regular	amod	46	SENT_40	[p5l1448t663r1752b764],
46	approval	NN	O	approval	prep_to	43	SENT_40	[p5l1781t664r2148b764],
47	(	CD	NUMBER	(	num	48	SENT_40	[p5l15t793r274b884],
48	Table	NNP	O	Table	tmod	40	SENT_40	[p5l15t793r274b884],
49	1	CD	NUMBER	1	num	48	SENT_40	[p5l302t788r455b884],
50	)	CD	NUMBER	)	number	51	SENT_40	[p5l302t788r455b884],
51	.9	CD	NUMBER	.9	num	54	SENT_40	[p5l302t788r455b884],
52	The	DT	O	the	det	54	SENT_40	[p5l477t793r642b871],
53	regulatory	JJ	O	regulatory	amod	54	SENT_40	[p5l667t793r1112b893],
54	standard	NN	O	standard	nsubj	61	SENT_40	[p5l1134t793r1514b871],
55	for	IN	O	for	_	0	SENT_40	[p5l1539t792r1665b871],
56	an	DT	O	a	det	58	SENT_40	[p5l1687t818r1788b871],
57	accelerated	VBN	O	accelerate	amod	58	SENT_40	[p5l1813t793r2145b871, p5l10t920r189b999],
58	approval	NN	O	approval	prep_for	54	SENT_40	[p5l216t921r585b1021],
59	is	VBZ	O	be	cop	61	SENT_40	[p5l610t921r675b999],
60	signiﬁcantly	RB	O	signiﬁcantly	advmod	61	SENT_40	[p5l704t920r1229b1021],
61	less	JJR	O	less	rcmod	48	SENT_40	[p5l1248t921r1404b999],
62	challenging	JJ	O	challenging	dep	73	SENT_40	[p5l1433t921r1936b1021],
63	than	IN	O	than	_	0	SENT_40	[p5l1959t921r2148b999],
64	the	DT	O	the	det	65	SENT_40	[p5l11t1048r140b1127],
65	standard	NN	O	standard	prep_than	62	SENT_40	[p5l166t1049r538b1127],
66	for	IN	O	for	_	0	SENT_40	[p5l562t1048r686b1127],
67	regular	JJ	O	regular	amod	68	SENT_40	[p5l706t1048r1011b1149],
68	approval	NN	O	approval	prep_for	65	SENT_40	[p5l1030t1049r1421b1149],
69	,	,	O	,	_	0	SENT_40	[p5l1030t1049r1421b1149],
70	since	IN	O	since	_	0	SENT_40	[p5l1451t1049r1665b1127],
71	regular	JJ	O	regular	amod	72	SENT_40	[p5l1689t1049r1994b1149],
72	approval	NN	O	approval	prep_since	62	SENT_40	[p5l2014t1075r2147b1149, p5l9t1177r277b1277],
73	requires	VBZ	O	require	dep	61	SENT_40	[p5l315t1177r666b1277],
74	convincing	JJ	O	convincing	amod	75	SENT_40	[p5l708t1177r1187b1277],
75	evidence	NN	O	evidence	dobj	73	SENT_40	[p5l1223t1177r1594b1256],
76	of	IN	O	of	_	0	SENT_40	[p5l1633t1176r1735b1255],
77	a	DT	O	a	det	79	SENT_40	[p5l1754t1203r1799b1255],
78	clinical	JJ	O	clinical	amod	79	SENT_40	[p5l1837t1177r2147b1255],
79	beneﬁt	NN	O	beneﬁt	prep_of	75	SENT_40	[p5l11t1304r316b1383],
80	(	CD	NUMBER	(	nsubj	73	SENT_40	[p5l354t1311r567b1405],
81	e.g.	FW	O	e.g.	dep	80	SENT_40	[p5l354t1311r567b1405],
82	,	,	O	,	_	0	SENT_40	[p5l354t1311r567b1405],
83	prolonged	JJ	O	prolonged	amod	84	SENT_40	[p5l611t1305r1062b1405],
84	survival	NN	O	survival	nsubj	73	SENT_40	[p5l1102t1305r1429b1384],
85	or	CC	O	or	_	0	SENT_40	[p5l1468t1330r1559b1383],
86	an	DT	O	a	det	88	SENT_40	[p5l1594t1330r1696b1383],
87	improved	JJ	O	improved	amod	88	SENT_40	[p5l1734t1304r2147b1405],
88	quality	NN	O	quality	nsubj	73	SENT_40	[p5l11t1433r304b1533],
89	of	IN	O	of	_	0	SENT_40	[p5l328t1432r430b1511],
90	life	NN	O	life	nn	91	SENT_40	[p5l436t1432r626b1528],
91	)	NN	O	)	prep_of	88	SENT_40	[p5l436t1432r626b1528],
92	,	,	O	,	_	0	SENT_40	[p5l436t1432r626b1528],
93	usually	RB	O	usually	advmod	73	SENT_40	[p5l657t1433r957b1533],
94	in	IN	O	in	_	0	SENT_40	[p5l977t1433r1059b1510],
95	controlled	JJ	O	controlled	amod	96	SENT_40	[p5l1085t1432r1519b1511],
96	phase	NN	O	phase	prep_in	73	SENT_40	[p5l1543t1433r1790b1533],
97	3	CD	NUMBER	3	num	98	SENT_40	[p5l1817t1438r1861b1511],
98	trials	NNS	O	trial	dep	39	SENT_40	[p5l1890t1433r2124b1511],
99	.	.	O	.	_	0	SENT_40	[p5l1890t1433r2124b1511],

1	Patients	NNS	O	patient	nsubj	4	SENT_41	[p5l138t1561r480b1639],
2	have	VBP	O	have	aux	4	SENT_41	[p5l530t1560r722b1640],
3	undoubtedly	RB	O	undoubtedly	advmod	4	SENT_41	[p5l770t1560r1320b1661],
4	gained	VBN	O	gain	_	0	SENT_41	[p5l1363t1561r1653b1661],
5	earlier	JJR	O	earlier	amod	6	SENT_41	[p5l1702t1560r1977b1639],
6	access	NN	O	access	dobj	4	SENT_41	[p5l2022t1587r2145b1639, p5l11t1715r185b1767],
7	to	TO	O	to	_	0	SENT_41	[p5l214t1705r294b1767],
8	new	JJ	O	new	amod	9	SENT_41	[p5l322t1714r501b1768],
9	drugs	NNS	O	drug	prep_to	4	SENT_41	[p5l523t1688r762b1789],
10	through	IN	O	through	_	0	SENT_41	[p5l788t1688r1132b1789],
11	the	DT	O	the	det	14	SENT_41	[p5l1156t1689r1286b1767],
12	accelerated	VBN	O	accelerate	amod	14	SENT_41	[p5l1309t1688r2145b1789],
13	—	NN	O	—	nn	14	SENT_41	[p5l1309t1688r2145b1789],
14	approv	NN	O	approv	prep_through	4	SENT_41	[p5l1309t1688r2145b1789],
15	—	CD	NUMBER	—	num	17	SENT_41	[p5l1309t1688r2145b1789],
16	al	NNP	O	al	nn	17	SENT_41	[p5l10t1817r82b1895],
17	mechanism	NN	O	mechanism	dep	14	SENT_41	[p5l116t1816r646b1895],
18	.	.	O	.	_	0	SENT_41	[p5l116t1816r646b1895],

1	Since	IN	O	since	_	0	SENT_42	[p5l689t1817r916b1895],
2	1992	CD	DATE	1992	prep_since	20	SENT_42	[p5l953t1822r1186b1912],
3	,	,	O	,	_	0	SENT_42	[p5l953t1822r1186b1912],
4	when	WRB	O	when	advmod	9	SENT_42	[p5l1222t1816r1460b1896],
5	accelerated	VBN	O	accelerate	amod	7	SENT_42	[p5l1494t1816r1977b1895],
6	approval	NN	O	approval	nn	7	SENT_42	[p5l2010t1843r2145b1917, p5l9t1945r278b2045],
7	ﬁrst	NN	O	ﬁrst	nsubj	9	SENT_42	[p5l315t1944r493b2023],
8	became	VBD	O	become	cop	9	SENT_42	[p5l525t1945r853b2023],
9	available	JJ	O	available	advcl	20	SENT_42	[p5l890t1944r1290b2040],
10	,	,	O	,	_	0	SENT_42	[p5l890t1944r1290b2040],
11	16	CD	NUMBER	16	nsubj	20	SENT_42	[p5l1335t1950r1434b2023],
12	of	IN	O	of	_	0	SENT_42	[p5l1471t1944r1574b2023],
13	the	DT	O	the	det	15	SENT_42	[p5l1592t1944r1725b2023],
14	18	CD	NUMBER	18	num	15	SENT_42	[p5l1765t1950r1862b2023],
15	drugs	NNS	O	drug	prep_of	11	SENT_42	[p5l1901t1944r2144b2045],
16	approved	VBN	O	approve	partmod	15	SENT_42	[p5l10t2072r404b2173],
17	to	TO	O	to	aux	18	SENT_42	[p5l430t2089r510b2151],
18	treat	VB	O	treat	xcomp	16	SENT_42	[p5l537t2089r730b2151],
19	patients	NNS	O	patient	dobj	18	SENT_42	[p5l750t2073r1086b2173],
20	infected	VBN	O	infect	_	0	SENT_42	[p5l1113t2072r1453b2151],
21	with	IN	O	with	_	0	SENT_42	[p5l1474t2073r1665b2152],
22	the	DT	O	the	det	25	SENT_42	[p5l1691t2073r1821b2151],
23	human	JJ	O	human	amod	25	SENT_42	[p5l1846t2073r2148b2152],
24	immunodeﬁciency	NN	O	immunodeﬁciency	nn	25	SENT_42	[p5l10t2200r798b2301],
25	virus	NN	O	virus	prep_with	20	SENT_42	[p5l816t2201r1017b2280],
26	(	CD	NUMBER	(	num	28	SENT_42	[p5l1052t2207r1274b2292],
27	HIV	NN	MISC	hiv	nn	28	SENT_42	[p5l1052t2207r1274b2292],
28	)	NN	O	)	nsubj	30	SENT_42	[p5l1052t2207r1274b2292],
29	initially	RB	O	initially	advmod	30	SENT_42	[p5l1306t2200r1619b2301],
30	gained	VBD	O	gain	rcmod	25	SENT_42	[p5l1641t2201r1922b2301],
31	marketing	NN	O	marketing	nn	32	SENT_42	[p5l1949t2227r2147b2279, p5l10t2329r280b2429],
32	approval	NN	O	approval	dobj	30	SENT_42	[p5l313t2329r688b2429],
33	by	IN	O	by	_	0	SENT_42	[p5l725t2329r823b2429],
34	this	DT	O	this	det	35	SENT_42	[p5l856t2328r1012b2407],
35	mechanism	NN	O	mechanism	prep_by	30	SENT_42	[p5l1052t2329r1582b2407],
36	.	.	O	.	_	0	SENT_42	[p5l1052t2329r1582b2407],

1	The	DT	O	the	det	4	SENT_43	[p5l1621t2329r1786b2407],
2	average	JJ	O	average	amod	4	SENT_43	[p5l1822t2355r2146b2429],
3	review	NN	O	review	nn	4	SENT_43	[p5l10t2457r289b2536],
4	time	NN	O	time	nsubj	12	SENT_43	[p5l337t2457r528b2535],
5	for	IN	O	for	_	0	SENT_43	[p5l580t2456r706b2535],
6	these	DT	O	these	det	7	SENT_43	[p5l754t2457r978b2535],
7	agents	NNS	O	agent	prep_for	4	SENT_43	[p5l1029t2473r1309b2557],
8	was	VBD	O	be	cop	12	SENT_43	[p5l1357t2483r1522b2536],
9	less	JJR	DURATION	less	mwe	10	SENT_43	[p5l1574t2457r1733b2535],
10	than	IN	DURATION	than	quantmod	11	SENT_43	[p5l1787t2456r1979b2535],
11	six	CD	DURATION	six	num	12	SENT_43	[p5l2032t2457r2149b2535],
12	months	NNS	NUMBER	month	_	0	SENT_43	[p5l10t2585r369b2680],
13	,	,	O	,	_	0	SENT_43	[p5l10t2585r369b2680],
14	which	WDT	O	which	nsubj	15	SENT_43	[p5l398t2585r664b2664],
15	met	VBD	O	meet	rcmod	12	SENT_43	[p5l692t2601r860b2663],
16	the	DT	O	the	det	17	SENT_43	[p5l883t2585r1015b2663],
17	FDA	NNP	ORGANIZATION	FDA	poss	19	SENT_43	[p5l1042t2590r1292b2663],
18	’s	POS	O	’s	_	0	SENT_43	[p5l1042t2590r1292b2663],
19	goal	NN	O	goal	dobj	15	SENT_43	[p5l1322t2585r1506b2685],
20	for	IN	O	for	_	0	SENT_43	[p5l1533t2584r1659b2663],
21	priority	NN	O	priority	nn	22	SENT_43	[p5l1683t2585r2008b2685],
22	review	NN	O	review	prep_for	15	SENT_43	[p5l2031t2611r2145b2663, p5l6t2713r216b2792],
23	.	.	O	.	_	0	SENT_43	[p5l2031t2611r2145b2663, p5l6t2713r216b2792],

1	In	IN	O	in	_	0	SENT_44	[p5l253t2720r341b2790],
2	regard	NN	O	regard	prepc_in	8	SENT_44	[p5l372t2712r646b2813],
3	to	TO	O	to	_	0	SENT_44	[p5l677t2729r757b2791],
4	cancer	NN	O	cancer	prep_to	2	SENT_44	[p5l790t2738r1082b2808],
5	,	,	O	,	_	0	SENT_44	[p5l790t2738r1082b2808],
6	the	DT	O	the	det	7	SENT_44	[p5l1119t2713r1249b2791],
7	FDA	NNP	ORGANIZATION	FDA	nsubj	8	SENT_44	[p5l1278t2719r1467b2791],
8	granted	VBD	O	grant	_	0	SENT_44	[p5l1494t2712r1820b2813],
9	its	PRP$	O	its	poss	10	SENT_44	[p5l1849t2713r1947b2791],
10	ﬁrst	NN	O	ﬁrst	nsubj	11	SENT_44	[p5l1979t2712r2153b2791],
11	accelerated	VBD	O	accelerate	ccomp	8	SENT_44	[p5l10t2840r491b2919],
12	approval	NN	O	approval	dobj	11	SENT_44	[p5l526t2841r901b2941],
13	in	IN	O	in	_	0	SENT_44	[p5l937t2841r1019b2918],
14	1995	CD	DATE	1995	prep_in	11	SENT_44	[p5l1059t2846r1294b2936],
15	;	:	O	;	_	0	SENT_44	[p5l1059t2846r1294b2936],
16	approximately	RB	O	approximately	quantmod	17	SENT_44	[p5l1334t2841r1958b2941],
17	one	CD	NUMBER	one	num	18	SENT_44	[p5l1991t2866r2146b2919],
18	third	JJ	ORDINAL	third	nsubj	31	SENT_44	[p5l11t2968r218b3047],
19	of	IN	O	of	_	0	SENT_44	[p5l238t2968r339b3047],
20	the	DT	O	the	det	23	SENT_44	[p5l341t2968r468b3047],
21	60	CD	NUMBER	60	num	23	SENT_44	[p5l489t2974r589b3047],
22	cancer	NN	O	cancer	nn	23	SENT_44	[p5l610t2994r882b3047],
23	drugs	NNS	O	drug	prep_of	18	SENT_44	[p5l900t2969r1135b3069],
24	that	WDT	O	that	nsubjpass	27	SENT_44	[p5l1157t2968r1322b3047],
25	have	VBP	O	have	aux	27	SENT_44	[p5l1337t2969r1524b3048],
26	been	VBN	O	be	auxpass	27	SENT_44	[p5l1544t2969r1743b3047],
27	approved	VBN	O	approve	rcmod	23	SENT_44	[p5l1762t2968r2149b3069],
28	since	IN	O	since	prep	27	SENT_44	[p5l12t3097r228b3175],
29	then	RB	O	then	pobj	28	SENT_44	[p5l258t3097r449b3175],
30	have	VBP	O	have	aux	31	SENT_44	[p5l478t3096r671b3176],
31	received	VBN	O	receive	parataxis	8	SENT_44	[p5l699t3096r1051b3176],
32	accelerated	VBN	O	accelerate	amod	33	SENT_44	[p5l1078t3097r1562b3175],
33	approvals	NNS	O	approval	dobj	31	SENT_44	[p5l1590t3096r2007b3197],
34	on	IN	O	on	_	0	SENT_44	[p5l2039t3122r2147b3175],
35	the	DT	O	the	det	36	SENT_44	[p5l11t3224r143b3303],
36	basis	NN	O	basis	prep_on	33	SENT_44	[p5l169t3225r384b3303],
37	of	IN	O	of	_	0	SENT_44	[p5l412t3224r514b3303],
38	surrogate	JJ	O	surrogate	amod	39	SENT_44	[p5l522t3241r933b3325],
39	measures	NNS	O	measure	prep_of	36	SENT_44	[p5l958t3251r1367b3304],
40	of	IN	O	of	_	0	SENT_44	[p5l1395t3224r1497b3303],
41	a	DT	O	a	det	43	SENT_44	[p5l1503t3251r1547b3303],
42	clinical	JJ	O	clinical	amod	43	SENT_44	[p5l1572t3225r1882b3303],
43	beneﬁt	NN	O	beneﬁt	prep_of	39	SENT_44	[p5l1907t3225r2145b3303, p5l10t3352r124b3431],
44	.	.	O	.	_	0	SENT_44	[p5l1907t3225r2145b3303, p5l10t3352r124b3431],

1	These	DT	O	these	det	2	SENT_45	[p5l162t3352r419b3431],
2	approvals	NNS	O	approval	nsubj	4	SENT_45	[p5l452t3352r869b3453],
3	have	VBP	O	have	aux	4	SENT_45	[p5l907t3352r1099b3432],
4	provided	VBN	O	provide	_	0	SENT_45	[p5l1132t3352r1513b3453],
5	access	NN	O	access	dobj	4	SENT_45	[p5l1548t3379r1818b3431],
6	to	TO	O	to	_	0	SENT_45	[p5l1855t3369r1935b3431],
7	new	JJ	O	new	amod	8	SENT_45	[p5l1971t3378r2151b3432],
8	drugs	NNS	O	drug	prep_to	4	SENT_45	[p5l11t3480r254b3581],
9	for	IN	O	for	_	0	SENT_45	[p5l291t3480r416b3559],
10	the	DT	O	the	det	11	SENT_45	[p5l446t3481r576b3559],
11	treatment	NN	O	treatment	prep_for	8	SENT_45	[p5l609t3497r1026b3559],
12	of	IN	O	of	_	0	SENT_45	[p5l1055t3480r1155b3559],
13	HIV	NN	MISC	hiv	nn	14	SENT_45	[p5l1169t3488r1339b3559],
14	infection	NN	O	infection	prep_of	11	SENT_45	[p5l1368t3480r1747b3559],
15	and	CC	O	and	_	0	SENT_45	[p5l1779t3480r1935b3559],
16	cancer	NN	O	cancer	nn	17	SENT_45	[p5l1968t3506r2147b3559, p5l11t3635r137b3687],
17	years	NNS	DATE	year	nsubj	22	SENT_45	[p5l162t3635r377b3709],
18	earlier	RBR	DATE	earlier	advmod	19	SENT_45	[p5l412t3609r680b3687],
19	than	IN	O	than	advmod	22	SENT_45	[p5l709t3609r899b3687],
20	would	MD	O	would	aux	22	SENT_45	[p5l926t3608r1194b3688],
21	be	VB	O	be	cop	22	SENT_45	[p5l1226t3609r1321b3687],
22	possible	JJ	O	possible	conj_and	4	SENT_45	[p5l1352t3608r1705b3709],
23	under	IN	O	under	_	0	SENT_45	[p5l1737t3608r1988b3688],
24	the	DT	O	the	det	28	SENT_45	[p5l2018t3609r2147b3687],
25	regular	JJ	O	regular	amod	28	SENT_45	[p6l10t21r732b121],
26	—	NN	O	—	nn	28	SENT_45	[p6l10t21r732b121],
27	approval	NN	O	approval	nn	28	SENT_45	[p6l10t21r732b121],
28	process	NN	O	process	prep_under	22	SENT_45	[p6l772t46r1126b121],
29	.	.	O	.	_	0	SENT_45	[p6l772t46r1126b121],

1	Though	IN	O	though	mark	7	SENT_46	[p6l1170t20r1515b121],
2	most	JJS	O	most	nsubjpass	7	SENT_46	[p6l1556t37r1777b99],
3	accelerated	VBN	O	accelerate	partmod	2	SENT_46	[p6l1813t20r2145b99, p6l10t148r189b227],
4	approvals	NNS	O	approval	dobj	3	SENT_46	[p6l220t149r631b249],
5	have	VBP	O	have	aux	7	SENT_46	[p6l662t148r851b228],
6	been	VBN	O	be	auxpass	7	SENT_46	[p6l882t149r1082b227],
7	accorded	VBN	O	accord	advcl	22	SENT_46	[p6l1112t148r1495b227],
8	to	TO	O	to	_	0	SENT_46	[p6l1525t165r1604b227],
9	drugs	NNS	O	drug	prep_to	7	SENT_46	[p6l1636t148r1875b249],
10	in	IN	O	in	_	0	SENT_46	[p6l1906t149r1987b226],
11	the	DT	O	the	det	12	SENT_46	[p6l2018t149r2147b227],
12	areas	NNS	O	area	prep_in	9	SENT_46	[p6l10t303r226b355],
13	of	IN	O	of	_	0	SENT_46	[p6l251t276r352b355],
14	oncology	NN	O	oncology	nn	17	SENT_46	[p6l357t276r749b377],
15	or	CC	O	or	_	0	SENT_46	[p6l768t302r858b355],
16	infectious	JJ	O	infectious	conj_or	14	SENT_46	[p6l877t276r1294b356],
17	diseases	NNS	O	disease	prep_of	12	SENT_46	[p6l1320t276r1692b372],
18	,	,	O	,	_	0	SENT_46	[p6l1320t276r1692b372],
19	the	DT	O	the	det	20	SENT_46	[p6l1721t277r1851b355],
20	FDA	NNP	ORGANIZATION	FDA	nsubj	22	SENT_46	[p6l1872t283r2061b355],
21	is	VBZ	O	be	aux	22	SENT_46	[p6l2080t277r2145b355],
22	granting	VBG	O	grant	_	0	SENT_46	[p6l10t405r378b505],
23	a	DT	O	a	det	25	SENT_46	[p6l399t431r444b483],
24	growing	VBG	O	grow	amod	25	SENT_46	[p6l468t405r827b505],
25	number	NN	O	number	dobj	22	SENT_46	[p6l849t405r1188b484],
26	of	IN	O	of	_	0	SENT_46	[p6l1211t404r1312b483],
27	such	JJ	O	such	amod	28	SENT_46	[p6l1321t404r1516b484],
28	approvals	NNS	O	approval	prep_of	25	SENT_46	[p6l1541t405r1949b505],
29	outside	IN	O	outside	advmod	28	SENT_46	[p6l1978t421r2147b484, p6l12t533r179b611],
30	of	IN	O	of	_	0	SENT_46	[p6l216t532r317b611],
31	these	DT	O	these	det	33	SENT_46	[p6l336t533r555b611],
32	two	CD	NUMBER	two	num	33	SENT_46	[p6l593t549r746b612],
33	ﬁelds	NNS	O	ﬁelds	prep_of	25	SENT_46	[p6l783t532r1037b628],
34	,	,	O	,	_	0	SENT_46	[p6l783t532r1037b628],
35	as	IN	O	as	mark	36	SENT_46	[p6l1079t559r1164b611],
36	exempliﬁed	VBN	O	exempliﬁed	dep	33	SENT_46	[p6l1203t532r1700b633],
37	by	IN	O	by	_	0	SENT_46	[p6l1738t532r1835b633],
38	the	DT	O	the	det	40	SENT_46	[p6l1867t533r1997b611],
39	recent	JJ	O	recent	amod	40	SENT_46	[p6l2035t559r2147b611, p6l11t677r191b739],
40	approval	NN	O	approval	prep_by	36	SENT_46	[p6l225t660r593b761],
41	of	IN	O	of	_	0	SENT_46	[p6l633t660r734b739],
42	treprostinil	NN	O	treprostinil	nn	45	SENT_46	[p6l756t661r1233b761],
43	(	CD	NUMBER	(	num	45	SENT_46	[p6l1277t660r1811b752],
44	Remodulin	NN	O	remodulin	nn	45	SENT_46	[p6l1277t660r1811b752],
45	)	NN	O	)	prep_of	40	SENT_46	[p6l1277t660r1811b752],
46	for	IN	O	for	_	0	SENT_46	[p6l1856t660r1980b739],
47	the	DT	O	the	det	48	SENT_46	[p6l2018t661r2148b739],
48	treatment	NN	O	treatment	prep_for	36	SENT_46	[p6l11t805r428b867],
49	of	IN	O	of	_	0	SENT_46	[p6l449t788r550b867],
50	pulmonary	JJ	O	pulmonary	amod	51	SENT_46	[p6l555t789r1024b889],
51	hypertension	NN	O	hypertension	prep_of	48	SENT_46	[p6l1044t789r1624b889],
52	.	.	O	.	_	0	SENT_46	[p6l1044t789r1624b889],

1	THE	DT	O	the	det	2	SENT_47	[p6l216t1109r410b1166],
2	LAG	NN	O	lag	_	0	SENT_47	[p6l470t1108r642b1167],
3	IN	IN	O	in	_	0	SENT_47	[p6l708t1109r802b1167],
4	PREDICTIVE	NNP	O	PREDICTIVE	nn	5	SENT_47	[p6l869t1108r1454b1167],
5	STUDIES	NNS	O	study	prep_in	2	SENT_47	[p6l1507t1108r1929b1168],

1	It	PRP	O	it	nsubj	4	SENT_48	[p6l9t1310r76b1381],
2	is	VBZ	O	be	cop	4	SENT_48	[p6l106t1303r172b1381],
3	certainly	RB	O	certainly	advmod	4	SENT_48	[p6l210t1302r585b1403],
4	laudable	JJ	O	laudable	_	0	SENT_48	[p6l615t1302r981b1382],
5	for	IN	O	for	_	0	SENT_48	[p6l1017t1302r1143b1381],
6	the	DT	O	the	det	7	SENT_48	[p6l1175t1303r1308b1381],
7	FDA	NNP	ORGANIZATION	FDA	prep_for	4	SENT_48	[p6l1342t1309r1533b1381],
8	to	TO	O	to	aux	9	SENT_48	[p6l1565t1319r1646b1381],
9	grant	VB	O	grant	xcomp	4	SENT_48	[p6l1682t1319r1915b1403],
10	early	JJ	O	early	amod	11	SENT_48	[p6l1946t1303r2151b1403],
11	marketing	NN	O	marketing	iobj	9	SENT_48	[p6l10t1431r462b1531],
12	approval	NN	O	approval	dobj	9	SENT_48	[p6l501t1430r876b1531],
13	for	IN	O	for	_	0	SENT_48	[p6l918t1430r1044b1509],
14	drugs	NNS	O	drug	prep_for	12	SENT_48	[p6l1085t1430r1328b1531],
15	used	VBN	O	use	partmod	14	SENT_48	[p6l1373t1430r1573b1510],
16	to	TO	O	to	aux	17	SENT_48	[p6l1616t1447r1696b1509],
17	treat	VB	O	treat	xcomp	15	SENT_48	[p6l1741t1447r1939b1509],
18	lifethreatening	VBG	O	lifethreaten	amod	19	SENT_48	[p6l1976t1430r2145b1509, p6l11t1558r516b1659],
19	illnesses	NNS	O	illness	dobj	17	SENT_48	[p6l543t1559r938b1637],
20	.	.	O	.	_	0	SENT_48	[p6l543t1559r938b1637],

1	It	PRP	O	it	nsubj	4	SENT_49	[p6l974t1566r1041b1637],
2	is	VBZ	O	be	cop	4	SENT_49	[p6l1067t1559r1133b1637],
3	also	RB	O	also	advmod	4	SENT_49	[p6l1166t1559r1338b1637],
4	appropriate	JJ	O	appropriate	_	0	SENT_49	[p6l1370t1559r1875b1659],
5	to	TO	O	to	aux	6	SENT_49	[p6l1908t1575r1988b1637],
6	expect	VB	O	expect	xcomp	4	SENT_49	[p6l2022t1585r2145b1637, p6l9t1703r187b1787],
7	that	DT	O	that	det	8	SENT_49	[p6l212t1686r377b1765],
8	much	JJ	O	much	nsubj	14	SENT_49	[p6l403t1686r641b1766],
9	of	IN	O	of	_	0	SENT_49	[p6l672t1686r772b1765],
10	the	DT	O	the	det	12	SENT_49	[p6l785t1686r912b1765],
11	drug	NN	O	drug	nn	12	SENT_49	[p6l943t1686r1142b1787],
12	development	NN	O	development	prep_of	8	SENT_49	[p6l1169t1686r1713b1787],
13	will	MD	O	will	aux	14	SENT_49	[p6l1734t1686r1889b1766],
14	occur	VB	O	occur	ccomp	6	SENT_49	[p6l1919t1712r2152b1766],
15	after	IN	O	after	_	0	SENT_49	[p6l10t1814r201b1893],
16	approval	NN	O	approval	prep_after	14	SENT_49	[p6l224t1809r693b1915],
17	.1	CD	NUMBER	.1	number	18	SENT_49	[p6l224t1809r693b1915],
18	°	CD	NUMBER	°	num	16	SENT_49	[p6l224t1809r693b1915],
19	However	RB	O	however	advmod	14	SENT_49	[p6l720t1822r1108b1910],
20	,	,	O	,	_	0	SENT_49	[p6l720t1822r1108b1910],
21	up	IN	O	up	advmod	14	SENT_49	[p6l1142t1841r1246b1915],
22	to	TO	O	to	_	0	SENT_49	[p6l1275t1831r1354b1893],
23	this	DT	O	this	det	24	SENT_49	[p6l1383t1815r1533b1893],
24	point	NN	O	point	prep_to	21	SENT_49	[p6l1561t1816r1788b1915],
25	the	DT	O	the	det	26	SENT_49	[p6l1810t1815r1939b1893],
26	FDA	NNP	ORGANIZATION	FDA	nsubj	29	SENT_49	[p6l1965t1822r2152b1893],
27	has	VBZ	O	have	aux	29	SENT_49	[p6l10t1943r153b2021],
28	not	RB	O	not	neg	29	SENT_49	[p6l183t1959r329b2021],
29	compelled	VBN	O	compel	rcmod	24	SENT_49	[p6l354t1942r806b2043],
30	sponsors	NNS	O	sponsor	dobj	29	SENT_49	[p6l835t1968r1227b2043],
31	that	WDT	O	that	nsubj	32	SENT_49	[p6l1258t1943r1429b2021],
32	beneﬁt	VBP	O	beneﬁt	rcmod	30	SENT_49	[p6l1453t1942r1758b2021],
33	from	IN	O	from	_	0	SENT_49	[p6l1782t1942r1994b2021],
34	accelerated	VBN	O	accelerate	amod	35	SENT_49	[p6l2022t1969r2145b2021, p6l11t2070r398b2149],
35	approval	NN	O	approval	prep_from	32	SENT_49	[p6l422t2071r797b2171],
36	to	TO	O	to	aux	37	SENT_49	[p6l821t2087r902b2149],
37	identify	VB	O	identify	infmod	24	SENT_49	[p6l926t2070r1258b2171],
38	the	DT	O	the	det	42	SENT_49	[p6l1278t2070r1411b2149],
39	speciﬁc	JJ	O	speciﬁc	amod	42	SENT_49	[p6l1436t2070r1765b2171],
40	subpop	NN	O	subpop	nn	42	SENT_49	[p6l1790t2071r2145b2171],
41	—	NN	O	—	nn	42	SENT_49	[p6l1790t2071r2145b2171],
42	ulations	NNS	O	ulation	dobj	37	SENT_49	[p6l10t2199r345b2278],
43	of	IN	O	of	_	0	SENT_49	[p6l368t2198r468b2277],
44	patients	NNS	O	patient	prep_of	42	SENT_49	[p6l469t2199r799b2299],
45	who	WP	O	who	nsubj	47	SENT_49	[p6l817t2199r999b2278],
46	are	VBP	O	be	cop	47	SENT_49	[p6l1021t2225r1145b2277],
47	likely	JJ	O	likely	rcmod	44	SENT_49	[p6l1164t2198r1388b2299],
48	to	TO	O	to	aux	49	SENT_49	[p6l1404t2215r1482b2277],
49	have	VB	O	have	xcomp	47	SENT_49	[p6l1504t2199r1690b2278],
50	a	DT	O	a	det	51	SENT_49	[p6l1710t2225r1755b2277],
51	response	NN	O	response	dobj	49	SENT_49	[p6l1773t2224r2148b2299],
52	to	TO	O	to	_	0	SENT_49	[p6l11t2343r92b2405],
53	a	DT	O	a	det	55	SENT_49	[p6l116t2353r161b2405],
54	given	VBN	O	give	amod	55	SENT_49	[p6l184t2327r413b2427],
55	drug	NN	O	drug	prep_to	51	SENT_49	[p6l438t2326r663b2427],
56	.	.	O	.	_	0	SENT_49	[p6l438t2326r663b2427],

1	We	PRP	O	we	nsubj	2	SENT_50	[p6l690t2334r824b2405],
2	believe	VBP	O	believe	_	0	SENT_50	[p6l850t2326r1144b2406],
3	that	IN	O	that	complm	10	SENT_50	[p6l1169t2327r1340b2405],
4	the	DT	O	the	det	5	SENT_50	[p6l1360t2326r1491b2405],
5	failure	NN	O	failure	nsubj	10	SENT_50	[p6l1517t2326r1794b2406],
6	to	TO	O	to	aux	7	SENT_50	[p6l1819t2343r1899b2405],
7	identiiy	VB	O	identiiy	infmod	5	SENT_50	[p6l1924t2327r2145b2405, p6l11t2454r149b2555],
8	such	JJ	O	such	amod	9	SENT_50	[p6l177t2455r376b2534],
9	populations	NNS	O	population	dobj	7	SENT_50	[p6l406t2455r925b2555],
10	represents	VBZ	O	represent	ccomp	2	SENT_50	[p6l958t2471r1408b2555],
11	a	DT	O	a	det	13	SENT_50	[p6l1440t2481r1486b2533],
12	missed	VBN	O	miss	amod	13	SENT_50	[p6l1515t2455r1821b2533],
13	opportunity	NN	O	opportunity	dobj	10	SENT_50	[p6l1853t2480r2145b2555, p6l11t2583r275b2683],
14	.	.	O	.	_	0	SENT_50	[p6l1853t2480r2145b2555, p6l11t2583r275b2683],

1	As	IN	O	as	_	0	SENT_51	[p6l302t2590r408b2661],
2	compared	VBN	O	compare	prepc_as	9	SENT_51	[p6l437t2583r870b2683],
3	with	IN	O	with	pcomp	2	SENT_51	[p6l891t2582r1085b2662],
4	cytotoxic	JJ	O	cytotoxic	amod	5	SENT_51	[p6l1112t2583r1496b2683],
5	agents	NNS	O	agent	pobj	3	SENT_51	[p6l1521t2599r1828b2683],
6	,	,	O	,	_	0	SENT_51	[p6l1521t2599r1828b2683],
7	targeted	VBN	O	target	amod	8	SENT_51	[p6l1860t2599r2145b2683, p6l11t2711r109b2789],
8	drugs	NNS	O	drug	nsubj	9	SENT_51	[p6l138t2710r381b2811],
9	hold	VBP	O	hold	_	0	SENT_51	[p6l413t2711r608b2789],
10	the	DT	O	the	det	11	SENT_51	[p6l638t2710r770b2789],
11	promise	NN	O	promise	dobj	9	SENT_51	[p6l799t2711r1156b2811],
12	that	IN	O	that	complm	16	SENT_51	[p6l1186t2710r1357b2789],
13	we	PRP	O	we	nsubj	16	SENT_51	[p6l1377t2737r1497b2790],
14	may	MD	O	may	aux	16	SENT_51	[p6l1527t2737r1707b2811],
15	be	VB	O	be	cop	16	SENT_51	[p6l1732t2711r1830b2789],
16	able	JJ	O	able	ccomp	9	SENT_51	[p6l1858t2710r2035b2789],
17	to	TO	O	to	aux	18	SENT_51	[p6l2065t2727r2145b2789],
18	deﬁne	VB	O	deﬁne	xcomp	16	SENT_51	[p6l11t2838r268b2917],
19	precisely	RB	O	precisely	advmod	18	SENT_51	[p6l288t2839r656b2939],
20	the	DT	O	the	det	21	SENT_51	[p6l673t2839r801b2917],
21	groups	NNS	O	group	dobj	18	SENT_51	[p6l821t2864r1112b2939],
22	of	IN	O	of	_	0	SENT_51	[p6l1136t2838r1236b2917],
23	patients	NNS	O	patient	prep_of	21	SENT_51	[p6l1237t2839r1568b2939],
24	in	IN	O	in	_	0	SENT_51	[p6l1589t2839r1670b2916],
25	whom	WP	O	whom	rel	29	SENT_51	[p6l1686t2839r1957b2918],
26	they	PRP	O	they	nsubj	29	SENT_51	[p6l1978t2838r2153b2939],
27	will	MD	O	will	aux	29	SENT_51	[p6l6t2966r167b3046],
28	be	VB	O	be	cop	29	SENT_51	[p6l195t2967r293b3045],
29	effective	JJ	O	effective	rcmod	23	SENT_51	[p6l323t2966r703b3046],
30	.	.	O	.	_	0	SENT_51	[p6l323t2966r703b3046],

1	This	DT	O	this	det	2	SENT_52	[p6l734t2967r924b3045],
2	ability	NN	O	ability	nsubj	31	SENT_52	[p6l954t2967r1222b3067],
3	to	TO	O	to	aux	4	SENT_52	[p6l1247t2983r1328b3045],
4	deﬁne	VB	O	deﬁne	infmod	2	SENT_52	[p6l1358t2966r1626b3045],
5	subpopula	NN	O	subpopulum	nn	7	SENT_52	[p6l1656t2967r2145b3067],
6	—	NN	O	—	nn	7	SENT_52	[p6l1656t2967r2145b3067],
7	tions	NNS	O	tion	dobj	4	SENT_52	[p6l11t3095r223b3173],
8	of	IN	O	of	_	0	SENT_52	[p6l253t3094r355b3173],
9	patients	NNS	O	patient	prep_of	7	SENT_52	[p6l362t3095r706b3195],
10	who	WP	O	who	nsubj	12	SENT_52	[p6l730t3095r917b3174],
11	are	VBP	O	be	cop	12	SENT_52	[p6l944t3121r1073b3173],
12	likely	JJ	O	likely	rcmod	9	SENT_52	[p6l1099t3094r1332b3195],
13	to	TO	O	to	aux	14	SENT_52	[p6l1355t3111r1435b3173],
14	have	VB	O	have	xcomp	12	SENT_52	[p6l1463t3094r1656b3174],
15	responses	NNS	O	response	dobj	14	SENT_52	[p6l1683t3120r2141b3195],
16	,	,	O	,	_	0	SENT_52	[p6l1683t3120r2141b3195],
17	which	WDT	O	which	nsubj	19	SENT_52	[p6l6t3223r272b3302],
18	thereby	RB	O	thereby	advmod	19	SENT_52	[p6l319t3223r642b3323],
19	avoids	VBZ	O	avoid	rcmod	15	SENT_52	[p6l682t3222r954b3302],
20	the	DT	O	the	det	24	SENT_52	[p6l1003t3223r1134b3301],
21	medical	JJ	O	medical	amod	24	SENT_52	[p6l1181t3222r1521b3301],
22	and	CC	O	and	_	0	SENT_52	[p6l1565t3223r1725b3301],
23	ﬁnancial	JJ	O	ﬁnancial	conj_and	21	SENT_52	[p6l1770t3222r2147b3301],
24	cost	NN	O	cost	dobj	19	SENT_52	[p6l11t3367r189b3429],
25	of	IN	O	of	_	0	SENT_52	[p6l210t3350r312b3429],
26	ineffective	JJ	O	ineffective	amod	27	SENT_52	[p6l318t3350r763b3430],
27	therapies	NNS	O	therapy	prep_of	24	SENT_52	[p6l789t3351r1212b3451],
28	,	,	O	,	_	0	SENT_52	[p6l789t3351r1212b3451],
29	is	VBZ	O	be	cop	31	SENT_52	[p6l1243t3351r1308b3429],
30	particularly	RB	O	particularly	advmod	31	SENT_52	[p6l1335t3350r1833b3451],
31	critical	JJ	O	critical	_	0	SENT_52	[p6l1854t3351r2147b3429],
32	in	IN	O	in	_	0	SENT_52	[p6l10t3479r92b3556],
33	ﬁelds	NNS	O	ﬁelds	prep_in	31	SENT_52	[p6l125t3478r358b3557],
34	such	JJ	O	such	_	0	SENT_52	[p6l394t3478r593b3558],
35	as	IN	O	as	_	0	SENT_52	[p6l625t3505r711b3557],
36	oncology	NN	O	oncology	prep_such_as	33	SENT_52	[p6l746t3478r1159b3579],
37	.	.	O	.	_	0	SENT_52	[p6l746t3478r1159b3579],

1	Wasting	VBG	O	waste	amod	2	SENT_53	[p6l1192t3479r1554b3579],
2	time	NN	O	time	nsubj	7	SENT_53	[p6l1583t3479r1774b3557],
3	with	IN	O	with	_	0	SENT_53	[p6l1803t3479r1996b3558],
4	ineffective	JJ	O	ineffective	amod	5	SENT_53	[p6l2028t3479r2145b3556, p6l11t3606r367b3686],
5	therapies	NNS	O	therapy	prep_with	2	SENT_53	[p6l391t3607r788b3707],
6	may	MD	O	may	aux	7	SENT_53	[p6l813t3633r994b3707],
7	entail	VB	O	entail	_	0	SENT_53	[p6l1013t3607r1255b3685],
8	the	DT	O	the	det	9	SENT_53	[p6l1279t3607r1411b3685],
9	loss	NN	O	loss	dobj	7	SENT_53	[p6l1435t3607r1602b3685],
10	of	IN	O	of	_	0	SENT_53	[p6l1629t3606r1731b3685],
11	a	DT	O	a	det	12	SENT_53	[p6l1736t3633r1781b3685],
12	window	NN	O	window	prep_of	9	SENT_53	[p6l1798t3607r2151b3686],
13	of	IN	O	of	_	0	SENT_53	[p7l11t20r113b99],
14	opportunity	NN	O	opportunity	prep_of	12	SENT_53	[p7l128t21r644b121],
15	for	IN	O	for	_	0	SENT_53	[p7l672t20r798b99],
16	patients	NNS	O	patient	prep_for	7	SENT_53	[p7l826t21r1169b121],
17	with	IN	O	with	_	0	SENT_53	[p7l1200t21r1394b100],
18	cancer	NN	O	cancer	prep_with	7	SENT_53	[p7l1426t46r1708b99],
19	to	TO	O	to	aux	20	SENT_53	[p7l1739t37r1818b99],
20	receive	VB	O	receive	xcomp	7	SENT_53	[p7l1853t21r2147b100],
21	an	DT	O	a	det	23	SENT_53	[p7l10t174r111b227],
22	effective	JJ	O	effective	amod	23	SENT_53	[p7l138t148r494b228],
23	treatment	NN	O	treatment	dobj	20	SENT_53	[p7l521t165r967b227],
24	.	.	O	.	_	0	SENT_53	[p7l521t165r967b227],

1	In	IN	O	in	_	0	SENT_54	[p7l997t156r1085b226],
2	some	DT	O	some	det	3	SENT_54	[p7l1113t174r1342b227],
3	instances	NNS	O	instance	prep_in	35	SENT_54	[p7l1368t149r1801b244],
4	,	,	O	,	_	0	SENT_54	[p7l1368t149r1801b244],
5	such	JJ	O	such	_	0	SENT_54	[p7l1835t149r2033b228],
6	as	IN	O	as	_	0	SENT_54	[p7l2059t175r2144b227],
7	when	WRB	O	when	advmod	13	SENT_54	[p7l6t278r240b357],
8	trastuzumab	JJ	O	trastuzumab	amod	11	SENT_54	[p7l269t278r794b357],
9	(	NN	O	(	nn	11	SENT_54	[p7l829t278r1301b378],
10	Herceptin	NN	O	herceptin	nn	11	SENT_54	[p7l829t278r1301b378],
11	)	NN	O	)	nsubjpass	13	SENT_54	[p7l829t278r1301b378],
12	is	VBZ	O	be	auxpass	13	SENT_54	[p7l1334t278r1399b356],
13	used	VBN	O	use	prepc_such_as	3	SENT_54	[p7l1429t278r1622b357],
14	to	TO	O	to	aux	15	SENT_54	[p7l1651t294r1729b356],
15	treat	VB	O	treat	xcomp	13	SENT_54	[p7l1759t294r1949b356],
16	only	RB	O	only	advmod	18	SENT_54	[p7l1974t278r2153b378],
17	those	DT	O	those	det	18	SENT_54	[p7l11t406r240b484],
18	tumors	NNS	O	tumor	dobj	15	SENT_54	[p7l269t422r578b485],
19	that	WDT	O	that	nsubj	20	SENT_54	[p7l610t406r781b484],
20	overexpress	VBP	O	overexpress	rcmod	18	SENT_54	[p7l806t431r1312b506],
21	the	DT	O	the	det	26	SENT_54	[p7l1344t405r1476b484],
22	human	JJ	O	human	amod	26	SENT_54	[p7l1505t406r1811b485],
23	epidermal	JJ	O	epidermal	amod	26	SENT_54	[p7l1841t405r2145b506, p7l10t534r168b612],
24	growth	NN	O	growth	nn	26	SENT_54	[p7l193t534r495b634],
25	factor	NN	O	factor	nn	26	SENT_54	[p7l520t533r765b612],
26	receptor	NN	O	receptor	nsubj	30	SENT_54	[p7l787t550r1137b634],
27	2	CD	NUMBER	2	number	28	SENT_54	[p7l1159t539r1207b611],
28	(	CD	NUMBER	(	num	30	SENT_54	[p7l1238t539r1733b629],
29	HER2/neu	NN	O	her2/neu	nn	30	SENT_54	[p7l1238t539r1733b629],
30	)	NN	O	)	xcomp	20	SENT_54	[p7l1238t539r1733b629],
31	,	,	O	,	_	0	SENT_54	[p7l1238t539r1733b629],
32	sponsors	NNS	O	sponsor	nsubj	35	SENT_54	[p7l1766t559r2145b634],
33	have	VBP	O	have	aux	35	SENT_54	[p7l10t662r200b741],
34	been	VBN	O	be	cop	35	SENT_54	[p7l226t662r430b740],
35	able	JJ	O	able	_	0	SENT_54	[p7l455t662r631b740],
36	to	TO	O	to	aux	37	SENT_54	[p7l657t678r737b740],
37	use	VB	O	use	xcomp	35	SENT_54	[p7l764t688r907b741],
38	molecular	JJ	O	molecular	amod	39	SENT_54	[p7l933t662r1369b741],
39	testing	NN	O	testing	dobj	37	SENT_54	[p7l1393t662r1690b762],
40	to	TO	O	to	aux	41	SENT_54	[p7l1713t678r1794b740],
41	identify	VB	O	identify	xcomp	37	SENT_54	[p7l1820t661r2152b762],
42	the	DT	O	the	det	43	SENT_54	[p7l11t789r141b868],
43	patients	NNS	O	patient	dobj	41	SENT_54	[p7l164t790r495b890],
44	who	WP	O	who	nsubj	47	SENT_54	[p7l517t789r701b869],
45	are	VBP	O	be	cop	47	SENT_54	[p7l726t816r851b868],
46	most	RBS	O	most	advmod	47	SENT_54	[p7l876t806r1091b868],
47	likely	JJ	O	likely	rcmod	43	SENT_54	[p7l1109t789r1336b890],
48	to	TO	O	to	aux	49	SENT_54	[p7l1357t806r1437b868],
49	have	VB	O	have	xcomp	47	SENT_54	[p7l1464t790r1651b869],
50	a	DT	O	a	det	51	SENT_54	[p7l1675t816r1720b868],
51	response	NN	O	response	dobj	49	SENT_54	[p7l1743t815r2141b890],
52	.	.	O	.	_	0	SENT_54	[p7l1743t815r2141b890],

1	There	EX	O	there	expl	3	SENT_55	[p7l7t918r257b996],
2	is	VBZ	O	be	aux	3	SENT_55	[p7l289t918r355b996],
3	growing	VBG	O	grow	_	0	SENT_55	[p7l389t918r755b1018],
4	evidence	NN	O	evidence	dobj	3	SENT_55	[p7l785t918r1155b997],
5	that	IN	O	that	complm	11	SENT_55	[p7l1187t917r1358b996],
6	such	JJ	O	such	amod	8	SENT_55	[p7l1387t918r1586b997],
7	selective	JJ	O	selective	amod	8	SENT_55	[p7l1619t918r1979b997],
8	approaches	NNS	O	approach	nsubj	11	SENT_55	[p7l2010t944r2145b1018, p7l9t1046r388b1146],
9	will	MD	O	will	aux	11	SENT_55	[p7l412t1045r567b1125],
10	be	VB	O	be	cop	11	SENT_55	[p7l594t1045r689b1124],
11	possible	JJ	O	possible	ccomp	3	SENT_55	[p7l715t1045r1061b1146],
12	for	IN	O	for	_	0	SENT_55	[p7l1088t1045r1211b1124],
13	other	JJ	O	other	amod	15	SENT_55	[p7l1235t1046r1456b1124],
14	targeted	VBN	O	target	amod	15	SENT_55	[p7l1480t1046r1822b1146],
15	agents	NNS	O	agent	prep_for	11	SENT_55	[p7l1848t1062r2143b1146],
16	.	.	O	.	_	0	SENT_55	[p7l1848t1062r2143b1146],

1	New	JJ	O	new	amod	2	SENT_56	[p7l8t1181r206b1253],
2	studies	NNS	O	study	nsubj	14	SENT_56	[p7l234t1173r524b1253],
3	of	IN	O	of	_	0	SENT_56	[p7l559t1173r659b1252],
4	geﬁtinib	NN	O	geﬁtinib	prep_of	2	SENT_56	[p7l671t1173r1045b1274],
5	,	,	O	,	_	0	SENT_56	[p7l671t1173r1045b1274],
6	an	DT	O	a	det	12	SENT_56	[p7l1081t1199r1181b1252],
7	epidermal	JJ	O	epidermal	amod	12	SENT_56	[p7l1213t1173r1634b1274],
8	growth	NN	O	growth	nn	12	SENT_56	[p7l1664t1174r1965b1274],
9	factor	NN	O	factor	nn	12	SENT_56	[p7l1996t1173r2147b1252, p7l11t1318r542b1402],
10	—	NN	O	—	nn	12	SENT_56	[p7l1996t1173r2147b1252, p7l11t1318r542b1402],
11	receptor	NN	O	receptor	nn	12	SENT_56	[p7l1996t1173r2147b1252, p7l11t1318r542b1402],
12	inhibitor	NN	O	inhibitor	appos	2	SENT_56	[p7l565t1302r969b1397],
13	,	,	O	,	_	0	SENT_56	[p7l565t1302r969b1397],
14	indicate	VBP	O	indicate	_	0	SENT_56	[p7l1001t1302r1343b1380],
15	that	IN	O	that	complm	23	SENT_56	[p7l1371t1302r1542b1380],
16	certain	JJ	O	certain	amod	17	SENT_56	[p7l1565t1302r1861b1380],
17	mutations	NNS	O	mutation	nsubjpass	23	SENT_56	[p7l1888t1318r2145b1381, p7l11t1430r223b1508],
18	in	IN	O	in	_	0	SENT_56	[p7l258t1430r340b1507],
19	the	DT	O	the	det	20	SENT_56	[p7l373t1430r506b1508],
20	receptor	NN	O	receptor	prep_in	17	SENT_56	[p7l538t1446r899b1530],
21	are	VBP	O	be	auxpass	23	SENT_56	[p7l929t1456r1058b1508],
22	strongly	RB	O	strongly	advmod	23	SENT_56	[p7l1092t1429r1448b1530],
23	associated	VBN	O	associate	ccomp	14	SENT_56	[p7l1476t1429r1925b1508],
24	with	IN	O	with	_	0	SENT_56	[p7l1953t1429r2147b1509],
25	a	DT	O	a	det	27	SENT_56	[p7l10t1584r54b1636],
26	clinical	JJ	O	clinical	amod	27	SENT_56	[p7l82t1558r392b1636],
27	response	NN	O	response	prep_with	23	SENT_56	[p7l417t1552r1027b1658],
28	.	.	O	.	_	0	SENT_56	[p7l417t1552r1027b1658],

1	“’	NN	O	“’	nsubj	5	SENT_57	[p7l417t1552r1027b1658],
2	12	CD	NUMBER	12	num	1	SENT_57	[p7l417t1552r1027b1658],
3	These	DT	O	these	det	4	SENT_57	[p7l1049t1558r1306b1636],
4	mutations	NNS	O	mutation	dep	1	SENT_57	[p7l1332t1559r1774b1637],
5	occur	VBP	O	occur	_	0	SENT_57	[p7l1802t1583r2042b1637],
6	in	IN	O	in	_	0	SENT_57	[p7l2063t1559r2147b1635],
7	only	RB	O	only	quantmod	9	SENT_57	[p7l11t1685r197b1786],
8	about	RB	O	about	quantmod	9	SENT_57	[p7l216t1685r466b1765],
9	10	CD	PERCENT	10	num	10	SENT_57	[p7l488t1691r586b1764],
10	percent	NN	PERCENT	percent	prep_in	5	SENT_57	[p7l611t1702r939b1786],
11	of	IN	O	of	_	0	SENT_57	[p7l959t1685r1061b1764],
12	patients	NNS	O	patient	prep_of	10	SENT_57	[p7l1065t1686r1409b1786],
13	with	IN	O	with	_	0	SENT_57	[p7l1431t1685r1625b1765],
14	non	JJ	O	non	amod	20	SENT_57	[p7l1649t1685r2145b1764],
15	—	JJ	O	—	amod	20	SENT_57	[p7l1649t1685r2145b1764],
16	small	JJ	O	small	amod	20	SENT_57	[p7l1649t1685r2145b1764],
17	—	NN	O	—	nn	20	SENT_57	[p7l1649t1685r2145b1764],
18	cell	NN	O	cell	nn	20	SENT_57	[p7l11t1813r157b1892],
19	lung	NN	O	lung	nn	20	SENT_57	[p7l187t1814r385b1914],
20	cancer	NN	O	cancer	prep_with	12	SENT_57	[p7l415t1839r715b1909],
21	,	,	O	,	_	0	SENT_57	[p7l415t1839r715b1909],
22	but	CC	O	but	_	0	SENT_57	[p7l753t1814r897b1893],
23	they	PRP	O	they	nsubj	24	SENT_57	[p7l924t1814r1105b1914],
24	appear	VBP	O	appear	conj_but	5	SENT_57	[p7l1131t1840r1427b1914],
25	to	TO	O	to	aux	26	SENT_57	[p7l1456t1830r1537b1892],
26	make	VB	O	make	xcomp	24	SENT_57	[p7l1570t1814r1804b1893],
27	tumors	NNS	O	tumor	nsubj	29	SENT_57	[p7l1836t1830r2144b1893],
28	exquisitely	RB	O	exquisitely	advmod	29	SENT_57	[p7l11t1942r474b2042],
29	sensitive	JJ	O	sensitive	xcomp	26	SENT_57	[p7l498t1942r868b2021],
30	to	TO	O	to	_	0	SENT_57	[p7l896t1958r977b2020],
31	inhibition	NN	O	inhibition	prep_to	29	SENT_57	[p7l1004t1941r1438b2020],
32	of	IN	O	of	_	0	SENT_57	[p7l1466t1941r1568b2020],
33	the	DT	O	the	det	34	SENT_57	[p7l1577t1942r1709b2020],
34	receptor	NN	O	receptor	prep_of	31	SENT_57	[p7l1736t1958r2115b2042],
35	.	.	O	.	_	0	SENT_57	[p7l1736t1958r2115b2042],

1	Despite	IN	O	despite	_	0	SENT_58	[p7l138t2070r459b2170],
2	the	DT	O	the	det	4	SENT_58	[p7l490t2069r620b2148],
3	great	JJ	O	great	amod	4	SENT_58	[p7l648t2086r866b2170],
4	promise	NN	O	promise	prep_despite	15	SENT_58	[p7l889t2070r1239b2170],
5	of	IN	O	of	_	0	SENT_58	[p7l1269t2069r1370b2148],
6	these	DT	O	these	det	7	SENT_58	[p7l1382t2070r1601b2148],
7	approaches	NNS	O	approach	prep_of	4	SENT_58	[p7l1630t2069r2142b2170],
8	,	,	O	,	_	0	SENT_58	[p7l1630t2069r2142b2170],
9	the	DT	O	the	det	11	SENT_58	[p7l11t2197r141b2276],
10	pharmaceutical	JJ	O	pharmaceutical	amod	11	SENT_58	[p7l176t2198r833b2298],
11	industry	NN	O	industry	nsubj	15	SENT_58	[p7l868t2197r1221b2298],
12	has	VBZ	O	have	aux	15	SENT_58	[p7l1252t2198r1394b2276],
13	thus	RB	O	thus	advmod	14	SENT_58	[p7l1432t2197r1613b2277],
14	far	RB	O	far	advmod	15	SENT_58	[p7l1652t2197r1768b2276],
15	invested	VBN	O	invest	_	0	SENT_58	[p7l1800t2198r2148b2277],
16	only	RB	O	only	advmod	17	SENT_58	[p7l11t2326r193b2426],
17	modestly	RB	O	modestly	advmod	15	SENT_58	[p7l221t2326r611b2426],
18	in	IN	O	in	_	0	SENT_58	[p7l639t2326r720b2403],
19	studies	NNS	O	study	prep_in	15	SENT_58	[p7l755t2325r1050b2405],
20	that	WDT	O	that	nsubj	21	SENT_58	[p7l1086t2326r1253b2404],
21	predict	VBP	O	predict	rcmod	19	SENT_58	[p7l1279t2325r1581b2426],
22	responses	NNS	O	response	dobj	21	SENT_58	[p7l1609t2351r2032b2426],
23	to	TO	O	to	_	0	SENT_58	[p7l2067t2342r2147b2404],
24	cancer	NN	O	cancer	nn	25	SENT_58	[p7l11t2479r288b2532],
25	drugs	NNS	O	drug	prep_to	21	SENT_58	[p7l308t2454r572b2554],
26	.	.	O	.	_	0	SENT_58	[p7l308t2454r572b2554],

1	Perhaps	RB	O	perhaps	advmod	5	SENT_59	[p7l599t2454r937b2554],
2	we	PRP	O	we	nsubj	5	SENT_59	[p7l956t2480r1076b2533],
3	should	MD	O	should	aux	5	SENT_59	[p7l1099t2454r1389b2533],
4	not	RB	O	not	neg	5	SENT_59	[p7l1410t2470r1555b2532],
5	expect	VB	O	expect	_	0	SENT_59	[p7l1573t2470r1845b2554],
6	it	PRP	O	it	nsubj	8	SENT_59	[p7l1861t2454r1922b2532],
7	to	TO	O	to	aux	8	SENT_59	[p7l1939t2470r2018b2532],
8	do	VB	O	do	xcomp	5	SENT_59	[p7l2043t2454r2147b2532],
9	so	RB	O	so	advmod	8	SENT_59	[p7l12t2607r127b2660],
10	.	.	O	.	_	0	SENT_59	[p7l12t2607r127b2660],

1	Market	NN	O	market	nn	2	SENT_60	[p7l168t2582r475b2661],
2	theory	NN	O	theory	nsubj	3	SENT_60	[p7l508t2581r778b2682],
3	suggests	VBZ	O	suggest	_	0	SENT_60	[p7l812t2598r1177b2682],
4	that	IN	O	that	complm	7	SENT_60	[p7l1217t2582r1385b2660],
5	sponsors	NNS	O	sponsor	nsubj	7	SENT_60	[p7l1418t2607r1803b2682],
6	will	MD	O	will	aux	7	SENT_60	[p7l1838t2582r1995b2661],
7	invest	VB	O	invest	ccomp	3	SENT_60	[p7l2031t2582r2147b2659, p7l6t2726r175b2789],
8	in	IN	O	in	_	0	SENT_60	[p7l190t2710r272b2787],
9	the	DT	O	the	det	10	SENT_60	[p7l294t2710r424b2788],
10	research	NN	O	research	prep_in	7	SENT_60	[p7l446t2710r803b2788],
11	necessary	JJ	O	necessary	amod	10	SENT_60	[p7l825t2735r1235b2810],
12	to	TO	O	to	aux	13	SENT_60	[p7l1253t2726r1333b2788],
13	identify	VB	O	identify	xcomp	11	SENT_60	[p7l1355t2709r1678b2810],
14	subgroups	NNS	O	subgroup	dobj	13	SENT_60	[p7l1697t2710r2145b2810],

1	502	CD	NUMBER	502	num	5	SENT_61	[p7l149t2885r205b2907],
2	N	NN	O	n	nn	5	SENT_61	[p7l917t2887r930b2902],
3	ENGLJMED35	NN	O	engljmed35	nn	5	SENT_61	[p7l946t2886r1170b2908],
4	'	''	O	'	_	0	SENT_61	[p7l946t2886r1170b2908],
5	|	NN	O	|	_	0	SENT_61	[p7l946t2886r1170b2908],
6	;	:	O	;	_	0	SENT_61	[p7l946t2886r1170b2908],
7	5	CD	NUMBER	5	dep	5	SENT_61	[p7l946t2886r1170b2908],
8	WWW	NNP	O	WWW	dep	7	SENT_61	[p7l1204t2887r1317b2902],
9	.	.	O	.	_	0	SENT_61	[p7l1204t2887r1317b2902],

1	NE	NN	O	ne	nn	3	SENT_62	[p7l1204t2887r1317b2902],
2	M.oRG	NN	O	m.org	nn	3	SENT_62	[p7l1333t2886r1416b2902],
3	JULY	NN	DATE	july	_	0	SENT_62	[p7l1449t2887r1510b2908],
4	29	CD	DATE	29	dep	3	SENT_62	[p7l1522t2886r1560b2908],
5	,	,	O	,	_	0	SENT_62	[p7l1522t2886r1560b2908],
6	2oo4	CD	NUMBER	2oo4	appos	4	SENT_62	[p7l1573t2886r1641b2908],

1	The	DT	O	the	det	5	SENT_63	[p7l935t2919r986b2943],
2	New	NNP	O	New	nn	5	SENT_63	[p7l995t2920r1057b2943],
3	England	NNP	O	England	nn	5	SENT_63	[p7l1066t2919r1177b2950],
4	Journal	NNP	O	Journal	nn	5	SENT_63	[p7l1186t2919r1283b2943],
5	o	NN	O	o	_	0	SENT_63	[p7l1293t2927r1308b2943],
6	edicine	NN	O	edicine	dep	5	SENT_63	[p7l1359t2919r1454b2943],

1	Downloaded	VBN	O	download	_	0	SENT_64	[p7l377t2960r547b2983],
2	from	IN	O	from	_	0	SENT_64	[p7l556t2960r620b2983],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_64	[p7l629t2960r747b2990],
4	at	IN	O	at	_	0	SENT_64	[p7l758t2964r781b2983],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_64	[p7l789t2960r972b2983],
6	on	IN	O	on	_	0	SENT_64	[p7l981t2967r1014b2983],
7	January	NNP	DATE	January	prep_on	1	SENT_64	[p7l1022t2960r1125b2990],
8	5	CD	DATE	5	num	7	SENT_64	[p7l1135t2960r1158b2987],
9	,	,	DATE	,	_	0	SENT_64	[p7l1135t2960r1158b2987],
10	2014	CD	DATE	2014	num	7	SENT_64	[p7l1169t2960r1241b2983],
11	.	.	O	.	_	0	SENT_64	[p7l1169t2960r1241b2983],

1	For	IN	O	for	_	0	SENT_65	[p7l1251t2960r1298b2983],
2	personal	JJ	O	personal	amod	3	SENT_65	[p7l1306t2960r1418b2990],
3	use	NN	O	use	pobj	1	SENT_65	[p7l1427t2967r1471b2983],
4	only	RB	O	only	advmod	3	SENT_65	[p7l1481t2960r1545b2990],
5	.	.	O	.	_	0	SENT_65	[p7l1481t2960r1545b2990],

1	No	DT	O	no	det	3	SENT_66	[p7l1556t2960r1596b2983],
2	other	JJ	O	other	amod	3	SENT_66	[p7l1606t2960r1674b2983],
3	uses	NNS	O	use	_	0	SENT_66	[p7l1682t2967r1738b2983],
4	without	IN	O	without	_	0	SENT_66	[p7l1748t2960r1849b2983],
5	permission	NN	O	permission	prep_without	3	SENT_66	[p7l1858t2960r2010b2990],
6	.	.	O	.	_	0	SENT_66	[p7l1858t2960r2010b2990],

1	Copyright	NN	O	copyright	_	0	SENT_67	[p7l727t3001r862b3032],
2	©	CD	NUMBER	©	num	6	SENT_67	[p7l871t3001r895b3025],
3	2004	CD	DATE	2004	num	6	SENT_67	[p7l905t3001r970b3025],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_67	[p7l979t3001r1170b3025],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_67	[p7l1180t3001r1288b3025],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_67	[p7l1299t3001r1404b3032],
7	.	.	O	.	_	0	SENT_67	[p7l1299t3001r1404b3032],

1	All	DT	O	all	det	2	SENT_68	[p7l1415t3001r1456b3025],
2	rights	NNS	O	rights	nsubj	3	SENT_68	[p7l1465t3001r1540b3032],
3	reserved	VBN	O	reserve	_	0	SENT_68	[p7l1550t3001r1669b3025],
4	.	.	O	.	_	0	SENT_68	[p7l1550t3001r1669b3025],

1	SOUNDING	VBG	O	sound	_	0	SENT_69	[p7l921t3045r1109b3064],
2	BOARD	NNP	O	BOARD	dobj	1	SENT_69	[p7l1123t3045r1236b3064],

1	Table	NNP	O	Table	_	0	SENT_70	[p8l263t74r334b99],
2	1	CD	NUMBER	1	dep	1	SENT_70	[p8l344t76r366b99],
3	.	.	O	.	_	0	SENT_70	[p8l344t76r366b99],

1	Accelerated	VBN	O	accelerate	_	0	SENT_71	[p8l375t74r532b99],
2	Approval	NN	O	approval	dobj	1	SENT_71	[p8l542t74r664b107],
3	of	IN	O	of	_	0	SENT_71	[p8l674t74r705b99],
4	Drugs	NNS	O	drug	prep_of	2	SENT_71	[p8l710t76r792b107],
5	for	IN	O	for	_	0	SENT_71	[p8l800t74r839b99],
6	the	DT	O	the	det	7	SENT_71	[p8l846t74r890b99],
7	Treatment	NN	O	treatment	prep_for	4	SENT_71	[p8l898t76r1038b99],
8	of	IN	O	of	_	0	SENT_71	[p8l1046t74r1077b99],
9	Cancer	NN	O	cancer	prep_of	7	SENT_71	[p8l1080t76r1175b99],
10	as	IN	O	as	_	0	SENT_71	[p8l1183t82r1212b99],
11	ofjune	JJ	O	ofjune	amod	12	SENT_71	[p8l1221t74r1317b106],
12	2004	CD	DATE	2004	prep_as	1	SENT_71	[p8l1326t76r1399b99],
13	.	.	O	.	_	0	SENT_71	[p8l1326t76r1399b99],

1	Year	NN	DURATION	year	_	0	SENT_72	[p8l826t143r881b164],
2	of	IN	O	of	_	0	SENT_72	[p8l888t140r917b164],
3	Response	NN	O	response	nn	4	SENT_72	[p8l1505t143r1627b171],
4	Post-Marketing	NN	O	post-marketing	prep_of	1	SENT_72	[p8l1682t141r1878b172],

1	Drug	NN	O	drug	nn	6	SENT_73	[p8l265t180r329b209],
2	or	CC	O	or	_	0	SENT_73	[p8l337t186r363b202],
3	Biologic	JJ	O	biologic	nn	6	SENT_73	[p8l372t178r473b209],
4	Agent	NNP	O	Agent	nn	6	SENT_73	[p8l481t180r557b209],
5	(	NNP	O	(	nn	6	SENT_73	[p8l566t178r643b209],
6	Trade	NNP	O	Trade	_	0	SENT_73	[p8l566t178r643b209],
7	Name	VB	O	name	rcmod	6	SENT_73	[p8l654t180r737b209],
8	)	CD	NUMBER	)	dobj	7	SENT_73	[p8l654t180r737b209],
9	Approval	NNP	O	Approval	nn	13	SENT_73	[p8l812t178r926b209],
10	Indication	NNP	O	Indication	nn	13	SENT_73	[p8l1153t178r1278b202],
11	Rate	NNP	O	Rate	nn	13	SENT_73	[p8l1531t180r1601b202],
12	*	NNP	O	*	nn	13	SENT_73	[p8l1531t180r1601b202],
13	Status	NNP	O	Status	dep	7	SENT_73	[p8l1738t180r1819b202],

1	Liposomal	JJ	O	liposomal	dep	217	SENT_74	[p8l266t285r406b318],
2	doxorubicin	NN	O	doxorubicin	dep	217	SENT_74	[p8l417t285r577b311],
3	(	CD	NUMBER	(	dep	217	SENT_74	[p8l591t285r679b318],
4	Doxil	NNP	O	Doxil	dep	217	SENT_74	[p8l591t285r679b318],
5	)	CD	NUMBER	)	dep	217	SENT_74	[p8l591t285r679b318],
6	1995	CD	DATE	1995	dep	217	SENT_74	[p8l839t288r900b311],
7	Kaposi	NN	PERSON	kaposus	dep	217	SENT_74	[p8l968t287r1073b316],
8	's	POS	O	's	dep	217	SENT_74	[p8l968t287r1073b316],
9	sarcoma	NN	O	sarcoma	dep	217	SENT_74	[p8l1084t294r1192b309],
10	27-48	CD	NUMBER	27-48	dep	217	SENT_74	[p8l1524t287r1605b311],
11	Not	RB	O	not	dep	217	SENT_74	[p8l1668t288r1715b309],
12	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t290r1759b316],
13	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t286r1888b317],
14	Dexrazoxane	NN	O	dexrazoxane	dep	217	SENT_74	[p8l266t338r438b361],
15	(	NN	O	(	dep	217	SENT_74	[p8l451t335r589b368],
16	Zinecard	NN	O	zinecard	dep	217	SENT_74	[p8l451t335r589b368],
17	)	CD	NUMBER	)	dep	217	SENT_74	[p8l451t335r589b368],
18	1995	CD	DATE	1995	dep	217	SENT_74	[p8l839t338r900b361],
19	Reduction	NN	O	reduction	dep	217	SENT_74	[p8l968t336r1095b359],
20	ofdoxorubicin	NN	O	ofdoxorubicin	dep	217	SENT_74	[p8l1105t335r1288b359],
21	toxicity	NN	O	toxicity	dep	217	SENT_74	[p8l1297t338r1388b367],
22	NA	NNP	O	NA	dep	217	SENT_74	[p8l1545t337r1587b360],
23	Regular	JJ	O	regular	dep	217	SENT_74	[p8l1668t336r1764b367],
24	approval	NN	O	approval	dep	217	SENT_74	[p8l1773t336r1881b366],
25	Amifostine	NN	O	amifostine	dep	217	SENT_74	[p8l263t385r413b411],
26	(	CD	NUMBER	(	dep	217	SENT_74	[p8l426t385r527b418],
27	Ethyol	NN	O	ethyol	dep	217	SENT_74	[p8l426t385r527b418],
28	)	CD	NUMBER	)	dep	217	SENT_74	[p8l426t385r527b418],
29	1996	CD	DATE	1996	dep	217	SENT_74	[p8l839t388r902b411],
30	Reduction	NN	O	reduction	dep	217	SENT_74	[p8l968t386r1095b409],
31	ofcisplatin	NN	O	ofcisplatin	dep	217	SENT_74	[p8l1105t385r1244b416],
32	toxicity	NN	O	toxicity	dep	217	SENT_74	[p8l1254t388r1344b416],
33	NA	NNP	O	NA	dep	217	SENT_74	[p8l1545t387r1587b410],
34	Not	RB	O	not	dep	217	SENT_74	[p8l1668t388r1715b409],
35	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t390r1759b416],
36	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t386r1888b417],
37	Docetaxel	NNP	O	Docetaxel	dep	217	SENT_74	[p8l266t435r396b461],
38	(	CD	NUMBER	(	dep	217	SENT_74	[p8l410t438r541b468],
39	Taxotere	NNP	O	Taxotere	dep	217	SENT_74	[p8l410t438r541b468],
40	)	CD	NUMBER	)	dep	217	SENT_74	[p8l410t438r541b468],
41	1996	CD	DATE	1996	dep	217	SENT_74	[p8l839t438r901b461],
42	Breast	NN	O	breast	dep	217	SENT_74	[p8l968t438r1047b459],
43	cancer	NN	O	cancer	dep	217	SENT_74	[p8l1056t444r1140b459],
44	35	CD	NUMBER	35	dep	217	SENT_74	[p8l1549t438r1578b461],
45	Regular	JJ	O	regular	dep	217	SENT_74	[p8l1668t436r1764b467],
46	approval	NN	O	approval	dep	217	SENT_74	[p8l1773t436r1881b466],
47	lrinotecan	NN	O	lrinotecan	dep	217	SENT_74	[p8l266t488r401b511],
48	(	CD	NUMBER	(	dep	217	SENT_74	[p8l415t487r583b518],
49	Camptosar	NNP	O	Camptosar	dep	217	SENT_74	[p8l415t487r583b518],
50	)	CD	NUMBER	)	dep	217	SENT_74	[p8l415t487r583b518],
51	1996	CD	DATE	1996	dep	217	SENT_74	[p8l839t488r902b511],
52	Colon	NN	O	colon	dep	217	SENT_74	[p8l967t486r1039b509],
53	cancer	NN	O	cancer	dep	217	SENT_74	[p8l1050t494r1133b509],
54	Regular	JJ	O	regular	dep	217	SENT_74	[p8l1668t486r1764b517],
55	approval	NN	O	approval	dep	217	SENT_74	[p8l1773t486r1881b516],
56	Capecitabine	NN	O	capecitabine	dep	217	SENT_74	[p8l265t535r440b568],
57	(	CD	NUMBER	(	dep	217	SENT_74	[p8l453t535r563b568],
58	Xeloda	NNP	LOCATION	Xeloda	dep	217	SENT_74	[p8l453t535r563b568],
59	)	CD	NUMBER	)	dep	217	SENT_74	[p8l453t535r563b568],
60	1998	CD	DATE	1998	dep	217	SENT_74	[p8l839t537r901b561],
61	Breast	NN	O	breast	dep	217	SENT_74	[p8l968t538r1047b559],
62	cancer	NN	O	cancer	dep	217	SENT_74	[p8l1056t544r1140b559],
63	26	CD	NUMBER	26	dep	217	SENT_74	[p8l1549t538r1580b561],
64	Regular	JJ	O	regular	dep	217	SENT_74	[p8l1668t536r1764b567],
65	approval	NN	O	approval	dep	217	SENT_74	[p8l1773t536r1881b566],
66	Liposomal	JJ	O	liposomal	dep	217	SENT_74	[p8l266t585r406b618],
67	doxorubicin	NN	O	doxorubicin	dep	217	SENT_74	[p8l417t585r577b611],
68	(	CD	NUMBER	(	dep	217	SENT_74	[p8l591t585r679b618],
69	Doxil	NNP	O	Doxil	dep	217	SENT_74	[p8l591t585r679b618],
70	)	CD	NUMBER	)	dep	217	SENT_74	[p8l591t585r679b618],
71	1999	CD	DATE	1999	dep	217	SENT_74	[p8l839t588r901b611],
72	Ovarian	JJ	MISC	ovarian	dep	217	SENT_74	[p8l967t587r1066b609],
73	cancer	NN	O	cancer	dep	217	SENT_74	[p8l1077t594r1160b609],
74	Not	RB	O	not	dep	217	SENT_74	[p8l1668t588r1715b609],
75	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t590r1759b616],
76	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t586r1888b617],
77	Temozolomide	NNP	O	Temozolomide	dep	217	SENT_74	[p8l263t635r467b661],
78	(	CD	NUMBER	(	dep	217	SENT_74	[p8l480t635r614b668],
79	Temodal	JJ	O	temodal	dep	217	SENT_74	[p8l480t635r614b668],
80	)	NN	O	)	dep	217	SENT_74	[p8l480t635r614b668],
81	1999	CD	DATE	1999	dep	217	SENT_74	[p8l839t638r901b661],
82	Anaplastic	JJ	MISC	anaplastic	dep	217	SENT_74	[p8l965t636r1100b666],
83	astrocytoma	NN	O	astrocytoma	dep	217	SENT_74	[p8l1109t640r1266b666],
84	22	CD	NUMBER	22	dep	217	SENT_74	[p8l1549t638r1579b660],
85	Not	RB	O	not	dep	217	SENT_74	[p8l1668t638r1715b659],
86	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t640r1759b666],
87	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t636r1888b667],
88	Denileukin	JJ	O	denileukin	dep	217	SENT_74	[p8l266t685r410b711],
89	diftitox	NN	O	diftitox	dep	217	SENT_74	[p8l421t685r515b711],
90	(	NN	O	(	dep	217	SENT_74	[p8l527t685r628b718],
91	Ontak	NN	O	ontak	dep	217	SENT_74	[p8l527t685r628b718],
92	)	CD	NUMBER	)	dep	217	SENT_74	[p8l527t685r628b718],
93	1999	CD	DATE	1999	dep	217	SENT_74	[p8l839t688r901b711],
94	Cutaneous	JJ	MISC	cutaneous	dep	217	SENT_74	[p8l967t687r1103b709],
95	T-cell	NN	MISC	t-cell	dep	217	SENT_74	[p8l1112t686r1179b709],
96	lymphoma	NN	O	lymphoma	dep	217	SENT_74	[p8l1191t686r1325b717],
97	Not	RB	O	not	dep	217	SENT_74	[p8l1668t688r1715b709],
98	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t690r1759b716],
99	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t686r1888b717],
100	Liposomal	JJ	O	liposomal	dep	217	SENT_74	[p8l266t735r406b768],
101	cytarabine	NN	O	cytarabine	dep	217	SENT_74	[p8l417t735r556b768],
102	(	CD	NUMBER	(	dep	217	SENT_74	[p8l569t737r704b768],
103	DepoCyt	NNP	O	DepoCyt	dep	217	SENT_74	[p8l569t737r704b768],
104	)	CD	NUMBER	)	dep	217	SENT_74	[p8l569t737r704b768],
105	1999	CD	DATE	1999	dep	217	SENT_74	[p8l839t738r901b761],
106	Lymphomatous	JJ	O	lymphomatous	dep	217	SENT_74	[p8l968t736r1166b766],
107	meningitis	NN	O	meningitis	dep	217	SENT_74	[p8l1177t738r1311b767],
108	41	CD	NUMBER	41	dep	217	SENT_74	[p8l1548t738r1579b760],
109	Not	RB	O	not	dep	217	SENT_74	[p8l1668t738r1715b759],
110	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t740r1759b766],
111	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t736r1888b767],
112	Celecoxib	NNP	MISC	Celecoxib	dep	217	SENT_74	[p8l265t785r392b811],
113	(	CD	NUMBER	(	dep	217	SENT_74	[p8l405t785r538b818],
114	Celebrex	NNP	O	Celebrex	dep	217	SENT_74	[p8l405t785r538b818],
115	)	CD	NUMBER	)	dep	217	SENT_74	[p8l405t785r538b818],
116	1999	CD	DATE	1999	dep	217	SENT_74	[p8l839t788r901b811],
117	Reduction	NN	O	reduction	dep	217	SENT_74	[p8l968t786r1095b809],
118	ofcolonic	JJ	O	ofcolonic	dep	217	SENT_74	[p8l1105t785r1230b809],
119	polyps	NNS	O	polyp	dep	217	SENT_74	[p8l1240t786r1320b817],
120	NA	NNP	O	NA	dep	217	SENT_74	[p8l1545t787r1587b810],
121	Not	RB	O	not	dep	217	SENT_74	[p8l1668t788r1715b809],
122	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t790r1759b816],
123	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t786r1888b817],
124	Gemtuzumab	JJ	O	gemtuzumab	dep	217	SENT_74	[p8l265t835r453b861],
125	ozogamicin	NN	O	ozogamicin	dep	217	SENT_74	[p8l462t838r619b869],
126	(	NN	O	(	dep	217	SENT_74	[p8l632t835r771b869],
127	Mylotarg	NN	LOCATION	mylotarg	dep	217	SENT_74	[p8l632t835r771b869],
128	)	CD	NUMBER	)	dep	217	SENT_74	[p8l632t835r771b869],
129	2000	CD	DATE	2000	dep	217	SENT_74	[p8l837t837r902b861],
130	Acute	JJ	O	acute	dep	217	SENT_74	[p8l965t837r1038b859],
131	myelogenous	JJ	O	myelogenous	dep	217	SENT_74	[p8l1049t836r1218b867],
132	leukemia	NN	O	leukemia	dep	217	SENT_74	[p8l1229t836r1342b859],
133	Not	RB	O	not	dep	217	SENT_74	[p8l1668t838r1715b859],
134	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t840r1759b866],
135	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t836r1888b867],
136	Alemtuzumab	NNP	O	Alemtuzumab	dep	217	SENT_74	[p8l263t885r457b911],
137	(	CD	NUMBER	(	dep	217	SENT_74	[p8l470t885r612b918],
138	Campath	NNP	O	Campath	dep	217	SENT_74	[p8l470t885r612b918],
139	)	CD	NUMBER	)	dep	217	SENT_74	[p8l470t885r612b918],
140	2001	CD	DATE	2001	dep	217	SENT_74	[p8l837t887r900b911],
141	Chronic	JJ	O	chronic	dep	217	SENT_74	[p8l967t886r1066b909],
142	lymphocytic	JJ	O	lymphocytic	dep	217	SENT_74	[p8l1076t886r1228b917],
143	leukemia	NN	O	leukemia	dep	217	SENT_74	[p8l1238t886r1352b909],
144	Not	RB	O	not	dep	217	SENT_74	[p8l1668t888r1715b909],
145	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t890r1759b916],
146	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t886r1888b917],
147	lmatinib	NN	O	lmatinib	dep	217	SENT_74	[p8l266t935r378b961],
148	mesylate	NN	O	mesylate	dep	217	SENT_74	[p8l390t935r509b968],
149	(	CD	NUMBER	(	dep	217	SENT_74	[p8l521t935r646b968],
150	Gleevec	NNP	O	Gleevec	dep	217	SENT_74	[p8l521t935r646b968],
151	)	CD	NUMBER	)	dep	217	SENT_74	[p8l521t935r646b968],
152	2001	CD	DATE	2001	dep	217	SENT_74	[p8l837t937r900b961],
153	Chronic	JJ	O	chronic	dep	217	SENT_74	[p8l967t936r1066b959],
154	myelogenous	JJ	O	myelogenous	dep	217	SENT_74	[p8l1076t936r1245b967],
155	leukemia	NN	O	leukemia	dep	217	SENT_74	[p8l1257t936r1370b959],
156	Regular	JJ	O	regular	dep	217	SENT_74	[p8l1668t936r1764b967],
157	approval	NN	O	approval	dep	217	SENT_74	[p8l1773t936r1881b966],
158	lmatinib	NN	O	lmatinib	dep	217	SENT_74	[p8l266t985r378b1011],
159	mesylate	NN	O	mesylate	dep	217	SENT_74	[p8l390t985r509b1018],
160	(	CD	NUMBER	(	dep	217	SENT_74	[p8l521t985r646b1018],
161	Gleevec	NNP	O	Gleevec	dep	217	SENT_74	[p8l521t985r646b1018],
162	)	CD	NUMBER	)	dep	217	SENT_74	[p8l521t985r646b1018],
163	2002	CD	DATE	2002	dep	217	SENT_74	[p8l837t987r901b1011],
164	Gastrointestinal	JJ	O	gastrointestinal	dep	217	SENT_74	[p8l967t986r1171b1009],
165	stromal	JJ	O	stromal	dep	217	SENT_74	[p8l1182t986r1278b1009],
166	tumor	NN	O	tumor	dep	217	SENT_74	[p8l1287t990r1367b1009],
167	Not	RB	O	not	dep	217	SENT_74	[p8l1668t988r1715b1009],
168	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t990r1759b1016],
169	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t986r1888b1017],
170	lbritumomab	NN	O	lbritumomab	dep	217	SENT_74	[p8l266t1035r445b1061],
171	tiuxetan	NN	O	tiuxetan	dep	217	SENT_74	[p8l454t1038r561b1061],
172	(	CD	NUMBER	(	dep	217	SENT_74	[p8l576t1035r693b1068],
173	Zevalin	NN	O	zevalin	dep	217	SENT_74	[p8l576t1035r693b1068],
174	)	CD	NUMBER	)	dep	217	SENT_74	[p8l576t1035r693b1068],
175	2002	CD	DATE	2002	dep	217	SENT_74	[p8l837t1037r901b1061],
176	Low-grade	JJ	O	low-grade	dep	217	SENT_74	[p8l968t1036r1099b1067],
177	non-Hodgkin	JJ	O	non-hodgkin	dep	217	SENT_74	[p8l1109t1036r1299b1067],
178	's	POS	O	's	dep	217	SENT_74	[p8l1109t1036r1299b1067],
179	lymphoma	NN	O	lymphoma	dep	217	SENT_74	[p8l1310t1036r1445b1066],
180	Not	RB	O	not	dep	217	SENT_74	[p8l1668t1038r1715b1059],
181	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t1040r1759b1066],
182	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t1036r1888b1067],
183	Oxaliplatin	NN	O	oxaliplatin	dep	217	SENT_74	[p8l265t1085r410b1118],
184	(	CD	NUMBER	(	dep	217	SENT_74	[p8l425t1085r550b1118],
185	Eloxatin	NNP	O	Eloxatin	dep	217	SENT_74	[p8l425t1085r550b1118],
186	)	CD	NUMBER	)	dep	217	SENT_74	[p8l425t1085r550b1118],
187	2002	CD	DATE	2002	dep	217	SENT_74	[p8l837t1087r901b1111],
188	Colon	NN	O	colon	dep	217	SENT_74	[p8l967t1086r1039b1109],
189	cancer	NN	O	cancer	dep	217	SENT_74	[p8l1050t1094r1133b1109],
190	Regular	JJ	O	regular	dep	217	SENT_74	[p8l1668t1086r1764b1117],
191	approval	NN	O	approval	dep	217	SENT_74	[p8l1773t1086r1881b1116],
192	Anastrozole	NNP	O	Anastrozole	dep	217	SENT_74	[p8l263t1135r427b1161],
193	(	CD	NUMBER	(	dep	217	SENT_74	[p8l440t1135r579b1168],
194	Arimidex	NNP	O	Arimidex	dep	217	SENT_74	[p8l440t1135r579b1168],
195	)	CD	NUMBER	)	dep	217	SENT_74	[p8l440t1135r579b1168],
196	2002	CD	DATE	2002	dep	217	SENT_74	[p8l837t1137r901b1161],
197	Breast	NN	O	breast	dep	217	SENT_74	[p8l968t1138r1047b1159],
198	cancer	NN	O	cancer	dep	217	SENT_74	[p8l1056t1144r1140b1159],
199	Not	RB	O	not	dep	217	SENT_74	[p8l1668t1138r1715b1159],
200	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t1140r1759b1166],
201	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t1136r1888b1167],
202	lmatinib	NN	O	lmatinib	dep	217	SENT_74	[p8l266t1185r378b1211],
203	mesylate	NN	O	mesylate	dep	217	SENT_74	[p8l390t1185r509b1218],
204	(	CD	NUMBER	(	dep	217	SENT_74	[p8l521t1185r646b1218],
205	Gleevec	NNP	O	Gleevec	dep	217	SENT_74	[p8l521t1185r646b1218],
206	)	CD	NUMBER	)	dep	217	SENT_74	[p8l521t1185r646b1218],
207	2002	CD	DATE	2002	dep	217	SENT_74	[p8l837t1187r901b1211],
208	Newly	RB	O	newly	dep	217	SENT_74	[p8l968t1186r1044b1217],
209	diagnosed	VBD	O	diagnose	dep	217	SENT_74	[p8l1053t1186r1184b1217],
210	chronic	JJ	O	chronic	dep	217	SENT_74	[p8l1195t1186r1290b1209],
211	myeloge	NN	O	myeloge	dep	217	SENT_74	[p8l1300t1186r1413b1217],
212	-	:	O	-	_	0	SENT_74	[p8l1300t1186r1413b1217],
213	Not	RB	O	not	dep	217	SENT_74	[p8l1668t1188r1715b1209],
214	yet	RB	O	yet	dep	217	SENT_74	[p8l1723t1190r1759b1216],
215	upgraded	VBN	O	upgrade	dep	217	SENT_74	[p8l1769t1186r1888b1217],
216	nous	JJ	O	nous	dep	217	SENT_74	[p8l1018t1231r1078b1247],
217	leukemia	NN	O	leukemia	_	0	SENT_74	[p8l1089t1223r1202b1247],

1	Gefitinib	JJ	O	gefitinib	amod	7	SENT_75	[p8l265t1271r381b1296],
2	(	NN	O	(	nn	7	SENT_75	[p8l394t1273r493b1304],
3	lressa	NN	O	lressa	nn	7	SENT_75	[p8l394t1273r493b1304],
4	)	CD	NUMBER	)	num	7	SENT_75	[p8l394t1273r493b1304],
5	2003	CD	DATE	2003	num	7	SENT_75	[p8l837t1272r900b1296],
6	Non-small-cell	JJ	O	non-small-cell	amod	7	SENT_75	[p8l968t1271r1158b1295],
7	lung	NN	O	lung	dep	13	SENT_75	[p8l1170t1271r1225b1302],
8	cancer	NN	O	cancer	nn	10	SENT_75	[p8l1234t1279r1317b1295],
9	Recent	JJ	O	recent	amod	10	SENT_75	[p8l1668t1273r1753b1295],
10	approval	NN	O	approval	dep	7	SENT_75	[p8l1762t1271r1871b1302],
11	Bortezomib	NN	O	bortezomib	dep	13	SENT_75	[p8l266t1321r424b1346],
12	(	CD	NUMBER	(	num	11	SENT_75	[p8l437t1321r558b1354],
13	Velcade	NNP	O	Velcade	dep	21	SENT_75	[p8l437t1321r558b1354],
14	)	CD	NUMBER	)	num	13	SENT_75	[p8l437t1321r558b1354],
15	2003	CD	DATE	2003	num	17	SENT_75	[p8l837t1322r900b1346],
16	Multiple	JJ	O	multiple	amod	17	SENT_75	[p8l968t1321r1073b1352],
17	myeloma	NN	O	myeloma	dep	13	SENT_75	[p8l1083t1321r1199b1352],
18	Recent	JJ	O	recent	amod	21	SENT_75	[p8l1668t1323r1753b1345],
19	approval	NN	O	approval	nn	21	SENT_75	[p8l1762t1321r1871b1352],
20	Tositu	NN	O	tositu	nn	21	SENT_75	[p8l263t1373r344b1396],
21	momab	NN	O	momab	dep	29	SENT_75	[p8l350t1371r453b1396],
22	(	CD	NUMBER	(	num	23	SENT_75	[p8l467t1373r572b1404],
23	Bexxar	NNP	ORGANIZATION	Bexxar	dep	21	SENT_75	[p8l467t1373r572b1404],
24	)	CD	NUMBER	)	num	23	SENT_75	[p8l467t1373r572b1404],
25	2003	CD	DATE	2003	num	29	SENT_75	[p8l837t1372r900b1396],
26	Low-grade	JJ	O	low-grade	amod	29	SENT_75	[p8l968t1371r1099b1402],
27	non-Hodgkin	JJ	O	non-hodgkin	amod	29	SENT_75	[p8l1109t1371r1299b1402],
28	‘	NN	O	‘	nn	29	SENT_75	[p8l1109t1371r1299b1402],
29	s	NNS	O	s	dep	33	SENT_75	[p8l1109t1371r1299b1402],
30	lymphoma	NN	O	lymphoma	nn	32	SENT_75	[p8l1310t1371r1445b1402],
31	Recent	JJ	O	recent	amod	32	SENT_75	[p8l1668t1373r1753b1395],
32	approval	NN	O	approval	dep	29	SENT_75	[p8l1762t1371r1871b1402],
33	Cetuximab	NNP	O	Cetuximab	dep	41	SENT_75	[p8l265t1421r408b1446],
34	(	CD	NUMBER	(	num	33	SENT_75	[p8l422t1421r535b1454],
35	Erbitux	NNP	ORGANIZATION	Erbitux	dep	33	SENT_75	[p8l422t1421r535b1454],
36	)	CD	NUMBER	)	num	35	SENT_75	[p8l422t1421r535b1454],
37	2004	CD	DATE	2004	num	39	SENT_75	[p8l837t1422r901b1446],
38	Colon	NN	O	colon	nn	39	SENT_75	[p8l967t1421r1039b1445],
39	cancer	NN	O	cancer	dep	35	SENT_75	[p8l1050t1429r1133b1445],
40	Recent	JJ	O	recent	amod	41	SENT_75	[p8l1668t1423r1753b1445],
41	approval	NN	O	approval	_	0	SENT_75	[p8l1762t1421r1871b1452],

1	*	NN	O	*	nn	3	SENT_76	[p8l237t1515r251b1528],
2	Response	NN	O	response	nn	3	SENT_76	[p8l264t1515r386b1543],
3	rates	NNS	O	rate	nsubj	4	SENT_76	[p8l397t1517r456b1536],
4	are	VBP	O	be	_	0	SENT_76	[p8l467t1521r505b1536],
5	from	IN	O	from	_	0	SENT_76	[p8l513t1512r573b1536],
6	studies	NNS	O	study	prep_from	4	SENT_76	[p8l584t1513r674b1536],
7	that	WDT	O	that	nsubj	9	SENT_76	[p8l684t1513r734b1536],
8	directly	RB	O	directly	advmod	9	SENT_76	[p8l743t1513r835b1543],
9	supported	VBD	O	support	rcmod	6	SENT_76	[p8l844t1513r973b1543],
10	approval	NN	O	approval	dobj	9	SENT_76	[p8l984t1513r1093b1543],
11	in	IN	O	in	_	0	SENT_76	[p8l1104t1515r1125b1536],
12	the	DT	O	the	det	15	SENT_76	[p8l1134t1513r1174b1536],
13	ﬁrst	NN	O	ﬁrst	nn	15	SENT_76	[p8l1183t1512r1233b1536],
14	marketing	NN	O	marketing	nn	15	SENT_76	[p8l1243t1513r1371b1544],
15	claim	NN	O	claim	prep_in	9	SENT_76	[p8l1380t1513r1447b1536],
16	for	IN	O	for	_	0	SENT_76	[p8l1457t1512r1492b1536],
17	the	DT	O	the	det	18	SENT_76	[p8l1500t1513r1540b1536],
18	agent	NN	O	agent	prep_for	9	SENT_76	[p8l1549t1517r1626b1544],
19	.	.	O	.	_	0	SENT_76	[p8l1549t1517r1626b1544],

1	Response	NN	O	response	nn	2	SENT_77	[p8l1638t1515r1760b1543],
2	data	NNS	O	datum	nsubjpass	4	SENT_77	[p8l1769t1513r1823b1536],
3	were	VBD	O	be	auxpass	4	SENT_77	[p8l1832t1521r1892b1536],
4	obtained	VBN	O	obtain	_	0	SENT_77	[p8l262t1550r373b1574],
5	either	CC	O	either	preconj	4	SENT_77	[p8l383t1550r456b1574],
6	from	IN	O	from	_	0	SENT_77	[p8l464t1550r524b1574],
7	the	DT	O	the	det	10	SENT_77	[p8l533t1550r573b1574],
8	FDA	NNP	ORGANIZATION	FDA	nn	10	SENT_77	[p8l585t1552r639b1573],
9	Web	NN	O	web	nn	10	SENT_77	[p8l646t1550r701b1574],
10	site	NN	O	site	prep_from	4	SENT_77	[p8l711t1552r754b1574],
11	or	CC	O	or	_	0	SENT_77	[p8l764t1558r790b1574],
12	from	IN	O	from	_	0	SENT_77	[p8l798t1550r857b1574],
13	the	DT	O	the	det	15	SENT_77	[p8l867t1550r907b1574],
14	product	NN	O	product	nn	15	SENT_77	[p8l918t1550r1016b1581],
15	label	NN	O	label	conj_or	10	SENT_77	[p8l1026t1550r1091b1574],
16	.	.	O	.	_	0	SENT_77	[p8l1026t1550r1091b1574],

1	Because	IN	O	because	mark	6	SENT_78	[p8l1103t1552r1207b1574],
2	the	DT	O	the	det	3	SENT_78	[p8l1215t1550r1255b1574],
3	studies	NNS	O	study	nsubjpass	6	SENT_78	[p8l1265t1550r1355b1574],
4	were	VBD	O	be	auxpass	6	SENT_78	[p8l1364t1558r1424b1574],
5	often	RB	O	often	advmod	6	SENT_78	[p8l1433t1550r1497b1574],
6	performed	VBN	O	perform	advcl	23	SENT_78	[p8l1509t1550r1640b1581],
7	in	IN	O	in	_	0	SENT_78	[p8l1652t1552r1672b1573],
8	patients	NNS	O	patient	prep_in	6	SENT_78	[p8l1684t1552r1785b1581],
9	whose	WP$	O	whose	poss	10	SENT_78	[p8l1794t1550r1876b1574],
10	disease	NN	O	disease	nsubj	13	SENT_78	[p8l262t1587r357b1611],
11	had	VBD	O	have	aux	13	SENT_78	[p8l367t1587r411b1611],
12	become	VBN	O	become	cop	13	SENT_78	[p8l422t1587r522b1611],
13	refractory	JJ	O	refractory	rcmod	8	SENT_78	[p8l532t1587r652b1618],
14	to	TO	O	to	_	0	SENT_78	[p8l660t1592r685b1611],
15	their	PRP$	O	they	poss	17	SENT_78	[p8l693t1587r752b1611],
16	previous	JJ	O	previous	amod	17	SENT_78	[p8l761t1589r868b1618],
17	chemotherapy	NN	O	chemotherapy	prep_to	13	SENT_78	[p8l878t1587r1064b1618],
18	,	,	O	,	_	0	SENT_78	[p8l878t1587r1064b1618],
19	response	NN	O	response	nn	20	SENT_78	[p8l1076t1595r1191b1618],
20	rates	NNS	O	rate	nsubj	23	SENT_78	[p8l1201t1592r1261b1611],
21	may	MD	O	may	aux	23	SENT_78	[p8l1272t1595r1323b1618],
22	be	VB	O	be	cop	23	SENT_78	[p8l1332t1587r1360b1611],
23	higher	JJR	O	higher	_	0	SENT_78	[p8l1370t1587r1450b1619],
24	when	WRB	O	when	advmod	28	SENT_78	[p8l1457t1587r1524b1611],
25	the	DT	O	the	det	26	SENT_78	[p8l1534t1587r1574b1611],
26	agents	NNS	O	agent	nsubjpass	28	SENT_78	[p8l1583t1592r1666b1619],
27	are	VBP	O	be	auxpass	28	SENT_78	[p8l1676t1595r1713b1611],
28	administered	VBN	O	administer	advcl	23	SENT_78	[p8l1723t1587r1890b1611],
29	at	IN	O	at	_	0	SENT_78	[p8l263t1629r285b1649],
30	earlier	JJR	O	earlier	amod	31	SENT_78	[p8l293t1625r373b1649],
31	stages	NNS	O	stage	prep_at	28	SENT_78	[p8l381t1630r461b1656],
32	oftreatment	NN	O	oftreatment	dep	31	SENT_78	[p8l470t1625r635b1649],
33	.	.	O	.	_	0	SENT_78	[p8l470t1625r635b1649],

1	Agents	NNS	O	agent	nsubjpass	10	SENT_79	[p8l644t1627r731b1656],
2	for	IN	O	for	_	0	SENT_79	[p8l740t1625r776b1649],
3	which	WDT	O	which	rel	8	SENT_79	[p8l783t1625r856b1649],
4	no	DT	O	no	det	6	SENT_79	[p8l868t1633r898b1649],
5	response	NN	O	response	nn	6	SENT_79	[p8l908t1633r1023b1656],
6	rate	NN	O	rate	nsubjpass	8	SENT_79	[p8l1033t1629r1080b1649],
7	is	VBZ	O	be	auxpass	8	SENT_79	[p8l1090t1627r1107b1649],
8	noted	VBN	O	note	rcmod	1	SENT_79	[p8l1118t1625r1188b1649],
9	were	VBD	O	be	auxpass	10	SENT_79	[p8l1198t1633r1257b1649],
10	approved	VBN	O	approve	dep	25	SENT_79	[p8l1266t1625r1384b1656],
11	on	IN	O	on	_	0	SENT_79	[p8l1394t1633r1425b1649],
12	the	DT	O	the	det	15	SENT_79	[p8l1434t1625r1474b1649],
13	basis	NN	O	basis	nn	15	SENT_79	[p8l1484t1625r1547b1649],
14	ofsurrogate	NN	O	ofsurrogate	nn	15	SENT_79	[p8l1556t1625r1710b1656],
15	data	NNS	O	datum	prep_on	10	SENT_79	[p8l1719t1625r1772b1649],
16	for	IN	O	for	_	0	SENT_79	[p8l1781t1625r1817b1649],
17	a	DT	O	a	det	20	SENT_79	[p8l1825t1633r1837b1649],
18	clinical	JJ	O	clinical	amod	20	SENT_79	[p8l1846t1625r1899b1649, p8l263t1662r303b1686],
19	beneﬁt	NN	O	beneﬁt	nn	20	SENT_79	[p8l315t1662r401b1686],
20	(	NN	O	(	prep_for	15	SENT_79	[p8l412t1662r479b1693],
21	such	JJ	O	such	_	0	SENT_79	[p8l412t1662r479b1693],
22	as	IN	O	as	_	0	SENT_79	[p8l490t1671r516b1686],
23	the	DT	O	the	det	24	SENT_79	[p8l525t1662r565b1686],
24	results	NNS	O	result	prep_such_as	20	SENT_79	[p8l576t1662r659b1686],
25	ofan	VBP	O	ofan	_	0	SENT_79	[p8l669t1662r730b1686],
26	interim	JJ	O	interim	amod	29	SENT_79	[p8l742t1664r831b1686],
27	analysis	NN	O	analysis	nn	29	SENT_79	[p8l842t1662r942b1693],
28	ofa	NN	O	ofa	nn	29	SENT_79	[p8l952t1662r997b1686],
29	phase	NN	O	phase	dobj	25	SENT_79	[p8l1008t1662r1082b1693],
30	3	CD	NUMBER	3	num	31	SENT_79	[p8l1092t1664r1103b1686],
31	trial	NN	O	trial	nsubj	25	SENT_79	[p8l1113t1662r1161b1686],
32	in	IN	O	in	_	0	SENT_79	[p8l1173t1664r1193b1686],
33	the	DT	O	the	det	35	SENT_79	[p8l1203t1662r1243b1686],
34	cases	NNS	O	case	nn	35	SENT_79	[p8l1252t1670r1321b1686],
35	ofoxaliplatin	NN	O	ofoxaliplatin	prep_in	31	SENT_79	[p8l1331t1662r1493b1693],
36	and	CC	O	and	_	0	SENT_79	[p8l1504t1662r1549b1686],
37	anastrozole	NN	O	anastrozole	nn	38	SENT_79	[p8l1560t1662r1727b1693],
38	)	NN	O	)	prep_in	31	SENT_79	[p8l1560t1662r1727b1693],
39	.	.	O	.	_	0	SENT_79	[p8l1560t1662r1727b1693],

1	NA	NNP	O	NA	nsubj	2	SENT_80	[p8l1739t1664r1778b1686],
2	denotes	VBZ	O	denote	_	0	SENT_80	[p8l1787t1662r1887b1686],
3	not	RB	O	not	neg	4	SENT_80	[p8l263t1704r304b1724],
4	applicable	JJ	O	applicable	acomp	2	SENT_80	[p8l313t1700r449b1731],
5	.	.	O	.	_	0	SENT_80	[p8l313t1700r449b1731],

1	of	IN	O	of	_	0	SENT_81	[p8l7t1956r108b2035],
2	patients	NNS	O	patient	prep_of	21	SENT_81	[p8l118t1957r449b2057],
3	who	WP	O	who	nsubj	5	SENT_81	[p8l477t1957r660b2036],
4	are	VBP	O	be	cop	5	SENT_81	[p8l691t1983r816b2035],
5	likely	JJ	O	likely	rcmod	2	SENT_81	[p8l845t1957r1069b2057],
6	to	TO	O	to	aux	7	SENT_81	[p8l1095t1973r1174b2035],
7	have	VB	O	have	xcomp	5	SENT_81	[p8l1206t1957r1392b2036],
8	responses	NNS	O	response	dobj	7	SENT_81	[p8l1423t1982r1840b2057],
9	only	RB	O	only	advmod	13	SENT_81	[p8l1873t1956r2053b2057],
10	if	IN	O	if	dep	13	SENT_81	[p8l2078t1956r2153b2034],
11	this	DT	O	this	det	12	SENT_81	[p8l7t2085r157b2163],
12	process	NN	O	process	nsubj	13	SENT_81	[p8l179t2110r494b2185],
13	helps	VBZ	O	help	dep	21	SENT_81	[p8l516t2085r737b2185],
14	them	PRP	O	they	nsubj	16	SENT_81	[p8l760t2085r975b2163],
15	to	TO	O	to	aux	16	SENT_81	[p8l995t2101r1073b2163],
16	achieve	VB	O	achieve	xcomp	13	SENT_81	[p8l1095t2084r1398b2164],
17	approval	NN	O	approval	dobj	16	SENT_81	[p8l1418t2085r1777b2185],
18	for	IN	O	for	_	0	SENT_81	[p8l1798t2084r1919b2163],
19	marketing	NN	O	marketing	prep_for	16	SENT_81	[p8l1936t2111r2134b2163, p8l6t2213r298b2313],
20	,	,	O	,	_	0	SENT_81	[p8l1936t2111r2134b2163, p8l6t2213r298b2313],
21	gives	VBZ	O	give	_	0	SENT_81	[p8l343t2213r555b2313],
22	them	PRP	O	they	iobj	21	SENT_81	[p8l597t2213r817b2291],
23	a	DT	O	a	det	25	SENT_81	[p8l856t2239r900b2291],
24	competitive	JJ	O	competitive	amod	25	SENT_81	[p8l939t2213r1440b2313],
25	advantage	NN	O	advantage	dobj	21	SENT_81	[p8l1479t2213r1914b2313],
26	over	IN	O	over	_	0	SENT_81	[p8l1954t2238r2136b2292],
27	another	DT	O	another	det	28	SENT_81	[p8l6t2341r343b2419],
28	product	NN	O	product	prep_over	25	SENT_81	[p8l375t2341r733b2441],
29	,	,	O	,	_	0	SENT_81	[p8l375t2341r733b2441],
30	or	CC	O	or	_	0	SENT_81	[p8l773t2366r863b2419],
31	increases	VBZ	O	increase	conj_or	21	SENT_81	[p8l893t2341r1281b2419],
32	their	PRP$	O	they	poss	34	SENT_81	[p8l1317t2341r1515b2419],
33	market	NN	O	market	nn	34	SENT_81	[p8l1546t2340r1849b2420],
34	share	NN	O	share	dobj	31	SENT_81	[p8l1879t2341r2129b2419],
35	.	.	O	.	_	0	SENT_81	[p8l1879t2341r2129b2419],

1	For	IN	O	for	_	0	SENT_82	[p8l6t2476r150b2547],
2	any	DT	O	any	det	4	SENT_82	[p8l175t2494r323b2569],
3	given	VBN	O	give	amod	4	SENT_82	[p8l347t2469r571b2569],
4	indication	NN	O	indication	prep_for	28	SENT_82	[p8l600t2469r1028b2547],
5	in	IN	O	in	_	0	SENT_82	[p8l1056t2469r1137b2546],
6	oncology	NN	O	oncology	prep_in	4	SENT_82	[p8l1167t2469r1568b2569],
7	,	,	O	,	_	0	SENT_82	[p8l1167t2469r1568b2569],
8	for	IN	O	for	_	0	SENT_82	[p8l1603t2468r1726b2547],
9	example	NN	O	example	prep_for	4	SENT_82	[p8l1753t2469r2129b2569],
10	,	,	O	,	_	0	SENT_82	[p8l1753t2469r2129b2569],
11	none	NN	O	none	nsubj	28	SENT_82	[p8l7t2622r217b2675],
12	of	IN	O	of	_	0	SENT_82	[p8l247t2596r348b2675],
13	these	DT	O	these	det	14	SENT_82	[p8l359t2597r577b2675],
14	incentives	NNS	O	incentive	prep_of	11	SENT_82	[p8l606t2597r1025b2676],
15	to	TO	O	to	aux	16	SENT_82	[p8l1057t2613r1136b2675],
16	deﬁne	VB	O	deﬁne	infmod	11	SENT_82	[p8l1167t2596r1427b2675],
17	the	DT	O	the	det	18	SENT_82	[p8l1458t2597r1586b2675],
18	subgroup	NN	O	subgroup	dobj	16	SENT_82	[p8l1618t2596r2021b2697],
19	of	IN	O	of	_	0	SENT_82	[p8l2052t2596r2153b2675],
20	patients	NNS	O	patient	prep_of	18	SENT_82	[p8l6t2725r341b2825],
21	who	WP	O	who	nsubj	23	SENT_82	[p8l371t2725r555b2804],
22	are	VBP	O	be	cop	23	SENT_82	[p8l589t2751r715b2803],
23	likely	JJ	O	likely	rcmod	20	SENT_82	[p8l747t2724r974b2825],
24	to	TO	O	to	aux	25	SENT_82	[p8l1003t2741r1082b2803],
25	have	VB	O	have	xcomp	23	SENT_82	[p8l1117t2725r1306b2804],
26	responses	NNS	O	response	dobj	25	SENT_82	[p8l1339t2750r1760b2825],
27	may	MD	O	may	aux	28	SENT_82	[p8l1795t2751r1972b2825],
28	apply	VB	O	apply	_	0	SENT_82	[p8l2000t2751r2132b2825, p8l6t2853r147b2953],
29	.	.	O	.	_	0	SENT_82	[p8l2000t2751r2132b2825, p8l6t2853r147b2953],

1	First	RB	ORDINAL	first	advmod	17	SENT_83	[p8l176t2853r395b2948],
2	,	,	O	,	_	0	SENT_83	[p8l176t2853r395b2948],
3	single	JJ	O	single	amod	7	SENT_83	[p8l427t2853r965b2953],
4	—	JJ	O	—	amod	7	SENT_83	[p8l427t2853r965b2953],
5	agent	NN	O	agent	nn	7	SENT_83	[p8l427t2853r965b2953],
6	response	NN	O	response	nn	7	SENT_83	[p8l985t2878r1373b2953],
7	rates	NNS	O	rate	nsubj	17	SENT_83	[p8l1398t2869r1601b2931],
8	as	RB	O	as	advmod	9	SENT_83	[p8l1627t2879r1713b2931],
9	low	JJ	O	low	advmod	17	SENT_83	[p8l1739t2852r1897b2932],
10	as	IN	O	as	_	0	SENT_83	[p8l1918t2879r2003b2931],
11	10	CD	NUMBER	10	number	13	SENT_83	[p8l2034t2858r2132b2931],
12	to	TO	O	to	dep	13	SENT_83	[p8l7t2997r87b3059],
13	15	CD	PERCENT	15	num	14	SENT_83	[p8l130t2986r223b3059],
14	percent	NN	PERCENT	percent	prep_as	9	SENT_83	[p8l263t2997r578b3081],
15	have	VBP	O	have	aux	17	SENT_83	[p8l610t2981r796b3060],
16	been	VBN	O	be	cop	17	SENT_83	[p8l834t2980r1032b3059],
17	adequate	JJ	O	adequate	_	0	SENT_83	[p8l1068t2980r1440b3081],
18	to	TO	O	to	aux	19	SENT_83	[p8l1479t2997r1557b3059],
19	Win	VB	O	win	xcomp	17	SENT_83	[p8l1591t2981r1748b3060],
20	FDA	NNP	ORGANIZATION	FDA	nn	21	SENT_83	[p8l1783t2987r1970b3059],
21	approval	NN	O	approval	dobj	19	SENT_83	[p8l2003t3007r2134b3081, p8l6t3109r271b3209],
22	for	IN	O	for	_	0	SENT_83	[p8l312t3108r438b3187],
23	indications	NNS	O	indication	prep_for	19	SENT_83	[p8l476t3108r956b3187],
24	in	IN	O	in	_	0	SENT_83	[p8l999t3109r1081b3186],
25	oncology	NN	O	oncology	prep_in	23	SENT_83	[p8l1124t3109r1521b3209],
26	for	IN	O	for	_	0	SENT_83	[p8l1559t3108r1684b3187],
27	which	WDT	O	which	rel	32	SENT_83	[p8l1718t3109r1983b3188],
28	no	DT	O	no	det	30	SENT_83	[p8l2025t3134r2131b3187],
29	other	JJ	O	other	amod	30	SENT_83	[p8l7t3237r236b3315],
30	treatments	NNS	O	treatment	nsubj	32	SENT_83	[p8l263t3253r724b3315],
31	are	VBP	O	be	cop	32	SENT_83	[p8l755t3263r883b3315],
32	available	JJ	O	available	rcmod	23	SENT_83	[p8l913t3236r1285b3316],
33	(	CD	NUMBER	(	nn	34	SENT_83	[p8l1321t3236r1580b3328],
34	Table	NNP	O	Table	dep	32	SENT_83	[p8l1321t3236r1580b3328],
35	1	CD	NUMBER	1	number	36	SENT_83	[p8l1613t3242r1718b3328],
36	)	CD	NUMBER	)	num	34	SENT_83	[p8l1613t3242r1718b3328],
37	.	.	O	.	_	0	SENT_83	[p8l1613t3242r1718b3328],

1	Deﬁning	VBG	O	deﬁning	amod	2	SENT_84	[p8l1752t3236r2136b3337],
2	subgroups	NNS	O	subgroup	nsubj	26	SENT_84	[p8l8t3364r457b3465],
3	of	IN	O	of	_	0	SENT_84	[p8l503t3364r603b3443],
4	patients	NNS	O	patient	prep_of	2	SENT_84	[p8l627t3365r962b3465],
5	who	WP	O	who	nsubj	7	SENT_84	[p8l1003t3365r1187b3444],
6	are	VBP	O	be	cop	7	SENT_84	[p8l1231t3391r1356b3443],
7	likely	JJ	O	likely	rcmod	4	SENT_84	[p8l1400t3365r1626b3465],
8	to	TO	O	to	aux	9	SENT_84	[p8l1665t3381r1744b3443],
9	have	VB	O	have	xcomp	7	SENT_84	[p8l1789t3365r1977b3444],
10	responses	NNS	O	response	dobj	9	SENT_84	[p8l2021t3391r2132b3443, p8l8t3518r370b3593],
11	,	,	O	,	_	0	SENT_84	[p8l2021t3391r2132b3443, p8l8t3518r370b3593],
12	Which	WDT	O	which	nsubj	14	SENT_84	[p8l392t3493r657b3572],
13	could	MD	O	could	aux	14	SENT_84	[p8l681t3492r917b3572],
14	boost	VB	O	boost	rcmod	10	SENT_84	[p8l941t3493r1184b3571],
15	response	NN	O	response	nn	16	SENT_84	[p8l1202t3518r1590b3593],
16	rates	NNS	O	rate	dobj	14	SENT_84	[p8l1613t3509r1816b3571],
17	in	IN	O	in	_	0	SENT_84	[p8l1840t3493r1923b3570],
18	a	DT	O	a	det	20	SENT_84	[p8l1946t3519r1990b3571],
19	selected	VBN	O	select	amod	20	SENT_84	[p8l2013t3519r2131b3571, p8l6t3621r259b3699],
20	group	NN	O	group	prep_in	14	SENT_84	[p8l294t3646r576b3721],
21	,	,	O	,	_	0	SENT_84	[p8l294t3646r576b3721],
22	may	MD	O	may	aux	26	SENT_84	[p8l616t3647r795b3721],
23	therefore	RB	O	therefore	advmod	26	SENT_84	[p8l826t3620r1218b3699],
24	not	RB	O	not	neg	26	SENT_84	[p8l1254t3637r1400b3699],
25	be	VB	O	be	cop	26	SENT_84	[p8l1431t3621r1527b3699],
26	necessary	JJ	O	necessary	_	0	SENT_84	[p8l1562t3646r1980b3721],
27	for	IN	O	for	_	0	SENT_84	[p8l2011t3620r2136b3699],
28	initial	JJ	O	initial	amod	29	SENT_84	[p9l6t21r247b99],
29	approval	NN	O	approval	prep_for	26	SENT_84	[p9l267t20r648b121],
30	.	.	O	.	_	0	SENT_84	[p9l267t20r648b121],

1	Second	RB	ORDINAL	second	advmod	4	SENT_85	[p9l677t21r999b116],
2	,	,	O	,	_	0	SENT_85	[p9l677t21r999b116],
3	there	EX	O	there	expl	4	SENT_85	[p9l1026t21r1235b99],
4	are	VBP	O	be	_	0	SENT_85	[p9l1256t47r1381b99],
5	only	RB	O	only	advmod	4	SENT_85	[p9l1402t21r1582b121],
6	a	DT	O	a	det	8	SENT_85	[p9l1597t47r1642b99],
7	small	JJ	O	small	amod	8	SENT_85	[p9l1663t21r1887b99],
8	number	NN	O	number	nsubj	4	SENT_85	[p9l1908t46r2134b100, p9l7t149r142b227],
9	of	IN	O	of	_	0	SENT_85	[p9l166t148r266b227],
10	approved	VBN	O	approve	amod	11	SENT_85	[p9l277t149r676b249],
11	therapies	NNS	O	therapy	prep_of	8	SENT_85	[p9l706t149r1100b249],
12	for	IN	O	for	_	0	SENT_85	[p9l1133t148r1258b227],
13	many	JJ	O	many	amod	14	SENT_85	[p9l1286t174r1523b249],
14	indications	NNS	O	indication	prep_for	11	SENT_85	[p9l1548t148r2025b227],
15	in	IN	O	in	_	0	SENT_85	[p9l2054t149r2134b226],
16	oncology	NN	O	oncology	prep_in	14	SENT_85	[p9l12t277r432b377],
17	;	:	O	;	_	0	SENT_85	[p9l12t277r432b377],
18	as	IN	O	as	_	0	SENT_85	[p9l461t303r547b355],
19	a	DT	O	a	det	20	SENT_85	[p9l574t303r619b355],
20	result	NN	O	result	prep_as	30	SENT_85	[p9l643t277r911b372],
21	,	,	O	,	_	0	SENT_85	[p9l643t277r911b372],
22	many	JJ	O	many	amod	25	SENT_85	[p9l943t302r1181b377],
23	newly	RB	O	newly	advmod	24	SENT_85	[p9l1202t277r1455b377],
24	approved	VBN	O	approve	amod	25	SENT_85	[p9l1476t277r1877b377],
25	drugs	NNS	O	drug	nsubj	30	SENT_85	[p9l1903t277r2146b377],
26	for	IN	O	for	_	0	SENT_85	[p9l12t404r136b483],
27	speciﬁc	NN	O	speciﬁc	nn	28	SENT_85	[p9l157t404r469b505],
28	indications	NNS	O	indication	prep_for	25	SENT_85	[p9l491t405r950b483],
29	will	MD	O	will	aux	30	SENT_85	[p9l971t404r1125b484],
30	have	VB	O	have	parataxis	4	SENT_85	[p9l1148t405r1334b484],
31	essentially	RB	O	essentially	advmod	33	SENT_85	[p9l1358t405r1788b505],
32	no	DT	O	no	det	33	SENT_85	[p9l1807t430r1912b483],
33	competition	NN	O	competition	dobj	30	SENT_85	[p9l1938t430r2149b483, p9l11t533r360b633],
34	.	.	O	.	_	0	SENT_85	[p9l1938t430r2149b483, p9l11t533r360b633],

1	Patients	NNS	O	patient	nsubj	8	SENT_86	[p9l391t533r722b611],
2	with	IN	O	with	_	0	SENT_86	[p9l747t533r935b612],
3	cancer	NN	O	cancer	prep_with	1	SENT_86	[p9l963t558r1237b611],
4	and	CC	O	and	_	0	SENT_86	[p9l1260t532r1416b611],
5	their	PRP$	O	they	poss	6	SENT_86	[p9l1443t533r1639b611],
6	oncologists	NNS	O	oncologist	conj_and	3	SENT_86	[p9l1665t533r2148b633],
7	will	MD	O	will	aux	8	SENT_86	[p9l7t661r167b740],
8	use	VB	O	use	_	0	SENT_86	[p9l198t687r341b740],
9	these	DT	O	these	det	11	SENT_86	[p9l373t661r598b739],
10	new	JJ	O	new	amod	11	SENT_86	[p9l630t686r808b740],
11	agents	NNS	O	agent	dobj	8	SENT_86	[p9l837t677r1117b761],
12	despite	IN	O	despite	_	0	SENT_86	[p9l1152t661r1460b761],
13	low	JJ	O	low	amod	14	SENT_86	[p9l1491t661r1650b740],
14	rates	NNS	O	rate	prep_despite	8	SENT_86	[p9l1678t677r1882b739],
15	of	IN	O	of	_	0	SENT_86	[p9l1917t660r2019b739],
16	response	NN	O	response	prep_of	14	SENT_86	[p9l2032t687r2147b739, p9l13t814r306b889],
17	and	CC	O	and	_	0	SENT_86	[p9l325t789r479b867],
18	despite	IN	O	despite	_	0	SENT_86	[p9l500t788r794b889],
19	enormous	JJ	O	enormous	amod	20	SENT_86	[p9l815t814r1237b868],
20	costs	NNS	O	cost	prep_despite	8	SENT_86	[p9l1260t805r1490b884],
21	,	,	O	,	_	0	SENT_86	[p9l1260t805r1490b884],
22	which	WDT	O	which	nsubj	28	SENT_86	[p9l1512t789r1769b868],
23	for	IN	O	for	_	0	SENT_86	[p9l1788t788r1910b867],
24	some	DT	O	some	det	26	SENT_86	[p9l1928t814r2151b867],
25	cancer	NN	O	cancer	nn	26	SENT_86	[p9l12t943r293b996],
26	agents	NNS	O	agent	prep_for	28	SENT_86	[p9l322t933r603b1018],
27	can	MD	O	can	aux	28	SENT_86	[p9l639t943r786b996],
28	exceed	VB	O	exceed	rcmod	20	SENT_86	[p9l821t917r1108b996],
29	$	$	MONEY	$	dobj	28	SENT_86	[p9l1144t914r1491b1013],
30	15,000	CD	MONEY	15,000	num	29	SENT_86	[p9l1144t914r1491b1013],
31	per	IN	O	per	_	0	SENT_86	[p9l1525t943r1666b1018],
32	treatment	NN	O	treatment	prep_per	29	SENT_86	[p9l1697t933r2143b996],
33	.	.	O	.	_	0	SENT_86	[p9l1697t933r2143b996],

1	Finally	RB	O	finally	advmod	3	SENT_87	[p9l10t1046r316b1146],
2	,	,	O	,	_	0	SENT_87	[p9l10t1046r316b1146],
3	selecting	VBG	O	select	_	0	SENT_87	[p9l357t1046r745b1146],
4	a	DT	O	a	det	5	SENT_87	[p9l775t1072r820b1124],
5	subgroup	NN	O	subgroup	dobj	3	SENT_87	[p9l855t1045r1267b1146],
6	of	IN	O	of	_	0	SENT_87	[p9l1304t1045r1406b1124],
7	patients	NNS	O	patient	prep_of	5	SENT_87	[p9l1421t1046r1765b1146],
8	who	WP	O	who	nsubj	10	SENT_87	[p9l1797t1046r1984b1125],
9	are	VBP	O	be	cop	10	SENT_87	[p9l2019t1072r2148b1124],
10	likely	JJ	O	likely	rcmod	7	SENT_87	[p9l11t1174r244b1274],
11	to	TO	O	to	aux	12	SENT_87	[p9l272t1190r353b1252],
12	have	VB	O	have	xcomp	10	SENT_87	[p9l387t1173r579b1253],
13	responses	NNS	O	response	dobj	12	SENT_87	[p9l612t1199r1044b1274],
14	could	MD	O	could	aux	21	SENT_87	[p9l1079t1173r1342b1269],
15	,	,	O	,	_	0	SENT_87	[p9l1079t1173r1342b1269],
16	in	IN	O	in	_	0	SENT_87	[p9l1379t1174r1462b1251],
17	the	DT	O	the	det	19	SENT_87	[p9l1495t1174r1627b1252],
18	short	JJ	O	short	amod	19	SENT_87	[p9l1661t1174r1890b1252],
19	term	NN	O	term	prep_in	21	SENT_87	[p9l1918t1190r2143b1269],
20	,	,	O	,	_	0	SENT_87	[p9l1918t1190r2143b1269],
21	limit	VB	O	limit	dep	3	SENT_87	[p9l11t1302r220b1380],
22	the	DT	O	the	det	23	SENT_87	[p9l247t1301r379b1380],
23	size	NN	O	size	dobj	21	SENT_87	[p9l413t1302r576b1380],
24	of	IN	O	of	_	0	SENT_87	[p9l609t1301r711b1380],
25	the	DT	O	the	det	26	SENT_87	[p9l725t1302r857b1380],
26	market	NN	O	market	prep_of	23	SENT_87	[p9l890t1302r1199b1381],
27	for	IN	O	for	_	0	SENT_87	[p9l1226t1301r1352b1380],
28	an	DT	O	a	det	30	SENT_87	[p9l1381t1327r1483b1380],
29	approved	VBN	O	approve	amod	30	SENT_87	[p9l1514t1302r1916b1402],
30	drug	NN	O	drug	prep_for	21	SENT_87	[p9l1948t1302r2152b1402],
31	for	IN	O	for	_	0	SENT_87	[p9l12t1429r137b1508],
32	use	NN	O	use	prep_for	30	SENT_87	[p9l176t1456r318b1509],
33	against	IN	O	against	_	0	SENT_87	[p9l359t1430r676b1530],
34	tumors	NNS	O	tumor	prep_against	32	SENT_87	[p9l712t1446r1020b1509],
35	that	WDT	O	that	nsubj	36	SENT_87	[p9l1064t1430r1235b1508],
36	express	VBP	O	express	rcmod	34	SENT_87	[p9l1271t1456r1591b1530],
37	the	DT	O	the	det	40	SENT_87	[p9l1635t1429r1767b1508],
38	relevant	JJ	O	relevant	amod	40	SENT_87	[p9l1808t1429r2153b1509],
39	molecular	JJ	O	molecular	amod	40	SENT_87	[p9l12t1557r437b1637],
40	proﬁle	NN	O	proﬁle	dobj	36	SENT_87	[p9l468t1557r768b1658],
41	.	.	O	.	_	0	SENT_87	[p9l468t1557r768b1658],

1	Thus	RB	O	thus	advmod	7	SENT_88	[p9l805t1558r1042b1653],
2	,	,	O	,	_	0	SENT_88	[p9l805t1558r1042b1653],
3	pharmaceutical	JJ	O	pharmaceutical	amod	4	SENT_88	[p9l1081t1558r1732b1658],
4	sponsors	NNS	O	sponsor	nsubj	7	SENT_88	[p9l1767t1583r2148b1658],
5	may	MD	O	may	aux	7	SENT_88	[p9l12t1712r189b1786],
6	not	RB	O	not	neg	7	SENT_88	[p9l220t1702r366b1764],
7	have	VB	O	have	_	0	SENT_88	[p9l396t1686r589b1765],
8	a	DT	O	a	det	10	SENT_88	[p9l625t1712r669b1764],
9	financial	JJ	O	financial	amod	10	SENT_88	[p9l703t1685r1081b1764],
10	incentive	NN	O	incentive	dobj	7	SENT_88	[p9l1115t1686r1503b1765],
11	to	TO	O	to	aux	12	SENT_88	[p9l1540t1702r1620b1764],
12	define	VB	O	define	infmod	10	SENT_88	[p9l1658t1685r1925b1764],
13	subgroups	NNS	O	subgroup	dobj	12	SENT_88	[p9l1962t1686r2147b1765, p9l11t1839r312b1914],
14	of	IN	O	of	_	0	SENT_88	[p9l342t1813r444b1892],
15	patients	NNS	O	patient	prep_of	13	SENT_88	[p9l451t1814r795b1914],
16	who	WP	O	who	nsubj	18	SENT_88	[p9l819t1814r1006b1893],
17	are	VBP	O	be	cop	18	SENT_88	[p9l1033t1840r1161b1892],
18	likely	JJ	O	likely	rcmod	15	SENT_88	[p9l1187t1813r1421b1914],
19	to	TO	O	to	aux	20	SENT_88	[p9l1443t1830r1524b1892],
20	have	VB	O	have	xcomp	18	SENT_88	[p9l1552t1814r1744b1893],
21	respons	NNS	O	respon	dobj	20	SENT_88	[p9l1771t1839r2147b1914],
22	—	CD	NUMBER	—	num	23	SENT_88	[p9l1771t1839r2147b1914],
23	es	NNS	O	e	dep	26	SENT_88	[p9l12t1968r96b2020],
24	as	IN	O	as	dep	26	SENT_88	[p9l131t1968r216b2020],
25	they	PRP	O	they	nsubj	26	SENT_88	[p9l251t1942r429b2042],
26	seek	VBP	O	seek	dep	20	SENT_88	[p9l459t1942r644b2021],
27	the	DT	O	the	det	30	SENT_88	[p9l670t1941r799b2020],
28	broadest	JJS	O	broadest	amod	30	SENT_88	[p9l830t1941r1196b2020],
29	marketing	NN	O	marketing	nn	30	SENT_88	[p9l1222t1942r1658b2042],
30	indications	NNS	O	indication	dobj	26	SENT_88	[p9l1685t1942r2148b2020],
31	possible	JJ	O	possible	amod	30	SENT_88	[p9l11t2064r464b2170],
32	.13	CD	NUMBER	.13	tmod	31	SENT_88	[p9l11t2064r464b2170],

1	There	EX	O	there	expl	2	SENT_89	[p9l138t2198r384b2276],
2	are	VBP	O	be	_	0	SENT_89	[p9l417t2224r544b2276],
3	additional	JJ	O	additional	amod	4	SENT_89	[p9l579t2198r1019b2276],
4	reasons	NNS	O	reason	nsubj	2	SENT_89	[p9l1053t2223r1384b2276],
5	why	WRB	O	why	dep	4	SENT_89	[p9l1417t2198r1597b2298],
6	pharmaceuENGLJ	NN	O	pharmaceuenglj	dep	5	SENT_89	[p9l1626t2197r2147b2298, p9l554t2374r638b2396],

1	MED	NN	O	med	_	0	SENT_90	[p9l653t2375r705b2390],
2	351	CD	NUMBER	351	num	1	SENT_90	[p9l717t2374r778b2396],
3	;	:	O	;	_	0	SENT_90	[p9l717t2374r778b2396],
4	5	CD	NUMBER	5	num	6	SENT_90	[p9l717t2374r778b2396],
5	WWW.NEJM.ORG	NN	O	www.nejm.org	nn	6	SENT_90	[p9l812t2374r1024b2396],
6	ULY	NN	O	uly	dep	1	SENT_90	[p9l1073t2375r1117b2390],
7	29	CD	NUMBER	29	dep	6	SENT_90	[p9l1129t2374r1168b2396],
8	,	,	O	,	_	0	SENT_90	[p9l1129t2374r1168b2396],
9	2004	CD	DATE	2004	num	10	SENT_90	[p9l1181t2374r1249b2396],
10	503	CD	NUMBER	503	appos	7	SENT_90	[p9l1960t2373r2015b2395],

1	The	DT	O	the	det	5	SENT_91	[p9l701t2407r752b2431],
2	New	NNP	O	New	nn	5	SENT_91	[p9l761t2408r823b2431],
3	England	NNP	O	England	nn	5	SENT_91	[p9l833t2407r943b2438],
4	Joumal	NNP	PERSON	Joumal	nn	5	SENT_91	[p9l952t2407r1049b2431],
5	o	NN	O	o	_	0	SENT_91	[p9l1059t2415r1074b2431],
6	edicine	NN	O	edicine	dep	5	SENT_91	[p9l1125t2407r1220b2431],

1	Downloaded	VBN	O	download	_	0	SENT_92	[p9l144t2448r313b2471],
2	from	IN	O	from	_	0	SENT_92	[p9l322t2448r387b2471],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_92	[p9l396t2448r514b2478],
4	at	IN	O	at	_	0	SENT_92	[p9l524t2452r547b2471],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_92	[p9l556t2448r738b2471],
6	on	IN	O	on	_	0	SENT_92	[p9l748t2455r780b2471],
7	January	NNP	DATE	January	prep_on	1	SENT_92	[p9l789t2448r891b2478],
8	5	CD	DATE	5	num	7	SENT_92	[p9l901t2448r924b2475],
9	,	,	DATE	,	_	0	SENT_92	[p9l901t2448r924b2475],
10	2014	CD	DATE	2014	num	7	SENT_92	[p9l935t2448r1007b2471],
11	.	.	O	.	_	0	SENT_92	[p9l935t2448r1007b2471],

1	For	IN	O	for	_	0	SENT_93	[p9l1017t2448r1064b2471],
2	personal	JJ	O	personal	amod	3	SENT_93	[p9l1072t2448r1184b2478],
3	use	NN	O	use	pobj	1	SENT_93	[p9l1194t2455r1237b2471],
4	only	RB	O	only	advmod	3	SENT_93	[p9l1247t2448r1311b2478],
5	.	.	O	.	_	0	SENT_93	[p9l1247t2448r1311b2478],

1	No	DT	O	no	det	3	SENT_94	[p9l1322t2448r1362b2471],
2	other	JJ	O	other	amod	3	SENT_94	[p9l1372t2448r1440b2471],
3	uses	NNS	O	use	_	0	SENT_94	[p9l1448t2455r1504b2471],
4	without	IN	O	without	_	0	SENT_94	[p9l1514t2448r1615b2471],
5	permission	NN	O	permission	prep_without	3	SENT_94	[p9l1624t2448r1776b2478],
6	.	.	O	.	_	0	SENT_94	[p9l1624t2448r1776b2478],

1	Copyright	NN	O	copyright	_	0	SENT_95	[p9l494t2489r628b2520],
2	©	CD	NUMBER	©	num	6	SENT_95	[p9l638t2489r661b2513],
3	2004	CD	DATE	2004	num	6	SENT_95	[p9l671t2489r736b2513],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_95	[p9l746t2489r937b2513],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_95	[p9l947t2489r1054b2513],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_95	[p9l1065t2489r1170b2520],
7	.	.	O	.	_	0	SENT_95	[p9l1065t2489r1170b2520],

1	All	DT	O	all	det	2	SENT_96	[p9l1181t2489r1222b2513],
2	rights	NNS	O	rights	nsubj	3	SENT_96	[p9l1231t2489r1306b2520],
3	reserved	VBN	O	reserve	_	0	SENT_96	[p9l1316t2489r1435b2513],
4	.	.	O	.	_	0	SENT_96	[p9l1316t2489r1435b2513],

1	The	DT	O	the	det	4	SENT_97	[p9l715t2595r752b2616],
2	NEW	NNP	O	NEW	nn	4	SENT_97	[p9l764t2597r845b2616],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_97	[p9l859t2597r1034b2616],
4	IOURNAL	NNP	O	IOURNAL	_	0	SENT_97	[p9l1048t2597r1214b2623],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_97	[p9l1228t2595r1444b2622],

1	tical	JJ	O	tical	amod	2	SENT_98	[p9l11t2817r189b2896],
2	sponsors	NNS	O	sponsor	nsubj	4	SENT_98	[p9l224t2843r613b2918],
3	have	VBP	O	have	aux	4	SENT_98	[p9l648t2817r839b2897],
4	failed	VBN	O	fail	_	0	SENT_98	[p9l873t2817r1111b2896],
5	to	TO	O	to	aux	6	SENT_98	[p9l1145t2834r1224b2896],
6	define	VB	O	define	xcomp	4	SENT_98	[p9l1260t2817r1525b2896],
7	subgroups	NNS	O	subgroup	dobj	6	SENT_98	[p9l1560t2817r2015b2918],
8	of	IN	O	of	_	0	SENT_98	[p9l2051t2817r2152b2896],
9	patients	NNS	O	patient	prep_of	7	SENT_98	[p9l9t2946r351b3046],
10	who	WP	O	who	nsubj	12	SENT_98	[p9l389t2946r575b3025],
11	are	VBP	O	be	cop	12	SENT_98	[p9l616t2972r744b3024],
12	likely	JJ	O	likely	rcmod	9	SENT_98	[p9l784t2946r1016b3046],
13	to	TO	O	to	aux	14	SENT_98	[p9l1052t2962r1132b3024],
14	have	VB	O	have	xcomp	12	SENT_98	[p9l1175t2946r1366b3025],
15	responses	NNS	O	response	dobj	14	SENT_98	[p9l1407t2971r1837b3046],
16	in	IN	O	in	_	0	SENT_98	[p9l1879t2946r1961b3023],
17	the	DT	O	the	det	18	SENT_98	[p9l2002t2946r2133b3024],
18	trials	NNS	O	trial	prep_in	15	SENT_98	[p9l11t3074r220b3152],
19	of	IN	O	of	_	0	SENT_98	[p9l249t3073r349b3152],
20	their	PRP$	O	they	poss	21	SENT_98	[p9l357t3074r555b3152],
21	drugs	NNS	O	drug	prep_of	18	SENT_98	[p9l579t3073r842b3174],
22	.	.	O	.	_	0	SENT_98	[p9l579t3073r842b3174],

1	First	RB	ORDINAL	first	advmod	17	SENT_99	[p9l872t3074r1085b3169],
2	,	,	O	,	_	0	SENT_99	[p9l872t3074r1085b3169],
3	with	IN	O	with	_	0	SENT_99	[p9l1112t3074r1301b3153],
4	few	JJ	O	few	amod	5	SENT_99	[p9l1327t3073r1478b3153],
5	exceptions	NNS	O	exception	prep_with	17	SENT_99	[p9l1501t3074r1973b3174],
6	,	,	O	,	_	0	SENT_99	[p9l1501t3074r1973b3174],
7	the	DT	O	the	det	9	SENT_99	[p9l2005t3073r2135b3152],
8	scientiﬁc	NN	O	scientiﬁc	nn	9	SENT_99	[p9l12t3201r384b3280],
9	determinants	NNS	O	determinant	nsubj	17	SENT_99	[p9l403t3201r953b3280],
10	of	IN	O	of	_	0	SENT_99	[p9l976t3201r1076b3280],
11	responses	NNS	O	response	prep_of	9	SENT_99	[p9l1076t3227r1490b3302],
12	to	TO	O	to	_	0	SENT_99	[p9l1512t3218r1590b3280],
13	cancer	NN	O	cancer	nn	14	SENT_99	[p9l1612t3227r1882b3280],
14	drugs	NNS	O	drug	prep_to	11	SENT_99	[p9l1900t3201r2133b3302],
15	are	VBP	O	be	cop	17	SENT_99	[p9l10t3356r134b3408],
16	neither	CC	O	neither	preconj	17	SENT_99	[p9l161t3329r468b3408],
17	obvious	JJ	O	obvious	_	0	SENT_99	[p9l493t3330r825b3409],
18	nor	CC	O	nor	_	0	SENT_99	[p9l854t3355r1003b3408],
19	readily	RB	O	readily	advmod	20	SENT_99	[p9l1028t3329r1317b3430],
20	accessible	JJ	O	accessible	conj_nor	17	SENT_99	[p9l1339t3330r1771b3408],
21	to	TO	O	to	aux	22	SENT_99	[p9l1799t3346r1878b3408],
22	study	VB	O	study	xcomp	20	SENT_99	[p9l1909t3329r2138b3430],
23	in	IN	O	in	_	0	SENT_99	[p9l10t3458r92b3535],
24	humans	NNS	O	human	prep_in	22	SENT_99	[p9l123t3458r496b3553],
25	,	,	O	,	_	0	SENT_99	[p9l123t3458r496b3553],
26	and	CC	O	and	_	0	SENT_99	[p9l532t3457r690b3536],
27	enhancing	VBG	O	enhance	csubj	33	SENT_99	[p9l722t3457r1179b3558],
28	our	PRP$	O	we	poss	29	SENT_99	[p9l1208t3483r1354b3537],
29	understanding	NN	O	understanding	dobj	27	SENT_99	[p9l1382t3458r2021b3558],
30	of	IN	O	of	_	0	SENT_99	[p9l2051t3457r2152b3536],
31	them	PRP	O	they	prep_of	29	SENT_99	[p9l11t3585r231b3664],
32	will	MD	O	will	aux	33	SENT_99	[p9l255t3585r415b3665],
33	require	VB	O	require	conj_and	17	SENT_99	[p9l443t3586r749b3686],
34	substantial	JJ	O	substantial	amod	35	SENT_99	[p9l780t3586r1254b3665],
35	investments	NNS	O	investment	dobj	33	SENT_99	[p9l1282t3586r1800b3665],
36	of	IN	O	of	_	0	SENT_99	[p9l1831t3585r1933b3664],
37	time	NN	O	time	prep_of	35	SENT_99	[p9l1944t3586r2134b3664],
38	and	CC	O	and	_	0	SENT_99	[p10l10t21r167b99],
39	capital	NN	O	capital	prep_of	35	SENT_99	[p10l217t21r527b121],
40	.	.	O	.	_	0	SENT_99	[p10l217t21r527b121],

1	Second	RB	ORDINAL	second	advmod	11	SENT_100	[p10l584t20r917b116],
2	,	,	O	,	_	0	SENT_100	[p10l584t20r917b116],
3	the	DT	O	the	det	4	SENT_100	[p10l972t20r1103b99],
4	process	NN	O	process	nsubj	13	SENT_100	[p10l1151t46r1477b121],
5	of	IN	O	of	_	0	SENT_100	[p10l1529t20r1630b99],
6	developing	VBG	O	develop	amod	8	SENT_100	[p10l1661t21r2137b121],
7	new	JJ	O	new	amod	8	SENT_100	[p10l10t174r188b228],
8	drugs	NNS	O	drug	prep_of	4	SENT_100	[p10l213t149r450b249],
9	is	VBZ	O	be	cop	11	SENT_100	[p10l479t149r544b227],
10	intrinsically	RB	O	intrinsically	advmod	11	SENT_100	[p10l574t148r1076b249],
11	complex	JJ	O	complex	_	0	SENT_100	[p10l1100t149r1481b249],
12	,	,	O	,	_	0	SENT_100	[p10l1100t149r1481b249],
13	expensive	JJ	O	expensive	conj_and	11	SENT_100	[p10l1515t149r1946b249],
14	,	,	O	,	_	0	SENT_100	[p10l1515t149r1946b249],
15	and	CC	O	and	_	0	SENT_100	[p10l1979t148r2135b227],
16	fraught	JJ	O	fraught	conj_and	11	SENT_100	[p10l10t276r331b377],
17	with	IN	O	with	_	0	SENT_100	[p10l372t277r561b356],
18	risk	NN	O	risk	prep_with	16	SENT_100	[p10l609t277r789b356],
19	.	.	O	.	_	0	SENT_100	[p10l609t277r789b356],

1	14	CD	NUMBER	14	npadvmod	7	SENT_101	[p10l802t271r877b316],
2	On	IN	O	on	_	0	SENT_101	[p10l924t282r1050b355],
3	average	NN	O	average	prep_on	7	SENT_101	[p10l1097t303r1437b377],
4	,	,	O	,	_	0	SENT_101	[p10l1097t303r1437b377],
5	sponsors	NNS	O	sponsor	nsubj	7	SENT_101	[p10l1491t302r1873b377],
6	must	MD	O	must	aux	7	SENT_101	[p10l1923t293r2139b356],
7	subject	VB	O	subject	_	0	SENT_101	[p10l12t404r310b505],
8	more	JJR	O	more	mwe	9	SENT_101	[p10l340t430r560b483],
9	than	IN	O	than	quantmod	10	SENT_101	[p10l596t405r784b483],
10	10	CD	NUMBER	10	num	11	SENT_101	[p10l822t410r919b483],
11	drugs	NNS	O	drug	dobj	7	SENT_101	[p10l956t404r1193b505],
12	to	TO	O	to	_	0	SENT_101	[p10l1231t421r1309b483],
13	clinical	JJ	O	clinical	amod	14	SENT_101	[p10l1347t404r1647b483],
14	testing	NN	O	testing	prep_to	7	SENT_101	[p10l1683t405r1972b505],
15	before	IN	O	before	_	0	SENT_101	[p10l2004t405r2133b483, p10l10t532r176b611],
16	1	CD	NUMBER	1	num	18	SENT_101	[p10l202t538r246b610],
17	gains	NNS	O	gain	nn	18	SENT_101	[p10l269t533r492b633],
18	approval	NN	O	approval	prep_before	7	SENT_101	[p10l516t533r904b633],
19	.	.	O	.	_	0	SENT_101	[p10l516t533r904b633],

1	The	DT	O	the	det	4	SENT_102	[p10l928t533r1090b611],
2	high	JJ	O	high	amod	4	SENT_102	[p10l1113t533r1304b633],
3	failure	NN	O	failure	nn	4	SENT_102	[p10l1327t532r1596b612],
4	rate	NN	O	rate	nsubj	9	SENT_102	[p10l1618t549r1799b628],
5	,	,	O	,	_	0	SENT_102	[p10l1618t549r1799b628],
6	in	IN	O	in	_	0	SENT_102	[p10l1826t533r1908b610],
7	turn	NN	O	turn	prep_in	4	SENT_102	[p10l1930t549r2129b628],
8	,	,	O	,	_	0	SENT_102	[p10l1930t549r2129b628],
9	drives	VBZ	O	drive	_	0	SENT_102	[p10l11t661r255b740],
10	the	DT	O	the	det	12	SENT_102	[p10l294t661r423b739],
11	average	JJ	O	average	amod	12	SENT_102	[p10l458t687r774b761],
12	cost	NN	O	cost	dobj	9	SENT_102	[p10l811t677r984b739],
13	of	IN	O	of	_	0	SENT_102	[p10l1015t660r1116b739],
14	developing	VBG	O	develop	prepc_of	12	SENT_102	[p10l1133t660r1599b761],
15	those	DT	O	those	det	16	SENT_102	[p10l1631t661r1859b739],
16	drugs	NNS	O	drug	dobj	14	SENT_102	[p10l1895t661r2132b761],
17	that	WDT	O	that	nsubj	19	SENT_102	[p10l11t788r178b866],
18	do	VBP	O	do	aux	19	SENT_102	[p10l194t788r296b866],
19	gain	VB	O	gain	rcmod	16	SENT_102	[p10l318t789r500b888],
20	approval	NN	O	approval	dobj	19	SENT_102	[p10l521t788r886b888],
21	to	TO	O	to	_	0	SENT_102	[p10l906t804r985b866],
22	more	JJR	O	more	quantmod	24	SENT_102	[p10l1008t813r1228b866],
23	than	IN	O	than	quantmod	24	SENT_102	[p10l1249t788r1437b866],
24	$	$	MONEY	$	prep_to	19	SENT_102	[p10l1461t785r1664b876],
25	800	CD	MONEY	800	number	24	SENT_102	[p10l1461t785r1664b876],
26	million	CD	MONEY	million	number	24	SENT_102	[p10l1686t788r2015b883],
27	,	,	O	,	_	0	SENT_102	[p10l1686t788r2015b883],
28	by	IN	O	by	_	0	SENT_102	[p10l2043t788r2140b888],
29	some	DT	O	some	det	30	SENT_102	[p10l12t942r235b995],
30	estimates	NNS	O	estimate	prep_by	19	SENT_102	[p10l259t911r758b995],
31	.	.	O	.	_	0	SENT_102	[p10l259t911r758b995],

1	”	NN	O	”	dep	8	SENT_103	[p10l259t911r758b995],
2	Although	IN	O	although	dep	8	SENT_103	[p10l781t917r1179b1017],
3	the	DT	O	the	det	5	SENT_103	[p10l1202t917r1330b995],
4	pharmaceutical	JJ	O	pharmaceutical	amod	5	SENT_103	[p10l1352t917r1998b1017],
5	industry	NN	O	industry	nsubj	8	SENT_103	[p10l2021t918r2134b994, p10l11t1045r275b1145],
6	has	VBZ	O	have	aux	8	SENT_103	[p10l303t1045r444b1123],
7	historically	RB	O	historically	advmod	8	SENT_103	[p10l478t1044r948b1145],
8	enjoyed	VBN	O	enjoy	advcl	19	SENT_103	[p10l976t1045r1296b1145],
9	healthy	JJ	O	healthy	amod	10	SENT_103	[p10l1329t1044r1638b1145],
10	proﬁt	NN	O	proﬁt	dobj	8	SENT_103	[p10l1665t1044r1906b1145],
11	mar	FW	DATE	mar	nn	13	SENT_103	[p10l1934t1071r2134b1123],
12	—	FW	O	—	nn	13	SENT_103	[p10l1934t1071r2134b1123],
13	gins	NNS	O	gin	dep	10	SENT_103	[p10l10t1173r216b1273],
14	,	,	O	,	_	0	SENT_103	[p10l10t1173r216b1273],
15	“	JJ	O	“	amod	18	SENT_103	[p10l260t1172r858b1252],
16	blockbuster	NN	O	blockbuster	nn	18	SENT_103	[p10l260t1172r858b1252],
17	”	NN	O	”	nn	18	SENT_103	[p10l260t1172r858b1252],
18	drugs	NNS	O	drug	nsubj	19	SENT_103	[p10l897t1172r1139b1273],
19	earn	VBP	O	earn	_	0	SENT_103	[p10l1176t1198r1361b1251],
20	most	JJS	O	most	dobj	19	SENT_103	[p10l1395t1189r1615b1251],
21	of	IN	O	of	_	0	SENT_103	[p10l1644t1172r1746b1251],
22	the	DT	O	the	det	23	SENT_103	[p10l1762t1173r1894b1251],
23	revenues	NNS	O	revenue	prep_of	20	SENT_103	[p10l1928t1199r2132b1252, p10l10t1326r235b1380],
24	.	.	O	.	_	0	SENT_103	[p10l1928t1199r2132b1252, p10l10t1326r235b1380],

1	It	PRP	O	it	dep	3	SENT_104	[p10l271t1308r338b1379],
2	is	VBZ	O	be	cop	3	SENT_104	[p10l364t1301r431b1379],
3	unlikely	JJ	O	unlikely	_	0	SENT_104	[p10l465t1300r822b1401],
4	,	,	O	,	_	0	SENT_104	[p10l465t1300r822b1401],
5	for	IN	O	for	dep	3	SENT_104	[p10l860t1300r985b1379],
6	example	NN	O	example	pobj	5	SENT_104	[p10l1015t1301r1398b1401],
7	,	,	O	,	_	0	SENT_104	[p10l1015t1301r1398b1401],
8	that	IN	O	that	complm	27	SENT_104	[p10l1436t1301r1606b1379],
9	in	IN	O	in	_	0	SENT_104	[p10l1632t1301r1714b1378],
10	the	DT	O	the	det	12	SENT_104	[p10l1747t1301r1878b1379],
11	short	JJ	O	short	amod	12	SENT_104	[p10l1912t1301r2139b1379],
12	term	NN	O	term	prep_in	27	SENT_104	[p10l11t1446r210b1508],
13	a	DT	O	a	det	15	SENT_104	[p10l235t1456r280b1508],
14	cancer	NN	O	cancer	nn	15	SENT_104	[p10l304t1455r585b1508],
15	drug	NN	O	drug	nsubj	27	SENT_104	[p10l608t1429r811b1530],
16	targeted	VBN	O	target	partmod	15	SENT_104	[p10l834t1429r1187b1530],
17	to	TO	O	to	_	0	SENT_104	[p10l1212t1446r1292b1508],
18	a	DT	O	a	det	19	SENT_104	[p10l1319t1456r1363b1508],
19	tumor	NN	O	tumor	prep_to	16	SENT_104	[p10l1388t1446r1655b1509],
20	With	IN	O	with	prep	16	SENT_104	[p10l1673t1429r1865b1509],
21	a	DT	O	a	det	22	SENT_104	[p10l1891t1456r1935b1508],
22	narrowly	RB	O	narrowly	pobj	20	SENT_104	[p10l1959t1455r2132b1508, p10l10t1557r250b1658],
23	deﬁned	VBN	O	deﬁned	partmod	22	SENT_104	[p10l269t1557r592b1636],
24	molecular	JJ	O	molecular	amod	25	SENT_104	[p10l615t1558r1049b1637],
25	proﬁle	NN	O	proﬁle	dobj	23	SENT_104	[p10l1068t1557r1353b1658],
26	could	MD	O	could	aux	27	SENT_104	[p10l1378t1557r1615b1637],
27	achieve	VB	O	achieve	ccomp	3	SENT_104	[p10l1637t1558r1951b1637],
28	revenues	NNS	O	revenue	dobj	27	SENT_104	[p10l1975t1584r2132b1637, p10l11t1711r255b1765],
29	on	IN	O	on	_	0	SENT_104	[p10l291t1711r398b1764],
30	the	DT	O	the	det	31	SENT_104	[p10l431t1686r562b1764],
31	level	NN	O	level	prep_on	27	SENT_104	[p10l594t1685r785b1765],
32	of	IN	O	of	_	0	SENT_104	[p10l818t1685r919b1764],
33	those	DT	O	those	prep_of	31	SENT_104	[p10l934t1686r1165b1764],
34	for	IN	O	for	_	0	SENT_104	[p10l1198t1685r1323b1764],
35	a	DT	O	a	det	36	SENT_104	[p10l1351t1712r1396b1764],
36	cholesterol	NN	O	cholesterol	prep_for	33	SENT_104	[p10l1428t1685r2132b1765],
37	—	CD	NUMBER	—	num	39	SENT_104	[p10l1428t1685r2132b1765],
38	loW	NN	O	low	nn	39	SENT_104	[p10l1428t1685r2132b1765],
39	—	NN	O	—	nsubj	3	SENT_104	[p10l1428t1685r2132b1765],

1	ering	VBG	O	ere	_	0	SENT_105	[p10l11t1814r236b1914],
2	drug	NN	O	drug	dobj	1	SENT_105	[p10l267t1813r491b1914],
3	.	.	O	.	_	0	SENT_105	[p10l267t1813r491b1914],

1	Third	NNP	ORDINAL	Third	nsubj	12	SENT_106	[p10l526t1814r792b1909],
2	,	,	O	,	_	0	SENT_106	[p10l526t1814r792b1909],
3	much	RB	O	much	appos	1	SENT_106	[p10l830t1814r1073b1893],
4	of	IN	O	of	_	0	SENT_106	[p10l1108t1813r1210b1892],
5	the	DT	O	the	det	6	SENT_106	[p10l1225t1814r1356b1892],
6	innovation	NN	O	innovation	prep_of	3	SENT_106	[p10l1389t1814r1853b1893],
7	in	IN	O	in	_	0	SENT_106	[p10l1886t1814r1968b1891],
8	the	DT	O	the	det	9	SENT_106	[p10l2002t1814r2133b1892],
9	development	NN	O	development	prep_in	6	SENT_106	[p10l11t1941r571b2042],
10	of	IN	O	of	_	0	SENT_106	[p10l592t1941r693b2020],
11	drugs	NNS	O	drug	prep_of	9	SENT_106	[p10l700t1942r941b2042],
12	occurs	VBZ	O	occur	_	0	SENT_106	[p10l969t1967r1246b2021],
13	in	IN	O	in	_	0	SENT_106	[p10l1273t1942r1354b2019],
14	small	JJ	O	small	amod	16	SENT_106	[p10l1380t1941r1612b2020],
15	biotechnology	NN	O	biotechnology	nn	16	SENT_106	[p10l1637t1941r2132b2020, p10l11t2095r164b2170],
16	companies	NNS	O	company	prep_in	12	SENT_106	[p10l193t2070r677b2170],
17	,	,	O	,	_	0	SENT_106	[p10l193t2070r677b2170],
18	the	DT	O	the	det	20	SENT_106	[p10l713t2070r842b2148],
19	vast	JJ	O	vast	amod	20	SENT_106	[p10l869t2086r1038b2148],
20	majority	NN	O	majority	appos	16	SENT_106	[p10l1064t2070r1415b2170],
21	of	IN	O	of	_	0	SENT_106	[p10l1442t2069r1542b2148],
22	which	WDT	O	which	nsubj	25	SENT_106	[p10l1549t2069r1810b2149],
23	are	VBP	O	be	cop	25	SENT_106	[p10l1839t2096r1966b2148],
24	not	RB	O	not	neg	25	SENT_106	[p10l1996t2086r2140b2148],
25	proﬁtable	JJ	O	proﬁtable	prepc_of	20	SENT_106	[p10l9t2197r447b2298],
26	.	.	O	.	_	0	SENT_106	[p10l9t2197r447b2298],

1	Many	JJ	O	many	nsubjpass	6	SENT_107	[p10l481t2205r718b2298],
2	of	IN	O	of	_	0	SENT_107	[p10l745t2197r845b2276],
3	these	DT	O	these	det	4	SENT_107	[p10l858t2197r1077b2276],
4	companies	NNS	O	company	prep_of	1	SENT_107	[p10l1108t2198r1565b2298],
5	were	VBD	O	be	auxpass	6	SENT_107	[p10l1594t2224r1795b2277],
6	formed	VBN	O	form	_	0	SENT_107	[p10l1826t2197r2135b2276],
7	in	IN	O	in	_	0	SENT_107	[p10l10t2326r91b2403],
8	the	DT	O	the	det	10	SENT_107	[p10l117t2326r246b2404],
9	boom	NN	O	boom	nn	10	SENT_107	[p10l273t2325r519b2404],
10	period	NN	O	period	prep_in	6	SENT_107	[p10l544t2326r818b2426],
11	of	IN	O	of	_	0	SENT_107	[p10l844t2325r944b2404],
12	the	DT	DATE	the	det	13	SENT_107	[p10l953t2325r1082b2404],
13	1990s	CD	DATE	1990s	prep_of	10	SENT_107	[p10l1111t2331r1382b2421],
14	,	,	O	,	_	0	SENT_107	[p10l1111t2331r1382b2421],
15	when	WRB	O	when	advmod	19	SENT_107	[p10l1409t2326r1643b2405],
16	investment	NN	O	investment	nsubj	19	SENT_107	[p10l1668t2326r2140b2405],
17	in	IN	O	in	_	0	SENT_107	[p10l10t2454r91b2530],
18	biotechnology	NN	O	biotechnology	prep_in	16	SENT_107	[p10l116t2453r713b2553],
19	exceeded	VBD	O	exceed	advcl	6	SENT_107	[p10l733t2453r1108b2531],
20	$	$	MONEY	$	dobj	19	SENT_107	[p10l1136t2450r1336b2541],
21	200	CD	MONEY	200	number	20	SENT_107	[p10l1136t2450r1336b2541],
22	billion	CD	MONEY	billion	number	20	SENT_107	[p10l1362t2453r1652b2531],
23	.	.	O	.	_	0	SENT_107	[p10l1362t2453r1652b2531],

1	The	DT	O	the	det	2	SENT_108	[p10l1679t2453r1838b2531],
2	lack	NN	O	lack	nsubj	13	SENT_108	[p10l1862t2453r2034b2532],
3	of	IN	O	of	_	0	SENT_108	[p10l2054t2452r2154b2531],
4	breakthrough	NN	O	breakthrough	nn	5	SENT_108	[p10l11t2581r585b2682],
5	success	NN	O	success	prep_of	2	SENT_108	[p10l617t2608r926b2661],
6	for	IN	O	for	_	0	SENT_108	[p10l958t2581r1080b2660],
7	many	JJ	O	many	amod	11	SENT_108	[p10l1106t2607r1339b2682],
8	high	JJ	O	high	amod	11	SENT_108	[p10l1364t2581r1867b2682],
9	—	NN	O	—	nn	11	SENT_108	[p10l1364t2581r1867b2682],
10	proﬁle	NN	O	proﬁle	nn	11	SENT_108	[p10l1364t2581r1867b2682],
11	drugs	NNS	O	drug	prep_for	5	SENT_108	[p10l1898t2582r2132b2682],
12	has	VBZ	O	have	aux	13	SENT_108	[p10l10t2710r152b2788],
13	dampened	VBN	O	dampen	_	0	SENT_108	[p10l194t2709r646b2810],
14	the	DT	O	the	det	15	SENT_108	[p10l686t2710r817b2788],
15	enthusiasm	NN	O	enthusiasm	dobj	13	SENT_108	[p10l857t2710r1357b2789],
16	of	IN	O	of	_	0	SENT_108	[p10l1397t2709r1499b2788],
17	investors	NNS	O	investor	prep_of	15	SENT_108	[p10l1519t2710r1931b2805],
18	,	,	O	,	_	0	SENT_108	[p10l1519t2710r1931b2805],
19	and	CC	O	and	_	0	SENT_108	[p10l1976t2709r2134b2788],
20	companies	NNS	O	company	nsubj	22	SENT_108	[p10l11t2838r473b2938],
21	are	VBP	O	be	aux	22	SENT_108	[p10l516t2864r642b2916],
22	ﬁnding	VBG	O	ﬁnding	conj_and	13	SENT_108	[p10l684t2837r996b2938],
23	it	PRP	O	it	nsubj	27	SENT_108	[p10l1033t2838r1094b2916],
24	increasingly	RB	O	increasingly	advmod	25	SENT_108	[p10l1129t2838r1644b2938],
25	difficult	JJ	O	difficult	dep	27	SENT_108	[p10l1682t2837r2017b2917],
26	to	TO	O	to	aux	27	SENT_108	[p10l2054t2854r2133b2916],
27	raise	VB	O	raise	xcomp	22	SENT_108	[p10l10t2966r206b3044],
28	capital	NN	O	capital	dobj	27	SENT_108	[p10l229t2965r531b3066],
29	.	.	O	.	_	0	SENT_108	[p10l229t2965r531b3066],

1	Continuous	JJ	O	continuous	amod	3	SENT_109	[p10l558t2966r1053b3045],
2	undercapitalization	NN	O	undercapitalization	nn	3	SENT_109	[p10l1077t2966r1901b3066],
3	pressures	NNS	O	pressure	nsubj	4	SENT_109	[p10l1921t2992r2133b3066, p10l12t3120r228b3173],
4	sponsors	VBZ	O	sponsor	_	0	SENT_109	[p10l264t3119r645b3194],
5	to	TO	O	to	aux	6	SENT_109	[p10l679t3110r758b3172],
6	subject	VB	O	subject	ccomp	4	SENT_109	[p10l793t3093r1091b3194],
7	their	PRP$	O	they	poss	9	SENT_109	[p10l1118t3094r1315b3172],
8	candidate	NN	O	candidate	nn	9	SENT_109	[p10l1344t3093r1750b3172],
9	drugs	NNS	O	drug	dobj	6	SENT_109	[p10l1783t3094r2020b3194],
10	to	TO	O	to	_	0	SENT_109	[p10l2054t3110r2133b3172],
11	clinical	JJ	O	clinical	amod	12	SENT_109	[p10l11t3221r312b3300],
12	testing	NN	O	testing	prep_to	6	SENT_109	[p10l340t3222r629b3322],
13	at	IN	O	at	_	0	SENT_109	[p10l653t3238r732b3300],
14	the	DT	O	the	det	17	SENT_109	[p10l755t3222r885b3300],
15	earliest	JJS	O	earliest	amod	17	SENT_109	[p10l914t3222r1220b3300],
16	possible	JJ	O	possible	amod	17	SENT_109	[p10l1242t3221r1592b3322],
17	point	NN	O	point	prep_at	6	SENT_109	[p10l1619t3222r1848b3322],
18	and	CC	O	and	_	0	SENT_109	[p10l1870t3222r2026b3300],
19	to	TO	O	to	aux	20	SENT_109	[p10l2055t3238r2133b3300],
20	obtain	VB	O	obtain	conj_and	6	SENT_109	[p10l11t3350r281b3428],
21	approval	NN	O	approval	dobj	20	SENT_109	[p10l310t3350r674b3450],
22	as	RB	O	as	advmod	23	SENT_109	[p10l702t3376r787b3428],
23	soon	RB	O	soon	advmod	20	SENT_109	[p10l820t3375r1023b3428],
24	as	IN	O	as	mark	25	SENT_109	[p10l1051t3376r1135b3428],
25	possible	JJ	O	possible	advcl	20	SENT_109	[p10l1165t3350r1540b3450],
26	,	,	O	,	_	0	SENT_109	[p10l1165t3350r1540b3450],
27	with	IN	O	with	_	0	SENT_109	[p10l1570t3350r1759b3429],
28	the	DT	O	the	det	31	SENT_109	[p10l1789t3349r1917b3428],
29	simplest	JJS	O	simplest	amod	31	SENT_109	[p10l1949t3350r2133b3428, p10l9t3477r215b3578],
30	possible	JJ	O	possible	amod	31	SENT_109	[p10l233t3477r584b3578],
31	strategy	NN	O	strategy	prep_with	20	SENT_109	[p10l611t3494r953b3578],
32	.	.	O	.	_	0	SENT_109	[p10l611t3494r953b3578],

1	A	DT	O	a	det	2	SENT_110	[p11l65t39r120b96],
2	PROPOSAL	NN	O	proposal	_	0	SENT_110	[p11l176t39r696b97],
3	FOR	IN	O	for	_	0	SENT_110	[p11l751t39r935b97],
4	SELECTIVE	JJ	O	selective	amod	5	SENT_110	[p11l987t39r1504b98],
5	APPROVAL	NN	O	approval	prep_for	2	SENT_110	[p11l1553t39r2074b97],

1	Can	MD	O	can	aux	5	SENT_111	[p11l10t238r177b310],
2	the	DT	O	the	det	3	SENT_111	[p11l208t232r339b310],
3	situation	NN	O	situation	nsubjpass	5	SENT_111	[p11l372t233r751b311],
4	be	VB	O	be	auxpass	5	SENT_111	[p11l782t232r878b310],
5	remedied	VBN	O	remedy	_	0	SENT_111	[p11l909t230r1353b310],
6	?	.	O	?	_	0	SENT_111	[p11l909t230r1353b310],

1	We	PRP	O	we	nsubj	2	SENT_112	[p11l1380t239r1515b310],
2	believe	VBP	O	believe	_	0	SENT_112	[p11l1547t232r1839b311],
3	it	PRP	O	it	nsubj	4	SENT_112	[p11l1870t233r1931b310],
4	can	MD	O	can	ccomp	2	SENT_112	[p11l1958t257r2128b310],
5	.	.	O	.	_	0	SENT_112	[p11l1958t257r2128b310],

1	The	DT	O	the	det	4	SENT_113	[p11l7t359r170b438],
2	fast	JJ	O	fast	amod	4	SENT_113	[p11l210t359r623b439],
3	—	NN	O	—	nn	4	SENT_113	[p11l210t359r623b439],
4	tracl	NN	O	tracl	nsubjpass	19	SENT_113	[p11l210t359r623b439],
5	<	JJR	O	<	amod	6	SENT_113	[p11l210t359r623b439],
6	programs	NNS	O	program	dep	4	SENT_113	[p11l656t385r1102b460],
7	,	,	O	,	_	0	SENT_113	[p11l656t385r1102b460],
8	which	WDT	O	which	nsubj	11	SENT_113	[p11l1142t360r1407b439],
9	have	VBP	O	have	aux	11	SENT_113	[p11l1447t360r1638b439],
10	already	RB	O	already	advmod	11	SENT_113	[p11l1677t359r1987b460],
11	facilitated	VBN	O	facilitate	rcmod	4	SENT_113	[p11l2021t359r2132b438, p11l11t487r356b566],
12	earlier	JJR	O	earlier	amod	13	SENT_113	[p11l395t487r669b566],
13	approvals	NNS	O	approval	dobj	11	SENT_113	[p11l704t487r1118b588],
14	of	IN	O	of	_	0	SENT_113	[p11l1161t487r1262b566],
15	drugs	NNS	O	drug	prep_of	13	SENT_113	[p11l1283t488r1552b588],
16	,	,	O	,	_	0	SENT_113	[p11l1283t488r1552b588],
17	could	MD	O	could	aux	19	SENT_113	[p11l1597t487r1833b567],
18	be	VB	O	be	auxpass	19	SENT_113	[p11l1873t487r1970b566],
19	expanded	VBN	O	expand	_	0	SENT_113	[p11l2009t514r2132b566, p11l9t615r328b716],
20	to	TO	O	to	aux	21	SENT_113	[p11l358t632r438b694],
21	encourage	VB	O	encourage	xcomp	19	SENT_113	[p11l470t641r916b716],
22	the	DT	O	the	det	23	SENT_113	[p11l946t616r1078b694],
23	use	NN	O	use	dobj	21	SENT_113	[p11l1108t642r1250b695],
24	of	IN	O	of	_	0	SENT_113	[p11l1280t615r1382b694],
25	targeted	VBN	O	target	amod	26	SENT_113	[p11l1394t616r1748b716],
26	drugs	NNS	O	drug	prep_of	23	SENT_113	[p11l1778t615r2020b716],
27	in	IN	O	in	_	0	SENT_113	[p11l2051t616r2134b693],
28	a	DT	O	a	det	31	SENT_113	[p11l10t770r54b822],
29	more	RBR	O	more	advmod	30	SENT_113	[p11l81t769r299b822],
30	selective	JJ	O	selective	amod	31	SENT_113	[p11l328t744r673b823],
31	manner	NN	O	manner	prep_in	26	SENT_113	[p11l700t769r1044b822],
32	.	.	O	.	_	0	SENT_113	[p11l700t769r1044b822],

1	To	TO	O	to	aux	2	SENT_114	[p11l1074t749r1178b822],
2	promote	VB	O	promote	purpcl	7	SENT_114	[p11l1205t760r1565b844],
3	these	DT	O	these	det	4	SENT_114	[p11l1593t744r1809b822],
4	efforts	NNS	O	effort	dobj	2	SENT_114	[p11l1837t743r2130b839],
5	,	,	O	,	_	0	SENT_114	[p11l1837t743r2130b839],
6	We	PRP	O	we	nsubj	7	SENT_114	[p11l6t898r125b951],
7	propose	VBP	O	propose	_	0	SENT_114	[p11l162t897r512b972],
8	a	DT	O	a	det	12	SENT_114	[p11l549t898r593b950],
9	new	JJ	O	new	amod	12	SENT_114	[p11l629t897r807b951],
10	FDA	NNP	ORGANIZATION	FDA	nn	12	SENT_114	[p11l839t878r1029b950],
11	approval	NN	O	approval	nn	12	SENT_114	[p11l1062t872r1434b972],
12	mechanism	NN	O	mechanism	dobj	7	SENT_114	[p11l1471t871r1974b950],
13	for	IN	O	for	_	0	SENT_114	[p11l2011t871r2136b950],
14	targeted	VBN	O	target	amod	15	SENT_114	[p11l11t1000r354b1100],
15	drugs	NNS	O	drug	prep_for	7	SENT_114	[p11l384t1000r645b1100],
16	,	,	O	,	_	0	SENT_114	[p11l384t1000r645b1100],
17	which	WDT	O	which	dobj	19	SENT_114	[p11l675t999r934b1079],
18	We	PRP	O	we	nsubj	19	SENT_114	[p11l959t1026r1077b1079],
19	call	VBP	O	call	rcmod	15	SENT_114	[p11l1108t1000r1248b1078],
20	“	RB	O	“	advmod	21	SENT_114	[p11l1281t1000r1670b1079],
21	selective	JJ	O	selective	amod	22	SENT_114	[p11l1281t1000r1670b1079],
22	approval	NN	O	approval	dobj	19	SENT_114	[p11l1700t1000r2131b1100],
23	.	.	O	.	_	0	SENT_114	[p11l1700t1000r2131b1100],

1	”	NN	O	”	dep	7	SENT_115	[p11l1700t1000r2131b1100],
2	Although	IN	O	although	dep	7	SENT_115	[p11l7t1128r413b1228],
3	the	DT	O	the	det	4	SENT_115	[p11l443t1127r574b1206],
4	mechanism	NN	O	mechanism	nsubjpass	7	SENT_115	[p11l603t1128r1107b1206],
5	could	MD	O	could	aux	7	SENT_115	[p11l1136t1127r1372b1207],
6	be	VB	O	be	auxpass	7	SENT_115	[p11l1403t1128r1499b1206],
7	used	VBN	O	use	advcl	16	SENT_115	[p11l1528t1128r1727b1207],
8	for	IN	O	for	_	0	SENT_115	[p11l1756t1127r1881b1206],
9	other	JJ	O	other	amod	10	SENT_115	[p11l1909t1128r2136b1206],
10	classes	NNS	O	class	prep_for	7	SENT_115	[p11l11t1256r306b1334],
11	of	IN	O	of	_	0	SENT_115	[p11l339t1255r441b1334],
12	therapeutic	JJ	O	therapeutic	amod	13	SENT_115	[p11l452t1256r939b1356],
13	drugs	NNS	O	drug	prep_of	10	SENT_115	[p11l969t1256r1237b1356],
14	,	,	O	,	_	0	SENT_115	[p11l969t1256r1237b1356],
15	We	PRP	O	we	nsubj	16	SENT_115	[p11l1269t1282r1388b1335],
16	recommend	VBP	O	recommend	_	0	SENT_115	[p11l1418t1256r1938b1334],
17	that	IN	O	that	complm	20	SENT_115	[p11l1968t1256r2139b1334],
18	it	PRP	O	it	nsubjpass	20	SENT_115	[p11l10t1384r71b1462],
19	be	VB	O	be	auxpass	20	SENT_115	[p11l98t1384r194b1462],
20	piloted	VBN	O	pilot	ccomp	16	SENT_115	[p11l225t1383r526b1484],
21	for	IN	O	for	_	0	SENT_115	[p11l558t1383r683b1462],
22	cancer	NN	O	cancer	nn	23	SENT_115	[p11l712t1409r993b1462],
23	drugs	NNS	O	drug	prep_for	20	SENT_115	[p11l1022t1383r1290b1484],
24	.	.	O	.	_	0	SENT_115	[p11l1022t1383r1290b1484],

1	Under	IN	O	under	_	0	SENT_116	[p11l1327t1383r1597b1462],
2	this	DT	O	this	det	3	SENT_116	[p11l1626t1384r1782b1462],
3	mechanism	NN	O	mechanism	prep_under	20	SENT_116	[p11l1816t1383r2132b1462, p11l10t1512r249b1607],
4	,	,	O	,	_	0	SENT_116	[p11l1816t1383r2132b1462, p11l10t1512r249b1607],
5	a	DT	O	a	det	8	SENT_116	[p11l296t1538r340b1590],
6	targeted	VBN	O	target	amod	8	SENT_116	[p11l381t1512r735b1612],
7	cancer	NN	O	cancer	nn	8	SENT_116	[p11l777t1537r1058b1590],
8	drug	NN	O	drug	nsubjpass	20	SENT_116	[p11l1098t1512r1300b1612],
9	that	WDT	O	that	nsubj	10	SENT_116	[p11l1340t1512r1509b1590],
10	demonstrates	VBZ	O	demonstrate	rcmod	8	SENT_116	[p11l1547t1511r2131b1590],
11	consistent	JJ	O	consistent	amod	13	SENT_116	[p11l11t1640r458b1718],
12	antitumor	NN	O	antitumor	nn	13	SENT_116	[p11l495t1640r931b1719],
13	responses	NNS	O	response	dobj	10	SENT_116	[p11l970t1665r1399b1740],
14	in	IN	O	in	_	0	SENT_116	[p11l1443t1640r1526b1717],
15	early	JJ	O	early	amod	17	SENT_116	[p11l1569t1639r1773b1740],
16	efficacy	NN	O	efficacy	nn	17	SENT_116	[p11l1812t1639r2138b1740],
17	trials	NNS	O	trial	prep_in	10	SENT_116	[p11l11t1768r223b1846],
18	could	MD	O	could	aux	20	SENT_116	[p11l269t1768r505b1847],
19	be	VB	O	be	auxpass	20	SENT_116	[p11l548t1767r645b1846],
20	submitted	VBN	O	submit	_	0	SENT_116	[p11l688t1768r1123b1847],
21	for	IN	O	for	_	0	SENT_116	[p11l1166t1767r1291b1846],
22	selective	JJ	O	selective	amod	23	SENT_116	[p11l1332t1767r1690b1847],
23	approval	NN	O	approval	prep_for	20	SENT_116	[p11l1732t1768r2128b1868],
24	,	,	O	,	_	0	SENT_116	[p11l1732t1768r2128b1868],
25	but	CC	O	but	_	0	SENT_116	[p11l11t1896r152b1975],
26	only	RB	O	only	advmod	31	SENT_116	[p11l172t1896r352b1996],
27	if	IN	O	if	dep	31	SENT_116	[p11l371t1895r445b1973],
28	the	DT	O	the	det	29	SENT_116	[p11l451t1896r579b1974],
29	sponsor	NN	O	sponsor	nsubj	31	SENT_116	[p11l606t1921r945b1996],
30	has	VBZ	O	have	aux	31	SENT_116	[p11l966t1896r1106b1974],
31	initiated	VBN	O	initiate	conj_but	20	SENT_116	[p11l1132t1896r1475b1974],
32	studies	NNS	O	study	dobj	31	SENT_116	[p11l1501t1895r1791b1975],
33	to	TO	O	to	aux	34	SENT_116	[p11l1817t1912r1896b1974],
34	identify	VB	O	identify	xcomp	31	SENT_116	[p11l1920t1896r2134b1974, p11l11t2023r147b2124],
35	subgroups	NNS	O	subgroup	dobj	34	SENT_116	[p11l182t2024r638b2124],
36	of	IN	O	of	_	0	SENT_116	[p11l679t2023r781b2102],
37	patients	NNS	O	patient	prep_of	35	SENT_116	[p11l799t2024r1143b2124],
38	who	WP	O	who	nsubj	40	SENT_116	[p11l1178t2024r1364b2103],
39	are	VBP	O	be	cop	40	SENT_116	[p11l1403t2050r1531b2102],
40	likely	JJ	O	likely	rcmod	37	SENT_116	[p11l1568t2023r1801b2124],
41	to	TO	O	to	aux	42	SENT_116	[p11l1835t2040r1915b2102],
42	have	VB	O	have	xcomp	40	SENT_116	[p11l1954t2024r2147b2103],
43	responses	NNS	O	response	dobj	42	SENT_116	[p11l10t2177r469b2252],
44	.	.	O	.	_	0	SENT_116	[p11l10t2177r469b2252],

1	These	DT	O	these	det	2	SENT_117	[p11l511t2152r768b2230],
2	studies	NNS	O	study	nsubj	6	SENT_117	[p11l811t2151r1112b2231],
3	ideally	RB	O	ideally	advmod	6	SENT_117	[p11l1154t2151r1437b2252],
4	Would	MD	O	would	aux	6	SENT_117	[p11l1469t2151r1739b2231],
5	have	VB	O	have	aux	6	SENT_117	[p11l1780t2151r1973b2231],
6	begun	VBN	O	begin	_	0	SENT_117	[p11l2014t2152r2145b2230, p11l10t2305r175b2380],
7	in	IN	O	in	_	0	SENT_117	[p11l199t2280r281b2357],
8	the	DT	O	the	det	10	SENT_117	[p11l307t2279r439b2358],
9	earliest	JJS	O	earliest	amod	10	SENT_117	[p11l464t2280r780b2358],
10	phases	NNS	O	phase	prep_in	6	SENT_117	[p11l798t2279r1093b2380],
11	of	IN	O	of	_	0	SENT_117	[p11l1121t2279r1222b2358],
12	development	NN	O	development	prep_of	10	SENT_117	[p11l1229t2280r1793b2380],
13	of	IN	O	of	_	0	SENT_117	[p11l1813t2279r1916b2358],
14	a	DT	O	a	det	16	SENT_117	[p11l1921t2306r1965b2358],
15	given	VBN	O	give	amod	16	SENT_117	[p11l1988t2280r2145b2380, p11l11t2433r109b2486],
16	drug	NN	O	drug	prep_of	12	SENT_117	[p11l138t2407r356b2508],
17	,	,	O	,	_	0	SENT_117	[p11l138t2407r356b2508],
18	with	IN	O	with	_	0	SENT_117	[p11l386t2407r574b2487],
19	the	DT	O	the	det	20	SENT_117	[p11l603t2408r732b2486],
20	use	NN	O	use	prep_with	6	SENT_117	[p11l761t2434r899b2487],
21	of	IN	O	of	_	0	SENT_117	[p11l929t2407r1029b2486],
22	such	JJ	O	such	amod	23	SENT_117	[p11l1042t2408r1234b2487],
23	tools	NNS	O	tool	prep_of	20	SENT_117	[p11l1264t2408r1465b2486],
24	as	IN	O	as	mark	27	SENT_117	[p11l1496t2434r1580b2486],
25	gene	NN	O	gene	nsubj	27	SENT_117	[p11l1611t2433r2147b2508],
26	—	CD	NUMBER	—	num	25	SENT_117	[p11l1611t2433r2147b2508],
27	eXpres	VBZ	O	expre	dep	20	SENT_117	[p11l1611t2433r2147b2508],
28	—	NN	O	—	nn	30	SENT_117	[p11l1611t2433r2147b2508],
29	sion	NN	O	sion	nn	30	SENT_117	[p11l12t2536r191b2614],
30	proﬁling	NN	O	proﬁling	dobj	27	SENT_117	[p11l216t2535r625b2636],
31	,	,	O	,	_	0	SENT_117	[p11l216t2535r625b2636],
32	gene	NN	O	gene	nn	33	SENT_117	[p11l657t2561r860b2636],
33	sequencing	NN	O	sequencing	conj_and	30	SENT_117	[p11l890t2536r1408b2636],
34	,	,	O	,	_	0	SENT_117	[p11l890t2536r1408b2636],
35	proteomics	NNS	O	proteomic	conj_and	30	SENT_117	[p11l1439t2536r1956b2636],
36	,	,	O	,	_	0	SENT_117	[p11l1439t2536r1956b2636],
37	and	CC	O	and	_	0	SENT_117	[p11l1988t2535r2147b2614],
38	molecular	JJ	O	molecular	amod	39	SENT_117	[p11l10t2663r447b2743],
39	imaging	NN	O	imaging	conj_and	30	SENT_117	[p11l467t2664r852b2764],
40	.	.	O	.	_	0	SENT_117	[p11l467t2664r852b2764],

1	These	DT	O	these	det	2	SENT_118	[p11l878t2664r1134b2742],
2	studies	NNS	O	study	nsubj	5	SENT_118	[p11l1160t2663r1461b2743],
3	would	MD	O	would	aux	5	SENT_118	[p11l1483t2664r1754b2743],
4	not	RB	O	not	neg	5	SENT_118	[p11l1778t2680r1924b2742],
5	need	VB	O	need	_	0	SENT_118	[p11l1943t2663r2147b2742],
6	to	TO	O	to	aux	8	SENT_118	[p11l11t2808r92b2870],
7	be	VB	O	be	auxpass	8	SENT_118	[p11l122t2792r219b2870],
8	completed	VBN	O	complete	xcomp	5	SENT_118	[p11l250t2792r704b2892],
9	by	IN	O	by	_	0	SENT_118	[p11l734t2792r832b2892],
10	the	DT	O	the	det	11	SENT_118	[p11l857t2792r989b2870],
11	time	NN	O	time	agent	8	SENT_118	[p11l1018t2792r1210b2870],
12	of	IN	O	of	_	0	SENT_118	[p11l1239t2791r1342b2870],
13	selective	JJ	O	selective	amod	14	SENT_118	[p11l1354t2792r1713b2871],
14	approval	NN	O	approval	prep_of	11	SENT_118	[p11l1743t2792r2141b2892],
15	.	.	O	.	_	0	SENT_118	[p11l1743t2792r2141b2892],

1	At	IN	O	at	_	0	SENT_119	[p11l7t2927r107b2998],
2	the	DT	O	the	det	3	SENT_119	[p11l127t2920r259b2998],
3	time	NN	O	time	prep_at	11	SENT_119	[p11l284t2920r475b2998],
4	of	IN	O	of	_	0	SENT_119	[p11l500t2919r602b2998],
5	the	DT	O	the	det	6	SENT_119	[p11l608t2919r741b2998],
6	review	NN	O	review	prep_of	3	SENT_119	[p11l765t2920r1057b3015],
7	,	,	O	,	_	0	SENT_119	[p11l765t2920r1057b3015],
8	the	DT	O	the	det	9	SENT_119	[p11l1087t2919r1219b2998],
9	FDA	NNP	ORGANIZATION	FDA	nsubj	11	SENT_119	[p11l1243t2926r1433b2998],
10	would	MD	O	would	aux	11	SENT_119	[p11l1450t2919r1721b2999],
11	negotiate	VB	O	negotiate	_	0	SENT_119	[p11l1745t2920r2147b3020],
12	the	DT	O	the	det	14	SENT_119	[p11l11t3047r143b3126],
13	speciﬁc	NN	O	speciﬁc	nn	14	SENT_119	[p11l176t3047r503b3148],
14	details	NNS	O	detail	dobj	11	SENT_119	[p11l534t3047r816b3126],
15	of	IN	O	of	_	0	SENT_119	[p11l850t3047r952b3126],
16	the	DT	O	the	det	17	SENT_119	[p11l965t3047r1097b3126],
17	sponsor	NN	O	sponsor	poss	19	SENT_119	[p11l1130t3053r1551b3148],
18	’s	POS	O	’s	_	0	SENT_119	[p11l1130t3053r1551b3148],
19	commitment	NN	O	commitment	prep_of	14	SENT_119	[p11l1584t3048r2152b3126],
20	to	TO	O	to	aux	21	SENT_119	[p11l11t3192r92b3254],
21	conduct	VB	O	conduct	infmod	19	SENT_119	[p11l128t3176r479b3255],
22	phase	NN	O	phase	dobj	21	SENT_119	[p11l507t3176r759b3276],
23	4	CD	NUMBER	4	num	24	SENT_119	[p11l792t3181r842b3254],
24	studies	NNS	O	study	dep	22	SENT_119	[p11l878t3175r1180b3255],
25	after	IN	O	after	_	0	SENT_119	[p11l1216t3175r1415b3254],
26	obtaining	VBG	O	obtain	prepc_after	21	SENT_119	[p11l1447t3175r1871b3276],
27	selective	JJ	O	selective	amod	28	SENT_119	[p11l1904t3175r2145b3254, p11l11t3304r157b3383],
28	approval	NN	O	approval	dobj	26	SENT_119	[p11l180t3303r578b3404],
29	.	.	O	.	_	0	SENT_119	[p11l180t3303r578b3404],

1	Progress	NNP	O	Progress	nsubjpass	4	SENT_120	[p11l605t3310r979b3404],
2	would	MD	O	would	aux	4	SENT_120	[p11l1000t3304r1272b3383],
3	be	VB	O	be	auxpass	4	SENT_120	[p11l1295t3304r1391b3382],
4	reviewed	VBN	O	review	_	0	SENT_120	[p11l1414t3303r1794b3383],
5	annually	RB	SET	annually	advmod	4	SENT_120	[p11l1816t3304r2145b3383, p11l9t3432r94b3532],
6	,	,	O	,	_	0	SENT_120	[p11l1816t3304r2145b3383, p11l9t3432r94b3532],
7	and	CC	O	and	_	0	SENT_120	[p11l134t3432r293b3510],
8	approval	NN	O	approval	nsubjpass	11	SENT_120	[p11l326t3432r701b3532],
9	could	MD	O	could	aux	11	SENT_120	[p11l735t3432r973b3511],
10	be	VB	O	be	auxpass	11	SENT_120	[p11l1008t3431r1105b3510],
11	withdrawn	VBN	O	withdraw	conj_and	4	SENT_120	[p11l1135t3431r1607b3511],
12	if	IN	O	if	mark	17	SENT_120	[p11l1640t3431r1717b3509],
13	the	DT	O	the	det	14	SENT_120	[p11l1734t3432r1865b3510],
14	sponsor	NN	O	sponsor	nsubj	17	SENT_120	[p11l1901t3457r2145b3532, p11l12t3585r143b3638],
15	had	VBD	O	have	aux	17	SENT_120	[p11l168t3559r322b3638],
16	not	RB	O	not	neg	17	SENT_120	[p11l350t3576r492b3638],
17	met	VBN	O	meet	advcl	11	SENT_120	[p11l515t3576r679b3638],
18	post	NN	O	post	nn	21	SENT_120	[p11l700t3560r1278b3660],
19	—	NN	O	—	nn	21	SENT_120	[p11l700t3560r1278b3660],
20	approval	NN	O	approval	nn	21	SENT_120	[p11l700t3560r1278b3660],
21	conditions	NNS	O	condition	dobj	17	SENT_120	[p11l1307t3559r1774b3638],
22	.	.	O	.	_	0	SENT_120	[p11l1307t3559r1774b3638],

1	Because	IN	O	because	mark	14	SENT_121	[p11l1806t3566r2147b3639],
2	the	DT	O	the	det	3	SENT_121	[p11l11t3687r143b3766],
3	identiﬁcation	NN	O	identiﬁcation	nsubj	14	SENT_121	[p11l186t3687r769b3766],
4	of	IN	O	of	_	0	SENT_121	[p11l814t3687r916b3766],
5	subgroups	NNS	O	subgroup	prep_of	3	SENT_121	[p11l943t3687r1400b3788],
6	of	IN	O	of	_	0	SENT_121	[p11l1447t3687r1549b3766],
7	patients	NNS	O	patient	prep_of	5	SENT_121	[p11l1573t3688r1917b3788],
8	who	WP	O	who	nsubj	10	SENT_121	[p11l1958t3687r2145b3767],
9	are	VBP	O	be	cop	10	SENT_121	[p12l10t47r139b99],
10	likely	JJ	O	likely	rcmod	7	SENT_121	[p12l169t20r402b121],
11	to	TO	O	to	aux	12	SENT_121	[p12l430t37r510b99],
12	have	VB	O	have	xcomp	10	SENT_121	[p12l543t21r736b100],
13	responses	NNS	O	response	dobj	12	SENT_121	[p12l768t46r1199b121],
14	is	VBZ	O	be	advcl	23	SENT_121	[p12l1232t21r1299b99],
15	in	IN	O	in	_	0	SENT_121	[p12l1331t21r1415b98],
16	the	DT	O	the	det	18	SENT_121	[p12l1447t21r1578b99],
17	public	JJ	O	public	amod	18	SENT_121	[p12l1609t21r1880b121],
18	interest	NN	O	interest	prep_in	14	SENT_121	[p12l1910t21r2145b99, p12l11t165r154b244],
19	,	,	O	,	_	0	SENT_121	[p12l1910t21r2145b99, p12l11t165r154b244],
20	the	DT	O	the	det	21	SENT_121	[p12l182t149r315b227],
21	sponsor	NN	O	sponsor	nsubj	41	SENT_121	[p12l339t174r692b249],
22	could	MD	O	could	aux	23	SENT_121	[p12l712t148r950b228],
23	form	VB	O	form	_	0	SENT_121	[p12l973t148r1185b227],
24	a	DT	O	a	det	25	SENT_121	[p12l1207t175r1251b227],
25	partnership	NN	O	partnership	dobj	23	SENT_121	[p12l1271t149r1778b249],
26	with	IN	O	with	_	0	SENT_121	[p12l1797t148r1991b228],
27	the	DT	O	the	det	33	SENT_121	[p12l2014t149r2147b227],
28	National	NNP	ORGANIZATION	National	dep	33	SENT_121	[p12l8t277r385b357],
29	Institutes	NNPS	ORGANIZATION	Institutes	dep	28	SENT_121	[p12l409t278r815b357],
30	of	IN	ORGANIZATION	of	_	0	SENT_121	[p12l844t277r946b356],
31	Health	NNP	ORGANIZATION	Health	prep_of	28	SENT_121	[p12l953t278r1243b356],
32	(	CD	NUMBER	(	num	31	SENT_121	[p12l1274t285r1521b369],
33	NIH	NNP	ORGANIZATION	NIH	prep_with	25	SENT_121	[p12l1274t285r1521b369],
34	)	CD	NUMBER	)	tmod	23	SENT_121	[p12l1274t285r1521b369],
35	to	TO	O	to	aux	36	SENT_121	[p12l1552t294r1633b356],
36	fulﬁll	VB	O	fulﬁll	xcomp	23	SENT_121	[p12l1661t277r1896b357],
37	these	DT	O	these	det	38	SENT_121	[p12l1922t278r2147b356],
38	obligations	NNS	O	obligation	dobj	36	SENT_121	[p12l11t405r498b506],
39	or	CC	O	or	_	0	SENT_121	[p12l525t431r616b484],
40	could	MD	O	could	aux	41	SENT_121	[p12l638t405r876b485],
41	use	VB	O	use	conj_or	23	SENT_121	[p12l899t432r1041b485],
42	the	DT	O	the	det	43	SENT_121	[p12l1066t406r1198b484],
43	expertise	NN	O	expertise	dobj	41	SENT_121	[p12l1223t406r1609b506],
44	of	IN	O	of	_	0	SENT_121	[p12l1634t405r1736b484],
45	academic	JJ	O	academic	amod	46	SENT_121	[p12l1740t405r2148b484],
46	centers	NNS	O	center	prep_of	43	SENT_121	[p12l11t550r345b629],
47	,	,	O	,	_	0	SENT_121	[p12l11t550r345b629],
48	but	CC	O	but	_	0	SENT_121	[p12l390t534r534b613],
49	the	DT	O	the	det	50	SENT_121	[p12l568t534r701b612],
50	sponsor	NN	O	sponsor	nsubj	52	SENT_121	[p12l741t559r1093b634],
51	would	MD	O	would	aux	52	SENT_121	[p12l1125t533r1396b613],
52	assume	VB	O	assume	conj_but	23	SENT_121	[p12l1434t560r1759b613],
53	the	DT	O	the	det	55	SENT_121	[p12l1799t534r1931b612],
54	ultimate	JJ	O	ultimate	amod	55	SENT_121	[p12l1970t534r2145b613, p12l10t678r221b740],
55	responsibility	NN	O	responsibility	dobj	52	SENT_121	[p12l254t662r850b762],
56	for	IN	O	for	_	0	SENT_121	[p12l877t661r1003b740],
57	initiating	VBG	O	initiate	prepc_for	52	SENT_121	[p12l1031t662r1433b762],
58	and	CC	O	and	_	0	SENT_121	[p12l1461t661r1620b740],
59	completing	VBG	O	complete	conj_and	57	SENT_121	[p12l1653t662r2150b762],
60	the	DT	O	the	det	61	SENT_121	[p12l11t789r143b868],
61	studies	NNS	O	study	dobj	57	SENT_121	[p12l172t789r501b869],
62	.	.	O	.	_	0	SENT_121	[p12l172t789r501b869],

1	The	DT	O	the	det	6	SENT_122	[p12l137t917r299b996],
2	proposed	VBN	O	propose	amod	6	SENT_122	[p12l329t918r732b1018],
3	selective	JJ	O	selective	amod	6	SENT_122	[p12l764t917r1522b1018],
4	—	NN	O	—	nn	6	SENT_122	[p12l764t917r1522b1018],
5	approval	NN	O	approval	nn	6	SENT_122	[p12l764t917r1522b1018],
6	mechanism	NN	O	mechanism	nsubjpass	8	SENT_122	[p12l1553t917r2049b996],
7	is	VBZ	O	be	auxpass	8	SENT_122	[p12l2080t918r2145b996],
8	intended	VBN	O	intend	_	0	SENT_122	[p12l10t1045r384b1124],
9	to	TO	O	to	aux	10	SENT_122	[p12l419t1062r498b1124],
10	complement	VB	O	complement	xcomp	8	SENT_122	[p12l534t1046r1076b1146],
11	the	DT	O	the	det	14	SENT_122	[p12l1105t1045r1234b1124],
12	fast	JJ	O	fast	amod	14	SENT_122	[p12l1269t1045r1674b1125],
13	—	NN	O	—	nn	14	SENT_122	[p12l1269t1045r1674b1125],
14	tracl	NN	O	tracl	dobj	10	SENT_122	[p12l1269t1045r1674b1125],
15	<	JJR	O	<	amod	16	SENT_122	[p12l1269t1045r1674b1125],
16	programs	NNS	O	program	dep	14	SENT_122	[p12l1702t1071r2142b1146],
17	.	.	O	.	_	0	SENT_122	[p12l1702t1071r2142b1146],

1	Sponsors	NNS	O	sponsor	nsubj	4	SENT_123	[p12l12t1179r411b1274],
2	could	MD	O	could	aux	4	SENT_123	[p12l449t1174r686b1253],
3	still	RB	O	still	advmod	4	SENT_123	[p12l722t1174r880b1252],
4	obtain	VB	O	obtain	_	0	SENT_123	[p12l914t1174r1192b1252],
5	accelerated	VBN	O	accelerate	amod	6	SENT_123	[p12l1226t1173r1709b1252],
6	approval	NN	O	approval	dobj	4	SENT_123	[p12l1743t1174r2141b1274],
7	,	,	O	,	_	0	SENT_123	[p12l1743t1174r2141b1274],
8	but	CC	O	but	_	0	SENT_123	[p12l11t1302r155b1381],
9	only	RB	O	only	_	0	SENT_123	[p12l191t1301r375b1402],
10	for	IN	O	for	conj_only	4	SENT_123	[p12l409t1301r533b1380],
11	those	DT	O	those	det	12	SENT_123	[p12l568t1302r797b1380],
12	drugs	NNS	O	drug	pobj	10	SENT_123	[p12l836t1302r1075b1402],
13	that	WDT	O	that	nsubj	14	SENT_123	[p12l1116t1302r1284b1380],
14	lacked	VBD	O	lack	ccomp	10	SENT_123	[p12l1316t1302r1589b1381],
15	a	DT	O	a	det	19	SENT_123	[p12l1626t1328r1670b1380],
16	clearly	RB	O	clearly	advmod	17	SENT_123	[p12l1708t1302r1982b1402],
17	defined	VBN	O	define	amod	19	SENT_123	[p12l2017t1302r2146b1380, p12l10t1429r230b1508],
18	molecular	JJ	O	molecular	amod	19	SENT_123	[p12l263t1430r700b1509],
19	target	NN	O	target	dobj	14	SENT_123	[p12l730t1446r987b1530],
20	or	CC	O	or	_	0	SENT_123	[p12l1016t1455r1107b1508],
21	that	IN	O	that	dep	28	SENT_123	[p12l1138t1430r1328b1525],
22	,	,	O	,	_	0	SENT_123	[p12l1138t1430r1328b1525],
23	for	IN	O	for	_	0	SENT_123	[p12l1367t1429r1493b1508],
24	other	JJ	O	other	amod	25	SENT_123	[p12l1523t1429r1753b1508],
25	reasons	NNS	O	reason	prep_for	28	SENT_123	[p12l1783t1455r2141b1525],
26	,	,	O	,	_	0	SENT_123	[p12l1783t1455r2141b1525],
27	might	MD	O	might	aux	28	SENT_123	[p12l10t1557r265b1658],
28	prove	VB	O	prove	conj_or	14	SENT_123	[p12l279t1583r508b1658],
29	difficult	JJ	O	difficult	acomp	28	SENT_123	[p12l529t1557r857b1637],
30	to	TO	O	to	aux	31	SENT_123	[p12l873t1574r951b1636],
31	study	VB	O	study	xcomp	29	SENT_123	[p12l974t1557r1196b1658],
32	as	IN	O	as	_	0	SENT_123	[p12l1211t1584r1294b1636],
33	single	JJ	O	single	amod	34	SENT_123	[p12l1318t1558r1564b1658],
34	agents	NNS	O	agent	prep_as	31	SENT_123	[p12l1584t1574r1877b1658],
35	.	.	O	.	_	0	SENT_123	[p12l1584t1574r1877b1658],

1	Sponsors	NNS	O	sponsor	nsubj	3	SENT_124	[p12l1905t1563r2148b1658, p12l12t1711r184b1764],
2	Would	MD	O	would	aux	3	SENT_124	[p12l209t1685r480b1765],
3	continue	VB	O	continue	_	0	SENT_124	[p12l508t1686r886b1765],
4	to	TO	O	to	aux	6	SENT_124	[p12l914t1702r994b1764],
5	be	VB	O	be	cop	6	SENT_124	[p12l1024t1685r1121b1764],
6	able	JJ	O	able	xcomp	3	SENT_124	[p12l1148t1685r1324b1764],
7	to	TO	O	to	aux	8	SENT_124	[p12l1352t1702r1432b1764],
8	seek	VB	O	seek	xcomp	6	SENT_124	[p12l1462t1686r1653b1765],
9	regular	JJ	O	regular	amod	10	SENT_124	[p12l1676t1686r1987b1786],
10	approval	NN	O	approval	dobj	8	SENT_124	[p12l2010t1712r2145b1786, p12l9t1814r278b1914],
11	without	IN	O	without	_	0	SENT_124	[p12l312t1813r656b1893],
12	the	DT	O	the	det	14	SENT_124	[p12l690t1814r822b1892],
13	formal	JJ	O	formal	amod	14	SENT_124	[p12l861t1813r1151b1892],
14	requirement	NN	O	requirement	prep_without	8	SENT_124	[p12l1190t1814r1731b1914],
15	for	IN	O	for	_	0	SENT_124	[p12l1765t1813r1891b1892],
16	postapproval	JJ	O	postapproval	amod	17	SENT_124	[p12l1925t1830r2145b1914, p12l10t1942r383b2042],
17	studies	NNS	O	study	prep_for	14	SENT_124	[p12l430t1941r725b2021],
18	of	IN	O	of	_	0	SENT_124	[p12l775t1941r876b2020],
19	selectivity	NN	O	selectivity	prep_of	17	SENT_124	[p12l905t1941r1317b2042],
20	if	IN	O	if	mark	23	SENT_124	[p12l1358t1941r1434b2019],
21	their	PRP$	O	they	poss	22	SENT_124	[p12l1462t1941r1661b2020],
22	drugs	NNS	O	drug	nsubj	23	SENT_124	[p12l1705t1941r1943b2042],
23	had	VBD	O	have	advcl	6	SENT_124	[p12l1992t1942r2148b2020],
24	clear	JJ	O	clear	amod	26	SENT_124	[p12l11t2070r215b2148],
25	clinical	JJ	O	clinical	amod	26	SENT_124	[p12l241t2069r550b2148],
26	beneﬁts	NNS	O	beneﬁts	dobj	23	SENT_124	[p12l578t2069r921b2148],
27	in	IN	O	in	_	0	SENT_124	[p12l950t2070r1033b2147],
28	controlled	JJ	O	controlled	amod	29	SENT_124	[p12l1061t2070r1505b2148],
29	trials	NNS	O	trial	prep_in	26	SENT_124	[p12l1533t2069r1774b2148],
30	.	.	O	.	_	0	SENT_124	[p12l1533t2069r1774b2148],

1	The	DT	O	the	det	2	SENT_125	[p12l1804t2070r1969b2148],
2	evidence	NN	O	evidence	_	0	SENT_125	[p12l1997t2070r2145b2149, p12l11t2197r257b2276],

1	required	VBN	O	require	csubj	7	SENT_126	[p12l278t2198r629b2298],
2	for	IN	O	for	_	0	SENT_126	[p12l650t2197r772b2276],
3	selective	JJ	O	selective	amod	4	SENT_126	[p12l791t2198r1136b2277],
4	approval	NN	O	approval	prep_for	1	SENT_126	[p12l1156t2198r1517b2298],
5	Would	MD	O	would	aux	7	SENT_126	[p12l1533t2197r1797b2277],
6	be	VB	O	be	cop	7	SENT_126	[p12l1818t2197r1913b2276],
7	identical	JJ	O	identical	_	0	SENT_126	[p12l1934t2197r2147b2276, p12l11t2326r186b2404],
8	to	TO	O	to	_	0	SENT_126	[p12l211t2342r291b2404],
9	that	DT	O	that	prep_to	7	SENT_126	[p12l317t2326r489b2404],
10	already	RB	O	already	advmod	11	SENT_126	[p12l508t2325r820b2426],
11	established	VBN	O	establish	partmod	9	SENT_126	[p12l840t2325r1332b2404],
12	for	IN	O	for	_	0	SENT_126	[p12l1356t2325r1482b2404],
13	accelerated	VBN	O	accelerate	amod	14	SENT_126	[p12l1504t2326r1987b2404],
14	approval	NN	O	approval	prep_for	11	SENT_126	[p12l2010t2352r2145b2426, p12l9t2454r302b2554],
15	,	,	O	,	_	0	SENT_126	[p12l2010t2352r2145b2426, p12l9t2454r302b2554],
16	and	CC	O	and	_	0	SENT_126	[p12l332t2454r491b2532],
17	the	DT	O	the	det	18	SENT_126	[p12l516t2453r648b2532],
18	conversion	NN	O	conversion	nsubj	26	SENT_126	[p12l673t2454r1147b2533],
19	of	IN	O	of	_	0	SENT_126	[p12l1172t2453r1274b2532],
20	selective	JJ	O	selective	amod	21	SENT_126	[p12l1282t2454r1642b2533],
21	approval	NN	O	approval	prep_of	18	SENT_126	[p12l1666t2453r2040b2554],
22	to	TO	O	to	_	0	SENT_126	[p12l2065t2470r2145b2532],
23	regular	JJ	O	regular	amod	24	SENT_126	[p12l10t2581r322b2682],
24	approval	NN	O	approval	prep_to	21	SENT_126	[p12l345t2581r720b2682],
25	would	MD	O	would	aux	26	SENT_126	[p12l742t2582r1013b2661],
26	require	VB	O	require	conj_and	7	SENT_126	[p12l1040t2582r1348b2682],
27	either	CC	O	either	preconj	30	SENT_126	[p12l1377t2582r1626b2660],
28	a	DT	O	a	det	30	SENT_126	[p12l1650t2608r1695b2660],
29	major	JJ	O	major	amod	30	SENT_126	[p12l1721t2582r1975b2682],
30	improvement	NN	O	improvement	dobj	26	SENT_126	[p12l1998t2582r2145b2659, p12l9t2726r480b2810],
31	in	IN	O	in	_	0	SENT_126	[p12l499t2710r582b2787],
32	the	DT	O	the	det	33	SENT_126	[p12l608t2710r740b2788],
33	selection	NN	O	selection	prep_in	30	SENT_126	[p12l767t2709r1151b2788],
34	of	IN	O	of	_	0	SENT_126	[p12l1177t2709r1278b2788],
35	patients	NNS	O	patient	prep_of	33	SENT_126	[p12l1283t2710r1627b2810],
36	or	CC	O	or	_	0	SENT_126	[p12l1656t2735r1747b2788],
37	the	DT	O	the	det	38	SENT_126	[p12l1769t2710r1901b2788],
38	completion	NN	O	completion	conj_or	30	SENT_126	[p12l1927t2735r2145b2788, p12l9t2838r315b2938],
39	of	IN	O	of	_	0	SENT_126	[p12l357t2837r459b2916],
40	randomized	VBN	O	randomize	prepc_of	38	SENT_126	[p12l482t2837r1006b2916],
41	trials	NNS	O	trial	dobj	40	SENT_126	[p12l1048t2838r1289b2916],
42	.	.	O	.	_	0	SENT_126	[p12l1048t2838r1289b2916],

1	Unlike	IN	O	unlike	_	0	SENT_127	[p12l1335t2838r1622b2917],
2	accelerated	VBN	O	accelerate	amod	3	SENT_127	[p12l1664t2837r2147b2916],
3	approval	NN	O	approval	prep_unlike	12	SENT_127	[p12l10t2965r407b3066],
4	,	,	O	,	_	0	SENT_127	[p12l10t2965r407b3066],
5	the	DT	O	the	det	9	SENT_127	[p12l436t2966r566b3044],
6	selective	JJ	O	selective	amod	9	SENT_127	[p12l589t2966r1346b3066],
7	—	NN	O	—	nn	9	SENT_127	[p12l589t2966r1346b3066],
8	approval	NN	O	approval	nn	9	SENT_127	[p12l589t2966r1346b3066],
9	mechanism	NN	O	mechanism	nsubj	21	SENT_127	[p12l1367t2966r1864b3044],
10	would	MD	O	would	aux	12	SENT_127	[p12l1881t2966r2148b3045],
11	be	VB	O	be	cop	12	SENT_127	[p12l11t3094r107b3172],
12	available	JJ	O	available	_	0	SENT_127	[p12l139t3094r506b3173],
13	for	IN	O	for	_	0	SENT_127	[p12l539t3093r663b3172],
14	all	DT	O	all	det	15	SENT_127	[p12l691t3094r791b3172],
15	new	JJ	O	new	prep_for	12	SENT_127	[p12l824t3119r1000b3173],
16	targeted	VBN	O	target	partmod	15	SENT_127	[p12l1030t3093r1377b3194],
17	cancer	NN	O	cancer	nn	18	SENT_127	[p12l1411t3119r1687b3172],
18	drugs	NNS	O	drug	dobj	16	SENT_127	[p12l1718t3093r1957b3194],
19	and	CC	O	and	_	0	SENT_127	[p12l1991t3094r2148b3172],
20	Would	MD	O	would	aux	21	SENT_127	[p12l6t3222r278b3301],
21	create	VB	O	create	conj_and	12	SENT_127	[p12l307t3238r563b3300],
22	a	DT	O	a	det	24	SENT_127	[p12l593t3248r637b3300],
23	financial	JJ	O	financial	amod	24	SENT_127	[p12l664t3221r1046b3300],
24	commitment	NN	O	commitment	dobj	21	SENT_127	[p12l1076t3222r1648b3300],
25	on	IN	O	on	_	0	SENT_127	[p12l1673t3247r1782b3300],
26	the	DT	O	the	det	27	SENT_127	[p12l1811t3222r1944b3300],
27	part	NN	O	part	prep_on	21	SENT_127	[p12l1972t3238r2151b3322],
28	of	IN	O	of	_	0	SENT_127	[p12l11t3349r114b3428],
29	the	DT	O	the	det	30	SENT_127	[p12l141t3350r274b3428],
30	sponsor	NN	O	sponsor	prep_of	27	SENT_127	[p12l321t3375r686b3450],
31	.	.	O	.	_	0	SENT_127	[p12l321t3375r686b3450],

1	Speciﬁcally	RB	O	speciﬁcally	advmod	4	SENT_128	[p12l734t3349r1225b3450],
2	,	,	O	,	_	0	SENT_128	[p12l734t3349r1225b3450],
3	we	PRP	O	we	nsubj	4	SENT_128	[p12l1267t3376r1386b3429],
4	propose	VBP	O	propose	_	0	SENT_128	[p12l1426t3375r1772b3450],
5	that	IN	O	that	complm	8	SENT_128	[p12l1814t3349r1982b3428],
6	the	DT	O	the	det	7	SENT_128	[p12l2018t3350r2148b3428],
7	FDA	NNP	ORGANIZATION	FDA	nsubj	8	SENT_128	[p12l9t3484r198b3556],
8	require	VBP	O	require	ccomp	4	SENT_128	[p12l239t3478r547b3578],
9	that	IN	O	that	dep	8	SENT_128	[p12l591t3477r762b3556],
10	a	DT	O	a	det	12	SENT_128	[p12l800t3504r845b3556],
11	minimal	JJ	O	minimal	amod	12	SENT_128	[p12l887t3478r1254b3556],
12	percentage	NN	O	percentage	dep	16	SENT_128	[p12l1296t3494r1773b3578],
13	of	IN	O	of	_	0	SENT_128	[p12l1818t3477r1921b3556],
14	drug	NN	O	drug	prep_of	12	SENT_128	[p12l1946t3478r2150b3578],
15	sales	NNS	O	sale	dep	16	SENT_128	[p12l12t3606r216b3684],
16	(	CD	NUMBER	(	dep	21	SENT_128	[p12l251t3613r464b3706],
17	e.g.	FW	O	e.g.	dep	16	SENT_128	[p12l251t3613r464b3706],
18	,	,	O	,	_	0	SENT_128	[p12l251t3613r464b3706],
19	5	CD	PERCENT	5	num	20	SENT_128	[p12l499t3613r542b3684],
20	percent	NN	PERCENT	percent	appos	17	SENT_128	[p12l571t3613r918b3706],
21	)	CD	NUMBER	)	dep	9	SENT_128	[p12l571t3613r918b3706],
22	be	VB	O	be	auxpass	23	SENT_128	[p12l949t3606r1045b3684],
23	allocated	VBN	O	allocate	rcmod	21	SENT_128	[p12l1070t3605r1450b3684],
24	either	DT	O	either	preconj	21	SENT_128	[p12l1475t3606r1720b3684],
25	to	TO	O	to	_	0	SENT_128	[p12l1743t3622r1822b3684],
26	studies	NNS	O	study	prep_to	21	SENT_128	[p12l1850t3605r2145b3685],
27	focused	VBN	O	focus	partmod	26	SENT_128	[p13l10t20r340b100],
28	on	IN	O	on	_	0	SENT_128	[p13l372t46r479b99],
29	identifying	VBG	O	identify	prepc_on	27	SENT_128	[p13l509t20r972b121],
30	subgroups	NNS	O	subgroup	dobj	29	SENT_128	[p13l1001t21r1450b121],
31	of	IN	O	of	_	0	SENT_128	[p13l1484t20r1585b99],
32	patients	NNS	O	patient	prep_of	30	SENT_128	[p13l1596t21r1933b121],
33	who	WP	O	who	nsubj	35	SENT_128	[p13l1962t21r2147b100],
34	are	VBP	O	be	cop	35	SENT_128	[p13l10t175r136b227],
35	likely	JJ	O	likely	rcmod	32	SENT_128	[p13l175t149r402b249],
36	to	TO	O	to	aux	37	SENT_128	[p13l438t165r517b227],
37	have	VB	O	have	xcomp	35	SENT_128	[p13l558t149r746b228],
38	responses	NNS	O	response	dobj	37	SENT_128	[p13l786t174r1209b249],
39	or	CC	O	or	_	0	SENT_128	[p13l1252t174r1341b227],
40	to	TO	O	to	_	0	SENT_128	[p13l1378t165r1457b227],
41	the	DT	O	the	det	42	SENT_128	[p13l1499t149r1629b227],
42	NIH	NNP	ORGANIZATION	NIH	conj_or	26	SENT_128	[p13l1666t156r1850b227],
43	for	IN	O	for	_	0	SENT_128	[p13l1889t148r2014b227],
44	its	PRP$	O	its	poss	45	SENT_128	[p13l2049t149r2145b227],
45	sponsorship	NN	O	sponsorship	prep_for	42	SENT_128	[p13l12t277r528b377],
46	of	IN	O	of	_	0	SENT_128	[p13l551t276r651b355],
47	related	JJ	O	related	amod	48	SENT_128	[p13l654t276r934b355],
48	research	NN	O	research	prep_of	45	SENT_128	[p13l956t277r1326b355],
49	.	.	O	.	_	0	SENT_128	[p13l956t277r1326b355],

1	This	DT	O	this	det	3	SENT_129	[p13l1349t277r1532b355],
2	ﬁnancial	JJ	O	ﬁnancial	amod	3	SENT_129	[p13l1556t276r1914b355],
3	commitment	NN	O	commitment	nsubj	5	SENT_129	[p13l1936t302r2148b355, p13l10t405r380b483],
4	would	MD	O	would	aux	5	SENT_129	[p13l411t405r677b484],
5	continue	VB	O	continue	_	0	SENT_129	[p13l718t405r1089b484],
6	until	IN	O	until	_	0	SENT_129	[p13l1130t404r1326b484],
7	the	DT	O	the	det	8	SENT_129	[p13l1366t405r1496b483],
8	drug	NN	O	drug	prep_until	5	SENT_129	[p13l1538t404r1738b505],
9	qualiﬁed	VBN	O	qualiﬁed	partmod	8	SENT_129	[p13l1776t404r2148b505],
10	for	IN	O	for	_	0	SENT_129	[p13l10t532r133b611],
11	regular	JJ	O	regular	amod	12	SENT_129	[p13l153t532r454b633],
12	approval	NN	O	approval	prep_for	9	SENT_129	[p13l474t533r860b633],
13	,	,	O	,	_	0	SENT_129	[p13l474t533r860b633],
14	until	IN	O	until	mark	19	SENT_129	[p13l889t533r1082b612],
15	the	DT	O	the	det	16	SENT_129	[p13l1105t532r1234b611],
16	sponsor	NN	O	sponsor	nsubj	19	SENT_129	[p13l1259t558r1602b633],
17	had	VBD	O	have	aux	19	SENT_129	[p13l1622t532r1777b611],
18	successfully	RB	O	successfully	advmod	19	SENT_129	[p13l1801t559r2147b612, p13l10t660r197b761],
19	identiﬁed	VBN	O	identiﬁed	dep	9	SENT_129	[p13l213t660r618b739],
20	subgroups	NNS	O	subgroup	dobj	19	SENT_129	[p13l641t660r1089b761],
21	of	IN	O	of	_	0	SENT_129	[p13l1113t660r1214b739],
22	patients	NNS	O	patient	prep_of	20	SENT_129	[p13l1215t661r1552b761],
23	who	WP	O	who	nsubj	25	SENT_129	[p13l1571t661r1755b740],
24	are	VBP	O	be	cop	25	SENT_129	[p13l1778t687r1904b739],
25	likely	JJ	O	likely	rcmod	22	SENT_129	[p13l1924t661r2152b761],
26	to	TO	O	to	aux	27	SENT_129	[p13l11t805r90b867],
27	have	VB	O	have	xcomp	25	SENT_129	[p13l116t789r306b868],
28	responses	NNS	O	response	dobj	27	SENT_129	[p13l330t814r780b889],
29	,	,	O	,	_	0	SENT_129	[p13l330t814r780b889],
30	or	CC	O	or	_	0	SENT_129	[p13l811t814r900b867],
31	until	IN	O	until	mark	36	SENT_129	[p13l922t789r1119b868],
32	the	DT	O	the	det	33	SENT_129	[p13l1143t789r1273b867],
33	drug	NN	O	drug	nsubjpass	36	SENT_129	[p13l1299t789r1499b889],
34	had	VBD	O	have	aux	36	SENT_129	[p13l1521t788r1677b867],
35	been	VBN	O	be	auxpass	36	SENT_129	[p13l1702t789r1903b867],
36	withdrawn	VBN	O	withdraw	conj_or	19	SENT_129	[p13l1923t788r2147b868, p13l11t916r277b996],
37	from	IN	O	from	_	0	SENT_129	[p13l302t916r511b995],
38	the	DT	O	the	det	39	SENT_129	[p13l537t917r667b995],
39	market	NN	O	market	prep_from	36	SENT_129	[p13l692t917r1015b996],
40	.	.	O	.	_	0	SENT_129	[p13l692t917r1015b996],

1	The	DT	O	the	det	2	SENT_130	[p13l137t1044r299b1123],
2	effect	NN	O	effect	_	0	SENT_130	[p13l323t1044r558b1123],
3	of	IN	O	of	_	0	SENT_130	[p13l576t1044r677b1123],
4	this	DT	O	this	det	6	SENT_130	[p13l682t1044r836b1123],
5	new	JJ	O	new	amod	6	SENT_130	[p13l860t1070r1037b1124],
6	mechanism	NN	O	mechanism	prep_of	2	SENT_130	[p13l1056t1045r1577b1140],
7	,	,	O	,	_	0	SENT_130	[p13l1056t1045r1577b1140],
8	if	IN	O	if	mark	9	SENT_130	[p13l1604t1044r1679b1122],
9	successful	JJ	O	successful	dep	6	SENT_130	[p13l1686t1044r2143b1140],
10	,	,	O	,	_	0	SENT_130	[p13l1686t1044r2143b1140],

1	U	NN	O	u	_	0	SENT_131	[p13l149t1215r205b1237],
2	+	CC	O	+	_	0	SENT_131	[p13l149t1215r205b1237],
3	N	NN	O	n	conj_+	1	SENT_131	[p13l917t1217r930b1232],
4	ENGLJMED35	NN	O	engljmed35	nn	6	SENT_131	[p13l946t1216r1170b1238],
5	'	''	O	'	_	0	SENT_131	[p13l946t1216r1170b1238],
6	|	NN	O	|	dep	3	SENT_131	[p13l946t1216r1170b1238],
7	;	:	O	;	_	0	SENT_131	[p13l946t1216r1170b1238],
8	5	CD	NUMBER	5	dep	1	SENT_131	[p13l946t1216r1170b1238],
9	WWW	NNP	O	WWW	dep	8	SENT_131	[p13l1204t1217r1317b1232],
10	.	.	O	.	_	0	SENT_131	[p13l1204t1217r1317b1232],

1	NE	NN	O	ne	nn	3	SENT_132	[p13l1204t1217r1317b1232],
2	M.ORG	NN	O	m.org	nn	3	SENT_132	[p13l1333t1216r1416b1232],
3	JULY	NN	DATE	july	_	0	SENT_132	[p13l1449t1217r1510b1238],
4	29,2004	CD	NUMBER	29,2004	dep	3	SENT_132	[p13l1522t1216r1641b1238],
5	.	.	O	.	_	0	SENT_132	[p13l1522t1216r1641b1238],

1	The	DT	O	the	det	5	SENT_133	[p13l935t1249r986b1273],
2	New	NNP	O	New	nn	5	SENT_133	[p13l995t1250r1057b1273],
3	England	NNP	O	England	nn	5	SENT_133	[p13l1066t1249r1177b1280],
4	Journal	NNP	O	Journal	nn	5	SENT_133	[p13l1186t1249r1283b1273],
5	o	NN	O	o	_	0	SENT_133	[p13l1293t1257r1308b1273],
6	edicine	NN	O	edicine	dep	5	SENT_133	[p13l1359t1249r1454b1273],

1	Downloaded	VBN	O	download	_	0	SENT_134	[p13l377t1290r547b1313],
2	from	IN	O	from	_	0	SENT_134	[p13l556t1290r620b1313],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_134	[p13l629t1290r747b1320],
4	at	IN	O	at	_	0	SENT_134	[p13l758t1294r781b1313],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_134	[p13l789t1290r972b1313],
6	on	IN	O	on	_	0	SENT_134	[p13l981t1297r1014b1313],
7	January	NNP	DATE	January	prep_on	1	SENT_134	[p13l1022t1290r1125b1320],
8	5	CD	DATE	5	num	7	SENT_134	[p13l1135t1290r1158b1317],
9	,	,	DATE	,	_	0	SENT_134	[p13l1135t1290r1158b1317],
10	2014	CD	DATE	2014	num	7	SENT_134	[p13l1169t1290r1241b1313],
11	.	.	O	.	_	0	SENT_134	[p13l1169t1290r1241b1313],

1	For	IN	O	for	_	0	SENT_135	[p13l1251t1290r1298b1313],
2	personal	JJ	O	personal	amod	3	SENT_135	[p13l1306t1290r1418b1320],
3	use	NN	O	use	pobj	1	SENT_135	[p13l1427t1297r1471b1313],
4	only	RB	O	only	advmod	3	SENT_135	[p13l1481t1290r1545b1320],
5	.	.	O	.	_	0	SENT_135	[p13l1481t1290r1545b1320],

1	No	DT	O	no	det	3	SENT_136	[p13l1556t1290r1596b1313],
2	other	JJ	O	other	amod	3	SENT_136	[p13l1606t1290r1674b1313],
3	uses	NNS	O	use	_	0	SENT_136	[p13l1682t1297r1738b1313],
4	without	IN	O	without	_	0	SENT_136	[p13l1748t1290r1849b1313],
5	permission	NN	O	permission	prep_without	3	SENT_136	[p13l1858t1290r2010b1320],
6	.	.	O	.	_	0	SENT_136	[p13l1858t1290r2010b1320],

1	Copyright	NN	O	copyright	_	0	SENT_137	[p13l727t1331r862b1362],
2	©	CD	NUMBER	©	num	6	SENT_137	[p13l871t1331r895b1355],
3	2004	CD	DATE	2004	num	6	SENT_137	[p13l905t1331r970b1355],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_137	[p13l979t1331r1170b1355],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_137	[p13l1180t1331r1288b1355],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_137	[p13l1299t1331r1404b1362],
7	.	.	O	.	_	0	SENT_137	[p13l1299t1331r1404b1362],

1	All	DT	O	all	det	2	SENT_138	[p13l1415t1331r1456b1355],
2	rights	NNS	O	rights	nsubj	3	SENT_138	[p13l1465t1331r1540b1362],
3	reserved	VBN	O	reserve	_	0	SENT_138	[p13l1550t1331r1669b1355],
4	.	.	O	.	_	0	SENT_138	[p13l1550t1331r1669b1355],

1	SOUNDING	VBG	O	sound	_	0	SENT_139	[p13l922t1437r1110b1456],
2	BOARD	NNP	O	BOARD	dobj	1	SENT_139	[p13l1124t1437r1237b1456],

1	would	MD	O	would	aux	3	SENT_140	[p13l6t1652r273b1731],
2	be	VB	O	be	cop	3	SENT_140	[p13l308t1652r404b1730],
3	profound	JJ	O	profound	_	0	SENT_140	[p13l437t1651r840b1752],
4	and	CC	O	and	_	0	SENT_140	[p13l873t1651r1030b1730],
5	would	MD	O	would	aux	6	SENT_140	[p13l1060t1651r1326b1731],
6	extend	VB	O	extend	conj_and	3	SENT_140	[p13l1361t1652r1640b1730],
7	beyond	IN	O	beyond	_	0	SENT_140	[p13l1675t1651r1983b1752],
8	the	DT	O	the	det	9	SENT_140	[p13l2018t1652r2148b1730],
9	ﬁeld	NN	O	ﬁeld	prep_beyond	6	SENT_140	[p13l11t1779r197b1858],
10	of	IN	O	of	_	0	SENT_140	[p13l221t1779r322b1858],
11	cancer	NN	O	cancer	prep_of	9	SENT_140	[p13l327t1805r620b1858],
12	.	.	O	.	_	0	SENT_140	[p13l327t1805r620b1858],

1	The	DT	O	the	det	2	SENT_141	[p13l646t1779r807b1858],
2	inability	NN	O	inability	nsubj	9	SENT_141	[p13l830t1779r1178b1880],
3	to	TO	O	to	aux	4	SENT_141	[p13l1197t1796r1276b1858],
4	predict	VB	O	predict	infmod	2	SENT_141	[p13l1299t1779r1601b1880],
5	responses	NNS	O	response	dobj	4	SENT_141	[p13l1619t1805r2042b1880],
6	in	IN	O	in	_	0	SENT_141	[p13l2067t1780r2148b1857],
7	patients	NNS	O	patient	prep_in	4	SENT_141	[p13l9t1908r346b2008],
8	has	VBZ	O	have	aux	9	SENT_141	[p13l395t1907r537b1986],
9	compromised	VBN	O	compromise	_	0	SENT_141	[p13l587t1908r1180b2008],
10	drug	NN	O	drug	nn	11	SENT_141	[p13l1227t1907r1428b2008],
11	development	NN	O	development	dobj	9	SENT_141	[p13l1473t1908r2026b2008],
12	in	IN	O	in	_	0	SENT_141	[p13l2067t1908r2148b1985],
13	many	JJ	O	many	amod	14	SENT_141	[p13l11t2061r246b2136],
14	classes	NNS	O	class	prep_in	9	SENT_141	[p13l271t2036r561b2114],
15	of	IN	O	of	_	0	SENT_141	[p13l592t2035r693b2114],
16	therapeutic	JJ	O	therapeutic	amod	17	SENT_141	[p13l703t2036r1181b2136],
17	agents	NNS	O	agent	prep_of	14	SENT_141	[p13l1208t2052r1508b2136],
18	,	,	O	,	_	0	SENT_141	[p13l1208t2052r1508b2136],
19	but	CC	O	but	_	0	SENT_141	[p13l1543t2035r1685b2115],
20	it	PRP	O	it	nsubj	21	SENT_141	[p13l1707t2036r1767b2114],
21	presents	VBZ	O	present	conj_but	9	SENT_141	[p13l1788t2052r2146b2136],
22	a	DT	O	a	det	24	SENT_141	[p13l10t2190r54b2242],
23	particular	JJ	O	particular	amod	24	SENT_141	[p13l79t2164r492b2264],
24	problem	NN	O	problem	dobj	21	SENT_141	[p13l515t2164r877b2264],
25	for	IN	O	for	_	0	SENT_141	[p13l904t2163r1028b2242],
26	cancer	NN	O	cancer	nn	27	SENT_141	[p13l1053t2189r1330b2242],
27	drugs	NNS	O	drug	prep_for	24	SENT_141	[p13l1355t2163r1619b2264],
28	.	.	O	.	_	0	SENT_141	[p13l1355t2163r1619b2264],

1	The	DT	O	the	det	4	SENT_142	[p13l1648t2164r1810b2242],
2	charac	NN	O	charac	nn	4	SENT_142	[p13l1839t2164r2147b2242],
3	—	NN	O	—	nn	4	SENT_142	[p13l1839t2164r2147b2242],
4	terization	NN	O	terization	nsubj	16	SENT_142	[p13l11t2292r416b2370],
5	of	IN	O	of	_	0	SENT_142	[p13l452t2291r554b2370],
6	subgroups	NNS	O	subgroup	prep_of	4	SENT_142	[p13l572t2292r1020b2392],
7	of	IN	O	of	_	0	SENT_142	[p13l1058t2291r1159b2370],
8	patients	NNS	O	patient	prep_of	6	SENT_142	[p13l1174t2292r1511b2392],
9	who	WP	O	who	nsubj	11	SENT_142	[p13l1544t2292r1728b2371],
10	are	VBP	O	be	cop	11	SENT_142	[p13l1764t2318r1891b2370],
11	likely	JJ	O	likely	rcmod	8	SENT_142	[p13l1925t2291r2153b2392],
12	to	TO	O	to	aux	13	SENT_142	[p13l11t2436r91b2498],
13	have	VB	O	have	xcomp	11	SENT_142	[p13l125t2420r315b2499],
14	responses	NNS	O	response	dobj	13	SENT_142	[p13l348t2445r772b2520],
15	would	MD	O	would	aux	16	SENT_142	[p13l803t2420r1069b2499],
16	reduce	VB	O	reduce	_	0	SENT_142	[p13l1103t2419r1384b2499],
17	the	DT	O	the	det	19	SENT_142	[p13l1418t2419r1548b2498],
18	needless	JJ	O	needless	amod	19	SENT_142	[p13l1582t2420r1943b2498],
19	cost	NN	O	cost	dobj	16	SENT_142	[p13l1979t2436r2153b2498],
20	of	IN	O	of	_	0	SENT_142	[p13l11t2547r113b2626],
21	ineffective	JJ	O	ineffective	amod	22	SENT_142	[p13l122t2547r557b2627],
22	therapy	NN	O	therapy	prep_of	19	SENT_142	[p13l586t2548r906b2648],
23	and	CC	O	and	_	0	SENT_142	[p13l929t2547r1086b2626],
24	the	DT	O	the	det	25	SENT_142	[p13l1115t2548r1245b2626],
25	size	NN	O	size	dobj	16	SENT_142	[p13l1275t2548r1435b2626],
26	of	IN	O	of	_	0	SENT_142	[p13l1465t2547r1566b2626],
27	clinical	JJ	O	clinical	amod	28	SENT_142	[p13l1577t2548r1879b2626],
28	trials	NNS	O	trial	prep_of	25	SENT_142	[p13l1909t2548r2143b2643],
29	,	,	O	,	_	0	SENT_142	[p13l1909t2548r2143b2643],
30	and	CC	O	and	_	0	SENT_142	[p13l10t2676r167b2754],
31	it	PRP	O	it	nsubj	34	SENT_142	[p13l192t2676r252b2754],
32	might	MD	O	might	aux	34	SENT_142	[p13l273t2676r533b2776],
33	even	RB	O	even	advmod	34	SENT_142	[p13l555t2701r742b2755],
34	broaden	VB	O	broaden	conj_and	16	SENT_142	[p13l769t2676r1119b2754],
35	the	DT	O	the	det	36	SENT_142	[p13l1145t2676r1275b2754],
36	range	NN	O	range	dobj	34	SENT_142	[p13l1301t2701r1539b2776],
37	of	IN	O	of	_	0	SENT_142	[p13l1567t2675r1668b2754],
38	indications	NNS	O	indication	prep_of	36	SENT_142	[p13l1675t2675r2146b2754],
39	to	TO	O	to	aux	40	SENT_142	[p13l11t2820r91b2882],
40	include	VB	O	include	xcomp	34	SENT_142	[p13l132t2804r444b2883],
41	diseases	NNS	O	disease	dobj	40	SENT_142	[p13l485t2804r832b2882],
42	with	IN	O	with	_	0	SENT_142	[p13l871t2804r1061b2883],
43	common	JJ	O	common	amod	45	SENT_142	[p13l1103t2829r1485b2882],
44	molecular	JJ	O	molecular	amod	45	SENT_142	[p13l1526t2804r1954b2883],
45	features	NNS	O	feature	prep_with	41	SENT_142	[p13l1992t2803r2147b2882, p13l11t2948r218b3011],
46	but	CC	O	but	_	0	SENT_142	[p13l276t2932r417b3011],
47	with	IN	O	with	_	0	SENT_142	[p13l462t2932r653b3011],
48	dissimilar	JJ	O	dissimilar	amod	49	SENT_142	[p13l708t2931r1133b3010],
49	pathologic	JJ	O	pathologic	amod	50	SENT_142	[p13l1183t2931r1639b3032],
50	manifestations	NNS	O	manifestation	prep_with	41	SENT_142	[p13l1693t2931r2147b3010, p13l11t3060r245b3138],
51	.	.	O	.	_	0	SENT_142	[p13l1693t2931r2147b3010, p13l11t3060r245b3138],

1	Many	JJ	O	many	amod	2	SENT_143	[p13l287t3067r525b3160],
2	specialties	NNS	O	specialty	nsubj	8	SENT_143	[p13l562t3059r998b3160],
3	in	IN	O	in	_	0	SENT_143	[p13l1038t3060r1120b3137],
4	medicine	NN	O	medicine	prep_in	2	SENT_143	[p13l1159t3060r1549b3138],
5	have	VBP	O	have	aux	8	SENT_143	[p13l1588t3060r1778b3139],
6	become	VBN	O	become	cop	8	SENT_143	[p13l1818t3060r2148b3138],
7	too	RB	O	too	advmod	8	SENT_143	[p13l11t3204r145b3266],
8	accustomed	JJ	O	accustomed	_	0	SENT_143	[p13l167t3188r676b3267],
9	to	TO	O	to	_	0	SENT_143	[p13l698t3204r776b3266],
10	low	JJ	O	low	amod	12	SENT_143	[p13l798t3188r954b3267],
11	response	NN	O	response	nn	12	SENT_143	[p13l972t3213r1353b3288],
12	rates	NNS	O	rate	prep_to	8	SENT_143	[p13l1374t3204r1573b3266],
13	and	CC	O	and	_	0	SENT_143	[p13l1596t3187r1753b3266],
14	have	VBP	O	have	aux	15	SENT_143	[p13l1774t3188r1963b3267],
15	emphasized	VBN	O	emphasize	conj_and	8	SENT_143	[p13l1985t3214r2147b3266, p13l9t3315r389b3416],
16	the	DT	O	the	det	17	SENT_143	[p13l414t3316r544b3394],
17	search	NN	O	search	dobj	15	SENT_143	[p13l569t3315r841b3394],
18	for	IN	O	for	_	0	SENT_143	[p13l865t3315r989b3394],
19	new	JJ	O	new	amod	20	SENT_143	[p13l1010t3341r1186b3395],
20	drugs	NNS	O	drug	prep_for	17	SENT_143	[p13l1208t3316r1446b3416],
21	without	IN	O	without	_	0	SENT_143	[p13l1468t3316r1805b3395],
22	making	VBG	O	make	prepc_without	15	SENT_143	[p13l1823t3316r2152b3416],
23	a	DT	O	a	det	25	SENT_143	[p13l10t3470r54b3522],
24	sufﬁcient	JJ	O	sufﬁcient	amod	25	SENT_143	[p13l110t3443r511b3523],
25	effort	NN	O	effort	dobj	22	SENT_143	[p13l563t3443r799b3522],
26	to	TO	O	to	aux	27	SENT_143	[p13l850t3460r929b3522],
27	deﬁne	VB	O	deﬁne	xcomp	22	SENT_143	[p13l987t3443r1249b3522],
28	the	DT	O	the	det	29	SENT_143	[p13l1305t3444r1435b3522],
29	markers	NNS	O	marker	dobj	27	SENT_143	[p13l1491t3444r1838b3523],
30	of	IN	O	of	_	0	SENT_143	[p13l1896t3443r1997b3522],
31	response	NN	O	response	prep_of	29	SENT_143	[p13l2035t3470r2147b3522, p13l12t3597r332b3672],
32	.	.	O	.	_	0	SENT_143	[p13l2035t3470r2147b3522, p13l12t3597r332b3672],

1	The	DT	O	the	det	3	SENT_144	[p13l355t3572r518b3650],
2	pharmaceutical	JJ	O	pharmaceutical	amod	3	SENT_144	[p13l538t3571r1196b3672],
3	industry	NN	O	industry	nsubj	12	SENT_144	[p13l1216t3572r1580b3672],
4	,	,	O	,	_	0	SENT_144	[p13l1216t3572r1580b3672],
5	the	DT	O	the	det	6	SENT_144	[p13l1608t3572r1738b3650],
6	NIH	NNP	ORGANIZATION	NIH	nsubj	12	SENT_144	[p13l1757t3579r1965b3667],
7	,	,	O	,	_	0	SENT_144	[p13l1757t3579r1965b3667],
8	and	CC	O	and	_	0	SENT_144	[p13l1992t3571r2148b3650],
9	the	DT	O	the	det	10	SENT_144	[p13l11t3700r141b3778],
10	FDA	NNP	ORGANIZATION	FDA	conj_and	3	SENT_144	[p13l182t3706r371b3778],
11	must	MD	O	must	aux	12	SENT_144	[p13l409t3716r628b3779],
12	cooperate	VB	O	cooperate	_	0	SENT_144	[p13l665t3716r1079b3800],
13	in	IN	O	in	_	0	SENT_144	[p13l1121t3700r1203b3777],
14	setting	VBG	O	set	prepc_in	12	SENT_144	[p13l1246t3700r1536b3800],
15	goals	NNS	O	goal	dobj	14	SENT_144	[p13l1574t3700r1796b3800],
16	beyond	IN	O	beyond	_	0	SENT_144	[p13l1840t3699r2148b3800],
17	that	DT	O	that	prep_beyond	14	SENT_144	[p14l11t21r179b99],
18	of	IN	O	of	_	0	SENT_144	[p14l211t20r313b99],
19	early	JJ	O	early	amod	20	SENT_144	[p14l332t21r532b121],
20	approval	NN	O	approval	prep_of	17	SENT_144	[p14l564t21r954b121],
21	.	.	O	.	_	0	SENT_144	[p14l564t21r954b121],

1	Molecular	JJ	O	molecular	amod	2	SENT_145	[p14l994t20r1425b100],
2	techniques	NNS	O	technique	nsubjpass	5	SENT_145	[p14l1460t21r1920b121],
3	have	VBP	O	have	aux	5	SENT_145	[p14l1958t21r2148b100],
4	been	VBN	O	be	auxpass	5	SENT_145	[p14l11t149r212b227],
5	developed	VBN	O	develop	_	0	SENT_145	[p14l242t148r669b249],
6	to	TO	O	to	aux	7	SENT_145	[p14l699t165r779b227],
7	identify	VB	O	identify	xcomp	5	SENT_145	[p14l809t148r1133b249],
8	populations	NNS	O	population	dobj	7	SENT_145	[p14l1157t149r1665b249],
9	of	IN	O	of	_	0	SENT_145	[p14l1698t148r1800b227],
10	patients	NNS	O	patient	prep_of	8	SENT_145	[p14l1809t149r2146b249],
11	Who	WP	O	who	nsubj	13	SENT_145	[p14l6t277r191b356],
12	are	VBP	O	be	cop	13	SENT_145	[p14l218t303r345b355],
13	likely	JJ	O	likely	rcmod	10	SENT_145	[p14l370t276r598b377],
14	to	TO	O	to	aux	15	SENT_145	[p14l620t293r699b355],
15	have	VB	O	have	xcomp	13	SENT_145	[p14l728t277r916b356],
16	responses	NNS	O	response	dobj	15	SENT_145	[p14l943t302r1367b377],
17	to	TO	O	to	_	0	SENT_145	[p14l1396t293r1475b355],
18	targeted	VBN	O	target	amod	19	SENT_145	[p14l1504t276r1851b377],
19	drugs	NNS	O	drug	prep_to	15	SENT_145	[p14l1878t277r2143b377],
20	,	,	O	,	_	0	SENT_145	[p14l1878t277r2143b377],
21	and	CC	O	and	_	0	SENT_145	[p14l10t405r167b483],
22	this	DT	O	this	nsubj	27	SENT_145	[p14l194t405r348b483],
23	is	VBZ	O	be	cop	27	SENT_145	[p14l376t405r442b483],
24	the	DT	O	the	det	27	SENT_145	[p14l472t405r602b483],
25	next	JJ	O	next	amod	27	SENT_145	[p14l629t421r812b483],
26	important	JJ	O	important	amod	27	SENT_145	[p14l834t405r1270b505],
27	step	NN	O	step	conj_and	5	SENT_145	[p14l1294t421r1464b505],
28	in	IN	O	in	_	0	SENT_145	[p14l1491t405r1573b482],
29	the	DT	O	the	det	30	SENT_145	[p14l1601t404r1730b483],
30	rationalization	NN	O	rationalization	prep_in	27	SENT_145	[p14l1758t405r2147b483, p14l10t533r274b611],
31	of	IN	O	of	_	0	SENT_145	[p14l299t532r401b611],
32	therapy	NN	O	therapy	prep_of	30	SENT_145	[p14l407t533r738b633],
33	.	.	O	.	_	0	SENT_145	[p14l407t533r738b633],

1	Supported	VBN	O	support	csubj	29	SENT_146	[p14l98t663r428b739],
2	in	IN	O	in	_	0	SENT_146	[p14l452t664r514b722],
3	part	NN	O	part	prep_in	1	SENT_146	[p14l537t676r668b739],
4	by	IN	O	by	_	0	SENT_146	[p14l690t663r763b739],
5	a	DT	O	a	det	6	SENT_146	[p14l783t683r817b723],
6	grant	NN	O	grant	prep_by	1	SENT_146	[p14l841t676r1013b740],
7	from	IN	O	from	_	0	SENT_146	[p14l1034t663r1190b723],
8	the	DT	O	the	det	13	SENT_146	[p14l1216t663r1313b723],
9	National	NNP	ORGANIZATION	National	nn	13	SENT_146	[p14l1337t663r1613b723],
10	Cancer	NNP	ORGANIZATION	Cancer	nn	13	SENT_146	[p14l1639t668r1861b723],
11	Institute	NNP	ORGANIZATION	Institute	nn	13	SENT_146	[p14l1883t664r2149b723],
12	(	NN	O	(	nn	13	SENT_146	[p14l14t754r209b818],
13	R25T	NN	O	r25t	prep_from	1	SENT_146	[p14l14t754r209b818],
14	CA	NNP	O	CA	nn	16	SENT_146	[p14l224t754r320b809],
15	92203	CD	NUMBER	92203	num	16	SENT_146	[p14l334t754r553b818],
16	)	NN	O	)	dep	13	SENT_146	[p14l334t754r553b818],
17	and	CC	O	and	_	0	SENT_146	[p14l573t749r691b809],
18	by	IN	O	by	_	0	SENT_146	[p14l708t750r781b826],
19	an	DT	O	a	det	24	SENT_146	[p14l795t769r871b809],
20	unrestricted	JJ	O	unrestricted	amod	24	SENT_146	[p14l887t749r1271b809],
21	Health	NNP	ORGANIZATION	Health	nn	24	SENT_146	[p14l1287t750r1501b809],
22	Outcomes	NNPS	ORGANIZATION	Outcomes	nn	24	SENT_146	[p14l1518t754r1842b809],
23	Research	NNP	ORGANIZATION	Research	nn	24	SENT_146	[p14l1859t750r2150b813],
24	Grant	NNP	ORGANIZATION	Grant	prep_by	1	SENT_146	[p14l10t840r198b895],
25	from	IN	O	from	_	0	SENT_146	[p14l213t835r370b895],
26	the	DT	O	the	det	28	SENT_146	[p14l389t835r486b895],
27	PhRMA	NNP	ORGANIZATION	PhRMA	nn	28	SENT_146	[p14l504t836r752b899],
28	Foundation	NNP	ORGANIZATION	Foundation	prep_from	24	SENT_146	[p14l767t835r1138b895],
29	(	VBD	O	(	_	0	SENT_146	[p14l1160t836r1329b904],
30	both	DT	O	both	dobj	29	SENT_146	[p14l1160t836r1329b904],
31	to	TO	O	to	_	0	SENT_146	[p14l1347t848r1407b895],
32	Dr.	NNP	O	Dr.	nn	34	SENT_146	[p14l1426t840r1520b895],
33	Roberts	NNP	PERSON	Roberts	nn	34	SENT_146	[p14l1541t835r1834b904],
34	)	NN	O	)	prep_to	29	SENT_146	[p14l1541t835r1834b904],
35	.	.	O	.	_	0	SENT_146	[p14l1541t835r1834b904],

1	Dr.	NNP	O	Dr.	nn	2	SENT_147	[p14l95t926r190b981],
2	Roberts	NNP	PERSON	Roberts	nsubj	3	SENT_147	[p14l224t922r471b985],
3	reports	VBZ	O	report	_	0	SENT_147	[p14l503t934r728b998],
4	having	VBG	O	have	aux	5	SENT_147	[p14l760t921r976b998],
5	received	VBN	O	receive	xcomp	3	SENT_147	[p14l1004t921r1261b981],
6	speaking	VBG	O	speak	xcomp	5	SENT_147	[p14l1293t921r1582b998],
7	fees	NNS	O	fee	dobj	6	SENT_147	[p14l1609t921r1731b981],
8	from	IN	O	from	_	0	SENT_147	[p14l1763t921r1920b981],
9	Roche	NNP	ORGANIZATION	Roche	nn	10	SENT_147	[p14l1949t922r2149b985],
10	Laboratories	NNPS	ORGANIZATION	Laboratories	prep_from	6	SENT_147	[p14l9t1008r408b1067],
11	and	CC	O	and	_	0	SENT_147	[p14l426t1007r544b1067],
12	AstraZeneca	NNP	ORGANIZATION	AstraZeneca	prep_from	6	SENT_147	[p14l558t1013r968b1067],
13	.	.	O	.	_	0	SENT_147	[p14l558t1013r968b1067],

1	Dr.	NNP	O	Dr.	nn	2	SENT_148	[p14l988t1012r1082b1067],
2	Chabner	NNP	PERSON	Chabner	nsubj	3	SENT_148	[p14l1104t1007r1378b1067],
3	reports	VBZ	O	report	_	0	SENT_148	[p14l1392t1020r1618b1084],
4	having	VBG	O	have	aux	5	SENT_148	[p14l1636t1007r1852b1084],
5	served	VBN	O	serve	dep	3	SENT_148	[p14l1867t1007r2068b1067],
6	as	IN	O	as	_	0	SENT_148	[p14l2084t1028r2148b1067],
7	a	DT	O	a	det	8	SENT_148	[p14l9t1114r43b1153],
8	consultant	NN	O	consultant	prep_as	5	SENT_148	[p14l67t1094r409b1153],
9	for	IN	O	for	prep	5	SENT_148	[p14l430t1093r535b1166],
10	,	,	O	,	_	0	SENT_148	[p14l430t1093r535b1166],
11	and	CC	O	and	_	0	SENT_148	[p14l564t1093r681b1153],
12	owning	VBG	O	own	conj_and	5	SENT_148	[p14l707t1094r951b1170],
13	equity	NN	O	equity	dobj	12	SENT_148	[p14l973t1094r1168b1170],
14	in	IN	O	in	prep	12	SENT_148	[p14l1188t1094r1268b1166],
15	,	,	O	,	_	0	SENT_148	[p14l1188t1094r1268b1166],
16	PharmaMar	NNP	O	PharmaMar	dobj	12	SENT_148	[p14l1296t1093r1686b1166],
17	,	,	O	,	_	0	SENT_148	[p14l1296t1093r1686b1166],
18	Cell	NNP	ORGANIZATION	Cell	nn	19	SENT_148	[p14l1715t1093r1837b1153],
19	Genesys	NNP	ORGANIZATION	Genesys	conj_and	16	SENT_148	[p14l1862t1098r2144b1170],
20	,	,	O	,	_	0	SENT_148	[p14l1862t1098r2144b1170],
21	Gloucester	NNP	ORGANIZATION	Gloucester	nn	22	SENT_148	[p14l10t1180r358b1239],
22	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	dobj	12	SENT_148	[p14l378t1179r920b1252],
23	,	,	O	,	_	0	SENT_148	[p14l378t1179r920b1252],
24	Cephalon	NNP	ORGANIZATION	Cephalon	conj_and	16	SENT_148	[p14l948t1179r1273b1256],
25	,	,	O	,	_	0	SENT_148	[p14l948t1179r1273b1256],
26	Oncotech	NNP	ORGANIZATION	Oncotech	conj_and	16	SENT_148	[p14l1301t1180r1625b1252],
27	,	,	O	,	_	0	SENT_148	[p14l1301t1180r1625b1252],
28	and	CC	O	and	_	0	SENT_148	[p14l1653t1179r1771b1239],
29	Kosan	NNP	ORGANIZATION	Kosan	nn	30	SENT_148	[p14l1794t1185r1995b1241],
30	Biosciences	NNPS	ORGANIZATION	Biosciences	conj_and	16	SENT_148	[p14l2018t1180r2149b1239, p14l11t1266r272b1325],
31	and	CC	O	and	_	0	SENT_148	[p14l292t1265r410b1325],
32	is	VBZ	O	be	cop	37	SENT_148	[p14l428t1266r477b1325],
33	a	DT	O	a	det	37	SENT_148	[p14l497t1285r531b1325],
34	board	NN	O	board	nn	37	SENT_148	[p14l548t1265r733b1325],
35	member	NN	O	member	nn	37	SENT_148	[p14l751t1265r1021b1325],
36	ofKosan	NNP	O	ofKosan	nn	37	SENT_148	[p14l1038t1265r1320b1326],
37	Biosciences	NNP	O	Biosciences	conj_and	3	SENT_148	[p14l1337t1266r1728b1325],
38	.	.	O	.	_	0	SENT_148	[p14l1337t1266r1728b1325],

1	We	PRP	O	we	nsubj	3	SENT_149	[p14l94t1357r194b1411],
2	are	VBP	O	be	cop	3	SENT_149	[p14l214t1372r309b1411],
3	indebted	JJ	O	indebted	_	0	SENT_149	[p14l328t1351r607b1411],
4	to	TO	O	to	_	0	SENT_149	[p14l627t1364r687b1411],
5	Dr.	NNP	O	Dr.	nn	7	SENT_149	[p14l707t1356r801b1411],
6	Steven	NNP	PERSON	Steven	nn	7	SENT_149	[p14l826t1356r1029b1411],
7	Hirschfeld	NNP	PERSON	Hirschfeld	prep_to	3	SENT_149	[p14l1048t1351r1385b1411],
8	of	IN	O	of	_	0	SENT_149	[p14l1405t1351r1481b1411],
9	the	DT	O	the	det	10	SENT_149	[p14l1487t1351r1585b1411],
10	FDA	NNP	ORGANIZATION	FDA	prep_of	7	SENT_149	[p14l1603t1356r1744b1411],
11	for	IN	O	for	_	0	SENT_149	[p14l1761t1351r1854b1411],
12	his	PRP$	O	he	poss	16	SENT_149	[p14l1871t1352r1964b1411],
13	helpﬁ	JJ	O	helpﬁ	amod	16	SENT_149	[p14l1984t1351r2148b1428, p14l10t1437r94b1497],
14	.1	NN	NUMBER	.1	nn	16	SENT_149	[p14l1984t1351r2148b1428, p14l10t1437r94b1497],
15	l	NN	O	l	nn	16	SENT_149	[p14l1984t1351r2148b1428, p14l10t1437r94b1497],
16	comments	NNS	O	comment	prep_for	10	SENT_149	[p14l113t1450r449b1497],
17	on	IN	O	on	_	0	SENT_149	[p14l469t1457r550b1497],
18	a	DT	O	a	det	20	SENT_149	[p14l568t1458r602b1497],
19	previous	JJ	O	previous	amod	20	SENT_149	[p14l619t1438r888b1514],
20	version	NN	O	version	prep_on	3	SENT_149	[p14l905t1438r1138b1497],
21	of	IN	O	of	_	0	SENT_149	[p14l1158t1437r1234b1497],
22	this	DT	O	this	det	23	SENT_149	[p14l1239t1437r1354b1497],
23	article	NN	O	article	prep_of	20	SENT_149	[p14l1374t1438r1587b1497],
24	.	.	O	.	_	0	SENT_149	[p14l1374t1438r1587b1497],

1	From	IN	O	from	_	0	SENT_150	[p14l16t1636r179b1691],
2	the	DT	O	the	det	3	SENT_150	[p14l229t1630r332b1692],
3	Division	NN	O	division	pobj	1	SENT_150	[p14l388t1636r651b1692],
4	of	IN	O	of	_	0	SENT_150	[p14l704t1629r777b1691],
5	Hemato	NNP	O	Hemato	nn	7	SENT_150	[p14l820t1630r1594b1711],
6	|	CD	NUMBER	|	num	7	SENT_150	[p14l820t1630r1594b1711],
7	ogy	NN	O	ogy	prep_of	3	SENT_150	[p14l820t1630r1594b1711],
8	.	.	O	.	_	0	SENT_150	[p14l820t1630r1594b1711],

1	—	NN	O	—	_	0	SENT_151	[p14l820t1630r1594b1711],
2	.	.	O	.	_	0	SENT_151	[p14l820t1630r1594b1711],

1	Oncology	NNP	O	Oncology	_	0	SENT_152	[p14l820t1630r1594b1711],
2	,	,	O	,	_	0	SENT_152	[p14l820t1630r1594b1711],
3	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	5	SENT_152	[p14l1653t1630r2145b1692],
4	General	NNP	ORGANIZATION	General	nn	5	SENT_152	[p14l11t1727r265b1788],
5	Hospital	NNP	ORGANIZATION	Hospital	appos	1	SENT_152	[p14l305t1727r580b1806],
6	and	CC	O	and	_	0	SENT_152	[p14l616t1727r733b1788],
7	Harvard	NNP	ORGANIZATION	Harvard	nn	13	SENT_152	[p14l773t1727r1033b1788],
8	Medical	NNP	ORGANIZATION	Medical	nn	13	SENT_152	[p14l1074t1727r1326b1788],
9	School	NNP	ORGANIZATION	School	nn	13	SENT_152	[p14l1362t1727r1602b1798],
10	,	,	O	,	_	0	SENT_152	[p14l1362t1727r1602b1798],
11	Boston	NNP	LOCATION	Boston	appos	13	SENT_152	[p14l1643t1732r1868b1788],
12	(	CD	NUMBER	(	num	13	SENT_152	[p14l1910t1732r2144b1807],
13	T.G.R.	NNP	O	T.G.R.	conj_and	5	SENT_152	[p14l1910t1732r2144b1807],
14	,	,	O	,	_	0	SENT_152	[p14l1910t1732r2144b1807],
15	B.A.C.	NNP	O	B.A.C.	appos	1	SENT_152	[p14l16t1827r258b1903],
16	)	CD	NUMBER	)	num	15	SENT_152	[p14l16t1827r258b1903],
17	;	:	O	;	_	0	SENT_152	[p14l16t1827r258b1903],
18	the	DT	O	the	det	19	SENT_152	[p14l281t1823r384b1884],
19	Program	NN	O	program	dep	1	SENT_152	[p14l412t1829r689b1903],
20	on	IN	O	on	_	0	SENT_152	[p14l715t1845r793b1884],
21	the	DT	O	the	det	23	SENT_152	[p14l817t1823r920b1884],
22	Pharmaceutical	NNP	O	Pharmaceutical	nn	23	SENT_152	[p14l948t1823r1452b1884],
23	Industry	NNP	O	Industry	prep_on	19	SENT_152	[p14l1484t1823r1760b1903],
24	,	,	O	,	_	0	SENT_152	[p14l1484t1823r1760b1903],
25	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	27	SENT_152	[p14l1791t1823r2147b1884, p14l12t1931r163b1980],
26	Institute	NNP	ORGANIZATION	Institute	nn	27	SENT_152	[p14l194t1925r465b1980],
27	ofTechno	NNP	O	ofTechno	nsubj	28	SENT_152	[p14l488t1919r954b1999],
28	|	VBD	O	|	dep	1	SENT_152	[p14l488t1919r954b1999],
29	ogy	NN	O	ogy	dobj	28	SENT_152	[p14l488t1919r954b1999],
30	,	,	O	,	_	0	SENT_152	[p14l488t1919r954b1999],
31	Cambridge	NNP	LOCATION	Cambridge	dobj	28	SENT_152	[p14l981t1919r1359b1999],
32	,	,	O	,	_	0	SENT_152	[p14l981t1919r1359b1999],
33	Mass.	NNP	LOCATION	Mass.	dobj	28	SENT_152	[p14l1390t1925r1579b1980],
34	(	CD	NUMBER	(	num	36	SENT_152	[p14l1612t1924r1877b1999],
35	T.G.R.	NNP	O	T.G.R.	nn	36	SENT_152	[p14l1612t1924r1877b1999],
36	)	NN	O	)	dep	33	SENT_152	[p14l1612t1924r1877b1999],
37	;	:	O	;	_	0	SENT_152	[p14l1612t1924r1877b1999],
38	and	CC	O	and	_	0	SENT_152	[p14l1903t1919r2019b1980],
39	the	DT	O	the	det	40	SENT_152	[p14l2044t1919r2147b1980],
40	Institute	NNP	ORGANIZATION	Institute	conj_and	29	SENT_152	[p14l16t2021r287b2076],
41	for	IN	ORGANIZATION	for	_	0	SENT_152	[p14l330t2015r422b2076],
42	Technology	NNP	ORGANIZATION	Technology	nn	43	SENT_152	[p14l461t2015r837b2095],
43	Assessment	NNP	ORGANIZATION	Assessment	prep_for	40	SENT_152	[p14l877t2019r1299b2086],
44	,	,	O	,	_	0	SENT_152	[p14l877t2019r1299b2086],
45	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	47	SENT_152	[p14l1352t2015r1844b2076],
46	General	NNP	ORGANIZATION	General	nn	47	SENT_152	[p14l1891t2015r2144b2076],
47	Hospital	NNP	ORGANIZATION	Hospital	appos	1	SENT_152	[p14l16t2111r305b2190],
48	,	,	O	,	_	0	SENT_152	[p14l16t2111r305b2190],
49	Boston	NNP	LOCATION	Boston	appos	1	SENT_152	[p14l337t2116r558b2172],
50	(	CD	NUMBER	(	num	49	SENT_152	[p14l591t2116r849b2191],
51	T.G.R.	NNP	O	T.G.R.	dep	49	SENT_152	[p14l591t2116r849b2191],
52	)	CD	NUMBER	)	num	51	SENT_152	[p14l591t2116r849b2191],
53	.	.	O	.	_	0	SENT_152	[p14l591t2116r849b2191],

1	Address	NN	O	address	nsubj	2	SENT_153	[p14l873t2111r1137b2172],
2	reprint	VB	O	reprint	conj_or	2	SENT_153	[p14l1165t2117r1378b2190],
3	requests	NNS	O	request	dobj	2	SENT_153	[p14l1404t2123r1674b2190],
4	to	TO	O	to	_	0	SENT_153	[p14l1697t2123r1760b2172],
5	Dr.	NNP	O	Dr.	nn	6	SENT_153	[p14l1788t2117r1872b2172],
6	Roberts	NNP	PERSON	Roberts	prep_to	2	SENT_153	[p14l1904t2111r2146b2172],
7	at	IN	O	at	_	0	SENT_153	[p14l11t2219r69b2268],
8	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	10	SENT_153	[p14l103t2207r596b2268],
9	General	NNP	ORGANIZATION	General	nn	10	SENT_153	[p14l630t2207r884b2268],
10	Hospital	NNP	ORGANIZATION	Hospital	prep_at	6	SENT_153	[p14l925t2207r1221b2286],
11	,	,	O	,	_	0	SENT_153	[p14l925t2207r1221b2286],
12	Cox	NNP	ORGANIZATION	Cox	nn	16	SENT_153	[p14l1257t2212r1374b2268],
13	640	CD	NUMBER	640	num	12	SENT_153	[p14l1406t2211r1538b2278],
14	,	,	O	,	_	0	SENT_153	[p14l1406t2211r1538b2278],
15	100	CD	NUMBER	100	num	12	SENT_153	[p14l1578t2211r1691b2268],
16	Blossom	NN	ORGANIZATION	blossom	appos	10	SENT_153	[p14l1727t2207r2008b2268],
17	St.	NNP	ORGANIZATION	St.	nn	21	SENT_153	[p14l2045t2212r2144b2279],
18	,	,	O	,	_	0	SENT_153	[p14l2045t2212r2144b2279],
19	Boston	NNP	LOCATION	Boston	appos	21	SENT_153	[p14l16t2309r262b2374],
20	,	,	O	,	_	0	SENT_153	[p14l16t2309r262b2374],
21	MA	NNP	LOCATION	MA	dep	16	SENT_153	[p14l295t2307r406b2363],
22	02114	CD	DATE	02114	num	21	SENT_153	[p14l428t2307r642b2374],
23	,	,	O	,	_	0	SENT_153	[p14l428t2307r642b2374],
24	or	CC	O	or	_	0	SENT_153	[p14l670t2325r738b2364],
25	at	IN	O	at	_	0	SENT_153	[p14l761t2314r819b2364],
26	troberts@partners.org	NN	O	troberts@partners.org	prep_at	2	SENT_153	[p14l840t2303r1614b2383],
27	.	.	O	.	_	0	SENT_153	[p14l840t2303r1614b2383],

1	1	LS	NUMBER	1	_	0	SENT_154	[p14l16t2408r64b2459],
2	.	.	O	.	_	0	SENT_154	[p14l16t2408r64b2459],

1	Food	NNP	O	Food	nn	4	SENT_155	[p14l141t2400r304b2459],
2	and	CC	O	and	_	0	SENT_155	[p14l338t2400r456b2459],
3	Drug	NNP	O	Drug	nn	4	SENT_155	[p14l490t2405r657b2476],
4	Administration	NNP	O	Administration	_	0	SENT_155	[p14l686t2400r1202b2459],
5	.	.	O	.	_	0	SENT_155	[p14l686t2400r1202b2459],

1	Statistical	JJ	O	statistical	amod	2	SENT_156	[p14l1242t2400r1556b2459],
2	review	NN	O	review	_	0	SENT_156	[p14l1590t2401r1798b2459],
3	of	IN	O	of	_	0	SENT_156	[p14l1830t2400r1907b2459],
4	Iressa	NNP	O	Iressa	prep_of	2	SENT_156	[p14l1927t2406r2135b2459],
5	.	.	O	.	_	0	SENT_156	[p14l1927t2406r2135b2459],

1	(	NN	O	(	nsubj	2	SENT_157	[p14l17t2496r334b2565],
2	Accessed	VBN	O	access	_	0	SENT_157	[p14l17t2496r334b2565],
3	July	NNP	DATE	July	tmod	2	SENT_157	[p14l353t2496r480b2572],
4	9	CD	DATE	9	num	3	SENT_157	[p14l504t2501r558b2568],
5	,	,	DATE	,	_	0	SENT_157	[p14l504t2501r558b2568],
6	2004	CD	DATE	2004	num	3	SENT_157	[p14l590t2501r766b2568],
7	,	,	O	,	_	0	SENT_157	[p14l590t2501r766b2568],
8	at	IN	O	at	_	0	SENT_157	[p14l798t2509r858b2555],
9	http://WWW.fda.gov/cderlfoilnda/2003/	NN	O	http://www.fda.gov/cderlfoilnda/2003/	prep_at	2	SENT_157	[p14l881t2496r2137b2572],
10	21	CD	NUMBER	21	number	11	SENT_157	[p14l14t2592r887b2668],
11	—	CD	NUMBER	—	num	12	SENT_157	[p14l14t2592r887b2668],
12	399_IRESSA_Statr	NN	O	399_iressa_statr	dep	2	SENT_157	[p14l14t2592r887b2668],
13	.	.	O	.	_	0	SENT_157	[p14l14t2592r887b2668],

1	pdf	NN	O	pdf	_	0	SENT_158	[p14l14t2592r887b2668],
2	.	.	O	.	_	0	SENT_158	[p14l14t2592r887b2668],
3	)	SYM	O	)	dep	1	SENT_158	[p14l14t2592r887b2668],

1	2	LS	NUMBER	2	_	0	SENT_159	[p14l12t2696r64b2747],
2	.	.	O	.	_	0	SENT_159	[p14l12t2696r64b2747],

1	Letter	NN	O	letter	_	0	SENT_160	[p14l141t2693r325b2747],
2	to	TO	O	to	_	0	SENT_160	[p14l352t2701r411b2747],
3	the	DT	O	the	det	4	SENT_160	[p14l441t2688r538b2747],
4	FDA	NNP	ORGANIZATION	FDA	prep_to	1	SENT_160	[p14l566t2693r706b2746],
5	expressing	VBG	O	express	partmod	1	SENT_160	[p14l732t2689r1076b2764],
6	concerns	NNS	O	concern	dobj	5	SENT_160	[p14l1102t2707r1386b2747],
7	about	IN	O	about	_	0	SENT_160	[p14l1416t2688r1599b2747],
8	the	DT	O	the	det	10	SENT_160	[p14l1624t2688r1721b2747],
9	pending	VBG	O	pend	amod	10	SENT_160	[p14l1749t2688r2015b2764],
10	approval	NN	O	approval	prep_about	5	SENT_160	[p14l2040t2707r2139b2763, p14l12t2785r210b2860],
11	of	IN	O	of	_	0	SENT_160	[p14l249t2784r325b2843],
12	the	DT	O	the	det	14	SENT_160	[p14l350t2785r447b2843],
13	cancer	NN	O	cancer	nn	14	SENT_160	[p14l488t2804r695b2843],
14	drug	NN	O	drug	prep_of	10	SENT_160	[p14l732t2784r882b2860],
15	geﬁtinib	NN	O	geﬁtinib	nn	17	SENT_160	[p14l919t2784r1185b2860],
16	(	CD	NUMBER	(	num	17	SENT_160	[p14l1229t2789r1514b2853],
17	IRESSA	NNP	O	IRESSA	dep	14	SENT_160	[p14l1229t2789r1514b2853],
18	)	CD	NUMBER	)	number	19	SENT_160	[p14l1229t2789r1514b2853],
19	(	CD	NUMBER	(	num	21	SENT_160	[p14l1560t2789r1739b2852],
20	HRG	NN	ORGANIZATION	hrg	nn	21	SENT_160	[p14l1560t2789r1739b2852],
21	publication	NN	O	publication	dep	17	SENT_160	[p14l1778t2784r2140b2860],
22	#	#	MONEY	#	number	24	SENT_160	[p14l14t2884r273b2948],
23	1665	CD	MONEY	1665	number	24	SENT_160	[p14l14t2884r273b2948],
24	)	CD	NUMBER	)	num	21	SENT_160	[p14l14t2884r273b2948],
25	.	.	O	.	_	0	SENT_160	[p14l14t2884r273b2948],

1	Washington	NNP	LOCATION	Washington	nn	3	SENT_161	[p14l299t2880r721b2956],
2	,	,	O	,	_	0	SENT_161	[p14l299t2880r721b2956],
3	D.C.	NNP	LOCATION	D.C.	_	0	SENT_161	[p14l749t2885r912b2939],
4	:	:	O	:	_	0	SENT_161	[p14l749t2885r912b2939],
5	Public	NNP	O	Public	nn	6	SENT_161	[p14l938t2881r1143b2940],
6	Citizen	NNP	O	Citizen	dep	3	SENT_161	[p14l1166t2881r1419b2952],
7	,	,	O	,	_	0	SENT_161	[p14l1166t2881r1419b2952],
8	May	NNP	DATE	May	appos	6	SENT_161	[p14l1445t2886r1583b2956],
9	2003	CD	DATE	2003	num	8	SENT_161	[p14l1604t2885r1784b2939],
10	.	.	O	.	_	0	SENT_161	[p14l1604t2885r1784b2939],

1	(	NN	O	(	_	0	SENT_162	[p14l1816t2880r2139b2948],
2	Accessed	VBN	O	access	partmod	1	SENT_162	[p14l1816t2880r2139b2948],
3	July	NNP	DATE	July	tmod	2	SENT_162	[p14l6t2976r134b3051],
4	9	CD	DATE	9	num	3	SENT_162	[p14l161t2980r215b3047],
5	,	,	DATE	,	_	0	SENT_162	[p14l161t2980r215b3047],
6	2004	CD	DATE	2004	num	3	SENT_162	[p14l249t2980r425b3047],
7	,	,	O	,	_	0	SENT_162	[p14l249t2980r425b3047],
8	at	IN	O	at	_	0	SENT_162	[p14l459t2988r520b3034],
9	http://vvvvw.citizen.orglpublicationslrelease.cfm	NN	O	http://vvvvw.citizen.orglpublicationslrelease.cfm	prep_at	2	SENT_162	[p14l545t2974r2139b3051],
10	?	.	O	?	_	0	SENT_162	[p14l545t2974r2139b3051],

1	ID	NN	O	id	_	0	SENT_163	[p14l12t3076r336b3139],
2	=	JJ	O	=	dep	1	SENT_163	[p14l12t3076r336b3139],
3	7242	CD	NUMBER	7242	dep	2	SENT_163	[p14l12t3076r336b3139],
4	.	.	O	.	_	0	SENT_163	[p14l12t3076r336b3139],
5	)	SYM	O	)	dep	1	SENT_163	[p14l12t3076r336b3139],

1	3	LS	NUMBER	3	_	0	SENT_164	[p14l14t3173r64b3225],
2	.	.	O	.	_	0	SENT_164	[p14l14t3173r64b3225],

1	Kris	NNP	PERSON	Kris	nn	2	SENT_165	[p14l142t3167r269b3227],
2	MG	NN	PERSON	mg	_	0	SENT_165	[p14l286t3171r424b3238],
3	,	,	O	,	_	0	SENT_165	[p14l286t3171r424b3238],
4	Natale	NNP	PERSON	Natale	nn	5	SENT_165	[p14l444t3166r650b3225],
5	RB	NN	O	rb	appos	2	SENT_165	[p14l666t3171r776b3238],
6	,	,	O	,	_	0	SENT_165	[p14l666t3171r776b3238],
7	Herbst	NNP	ORGANIZATION	Herbst	nn	8	SENT_165	[p14l797t3166r1016b3225],
8	RS	NN	ORGANIZATION	r	appos	2	SENT_165	[p14l1028t3171r1131b3238],
9	,	,	O	,	_	0	SENT_165	[p14l1028t3171r1131b3238],
10	et	FW	O	et	nn	11	SENT_165	[p14l1153t3179r1211b3225],
11	al.	FW	O	al.	appos	2	SENT_165	[p14l1224t3166r1294b3225],
12	.	.	O	.	_	0	SENT_165	[p14l1224t3166r1294b3225],

1	Efficacy	NN	O	efficacy	nn	2	SENT_166	[p14l1314t3166r1563b3241],
2	ofgeﬁtinib	NN	O	ofgeﬁtinib	_	0	SENT_166	[p14l1577t3166r1941b3242],
3	,	,	O	,	_	0	SENT_166	[p14l1577t3166r1941b3242],
4	an	DT	O	a	det	5	SENT_166	[p14l1962t3185r2037b3225],
5	inhibitor	NN	O	inhibitor	appos	2	SENT_166	[p14l2053t3167r2139b3224, p14l14t3263r231b3321],
6	of	IN	O	of	_	0	SENT_166	[p14l255t3262r330b3321],
7	the	DT	O	the	det	13	SENT_166	[p14l341t3262r438b3321],
8	epidermal	JJ	O	epidermal	amod	13	SENT_166	[p14l464t3262r783b3338],
9	growth	NN	O	growth	nn	13	SENT_166	[p14l807t3262r1035b3338],
10	factor	NN	O	factor	nn	13	SENT_166	[p14l1060t3262r1245b3321],
11	receptor	NN	O	receptor	nn	13	SENT_166	[p14l1267t3275r1531b3338],
12	tyrosine	NN	O	tyrosine	nn	13	SENT_166	[p14l1554t3263r1806b3338],
13	kinase	NN	O	kinase	prep_of	5	SENT_166	[p14l1830t3262r2051b3334],
14	,	,	O	,	_	0	SENT_166	[p14l1830t3262r2051b3334],
15	in	IN	O	in	_	0	SENT_166	[p14l2079t3263r2141b3320],
16	symptomatic	JJ	O	symptomatic	amod	17	SENT_166	[p14l15t3359r426b3434],
17	patients	NNS	O	patient	prep_in	2	SENT_166	[p14l451t3359r703b3434],
18	with	IN	O	with	_	0	SENT_166	[p14l728t3358r870b3418],
19	non	JJ	O	non	amod	24	SENT_166	[p14l896t3358r1222b3417],
20	—	JJ	O	—	amod	21	SENT_166	[p14l896t3358r1222b3417],
21	small	JJ	O	small	amod	24	SENT_166	[p14l896t3358r1222b3417],
22	cell	NN	O	cell	nn	24	SENT_166	[p14l1249t3358r1356b3417],
23	lung	NN	O	lung	nn	24	SENT_166	[p14l1381t3358r1527b3434],
24	cancer	NN	O	cancer	prep_with	17	SENT_166	[p14l1552t3378r1775b3417],
25	:	:	O	:	_	0	SENT_166	[p14l1552t3378r1775b3417],
26	a	DT	O	a	det	28	SENT_166	[p14l1805t3378r1838b3417],
27	randomized	JJ	O	randomized	amod	28	SENT_166	[p14l1864t3358r2140b3417, p14l13t3453r143b3512],
28	trial	NN	O	trial	dep	24	SENT_166	[p14l162t3454r304b3512],
29	.	.	O	.	_	0	SENT_166	[p14l162t3454r304b3512],

1	JAMA	NNP	O	JAMA	_	0	SENT_167	[p14l319t3459r510b3521],
2	2003	CD	DATE	2003	num	1	SENT_167	[p14l526t3458r1127b3525],
3	;	:	O	;	_	0	SENT_167	[p14l526t3458r1127b3525],
4	290:2149	CD	NUMBER	290:2149	number	5	SENT_167	[p14l526t3458r1127b3525],
5	-58	CD	NUMBER	-58	dep	1	SENT_167	[p14l526t3458r1127b3525],
6	.	.	O	.	_	0	SENT_167	[p14l526t3458r1127b3525],

1	4	LS	NUMBER	4	_	0	SENT_168	[p14l12t3557r64b3608],
2	.	.	O	.	_	0	SENT_168	[p14l12t3557r64b3608],

1	Castro	NNP	PERSON	Castro	nn	3	SENT_169	[p14l143t3554r347b3608],
2	M.	NNP	O	M.	nn	3	SENT_169	[p14l376t3555r458b3608],
3	The	NNP	O	The	_	0	SENT_169	[p14l490t3549r611b3608],
4	simpleton	NN	O	simpleton	poss	6	SENT_169	[p14l642t3549r1013b3624],
5	’s	POS	O	’s	_	0	SENT_169	[p14l642t3549r1013b3624],
6	error	NN	O	error	dep	3	SENT_169	[p14l1046t3568r1203b3608],
7	in	IN	O	in	_	0	SENT_169	[p14l1230t3550r1292b3607],
8	drug	NN	O	drug	nn	9	SENT_169	[p14l1322t3549r1472b3625],
9	development	NN	O	development	prep_in	6	SENT_169	[p14l1500t3549r1927b3624],
10	.	.	O	.	_	0	SENT_169	[p14l1500t3549r1927b3624],

1	J	NNP	O	J	nn	3	SENT_170	[p14l1954t3555r1982b3617],
2	Clin	NNP	O	Clin	nn	3	SENT_170	[p14l2011t3549r2141b3608],
3	Oncol	NNP	O	Oncol	_	0	SENT_170	[p14l14t3646r205b3704],
4	2002	CD	DATE	2002	num	3	SENT_170	[p14l223t3650r744b3717],
5	;	:	O	;	_	0	SENT_170	[p14l223t3650r744b3717],
6	20:4606	CD	NUMBER	20:4606	num	7	SENT_170	[p14l223t3650r744b3717],
7	—	NN	O	—	dep	3	SENT_170	[p14l223t3650r744b3717],
8	7	CD	NUMBER	7	dep	7	SENT_170	[p14l223t3650r744b3717],
9	.	.	O	.	_	0	SENT_170	[p14l223t3650r744b3717],

1	5	CD	NUMBER	5	_	0	SENT_171	[p15l15t27r64b78],
2	.	.	O	.	_	0	SENT_171	[p15l15t27r64b78],

1	Food	NNP	O	Food	nn	4	SENT_172	[p15l141t19r303b78],
2	and	CC	O	and	_	0	SENT_172	[p15l345t19r463b78],
3	Drug	NNP	O	Drug	nn	4	SENT_172	[p15l505t24r669b95],
4	Administration	NNP	O	Administration	_	0	SENT_172	[p15l708t19r1212b78],
5	.	.	O	.	_	0	SENT_172	[p15l708t19r1212b78],

1	Oncologic	JJ	ORGANIZATION	oncologic	amod	2	SENT_173	[p15l1260t19r1588b95],
2	Drugs	NNS	ORGANIZATION	drug	nsubj	6	SENT_173	[p15l1630t24r1822b95],
3	Advisory	NNP	ORGANIZATION	Advisory	nn	5	SENT_173	[p15l1865t19r2144b94],
4	Committee	NNP	ORGANIZATION	Committee	nn	5	SENT_173	[p15l14t116r367b174],
5	72nd	NNP	ORDINAL	72nd	dep	2	SENT_173	[p15l389t115r549b174],
6	Meeting	VBG	O	meet	_	0	SENT_173	[p15l567t116r846b191],
7	,	,	O	,	_	0	SENT_173	[p15l567t116r846b191],
8	Silver	NNP	O	Silver	nn	9	SENT_173	[p15l873t116r1045b175],
9	Spring	NNP	DATE	Spring	dep	6	SENT_173	[p15l1065t116r1292b191],
10	,	,	O	,	_	0	SENT_173	[p15l1065t116r1292b191],
11	Md.	NNP	LOCATION	Md.	appos	9	SENT_173	[p15l1314t115r1459b187],
12	,	,	O	,	_	0	SENT_173	[p15l1314t115r1459b187],
13	September	NNP	DATE	September	appos	9	SENT_173	[p15l1486t116r1826b191],
14	24	CD	DATE	24	num	13	SENT_173	[p15l1845t120r1938b187],
15	,	,	DATE	,	_	0	SENT_173	[p15l1845t120r1938b187],
16	2002	CD	DATE	2002	num	13	SENT_173	[p15l1963t120r2136b174],
17	.	.	O	.	_	0	SENT_173	[p15l1963t120r2136b174],

1	(	NN	O	(	nsubj	2	SENT_174	[p15l17t211r327b280],
2	Accessed	VBN	O	access	_	0	SENT_174	[p15l17t211r327b280],
3	July	NNP	DATE	July	tmod	2	SENT_174	[p15l335t211r459b287],
4	9	CD	DATE	9	num	3	SENT_174	[p15l472t216r526b283],
5	,	,	DATE	,	_	0	SENT_174	[p15l472t216r526b283],
6	2004	CD	DATE	2004	dep	11	SENT_174	[p15l545t216r718b283],
7	,	,	O	,	_	0	SENT_174	[p15l545t216r718b283],
8	at	IN	O	at	dep	6	SENT_174	[p15l738t224r797b270],
9	http	NN	O	http	pobj	8	SENT_174	[p15l809t211r956b287],
10	:	:	O	:	_	0	SENT_174	[p15l809t211r956b287],
11	I	PRP	O	I	dep	13	SENT_174	[p15l963t215r980b278],
12	/	:	O	/	punct	13	SENT_174	[p15l986t216r1180b278],
13	wvvw	NN	O	wvvw	dep	2	SENT_174	[p15l986t216r1180b278],
14	.	.	O	.	_	0	SENT_174	[p15l986t216r1180b278],

1	fda	NN	O	fda	_	0	SENT_175	[p15l1188t211r1304b270],
2	.	.	O	.	_	0	SENT_175	[p15l1188t211r1304b270],

1	gov	NN	O	gov	_	0	SENT_176	[p15l1311t216r1442b287],
2	]	CD	NUMBER	]	num	3	SENT_176	[p15l1311t216r1442b287],
3	ohrms	NNS	O	ohrm	dep	1	SENT_176	[p15l1448t212r1652b270],
4	I	PRP	O	I	nsubj	5	SENT_176	[p15l1658t216r1674b278],
5	docketsl	VBP	O	docketsl	rcmod	1	SENT_176	[p15l1680t211r1944b278],
6	acl	NN	O	acl	dobj	5	SENT_176	[p15l1949t216r2035b278],
7	02	CD	NUMBER	02	num	6	SENT_176	[p15l2041t216r2137b278],
8	/	:	O	/	punct	9	SENT_176	[p15l2041t216r2137b278],
9	transcripts/3894T1	NN	O	transcripts/3894t1	dep	6	SENT_176	[p15l14t308r816b383],
10	.	.	O	.	_	0	SENT_176	[p15l14t308r816b383],

1	htrn	NN	O	htrn	_	0	SENT_177	[p15l14t308r816b383],
2	.	.	O	.	_	0	SENT_177	[p15l14t308r816b383],
3	)	SYM	O	)	dep	1	SENT_177	[p15l14t308r816b383],

1	6	CD	NUMBER	6	_	0	SENT_178	[p15l14t410r64b463],
2	.	.	O	.	_	0	SENT_178	[p15l14t410r64b463],

1	FDA	NNP	ORGANIZATION	FDA	dep	2	SENT_179	[p15l141t408r282b462],
2	to	TO	O	to	dep	6	SENT_179	[p15l299t416r358b463],
3	cancer	NN	O	cancer	nn	4	SENT_179	[p15l379t422r586b462],
4	patients	NNS	O	patient	pobj	2	SENT_179	[p15l601t404r873b478],
5	:	:	O	:	_	0	SENT_179	[p15l601t404r873b478],
6	drop	VB	O	drop	_	0	SENT_179	[p15l895t403r1042b478],
7	dead	JJ	O	dead	acomp	6	SENT_179	[p15l1063t403r1229b463],
8	.	.	O	.	_	0	SENT_179	[p15l1063t403r1229b463],

1	Wall	NNP	O	Wall	nn	2	SENT_180	[p15l1249t403r1392b462],
2	StreetJournal	NNP	O	StreetJournal	_	0	SENT_180	[p15l1412t403r1855b472],
3	.	.	O	.	_	0	SENT_180	[p15l1412t403r1855b472],

1	September	NNP	DATE	September	_	0	SENT_181	[p15l1880t408r2139b478, p15l14t499r116b557],
2	24	CD	DATE	24	num	1	SENT_181	[p15l133t503r226b570],
3	,	,	DATE	,	_	0	SENT_181	[p15l133t503r226b570],
4	2002	CD	DATE	2002	num	1	SENT_181	[p15l249t503r571b557],
5	:	:	O	:	_	0	SENT_181	[p15l249t503r571b557],
6	A18	NN	O	a18	dep	1	SENT_181	[p15l249t503r571b557],
7	.	.	O	.	_	0	SENT_181	[p15l249t503r571b557],

1	7	CD	NUMBER	7	_	0	SENT_182	[p15l15t602r64b653],
2	.	.	O	.	_	0	SENT_182	[p15l15t602r64b653],

1	Food	NNP	O	Food	nn	4	SENT_183	[p15l141t594r303b653],
2	and	CC	O	and	_	0	SENT_183	[p15l340t594r457b653],
3	Drug	NNP	O	Drug	nn	4	SENT_183	[p15l494t599r658b670],
4	Administration	NNP	O	Administration	_	0	SENT_183	[p15l691t594r1196b653],
5	.	.	O	.	_	0	SENT_183	[p15l691t594r1196b653],

1	Guidance	NN	O	guidance	_	0	SENT_184	[p15l1238t594r1541b653],
2	for	IN	O	for	_	0	SENT_184	[p15l1580t594r1673b653],
3	industry	NN	O	industry	prep_for	1	SENT_184	[p15l1708t594r1986b669],
4	:	:	O	:	_	0	SENT_184	[p15l1708t594r1986b669],
5	fast	JJ	O	fast	amod	9	SENT_184	[p15l2027t594r2144b653],
6	track	NN	O	track	nn	9	SENT_184	[p15l14t690r174b750],
7	drug	NN	O	drug	nn	9	SENT_184	[p15l205t690r355b766],
8	development	NN	O	development	nn	9	SENT_184	[p15l386t690r799b766],
9	programs	NNS	O	program	dep	1	SENT_184	[p15l828t709r1136b766],
10	—	CD	NUMBER	—	num	11	SENT_184	[p15l1169t724r1250b730],
11	designation	NN	O	designation	dep	9	SENT_184	[p15l1281t690r1672b766],
12	,	,	O	,	_	0	SENT_184	[p15l1281t690r1672b766],
13	development	NN	O	development	dep	9	SENT_184	[p15l1710t690r2136b766],
14	,	,	O	,	_	0	SENT_184	[p15l1710t690r2136b766],
15	and	CC	O	and	_	0	SENT_184	[p15l13t786r130b845],
16	application	NN	O	application	nn	17	SENT_184	[p15l152t787r508b862],
17	review	NN	O	review	dep	9	SENT_184	[p15l530t787r743b846],
18	.	.	O	.	_	0	SENT_184	[p15l530t787r743b846],

1	September	NNP	DATE	September	_	0	SENT_185	[p15l771t786r1112b862],
2	1998	CD	DATE	1998	dep	1	SENT_185	[p15l1135t791r1305b845],
3	.	.	O	.	_	0	SENT_185	[p15l1135t791r1305b845],

1	(	NN	O	(	nsubj	2	SENT_186	[p15l1336t786r1646b855],
2	Accessed	VBN	O	access	_	0	SENT_186	[p15l1336t786r1646b855],
3	July	NNP	DATE	July	tmod	2	SENT_186	[p15l1661t787r1785b862],
4	9	CD	DATE	9	num	3	SENT_186	[p15l1804t791r1858b858],
5	,	,	DATE	,	_	0	SENT_186	[p15l1804t791r1858b858],
6	2004	CD	DATE	2004	num	3	SENT_186	[p15l1885t791r2058b858],
7	,	,	O	,	_	0	SENT_186	[p15l1885t791r2058b858],
8	at	IN	O	at	_	0	SENT_186	[p15l2084t799r2144b845],
9	http://wvvw.fda.gov/cber/gdlns/fsttrk.pdﬁ	NN	O	http://wvvw.fda.gov/cber/gdlns/fsttrk.pdﬁ	prep_at	2	SENT_186	[p15l14t882r1357b958],
10	)	CD	NUMBER	)	number	11	SENT_186	[p15l14t882r1357b958],
11	8	CD	NUMBER	8	num	9	SENT_186	[p15l13t984r64b1037],
12	.	.	O	.	_	0	SENT_186	[p15l13t984r64b1037],

1	Anderson	NNP	PERSON	Anderson	nn	2	SENT_187	[p15l140t978r451b1037],
2	LF	NNP	O	LF	_	0	SENT_187	[p15l466t984r553b1037],
3	.	.	O	.	_	0	SENT_187	[p15l466t984r553b1037],

1	Cancer	NN	O	cancer	nn	4	SENT_188	[p15l574t983r796b1037],
2	and	CC	O	and	_	0	SENT_188	[p15l810t978r927b1037],
3	AIDS	NN	MISC	aid	nn	4	SENT_188	[p15l940t983r1104b1037],
4	groups	NNS	O	group	nsubj	5	SENT_188	[p15l1122t997r1343b1054],
5	push	VBP	O	push	_	0	SENT_188	[p15l1360t978r1517b1053],
6	for	IN	O	for	_	0	SENT_188	[p15l1533t978r1625b1037],
7	changes	NNS	O	change	prep_for	5	SENT_188	[p15l1640t978r1897b1054],
8	in	IN	O	in	_	0	SENT_188	[p15l1915t979r1976b1036],
9	drug	NN	O	drug	nn	11	SENT_188	[p15l1993t978r2143b1054],
10	approval	NN	O	approval	nn	11	SENT_188	[p15l13t1075r287b1150],
11	process	NN	O	process	prep_in	7	SENT_188	[p15l304t1093r564b1150],
12	.	.	O	.	_	0	SENT_188	[p15l304t1093r564b1150],

1	J	NNP	O	J	nn	4	SENT_189	[p15l579t1080r607b1143],
2	Natl	NNP	O	Natl	nn	4	SENT_189	[p15l622t1075r758b1134],
3	Cancer	NNP	O	Cancer	nn	4	SENT_189	[p15l776t1079r998b1133],
4	Inst	NNP	O	Inst	_	0	SENT_189	[p15l1013t1080r1139b1133],
5	1989	CD	DATE	1989	num	4	SENT_189	[p15l1156t1079r1674b1146],
6	;	:	O	;	_	0	SENT_189	[p15l1156t1079r1674b1146],
7	81:829	CD	NUMBER	81:829	number	8	SENT_189	[p15l1156t1079r1674b1146],
8	—	CD	NUMBER	—	dep	4	SENT_189	[p15l1156t1079r1674b1146],
9	31	CD	NUMBER	31	dep	8	SENT_189	[p15l1156t1079r1674b1146],
10	.	.	O	.	_	0	SENT_189	[p15l1156t1079r1674b1146],

1	9	CD	NUMBER	9	_	0	SENT_190	[p15l13t1178r64b1230],
2	.	.	O	.	_	0	SENT_190	[p15l13t1178r64b1230],

1	Mitka	NNP	O	Mitka	nn	4	SENT_191	[p15l140t1170r325b1230],
2	M.	NNP	O	M.	nn	4	SENT_191	[p15l343t1176r424b1230],
3	Accelerated	NNP	O	Accelerated	nn	4	SENT_191	[p15l446t1170r814b1230],
4	approval	NN	O	approval	nsubj	5	SENT_191	[p15l834t1170r1108b1245],
5	scrutinized	VBD	O	scrutinize	_	0	SENT_191	[p15l1129t1170r1499b1230],
6	:	:	O	:	_	0	SENT_191	[p15l1129t1170r1499b1230],
7	conﬁrmatory	JJ	O	conﬁrmatory	amod	10	SENT_191	[p15l1523t1170r1939b1245],
8	phase	NN	O	phase	nn	10	SENT_191	[p15l1955t1170r2140b1245],
9	4	CD	NUMBER	4	num	10	SENT_191	[p15l12t1271r50b1325],
10	studies	NNS	O	study	nsubj	14	SENT_191	[p15l69t1266r290b1326],
11	on	IN	O	on	_	0	SENT_191	[p15l311t1285r391b1325],
12	new	JJ	O	new	amod	13	SENT_191	[p15l409t1285r542b1326],
13	drugs	NNS	O	drug	prep_on	10	SENT_191	[p15l558t1266r736b1342],
14	languish	VBP	O	languish	parataxis	5	SENT_191	[p15l755t1266r1048b1342],
15	.	.	O	.	_	0	SENT_191	[p15l755t1266r1048b1342],

1	JAMA	NNP	O	JAMA	_	0	SENT_192	[p15l1063t1272r1254b1335],
2	2003	CD	DATE	2003	num	1	SENT_192	[p15l1270t1271r1831b1338],
3	;	:	O	;	_	0	SENT_192	[p15l1270t1271r1831b1338],
4	289:3227	CD	NUMBER	289:3227	number	5	SENT_192	[p15l1270t1271r1831b1338],
5	—	CD	NUMBER	—	dep	1	SENT_192	[p15l1270t1271r1831b1338],
6	9	CD	NUMBER	9	dep	5	SENT_192	[p15l1270t1271r1831b1338],
7	.	.	O	.	_	0	SENT_192	[p15l1270t1271r1831b1338],

1	10	CD	NUMBER	10	_	0	SENT_193	[p15l16t1368r102b1421],
2	.	.	O	.	_	0	SENT_193	[p15l16t1368r102b1421],

1	Gelijns	NNP	O	Gelijns	nn	2	SENT_194	[p15l143t1362r365b1437],
2	AC	NN	O	ac	_	0	SENT_194	[p15l390t1367r502b1434],
3	,	,	O	,	_	0	SENT_194	[p15l390t1367r502b1434],
4	Rosenberg	NNP	PERSON	Rosenberg	nn	5	SENT_194	[p15l532t1362r877b1438],
5	N	NNP	O	N	appos	2	SENT_194	[p15l899t1368r969b1434],
6	,	,	O	,	_	0	SENT_194	[p15l899t1368r969b1434],
7	Moskowitz	NNP	PERSON	Moskowitz	nn	8	SENT_194	[p15l998t1362r1351b1422],
8	AJ	NNP	O	AJ	appos	5	SENT_194	[p15l1375t1368r1463b1430],
9	.	.	O	.	_	0	SENT_194	[p15l1375t1368r1463b1430],

1	Capturing	VBG	O	capture	_	0	SENT_195	[p15l1493t1363r1816b1438],
2	the	DT	O	the	det	4	SENT_195	[p15l1839t1362r1936b1421],
3	unexpected	JJ	O	unexpected	amod	4	SENT_195	[p15l1963t1381r2139b1421, p15l12t1458r220b1534],
4	beneﬁts	NNS	O	beneﬁts	dobj	1	SENT_195	[p15l239t1458r489b1517],
5	of	IN	O	of	_	0	SENT_195	[p15l509t1458r585b1517],
6	medical	JJ	O	medical	amod	7	SENT_195	[p15l589t1458r839b1517],
7	research	NN	O	research	prep_of	4	SENT_195	[p15l857t1458r1141b1517],
8	.	.	O	.	_	0	SENT_195	[p15l857t1458r1141b1517],

1	N	NN	O	n	nn	2	SENT_196	[p15l1162t1464r1219b1518],
2	EnglJ	NN	O	englj	nsubj	3	SENT_196	[p15l1235t1459r1420b1534],
3	Med	VBD	O	med	_	0	SENT_196	[p15l1434t1458r1575b1517],
4	1998	CD	DATE	1998	dobj	3	SENT_196	[p15l1595t1463r2114b1530],
5	;	:	O	;	_	0	SENT_196	[p15l1595t1463r2114b1530],
6	339:693	CD	NUMBER	339:693	number	7	SENT_196	[p15l1595t1463r2114b1530],
7	—	CD	NUMBER	—	dep	4	SENT_196	[p15l1595t1463r2114b1530],
8	8	CD	NUMBER	8	dep	7	SENT_196	[p15l1595t1463r2114b1530],
9	.	.	O	.	_	0	SENT_196	[p15l1595t1463r2114b1530],

1	11	CD	NUMBER	11	_	0	SENT_197	[p15l16t1562r102b1613],
2	.	.	O	.	_	0	SENT_197	[p15l16t1562r102b1613],

1	Lynch	NNP	PERSON	Lynch	nn	2	SENT_198	[p15l141t1554r331b1629],
2	TJ	NNP	PERSON	TJ	_	0	SENT_198	[p15l348t1559r432b1626],
3	,	,	O	,	_	0	SENT_198	[p15l348t1559r432b1626],
4	Bell	NNP	ORGANIZATION	Bell	nn	5	SENT_198	[p15l455t1554r575b1613],
5	DW	NNP	ORGANIZATION	DW	appos	2	SENT_198	[p15l593t1559r723b1626],
6	,	,	O	,	_	0	SENT_198	[p15l593t1559r723b1626],
7	Sordella	NNP	PERSON	Sordella	nn	8	SENT_198	[p15l749t1554r1006b1613],
8	R	NNP	PERSON	R	appos	2	SENT_198	[p15l1024t1559r1087b1626],
9	,	,	O	,	_	0	SENT_198	[p15l1024t1559r1087b1626],
10	et	FW	O	et	nn	11	SENT_198	[p15l1113t1567r1170b1613],
11	al.	FW	O	al.	appos	2	SENT_198	[p15l1185t1554r1256b1613],
12	.	.	O	.	_	0	SENT_198	[p15l1185t1554r1256b1613],

1	Activating	VBG	O	activate	amod	2	SENT_199	[p15l1277t1555r1601b1630],
2	mutations	NNS	O	mutation	_	0	SENT_199	[p15l1617t1555r1940b1613],
3	in	IN	O	in	_	0	SENT_199	[p15l1961t1555r2022b1612],
4	the	DT	O	the	det	7	SENT_199	[p15l2042t1554r2139b1613],
5	epidermal	JJ	O	epidermal	amod	7	SENT_199	[p15l14t1650r334b1726],
6	growth	NN	O	growth	nn	7	SENT_199	[p15l375t1650r602b1726],
7	factor	NN	O	factor	prep_in	2	SENT_199	[p15l644t1650r829b1709],
8	receptor	NN	O	receptor	nn	10	SENT_199	[p15l868t1663r1132b1726],
9	underlying	VBG	O	underlie	amod	10	SENT_199	[p15l1172t1650r1517b1726],
10	responsiveness	NN	O	responsiveness	dep	2	SENT_199	[p15l1556t1651r2035b1726],
11	of	IN	O	of	_	0	SENT_199	[p15l2079t1650r2154b1709],
12	non	JJ	O	non	amod	18	SENT_199	[p15l14t1746r488b1805],
13	—	JJ	O	—	amod	18	SENT_199	[p15l14t1746r488b1805],
14	small	JJ	O	small	amod	18	SENT_199	[p15l14t1746r488b1805],
15	—	NN	O	—	nn	18	SENT_199	[p15l14t1746r488b1805],
16	cell	NN	O	cell	nn	18	SENT_199	[p15l14t1746r488b1805],
17	lung	NN	O	lung	nn	18	SENT_199	[p15l518t1746r664b1822],
18	cancer	NN	O	cancer	prep_of	10	SENT_199	[p15l693t1766r900b1805],
19	to	TO	O	to	_	0	SENT_199	[p15l930t1759r989b1805],
20	gefitinib	NN	O	gefitinib	prep_to	10	SENT_199	[p15l1021t1746r1306b1822],
21	.	.	O	.	_	0	SENT_199	[p15l1021t1746r1306b1822],

1	N	NN	O	n	nn	3	SENT_200	[p15l1340t1752r1396b1806],
2	Engl	NNP	O	Engl	nn	3	SENT_200	[p15l1425t1747r1571b1822],
3	J	NNP	O	J	nsubj	4	SENT_200	[p15l1595t1752r1623b1815],
4	Med	VBD	O	med	_	0	SENT_200	[p15l1651t1746r1791b1805],
5	2004	CD	DATE	2004	dobj	4	SENT_200	[p15l1822t1751r2137b1818],
6	;	:	O	;	_	0	SENT_200	[p15l1822t1751r2137b1818],
7	350	CD	NUMBER	350	num	9	SENT_200	[p15l1822t1751r2137b1818],
8	:	:	O	:	_	0	SENT_200	[p15l1822t1751r2137b1818],
9	2129-39	CD	NUMBER	2129-39	dep	5	SENT_200	[p15l14t1847r292b1901],
10	.	.	O	.	_	0	SENT_200	[p15l14t1847r292b1901],

1	12	CD	NUMBER	12	_	0	SENT_201	[p15l16t1945r102b1996],
2	.	.	O	.	_	0	SENT_201	[p15l16t1945r102b1996],

1	Paez	NNP	PERSON	Paez	nn	2	SENT_202	[p15l141t1942r285b1996],
2	JG	NNP	O	JG	_	0	SENT_202	[p15l296t1942r397b2009],
3	,	,	O	,	_	0	SENT_202	[p15l296t1942r397b2009],
4	Janne	NNP	PERSON	Janne	nn	5	SENT_202	[p15l411t1943r594b2005],
5	PA	NN	PERSON	pa	appos	2	SENT_202	[p15l611t1942r711b2009],
6	,	,	O	,	_	0	SENT_202	[p15l611t1942r711b2009],
7	Lee	NNP	PERSON	Lee	nn	8	SENT_202	[p15l732t1943r838b1996],
8	JC	NNP	PERSON	JC	appos	2	SENT_202	[p15l849t1942r941b2009],
9	,	,	O	,	_	0	SENT_202	[p15l849t1942r941b2009],
10	et	FW	O	et	nn	11	SENT_202	[p15l964t1950r1022b1996],
11	al.	FW	O	al.	appos	2	SENT_202	[p15l1035t1937r1107b1996],
12	.	.	O	.	_	0	SENT_202	[p15l1035t1937r1107b1996],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_203	[p15l1127t1942r1322b2000],
2	mutations	NNS	O	mutation	_	0	SENT_203	[p15l1332t1938r1655b1996],
3	in	IN	O	in	_	0	SENT_203	[p15l1674t1938r1735b1995],
4	lung	NN	O	lung	nn	5	SENT_203	[p15l1751t1937r1897b2013],
5	cancer	NN	O	cancer	prep_in	2	SENT_203	[p15l1913t1956r2136b1996],
6	:	:	O	:	_	0	SENT_203	[p15l1913t1956r2136b1996],
7	correlation	NN	O	correlation	dep	2	SENT_203	[p15l14t2033r360b2092],
8	with	IN	O	with	_	0	SENT_203	[p15l374t2033r516b2093],
9	clinical	JJ	O	clinical	amod	10	SENT_203	[p15l534t2033r760b2092],
10	response	NN	O	response	prep_with	7	SENT_203	[p15l776t2052r1061b2109],
11	to	TO	O	to	_	0	SENT_203	[p15l1079t2046r1138b2092],
12	geﬁtinib	NN	O	geﬁtinib	nn	13	SENT_203	[p15l1157t2033r1423b2109],
13	therapy	NN	O	therapy	prep_to	10	SENT_203	[p15l1442t2034r1687b2109],
14	.	.	O	.	_	0	SENT_203	[p15l1442t2034r1687b2109],

1	Science	NNP	O	Science	_	0	SENT_204	[p15l1710t2034r1944b2092],
2	2004	CD	DATE	2004	num	1	SENT_204	[p15l1962t2038r2136b2105],
3	;	:	O	;	_	0	SENT_204	[p15l1962t2038r2136b2105],
4	304:1497	CD	NUMBER	304:1497	number	5	SENT_204	[p15l15t2134r473b2188],
5	—	CD	NUMBER	—	dep	1	SENT_204	[p15l15t2134r473b2188],
6	500	CD	NUMBER	500	dep	5	SENT_204	[p15l15t2134r473b2188],
7	.	.	O	.	_	0	SENT_204	[p15l15t2134r473b2188],

1	13	CD	NUMBER	13	_	0	SENT_205	[p15l16t2232r102b2283],
2	.	.	O	.	_	0	SENT_205	[p15l16t2232r102b2283],

1	Danzon	NNP	PERSON	Danzon	nn	2	SENT_206	[p15l141t2229r392b2283],
2	P	NN	PERSON	p	nsubj	13	SENT_206	[p15l422t2229r470b2296],
3	,	,	O	,	_	0	SENT_206	[p15l422t2229r470b2296],
4	Towse	NNP	PERSON	Towse	nn	6	SENT_206	[p15l503t2229r704b2284],
5	A.	NNP	O	A.	nn	6	SENT_206	[p15l733t2230r798b2283],
6	The	NNP	O	The	appos	2	SENT_206	[p15l830t2224r952b2283],
7	genomic	JJ	O	genomic	amod	8	SENT_206	[p15l983t2225r1260b2300],
8	revolution	NN	O	revolution	dep	6	SENT_206	[p15l1291t2224r1632b2283],
9	:	:	O	:	_	0	SENT_206	[p15l1291t2224r1632b2283],
10	is	VBZ	O	be	cop	13	SENT_206	[p15l1665t2225r1714b2283],
11	the	DT	O	the	det	13	SENT_206	[p15l1747t2224r1844b2283],
12	real	JJ	O	real	amod	13	SENT_206	[p15l1875t2224r1991b2283],
13	risk	NN	O	risk	_	0	SENT_206	[p15l2022t2224r2144b2284],
14	under	IN	O	under	_	0	SENT_206	[p15l14t2320r581b2379],
15	—	CD	NUMBER	—	num	16	SENT_206	[p15l14t2320r581b2379],
16	investment	NN	O	investment	prep_under	13	SENT_206	[p15l14t2320r581b2379],
17	rather	RB	O	rather	_	0	SENT_206	[p15l633t2320r825b2378],
18	than	IN	O	than	_	0	SENT_206	[p15l879t2320r1020b2378],
19	bankrupt	JJ	O	bankrupt	amod	22	SENT_206	[p15l1077t2320r1371b2395],
20	health	NN	O	health	nn	22	SENT_206	[p15l1424t2320r1621b2378],
21	care	NN	O	care	nn	22	SENT_206	[p15l1678t2339r1805b2378],
22	systems	NNS	O	system	conj_negcc	13	SENT_206	[p15l1862t2318r2140b2395],
23	?	.	O	?	_	0	SENT_206	[p15l1862t2318r2140b2395],

1	J	NNP	O	J	nn	5	SENT_207	[p15l6t2421r34b2483],
2	Health	NNP	O	Health	nn	5	SENT_207	[p15l51t2415r264b2474],
3	Serv	NNP	O	Serv	nn	5	SENT_207	[p15l284t2420r416b2475],
4	Res	NNP	O	Res	nn	5	SENT_207	[p15l430t2420r543b2478],
5	Policy	NNP	O	Policy	_	0	SENT_207	[p15l562t2415r752b2491],
6	2000	CD	DATE	2000	num	5	SENT_207	[p15l767t2420r1208b2486],
7	;	:	O	;	_	0	SENT_207	[p15l767t2420r1208b2486],
8	5:253	CD	NUMBER	5:253	number	9	SENT_207	[p15l767t2420r1208b2486],
9	—	CD	NUMBER	—	dep	5	SENT_207	[p15l767t2420r1208b2486],
10	5	CD	NUMBER	5	dep	9	SENT_207	[p15l767t2420r1208b2486],
11	.	.	O	.	_	0	SENT_207	[p15l767t2420r1208b2486],

1	14	CD	NUMBER	14	_	0	SENT_208	[p15l16t2519r102b2570],
2	.	.	O	.	_	0	SENT_208	[p15l16t2519r102b2570],

1	Roberts	NNP	PERSON	Roberts	nn	3	SENT_209	[p15l141t2511r388b2574],
2	TG	NN	PERSON	tg	nn	3	SENT_209	[p15l404t2516r504b2571],
3	Jr	NNP	PERSON	Jr	_	0	SENT_209	[p15l515t2517r584b2583],
4	,	,	O	,	_	0	SENT_209	[p15l515t2517r584b2583],
5	Lynch	NNP	PERSON	Lynch	nn	7	SENT_209	[p15l605t2511r794b2586],
6	TJ	NNP	PERSON	TJ	nn	7	SENT_209	[p15l809t2516r877b2580],
7	Jr	NNP	PERSON	Jr	appos	3	SENT_209	[p15l886t2517r954b2583],
8	,	,	O	,	_	0	SENT_209	[p15l886t2517r954b2583],
9	Chabner	NNP	PERSON	Chabner	nn	10	SENT_209	[p15l976t2511r1250b2571],
10	BA	NN	O	ba	appos	7	SENT_209	[p15l1264t2516r1372b2571],
11	.	.	O	.	_	0	SENT_209	[p15l1264t2516r1372b2571],

1	The	DT	O	the	det	4	SENT_210	[p15l1392t2511r1513b2570],
2	phase	NN	O	phase	nn	4	SENT_210	[p15l1530t2511r1715b2586],
3	III	CD	NUMBER	iii	num	4	SENT_210	[p15l1732t2517r1805b2569],
4	trial	NN	O	trial	_	0	SENT_210	[p15l1822t2511r1947b2570],
5	in	IN	O	in	_	0	SENT_210	[p15l1963t2512r2025b2569],
6	the	DT	O	the	det	7	SENT_210	[p15l2043t2511r2140b2570],
7	era	NN	O	era	prep_in	4	SENT_210	[p15l14t2627r109b2666],
8	of	IN	O	of	_	0	SENT_210	[p15l126t2607r202b2666],
9	targeted	VBN	O	target	amod	10	SENT_210	[p15l206t2607r465b2683],
10	therapy	NN	O	therapy	prep_of	7	SENT_210	[p15l483t2607r736b2683],
11	:	:	O	:	_	0	SENT_210	[p15l483t2607r736b2683],
12	unraveling	VBG	O	unravel	dep	4	SENT_210	[p15l757t2608r1096b2683],
13	the	DT	O	the	det	14	SENT_210	[p15l1111t2607r1209b2666],
14	“	CD	NUMBER	“	nsubj	15	SENT_210	[p15l1229t2611r1339b2683],
15	go	VBP	O	go	ccomp	12	SENT_210	[p15l1229t2611r1339b2683],
16	or	CC	O	or	_	0	SENT_210	[p15l1358t2626r1425b2666],
17	no	DT	O	no	advmod	12	SENT_210	[p15l1440t2626r1520b2666],
18	go	VB	O	go	dep	4	SENT_210	[p15l1538t2612r1648b2683],
19	”	RB	O	”	advmod	20	SENT_210	[p15l1538t2612r1648b2683],
20	decision	NN	O	decision	dobj	18	SENT_210	[p15l1670t2607r1952b2666],
21	.	.	O	.	_	0	SENT_210	[p15l1670t2607r1952b2666],

1	J	NNP	O	J	nn	3	SENT_211	[p15l1966t2613r1994b2676],
2	Clin	NNP	O	Clin	nn	3	SENT_211	[p15l2010t2608r2140b2666],
3	Oncol	NNP	O	Oncol	_	0	SENT_211	[p15l14t2704r205b2762],
4	2003	CD	DATE	2003	num	3	SENT_211	[p15l223t2708r784b2775],
5	;	:	O	;	_	0	SENT_211	[p15l223t2708r784b2775],
6	21:3683	CD	NUMBER	21:3683	number	7	SENT_211	[p15l223t2708r784b2775],
7	—	CD	NUMBER	—	dep	3	SENT_211	[p15l223t2708r784b2775],
8	95	CD	NUMBER	95	dep	7	SENT_211	[p15l223t2708r784b2775],
9	.	.	O	.	_	0	SENT_211	[p15l223t2708r784b2775],

1	15	CD	NUMBER	15	_	0	SENT_212	[p15l16t2807r102b2858],
2	.	.	O	.	_	0	SENT_212	[p15l16t2807r102b2858],

1	DiMasi	NNP	PERSON	DiMasi	nn	2	SENT_213	[p15l141t2800r369b2858],
2	JA	NNP	O	JA	_	0	SENT_213	[p15l390t2805r482b2872],
3	,	,	O	,	_	0	SENT_213	[p15l390t2805r482b2872],
4	Hansen	NNP	PERSON	Hansen	nn	5	SENT_213	[p15l515t2804r759b2858],
5	RW	NNP	O	RW	appos	2	SENT_213	[p15l786t2804r907b2871],
6	,	,	O	,	_	0	SENT_213	[p15l786t2804r907b2871],
7	Grabowski	NNP	PERSON	Grabowski	nn	8	SENT_213	[p15l940t2799r1288b2859],
8	HG	NNP	O	HG	appos	5	SENT_213	[p15l1316t2804r1446b2859],
9	.	.	O	.	_	0	SENT_213	[p15l1316t2804r1446b2859],

1	The	DT	O	the	det	2	SENT_214	[p15l1476t2799r1597b2858],
2	price	NN	O	price	_	0	SENT_214	[p15l1625t2800r1782b2874],
3	of	IN	O	of	_	0	SENT_214	[p15l1812t2799r1887b2859],
4	innovation	NN	O	innovation	prep_of	2	SENT_214	[p15l1901t2800r2139b2859, p15l14t2896r157b2954],
5	:	:	O	:	_	0	SENT_214	[p15l1901t2800r2139b2859, p15l14t2896r157b2954],
6	new	JJ	O	new	amod	7	SENT_214	[p15l179t2914r311b2955],
7	estimates	NNS	O	estimate	dep	2	SENT_214	[p15l327t2896r624b2954],
8	of	IN	O	of	_	0	SENT_214	[p15l645t2895r720b2954],
9	drug	NN	O	drug	nn	11	SENT_214	[p15l726t2895r876b2971],
10	development	NN	O	development	nn	11	SENT_214	[p15l892t2895r1304b2971],
11	costs	NNS	O	cost	prep_of	7	SENT_214	[p15l1319t2908r1496b2954],
12	.	.	O	.	_	0	SENT_214	[p15l1319t2908r1496b2954],

1	J	NNP	O	J	nn	3	SENT_215	[p15l1511t2901r1540b2964],
2	Health	NNP	O	Health	nn	3	SENT_215	[p15l1556t2895r1769b2954],
3	Econ	NNP	O	Econ	_	0	SENT_215	[p15l1786t2901r1945b2954],
4	2003	CD	DATE	2003	num	3	SENT_215	[p15l1963t2900r2137b2967],
5	;	:	O	;	_	0	SENT_215	[p15l1963t2900r2137b2967],
6	22:151	CD	NUMBER	22:151	number	7	SENT_215	[p15l14t2996r353b3050],
7	-85	CD	NUMBER	-85	dep	3	SENT_215	[p15l14t2996r353b3050],
8	.	.	O	.	_	0	SENT_215	[p15l14t2996r353b3050],

1	Copyright	NN	O	copyright	_	0	SENT_216	[p15l15t3077r254b3142],
2	©	CD	NUMBER	©	num	6	SENT_216	[p15l276t3082r329b3136],
3	2004	CD	DATE	2004	num	6	SENT_216	[p15l353t3080r479b3126],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_216	[p15l499t3077r861b3126],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_216	[p15l882t3077r1080b3126],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_216	[p15l1097t3079r1281b3141],
7	.	.	O	.	_	0	SENT_216	[p15l1097t3079r1281b3141],

1	N	NN	O	n	_	0	SENT_217	[p15l525t3219r539b3234],
2	ENGLJ	NN	O	englj	prep	1	SENT_217	[p15l554t3218r638b3240],
3	MED	NN	O	med	nn	6	SENT_217	[p15l653t3219r706b3234],
4	35	CD	NUMBER	35	num	6	SENT_217	[p15l718t3218r778b3240],
5	'	''	O	'	_	0	SENT_217	[p15l718t3218r778b3240],
6	|	NN	O	|	dep	2	SENT_217	[p15l718t3218r778b3240],
7	;	:	O	;	_	0	SENT_217	[p15l718t3218r778b3240],
8	S	NN	O	s	nn	10	SENT_217	[p15l718t3218r778b3240],
9	WWW.NEjM.ORG	NN	O	www.nejm.org	nn	10	SENT_217	[p15l813t3218r1024b3240],
10	JULY	NN	DATE	july	dep	1	SENT_217	[p15l1058t3219r1118b3240],
11	29,2004	CD	NUMBER	29,2004	dep	10	SENT_217	[p15l1130t3218r1249b3240],
12	`	``	O	`	_	0	SENT_217	[p15l1960t3217r2015b3239],
13	^	CD	NUMBER	^	num	14	SENT_217	[p15l1960t3217r2015b3239],
14	h	NN	O	h	dep	1	SENT_217	[p15l1960t3217r2015b3239],
15	+	CC	O	+	rcmod	14	SENT_217	[p15l1960t3217r2015b3239],

1	The	DT	O	the	det	4	SENT_218	[p15l702t3251r753b3275],
2	New	NNP	O	New	nn	4	SENT_218	[p15l762t3252r824b3275],
3	England	NNP	O	England	nn	4	SENT_218	[p15l833t3251r944b3282],
4	Journal	NNP	O	Journal	_	0	SENT_218	[p15l953t3251r1050b3275],
5	of	IN	O	of	_	0	SENT_218	[p15l1060t3251r1089b3275],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_218	[p15l1095t3251r1220b3275],

1	Downloaded	VBN	O	download	_	0	SENT_219	[p15l144t3292r314b3315],
2	from	IN	O	from	_	0	SENT_219	[p15l323t3292r387b3315],
3	nejmorg	NN	O	nejmorg	prep_from	1	SENT_219	[p15l396t3292r514b3322],
4	at	IN	O	at	_	0	SENT_219	[p15l524t3296r548b3315],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_219	[p15l556t3292r739b3315],
6	on	IN	O	on	_	0	SENT_219	[p15l748t3299r780b3315],
7	January	NNP	DATE	January	prep_on	1	SENT_219	[p15l789t3292r892b3322],
8	5	CD	DATE	5	num	7	SENT_219	[p15l902t3292r924b3320],
9	,	,	DATE	,	_	0	SENT_219	[p15l902t3292r924b3320],
10	2014	CD	DATE	2014	num	7	SENT_219	[p15l935t3292r1007b3315],
11	.	.	O	.	_	0	SENT_219	[p15l935t3292r1007b3315],

1	For	IN	O	for	_	0	SENT_220	[p15l1018t3292r1064b3315],
2	personal	JJ	O	personal	amod	3	SENT_220	[p15l1072t3292r1185b3322],
3	use	NN	O	use	pobj	1	SENT_220	[p15l1194t3299r1237b3315],
4	only	RB	O	only	advmod	3	SENT_220	[p15l1247t3292r1312b3322],
5	.	.	O	.	_	0	SENT_220	[p15l1247t3292r1312b3322],

1	No	DT	O	no	det	3	SENT_221	[p15l1322t3292r1362b3315],
2	other	JJ	O	other	amod	3	SENT_221	[p15l1372t3292r1440b3315],
3	uses	NNS	O	use	_	0	SENT_221	[p15l1449t3299r1504b3315],
4	without	IN	O	without	_	0	SENT_221	[p15l1515t3292r1616b3315],
5	permission	NN	O	permission	prep_without	3	SENT_221	[p15l1624t3292r1777b3322],
6	.	.	O	.	_	0	SENT_221	[p15l1624t3292r1777b3322],

1	Copyright	NN	O	copyright	_	0	SENT_222	[p15l494t3333r629b3364],
2	©	CD	NUMBER	©	num	6	SENT_222	[p15l638t3333r661b3357],
3	2004	CD	DATE	2004	num	6	SENT_222	[p15l672t3333r737b3357],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_222	[p15l746t3333r937b3357],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_222	[p15l947t3333r1055b3357],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_222	[p15l1065t3333r1170b3364],
7	.	.	O	.	_	0	SENT_222	[p15l1065t3333r1170b3364],

1	All	DT	O	all	det	2	SENT_223	[p15l1181t3333r1223b3357],
2	rights	NNS	O	rights	nsubj	3	SENT_223	[p15l1232t3333r1307b3364],
3	reserved	VBN	O	reserve	_	0	SENT_223	[p15l1316t3333r1435b3357],
4	.	.	O	.	_	0	SENT_223	[p15l1316t3333r1435b3357],

